<?xml version="1.0" encoding="utf-8"?>
<documents>
  <document>
    <id>328907</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=328907]]&gt;</url>
    <title>2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Commentary</title>
    <publicationDate>2009-11-16T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,COPD AEU - HOME]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Commentary&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Written by Dr Tom Wilkinson, Southampton university School of Medicine&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;The implementation of the COPD National Service Framework is scheduled for 2010 and will aim to standardise the management of this highly prevalent condition. However, in the interim a review of recent evidence highlights some key findings that may impact on current clinical practice.&lt;/P&gt;
&lt;P&gt;Importantly, the British Thoracic Society Guidelines on Physiotherapy for Spontaneously Ventilated Patients were published this year. This comprehensive document surveyed the range of evidence available on physiotherapy interventions in COPD. The conclusions of this guideline are too large for adequate summary in this short review but it is important to note that the strength of evidence available was variable and whilst interventions such as pulmonary rehabilitation or acute non-invasive ventilation can be rigorously recommended other treatments require more studies to confirm their exact role in COPD.&lt;/P&gt;
&lt;P&gt;A review of meta-analysis and larger randomised controlled trials published recently confirms that many current interventions lack a strong evidence base or controversy exists in their use. For example in the setting of acute exacerbations, in their meta-analysis (Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM Thorax 2008;63(5):415-22) equivalence of short course to longer course antibiotic therapy was found but in a systematic review entitled Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. Puhan MA, Vollenweider D, Steurer J, Bossuyt PM, Ter Riet G.&amp;nbsp; BMC Med. 2008 Oct 10;6:28, the authors conclude ‘Placebo-controlled trials do not support the use of antibiotics in chronic obstructive pulmonary disease patients with mild to moderate exacerbations.’ Whereas in more severe hospitalised exacerbations meta-analsyis would seem to confirm a mortality benefit for antibiotic use. Contemporary management of acute exacerbations of COPDA: Systematic review and metaanalysis. Quon B.S., Gan W.Q., Sin D.D.&amp;nbsp;&amp;nbsp; Chest 2008;133(3):756-766. Clearly more studies are required.&lt;/P&gt;
&lt;P&gt;Similar controversy lies in the safety profile of currently prescribed inhaled therapies. Singh and colleagues had raised safety concerns about the use of anti-cholinergics in COPD; Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Singh S., Loke Y.K., Furberg C.D.&amp;nbsp; JAMA 2008;300(12):1439-1450. However subsequent analysis has in fact suggested a diminution of risk in terms of all cause and cardiovascular mortality with the use of Tiotropium. (Cardiovascular Safety of Tiotropium in Patients With COPD. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Chest 2009 Jul 10, A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Hilleman DE, Malesker MA, Morrow LE, Schuller D. Int.J.Chron.Obstruct Pulmon Dis. 2009;4(2):253-263, Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis.. Respir.Med. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA&amp;nbsp; 2009 Oct;103(10):1421-1429.)&lt;/P&gt;
&lt;P&gt;The potential for inhaled- corticosteroids to impact on the incidence of pneumonia has been highlighted. (Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Singh S, Amin AV, Loke YK. Arch.Intern.Med. 2009 Feb 9;169(3):219-229), by a potential impact on severe pneumonia rates without an effect on mortality. However, this must be reviewed in the context of improved perceived health status and reduced exacerbation frequency associated with ICS use in COPD. (Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Sobieraj DM, White CM, Coleman CI Clin.Ther. 2008 Aug;30(8):1416-1425.)&lt;/P&gt;
&lt;P&gt;The potential role for statin therapy in COPD was highlighted by two publications reviewing the literature. Statins in COPD: a systematic review. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J Chest 2009 Sep;136(3):734-743&lt;BR&gt;Associations between statins and COPD: A systematic review. Dobler C.C., Wong K.K., Marks G.B. BMC Pulmonary Medicine 2009;9. However both conclude that further well designed clinical trials are required before full recommendations on statin use can be made.&lt;/P&gt;
&lt;P&gt;The benefit of large multi-centred randomised controlled trials was highlighted by a sub-group analysis of the UPLIFT –Tiotropium intervention study. (Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al&amp;nbsp; Lancet 2009 Oct 3;374(9696):1171-1178.) This suggested a potential impact of treatment on lung function decline in GOLD stage 2 patients and confirms the need for long term intervention studies in early disease.&lt;/P&gt;
&lt;P&gt;Reviews of clinical management strategies suggest benefit from non- pharmacological interventions in combination (Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review and meta-analysis. Peytremann-Bridevaux I, Staeger P, Bridevaux PO, Ghali WA, Burnand B.&amp;nbsp; Am.J.Med. 2008;121(5):433-443.e4, A systematic review of integrated use of disease-management interventions in asthma and COPD. Lemmens KM, Nieboer AP, Huijsman R. Respir.Med. 2009 May;103(5):670-691). Although studies of similar magnitude to the pharmaceutical trials may be required to determine the most beneficial interventions for patients manifesting different aspects of this heterogeneous disease.&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;B&gt;&lt;A href="nelh:328903:0" name=internalLink&gt;COPD Annual Evidence Update Home Page&lt;/A&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328903</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=328903]]&gt;</url>
    <title>2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Home Page</title>
    <publicationDate>2009-11-16T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,EMERGENCY CARE,CLINICAL LIBRARY,STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),COPD AEU - HOME]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Welcome to the 2009 Annual Evidence Update for COPD. We have presented the latest evidence published in the 12 months, to build on those updates from previous years.&lt;/P&gt;
&lt;P&gt;Dr Tom Wilkinson has summarised the latest&amp;nbsp;key devlopments in COPD in our invited commentary, and we hope to have further commentaries on the publication of the National Strategy for COPD in 2010.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="nelh:328907:1" name=internalLink&gt;Invited commentary&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:328909:1" name=internalLink&gt;2009 Annual Evidence Update for COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:328904:1" name=internalLink&gt;Methodology&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328904</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=328904]]&gt;</url>
    <title>2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Methodology</title>
    <publicationDate>2009-11-16T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,COPD AEU - HOME]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A literature search was carried out to identify systematic reviews on COPD published in the last 12 months, since the searches were carried out for the 2008 AEU on COPD.&lt;/P&gt;
&lt;P&gt;The searches were carried out on 22 October 2009, using the following terms:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;COPD&lt;BR&gt;chronic obstructive pulmonary disease&lt;BR&gt;chronic bronchitis&lt;BR&gt;emphysema&lt;BR&gt;chronic obstructive airway disease&lt;BR&gt;chronic airflow limitation&lt;BR&gt;chronic obstructive respiratory disease&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sources searched:&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;PubMed - using the &lt;A href="http://www.ncbi.nlm.nih.gov/corehtml/query/static/clinical.shtml" target="_blank"&gt;PubMed clinical queries systematic review filter&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cochrane Database of Systematic Reviews&lt;/P&gt;
&lt;P&gt;NHS Evidence - respiratory&lt;/P&gt;
&lt;P&gt;NHS Evidence - searching Medline, AMED, CINAHL, BNI and PsychInfo&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;STRONG&gt;Timeframe&lt;/STRONG&gt;&lt;BR&gt;Where possible sources were searched from June 2008 to include reviews that may not have been indexed in time for the 2008 AEU on COPD. Where it was not possible to search over within such a defined time period, sources were searched from the beginning of 2008.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;/STRONG&gt;&lt;BR&gt;Results from the searches were collated and duplicates removed. They were also compared with the 2008 AEU on COPD, and those citations presented last year were also removed. Citations were hand searched to identify systematic reviews for inclusion, with the final results approved by Dr Mark Everard, clinical lead for NHS Evidence - respiratory&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:328903:0" name=internalLink&gt;COPD Annual Evidence Update Home Page&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>328909</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=328909]]&gt;</url>
    <title>2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Results</title>
    <publicationDate>2009-11-16T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,COPD AEU - HOME]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Results&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Links are provided to PubMed Abstracts for all citations, and to the full text where these are freely available.&lt;/P&gt;
&lt;P&gt;
&lt;P&gt;&lt;B&gt;Management of exacerbations&lt;/B&gt; 
&lt;P&gt;Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: A systematic review. Chronic Respiratory Disease 2009 Oct 9. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19819912" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Puhan M, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009 Jan 21;(1)(1):CD005305. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160250" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005305/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009 Mar;135(3):786-793. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812453" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Sorensen SV, Baker T, Fleurence R, Dixon J, Roberts C, Haider S, et al. Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis. The International Journal of Tuberculosis and Lung Disease 2009 Aug;13(8):945-954. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19723373" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2009 Jan 21;(1)(1):CD001288. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160195" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001288/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Drug Therapy&lt;/B&gt; 
&lt;P&gt;Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs. placebo for preventing COPD exacerbations:a systematic review and meta-regression of randomized controlled trials. Chest 2009 Sep 25. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19783669" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009 Aug;29(8):891-905. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19637942" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009 Oct 3;374(9696):1171-1178. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19716598" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Drummond M.B., Dasenbrook E.C., Pitz M.W., Murphy D.J., Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. JAMA - Journal of the American Medical Association 2008;300(20):2407-2416. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19033591" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://jama.ama-assn.org/cgi/content/full/300/20/2407" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Medicine 2009 Jan 14;7:2. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19144173" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://www.biomedcentral.com/1741-7015/7/2" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009 Oct;136(4):1029-1038. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19633090" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;&lt;B&gt;Statins&lt;/B&gt; 
&lt;P&gt;Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulmonary Medicine 2009 Jul 12;9:32. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19594891" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://www.biomedcentral.com/1471-2466/9/32" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009 Sep;136(3):734-743. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19376844" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Drug Therapy Safety&lt;/B&gt; 
&lt;P&gt;Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular Safety of Tiotropium in Patients With COPD. Chest 2009 Jul 10. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19592475" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Hilleman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2009;4(2):253-263. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19657399" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respiratory Medicine 2009 Oct;103(10):1421-1429. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19556116" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: A systematic review. Chest 2008;133(5):1079-1087. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18460518" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;&lt;B&gt;Steroids&lt;/B&gt; 
&lt;P&gt;Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Archives of Internal Medicine 2009 Feb 9;169(3):219-229. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19204211" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Physiotherapy&lt;/B&gt; 
&lt;P&gt;Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, et al. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. Thorax 2009 May;64 Suppl 1:i1-51. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19406863" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://www.brit-thoracic.org.uk/ClinicalInformation/Physiotherapy/PhysiotherapyGuideline/tabid/375/Default.aspx" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt;&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Geddes EL, O'Brien K, Reid WD, Brooks D, Crowe J. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. Respiratory Medicine 2008 Dec;102(12):1715-1729. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18708282" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Houchen L, Steiner MC, Singh SJ. How sustainable is strength training in chronic obstructive pulmonary disease? Physiotherapy 2009 Mar;95(1):1-7. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19627679" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Langer D, Hendriks E, Burtin C, Probst V, van der Schans C, Paterson W, et al. A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence. Clinical Rehabilitation 2009 May;23(5):445-462. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19389745" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;O'Brien K, Geddes EL, Reid WD, Brooks D, Crowe J. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. Journal of Cardiopulmonary Rehabilitation &amp;amp; Prevention 2008;28(2):128-41[ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18360190" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;O'Shea SD, Taylor NF, Paratz JD. Progressive Resistance Exercise Improves Muscle Strength and May Improve Elements of Performance of Daily Activities for People With COPD: A Systematic Review. Chest 2009 Sep 4. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19734323" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Roig M, Reid WD. Electrical stimulation and peripheral muscle function in COPD: a systematic review. Respiratory Medicine 2009 Apr;103(4):485-495. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19091537" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Sillen MJ, Speksnijder CM, Eterman RM, Janssen PP, Wagers SS, Wouters EF, et al. Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. Chest 2009 Jul;136(1):44-61. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19363213" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Miscellaneous Interventions&lt;/B&gt; 
&lt;P&gt;Fagevik Olsen M, Westerdahl E. Positive expiratory pressure in patients with chronic obstructive pulmonary disease--a systematic review. Respiration 2009;77(1):110-118[ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843173" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. European Respiratory Journal 2009 Jul;34(1):209-218. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19567604" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Jing JY, Huang TC, Cui W, Xu F, Shen HH. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest 2009 Apr;135(4):991-998. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19349398" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respiratory Medicine 2009 May;103(5):670-691. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19155168" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. European Respiratory Journal 2009 Sep;34(3):634-640. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19357145" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P align=center&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:328903:0" name=internalLink&gt;COPD Annual Evidence Update Home Page&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311638</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311638]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Annual Evidence Update</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ NEWBORN,BLOODSPOT (&lt;1WK),CYSTIC FIBROSIS,NOT ROUTINELY OFFERED,CYSTIC FIBROSIS,CYSTIC FIBROSIS,SCREENING,RESPIRATORY,STAFF USE,ANTENATAL,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Annual Evidence Update&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Annual Evidence Update presents the latest available evidence in cystic fibrosis. The following guidelines and systematic reviews have been published since the beginning of 2005. For more information about the sources searched and the dates of the search see the &lt;A href="nelh:311631:1" name=internalLink&gt;methodology &lt;/A&gt;section. Links to abstracts in PubMed have been provided for references and full text also for Cochrane systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Clinical Guidelines&lt;/B&gt;&lt;BR&gt;Festini, F., Buzzetti, R., Bassi, C., et al. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review J Hosp Infect. 2006 Sep;64(1):1-6. Epub 2006 Jul 10. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16835001" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;Flume, P. A., O'Sullivan, B. P., Robinson, K. A., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17761616" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Kerem, E., Conway, S., Elborn, S., Heijerman, H. and Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus J Cyst Fibros. 2005 Mar;4(1):7-26. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15752677" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Vonberg, R. P., Gastmeier, P. Isolation of infectious cystic fibrosis patients: results of a systematic review Infect Control Hosp Epidemiol. 2005 Apr;26(4):401-9. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15865277" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Antibiotic therapy&lt;/B&gt;&lt;BR&gt;Avgeri, S. G., Matthaiou, D. K., Dimopoulos, G., Grammatikos, A. P. and Falagas, M. E. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence Int J Antimicrob Agents. 2009 May;33(5):394-404. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19097867" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;Balaguer A, González de Dios J. Home intravenous antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD001917. DOI: 10.1002/14651858.CD001917.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11034733" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001917.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Elphick HE, Tan AA. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD002007. DOI: 10.1002/14651858.CD002007.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15846627" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002007.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Fernandes BN, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006682. DOI: 10.1002/14651858.CD006682.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18425963" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006682.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Florescu, D. F., Murphy, P. J. and Kalil, A. C. Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis Pulm Pharmacol Ther. 2009 Mar 27 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19328860" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Remmington T, Jahnke N, Harkensee C. Oral anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD005405. DOI: 10.1002/14651858.CD005405.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17636796" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD005405.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;?xml:namespace prefix = st1 /&gt;&lt;st1:place&gt;&lt;st1:City&gt;Smyth&lt;/st1:City&gt; &lt;st1:State&gt;AR&lt;/st1:State&gt;&lt;/st1:place&gt;, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD002009. DOI: 10.1002/14651858.CD002009.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11034740" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002009.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006961. DOI: 10.1002/14651858.CD006961.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18646176" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006961.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004197. DOI: 10.1002/14651858.CD004197.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16437476" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD004197.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Non-antibiotic medical therapy &lt;/B&gt;&lt;BR&gt;Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD001915. DOI: 10.1002/14651858.CD001915.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10796838" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001915.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Burrows EF, Southern KW, Noone PG. Sodium channel blockers for cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD005087. DOI: 10.1002/14651858.CD005087.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16856076" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD005087.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003884. DOI: 10.1002/14651858.CD003884.pub3. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160226" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD003884.pub3" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003428. DOI: 10.1002/14651858.CD003428.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16235319" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD003428.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD001399. DOI: 10.1002/14651858.CD001399.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843616" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001399.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD001505. DOI: 10.1002/14651858.CD001505.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17943753" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001505.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Lee T, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: CD005599. DOI: 10.1002/14651858.CD005599.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17443603" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD005599.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007168. DOI: 10.1002/14651858.CD007168.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160327" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD007168.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Thornton J, Rangaraj S. Anti-inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis-related arthritis. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006838. DOI: 10.1002/14651858.CD006838.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18254117" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006838.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Thornton J, Rangaraj S. Disease modifying anti-rheumatic drugs in people with cystic fibrosis-related arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007336. DOI: 10.1002/14651858.CD007336.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160333" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD007336.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD001506. DOI: 10.1002/14651858.CD001506.pub3. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16034863" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001506.pub3" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Non-invasive ventilation&lt;/B&gt;&lt;BR&gt;Chinuck, R. S., Fortnum, H. and Baldwin, D. R. Appetite stimulants in cystic fibrosis: A systematic review. J Hum Nutr Diet. 2007 Dec;20(6):526-37 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18001374" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;Conway S, Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD001198. DOI: 10.1002/14651858.CD001198.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10796753" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001198.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;McKarney C, Everard M, N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD002201. DOI: 10.1002/14651858.CD002201.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17943770" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002201.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD002769. DOI: 10.1002/14651858.CD002769.pub3. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160211" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002769.pub3" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] Gastroenterology &amp;amp; Nutrition &lt;/P&gt;
&lt;P&gt;O'Neil CB, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD006751. DOI: 10.1002/14651858.CD006751.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18254115" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006751.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Smyth RL, Walters S. Oral calorie supplements for cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000406. DOI: 10.1002/14651858.CD000406.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17253450" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD000406.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Stallings, V. A., Stark, L. J., Robinson, K. A., et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review J Am Diet Assoc. 2008 May;108(5):832-9 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18442507" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Waljee, A. K., Dimagno, M. J., Wu, B. U., Schoenfeld, P. S. and Conwell, D. L. Systematic review: pancreatic enzyme treatment of malabsorption associated with chronic pancreatitis Aliment Pharmacol Ther. 2009 Feb 1;29(3):235-46. Epub 2008 Nov 8 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19035969" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Surgical interventions&lt;/B&gt;&lt;BR&gt;Amin R, Noone PG, Ratjen F. Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007481. DOI: 10.1002/14651858.CD007481.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19370689" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD007481.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Physiotherapy &amp;amp; Exercise&lt;/B&gt;&lt;BR&gt;Bradley JM, Moran F. Physical training for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD002768. DOI: 10.1002/14651858.CD002768.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18254007" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002768.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Elkins M, Jones A, van der Schans CP. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003147. DOI: 10.1002/14651858.CD003147.pub3. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16625571" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD003147.pub3" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Flume, P. A., Robinson, K. A., O'Sullivan, B. P., et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies Respir Care. 2009 Apr;54(4):522-37 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19327189" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Houston BW, Mills N, Solis-Moya A. Inspiratory muscle training for cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD006112. DOI: 10.1002/14651858.CD006112.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843703" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006112.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Huth, M. M., Zink, K. A. and Van Horn, N. R. The effects of massage therapy in improving outcomes for youth with cystic fibrosis: an evidence review Pediatr Nurs. 2005 Jul-Aug;31(4):328-32 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16229132" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;Main E, Prasad A, van der Schans CP. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD002011. DOI: 10.1002/14651858.CD002011.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15674888" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD002011.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006842. DOI: 10.1002/14651858.CD006842.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160305" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD006842.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Prasad, S. A., &lt;st1:place&gt;Main&lt;/st1:place&gt;, E., Dodd, M. E. and Association of Chartered Physiotherapists. Finding consensus on the physiotherapy management of asymptomatic infants with cystic fibrosis Pediatr Pulmonol. 2008 Mar;43(3):236-44 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18214945" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Reid, W. D., Geddes, E. L., O'Brien, K., Brooks, D. and Crowe, J. Effects of inspiratory muscle training in cystic fibrosis: a systematic review Clin Rehabil. 2008 Oct-Nov;22(10-11):1003-13 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18955432" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Quality of life and psychological issues&lt;/B&gt;&lt;BR&gt;Abbott, J., Hart, A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review Health Qual Life Outcomes. 2005 Mar 24;&lt;st1:time Hour="3" Minute="19"&gt;3:19&lt;/st1:time&gt; [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15790407" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;st1:place&gt;&lt;st1:City&gt;Glasscoe&lt;/st1:City&gt; &lt;st1:State&gt;CA&lt;/st1:State&gt;&lt;/st1:place&gt;, Quittner AL. Psychological interventions for people with cystic fibrosis and their families. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD003148. DOI: 10.1002/14651858.CD003148.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18646087" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD003148.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;Quittner, A. L., Modi, A. and Cruz, I. Systematic review of health-related quality of life measures for children with respiratory conditions Paediatr Respir Rev. 2008 Sep;9(3):220-32 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18694714" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Cystic fibrosis related diabetes&lt;/B&gt;&lt;BR&gt;Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004730. DOI: 10.1002/14651858.CD004730.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16034943" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD004730.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;Screening, diagnosis and genetics&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;Castellani, C., Cuppens, H., Macek, M.,Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice J Cyst Fibros. 2008 May;7(3):179-96 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18456578" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Chen, L. -., Goodson, P. Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: A theory-guided systematic review. 20 Genet Med. 2007 Jul;9(7):442-50 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17666890" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Comeau, A. M., Accurso, F. J., White, T. B., et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report Pediatrics. 2007 Feb;119(2):e495-518 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17272609" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Dequeker, E., Stuhrmann, M., Morris, M. A., et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations Eur J Hum Genet. 2009 Jan;17(1):51-65 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18685558" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Farrell, P. M., Rosenstein, B. J., White, T. B., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report J Pediatr. 2008 Aug;153(2):S4-S14 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18639722" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Grosse, S. D., Rosenfeld, M., Devine, O. J., Lai, H. J. and Farrell, P. M. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis J Pediatr. 2006 Sep;149(3):362-6 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16939748" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Hayeems, R. Z., Bytautas, J. P. and Miller, F. A. A systematic review of the effects of disclosing carrier results generated through newborn screening J Genet Couns. 2008 Dec;17(6):538-49 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18956236" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Langfelder-Schwind, E., Kloza, E., Sugarman, E., et al. Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors J Genet Couns. 2005 Feb;14(1):1-15 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15789152" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;LeGrys, V. A., Yankaskas, J. R., Quittell, L. M., Marshall, B. C., Mogayzel, P. J.,Jr and Cystic Fibrosis Foundation. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines J Pediatr. 2007 Jul;151(1):85-9 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17586196" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Massie, J., Clements, B. and Australian Paediatric Respiratory Group. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience--twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group Pediatr Pulmonol. 2005 May;39(5):440-6 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15704202" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Mayell, S. J., Munck, A., Craig, J. V., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis J Cyst Fibros. 2009 Jan;8(1):71-8 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18957277" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Mishra, A., Greaves, R. and Massie, J. The Limitations of Sweat Electrolyte Reference Intervals for the Diagnosis of Cystic Fibrosis: A Systematic Review Clin Biochem Rev. 2007 May;28(2):60-76 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17687417" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P&gt;Southern KW, Mérelle MME, Dankert-Roelse JE, Nagelkerke A. Newborn screening for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD001402. DOI: 10.1002/14651858.CD001402.pub2. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19160197" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] [&lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001402.pub2" target="_blank"&gt;Full text&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;&lt;STRONG&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt; 
&lt;P&gt;&amp;nbsp; &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311639</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311639]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Cochrane protocols and vacant titles</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Cochrane protocols and vacant titles&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following protocols are currently published in the Cochrane Database of Systematic Reviews: 
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Protocols&lt;/STRONG&gt;&lt;BR&gt;Amin Reshma, Noone Peadar G, Ratjen Felix. Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 4 John Wiley &amp;amp; Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007481&lt;/P&gt;
&lt;P&gt;Hughes Tracey, Mills Nicola. Nebuliser devices for drug delivery in cystic fibrosis. Cochrane Database of Systematic Reviews: Protocols 2009 Issue 1 John Wiley &amp;amp; Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007639&lt;/P&gt;
&lt;P&gt;Savage Eileen, Beirne Paul V, Ni Chroinin Muireann, Duff Alistair, Fitzgerald Tony. Self-management education for cystic fibrosis. Cochrane Database of Systematic Reviews: Protocols 2009 Issue 1 John Wiley &amp;amp; Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007641&lt;/P&gt;
&lt;P&gt;Shamseer Larissa, Adams Denise, Vohra Sunita. Antioxidant micronutrients for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews: Protocols 2008 Issue 2 John Wiley &amp;amp; Sons, Ltd Chichester, UK DOI: 10.1002/14651858.CD007020&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The following titles are currently listed as 'vacant' and needing authors. 
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Vacant titles&lt;/STRONG&gt; &lt;BR&gt;Antenatal screening for cystic fibrosis &lt;BR&gt;Anti-depressant medication for people with cystic fibrosis &lt;BR&gt;Antibiotic sensitivity testing for guiding choice of intravenous antibiotics in cystic fibrosis &lt;BR&gt;Antibiotic sensitivity testing to guide choice of intravenous antibiotics in CF &lt;BR&gt;Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis &lt;BR&gt;Antibiotic treatment for non-tuberculous mycobacteria in people with cystic fibrosis &lt;BR&gt;Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis &lt;BR&gt;Autogenic drainage for cystic fibrosis &lt;BR&gt;CFTR correctors for cystic fibrosis &lt;BR&gt;CFTR potentiators for cystic fibrosis &lt;BR&gt;CFTR stop codon therapy for cystic fibrosis &lt;BR&gt;Drugs to regulate mucus production in cystic fibrosis &lt;BR&gt;Eradication therapy for MRSA in cystic fibrosis &lt;BR&gt;Eradication therapy for MRSA in cystic fibrosis &lt;BR&gt;High strength pancreatic enzyme supplements versus other enzyme formulations for CF &lt;BR&gt;Inhaled chloride secreteagogues for cystic fibrosis &lt;BR&gt;Inhaled denufusol for cystic fibrosis &lt;BR&gt;Interventions for asthma in cystic fibrosis &lt;BR&gt;Interventions for the eradication of Burkholderia cepacia complex in people with cystic fibrosis &lt;BR&gt;Interventions for the managing liver disease in cystic fibrosis &lt;BR&gt;Interventions for the prevention and treatment of distal intestinal obstruction in cystic fibrosis &lt;BR&gt;Lung transplant for cystic fibrosis &lt;BR&gt;Medical and surgical interventions for chronic rhinosinusitis in cystic fibrosis &lt;BR&gt;Medical and surgical interventions for nasal polyps in cystic fibrosis &lt;BR&gt;Mutation-specific therapies for cystic fibrosis &lt;BR&gt;Neuraminidase inhibitors and other antiviral agents for influenza infection in people with cystic fibrosis &lt;BR&gt;Pancreatic enzymes for asymptomatic people with cystic fibrosis &lt;BR&gt;Pharmacological interventions for depression in cystic fibrosis &lt;BR&gt;Pneumococcal vaccines for cystic fibrosis &lt;BR&gt;Postural therapies for cystic fibrosis &lt;BR&gt;Quorum sensing inhibitors in CF &lt;BR&gt;Silastic and other infusion devices for intravenous drug therapy in cystic fibrosis &lt;BR&gt;Thiol derivatives for gastro-intestinal obstruction in cystic fibrosis &lt;BR&gt;Treatment for urinary incontinence in cystic fibrosis &lt;BR&gt;Treatment of chronic pulmonary infection with sensitive or resistant strains of Staphylococcus aureus in CF &lt;BR&gt;Vitamin E for cystic fibrosis &lt;BR&gt;Vitamin K supplementation for cystic fibrosis &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;B&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;&lt;/B&gt;
&lt;P align=center&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311643</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311643]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Cystic Fibrosis and Genetics</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>Respiratory specialist collection</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Cystic Fibrosis and Genetics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;B&gt;by Dr Denise Williams, Consultant Clinical Geneticist, Birmingham Women's NHS Foundation Trust and Clinical Lead NHS Evidence - genetics&lt;/B&gt; 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;What is cystic fibrosis?&lt;/B&gt; 
&lt;P&gt;Cystic fibrosis (CF) is an inherited condition of the exocrine glands and usually presents in early childhood. It is a multi-system disorder commonly affecting the respiratory system, the pancreas and reproductive systems, resulting in failure to thrive, chronic respiratory infections and impaired pancreatic function as a consequence of the production of abnormally thick mucus by the affected glands. Newborns may present with meconium ileus. Most men with cystic fibrosis are infertile as a result of azoospermia caused by absent, atrophic or fibrotic vas deferens (congenital absence of the vas deferens, CBAVD) and indeed some men with CABVD and known mutations in the cystic fibrosis gene are without pulmonary or gastrointestinal symptoms.&lt;B&gt;&lt;A href="#1"&gt;[1,2]&lt;/A&gt;&lt;/B&gt; Reduced fertility although less common, is also seen in adult females. 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;How common is cystic fibrosis? &lt;/B&gt;
&lt;P&gt;CF is one of the most common genetic diseases, affecting approximately 1 in 2000 to 1 in 3000 newborns within the Caucasian population of North Europe. This gives a carrier frequency of 1 in 22 to 1 in 27.&lt;B&gt;&lt;A href="#3"&gt;[3]&lt;/A&gt;&lt;/B&gt; The condition is much less common in other ethnic groups. 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;What is the inheritance of cystic fibrosis and why does it occur?&lt;/B&gt; 
&lt;P&gt;CF is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) on chromosome 7q31 – 32 . An individual with CF has disease-causing mutations in both copies of the CFTR gene, causing either total loss, or severe reduction, of the function of the CFTR protein. An individual with CF will have inherited one mutated CFTR gene from each parent. In addition to the mutated CFTR gene, the parents will have one normal copy of the gene and will typically not have any clinical manifestations of the condition. They are said to be CF carriers. 
&lt;P&gt;The CFTR gene is the only gene known to cause cystic fibrosis. More than 1000 mutations have been identified, the commonest in the white North European population is known as ?F508, technically now known as C.1521_1523 delCTT:p Phe 508 del. Within this ethnic group, this accounts for about 76% of mutations. The majority of the remaining mutations are individually rare, but their frequency varies between different ethnic groups. Routine molecular genetic testing, using commercial kits is currently able to identify 85 – 90% of known mutations. Testing for the rare CFTR mutations which account for the remainder of cases of cystic fibrosis is available in designated NHS laboratories.&lt;B&gt;&lt;A href="#4"&gt;[4]&lt;/A&gt;&lt;/B&gt; 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Genetic counselling&lt;/B&gt; 
&lt;P&gt;Genetic counselling is the process by which patients or their relatives, at risk of an inherited disorder, are advised of the consequences and nature of the disorder, the probability of developing it, and the options available to them in the management of the disorder and in future reproductive plans. 
&lt;P&gt;Genetic counselling should be offered to all couples who have had a child with cystic fibrosis as the risk of a further affected child is 1 in 4. Genetic counselling is straightforward when both mutations are identified, but much more complicated when one partner has a known mutation and the other is negative on routine testing, or when neither mutation is identified despite a confirmed diagnosis of cystic fibrosis in the index case. Once mutations are identified in an affected family member, carrier testing for the extended family and accurate prenatal diagnosis (see below), can be offered. 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Cystic fibrosis and prenatal testing&lt;/B&gt; 
&lt;P&gt;High-risk pregnancies: For couples with a child affected by cystic fibrosis and therefore known to be at 1 in 4 risk of having a further affected child, providing the causative mutations are known then accurate prenatal diagnosis, either by chorionic villus sampling or amniocentesis, can be offered. Even when the specific mutations have not been identified in a family, prenatal diagnosis is usually possible, but the patients must already be known to their local genetics service so that appropriate DNA studies have already been undertaken. Alternatives to antenatal tests include preimplantation genetic diagnosis, artificial insemination using donor sperm and artificial insemination using egg donation. Each of these options is difficult and needs careful discussion with the couple by their local clinical genetics service and specialist fertility centres. 
&lt;P&gt;Low-risk pregnancies: The presence of certain “soft markers”, such as echogenic bowel, on detailed fetal anomaly scans, is associated with an increased risk of cystic fibrosis. In this situation, genetic counselling, followed by CFTR molecular genetic testing of the parents and possibly the fetus should be offered. The results can be used to calculate the overall risk of the fetus being affected by cystic fibrosis.&lt;B&gt;&lt;A href="#5"&gt;[5,6]&lt;/A&gt;&lt;/B&gt; 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Cystic fibrosis and newborn screening&lt;/B&gt; 
&lt;P&gt;Early diagnosis, treatment and management of cystic fibrosis through a network of specialist centres, greatly influences the outcome and quality of life for affected individuals.&lt;B&gt;&lt;A href="#7"&gt;[7]&lt;/A&gt;&lt;/B&gt; In order to improve rates of early diagnosis a programme to screen all newborn babies was introduced in the UK in 2004&lt;B&gt;&lt;A href="#8"&gt;[8]&lt;/A&gt;&lt;/B&gt; and this is now fully implemented. The screening test is offered within the first week of life as part of the 'Guthrie test' and is based upon the measurement of immunoreactive trypsin (IRT) on the blood spot. If the IRT levels are elevated, then a combination of a second IRT test and CFTR analysis for the common mutations is undertaken. This screening programme now means that most, but not all, children with CF will be diagnosed shortly after birth and couples need to be counselled carefully about what their babies results mean. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%"&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;References&lt;/B&gt; 
&lt;P&gt;&lt;A name=1&gt;&lt;/A&gt;1. De Braekeleer M, Férec C. Mutations in the cystic fibrosis gene in men with congenital bilateral absence of the vas deferens. Mol Hum Reprod. 1996; 2: 669 – 77 [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9239681" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=2&gt;&lt;/A&gt;2. Dork T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Bohm I, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, Pander HJ, Sperling H, Ratjen F, Passarge E, Schmidtke J, Stuhrmann M. Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet. 1997; 100: 365–77. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9272157" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=3&gt;&lt;/A&gt;3. Brock DJ, Gilfillan A, Holloway S. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. Clin Genet. 1998; 53: 47–9. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9550361" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=4&gt;&lt;/A&gt;4. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, McGinnis MJ, Prior TW, Popovich BW, Watson MS, Palomaki GE. Standards and guidelines for CFTR mutation testing. Genet Med. 2002; 4: 379–91. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12394352" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=5&gt;&lt;/A&gt;5. Bosco AF, Norton ME, Lieberman E. Predicting the risk of cystic fibrosis with echogenic fetal bowel and one cystic fibrosis mutation. Obstet Gynecol. 1999; 94: 1020–3. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10576193" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=6&gt;&lt;/A&gt;6. Hodge SE, Lebo RV, Yesley AR, Cheney SM, Angle H, Milunsky J. Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: avoiding pitfalls in the risk calculations. Am J Med Genet. 1999; 82: 329–35. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10051167" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=7&gt;&lt;/A&gt;7. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr. 2006; 149: 362–6. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16939748" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] 
&lt;P&gt;&lt;A name=8&gt;&lt;/A&gt;8. Lagoe E, Labella S, Arnold G, Rowley PT. Cystic fibrosis newborn screening: a pilot study to maximize carrier screening. Genet Test. 2005; 9: 255–60. [&lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16225405" target="_blank"&gt;PubMed&lt;/A&gt;&lt;/B&gt;] &lt;/P&gt;&lt;B&gt;
&lt;P align=center&gt;&lt;B&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/A&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;&lt;/B&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311628</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311628]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Home Page</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Welcome to the first Annual Evidence Update on Cystic Fibrosis produced by NHS Evidence – respiratory, published on 11 May 2009. The Annual Evidence Update presents the latest systematic reviews and guidelines in Cystic Fibrosis since the beginning of 2005. There are a number of invited commentaries from experts in the field, also featuring extensive bibliographies.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Contents:&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;Invited Commentaries:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="nelh:311641:0" name=internalLink&gt;&lt;A href="nelh:311641:1" name=internalLink&gt;Major publications for cystic fibrosis in recent years&lt;BR&gt;&lt;/A&gt;- by Dr Jim Littlewood, Chairman of Cystic Fibrosis Trust&lt;A href="nelh:311640:1" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311640:1" name=internalLink&gt;&lt;A href="nelh:311640:1" name=internalLink&gt;Major Cochrane reviews&lt;/A&gt;&lt;BR&gt;- by Tracey Remmington and Nicki Jahne, Cochrane Cystic Fibrosis and Genetics Disorders Group&lt;A href="nelh:311641:1" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311642:1" name=internalLink&gt;&lt;A href="nelh:311642:0" name=internalLink&gt;Physiotherapy&lt;/A&gt;&lt;BR&gt;- by Sammani Prasad, Cystic Fibrosis Unit, Great Ormond Street Hospital for Children NHS Trust&lt;A href="nelh:311642:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311643:0" name=internalLink&gt;Cystic Fibrosis andGenetics&lt;/A&gt;&lt;BR&gt;- by Dr Denise Williams, Consultant Clinical Geneticist, Birmingham Women's NHS Foundation Trust and Clinical Lead NHS Evidence - genetics&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;A href="nelh:311638:1" name=internalLink&gt;Annual Evidence Update&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:311639:0" name=internalLink&gt;Cochrane protocols and vacant titles&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:311631:0" name=internalLink&gt;Methodology&lt;/A&gt;&lt;A href="nelh:311638:1" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;/A&gt;&lt;A href="nelh:314091:0" name=internalLink&gt;Supporting Resources&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311640</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311640]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Major Cochrane Reviews</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Major Cochrane Reviews&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;by Tracey Remmington and Nicki Jahne, Cochrane Cystic Fibrosis and Genetic Disorders Group&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The Cochrane Cystic Fibrosis &amp;amp; Genetic Disorders Group has been producing systematic reviews of interventions for managing cystic fibrosis since 1995. We currently have 45 cystic fibrosis reviews published in The Cochrane Library. These reviews have had a great impact on current clinical practice and care of those with cystic fibrosis; some of the most significant are highlighted below. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Dornase alfa for cystic fibrosis&lt;/B&gt;&lt;BR&gt;The current published review highlights evidence that dornase alfa improves lung function up to one month and, in one trial, also at six months. No serious adverse effects were reported, only minor ones such as rash and change in voice. It's likely that further trials comparing daily dornase alfa with other regimens, e.g. alternate day dornase alfa or other mucolytics, will be important in the future and an update of this review is due to be published later in 2009. This review has been cited in the latest CFF guidelines&lt;A href="#1"&gt;[1]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Nebulised hypertonic saline for cystic fibrosis &lt;/B&gt;&lt;BR&gt;This review, including 12 trials, was updated early in 2009. It found that 10 ml of saline at 3% to 7% concentration, twice-a-day, helped clear mucus without major adverse effects. Treatment after 48 weeks with hypertonic saline at 7% inhaled twice per day reduced episodes of chest infection and was linked to improved lung function, improved quality of life and better attendance at school or work. However, it had a limited effect on improving lung function. This review has been cited in the latest CFF guidelines&lt;A href="#1"&gt;[1]&lt;/A&gt; and the ERS report on pulmonary disease in children and adults&lt;A href="#2"&gt;[2]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis&lt;/B&gt;&lt;BR&gt;This review (updated 2009) includes twice as many participants as the original published review and found evidence supporting the use of high-dose non-steroidal anti-inflammatory drugs, most notably ibuprofen, to slow the progression of lung damage in people with cystic fibrosis, especially in younger people. Long-term safety data are limited; however, there are sufficient data to recommend that NSAIDs be temporarily discontinued during administration of intravenous aminoglycosides or other agents toxic to the kidneys. This review has been cited in the latest CFF guidelines&lt;A href="#1"&gt;[1]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Inhaled corticosteroids for cystic fibrosis&lt;/B&gt;&lt;BR&gt;The original published review did not find enough evidence of either benefit or harm and led to a randomised controlled trial to test the feasibility and safety of withdrawal of inhaled corticosteroids in people with cystic fibrosis already taking inhaled corticosteroids (CF WISE Study)&lt;A href="#3"&gt;[3]&lt;/A&gt;. The results from this study are included in the updated review (2009). The 13 clinical trials in the review failed to prove that inhaled corticosteroids reduce inflammation and one trial has shown that they can slow down children's growth when used in high doses. Furthermore it was shown that under close supervision of the cystic fibrosis team, it may be safe for people who have been taking inhaled corticosteroids for a while to stop doing so. This review has been cited in the latest CFF guidelines&lt;A href="#1"&gt;[1]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Once vs 3 times daily aminoglycosides&lt;/B&gt;&lt;BR&gt;The review highlighted a lack of evidence in this area and a trial was undertaken&lt;A href="#4"&gt;[4]&lt;/A&gt;, the results of which have now been incorporated in the review. All trials compared once-a-day dosing with three times-a-day dosing. The review found that giving the antibiotics once per day was just as good at treating lung infections in people with cystic fibrosis as the alternative treatment. Results suggest once daily treatment is less toxic to the kidneys in children, but may not be in adults. There were no differences between treatments for other outcomes. While once-daily treatment can be just as effective and more convenient than three-times daily treatment, it was recommended that further studies look at the long-term safety of this treatment regimen. This review has had a major impact on clinical practice and been widely cited in such documents as the CF Trust report on antibiotic treatment in CF&lt;A href="#5"&gt;[5]&lt;/A&gt; and the ERS report on pulmonary disease in children and adults&lt;A href="#2"&gt;[2]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;References&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;&lt;A name=1&gt;&lt;/A&gt;1. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel Jr. PJ, Willey-Courand DB, Bujan, J, et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007. 176 (10); 957-69. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17761616" target="_blank"&gt;&lt;STRONG&gt;[PubMed]&lt;/STRONG&gt;&lt;/A&gt; &lt;A name=2&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;2. European Respiratory Society. Respiratory Medicines for Children: Current Evidence, Unlicensed Use and Research Priorities. Report of a European Respiratory Society Task Force on Pulmonary Disease Seen in Children and Adults. Editors: Alan Smyth, Peter Merkus. &lt;A name=3&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;3. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, Elborn JS; CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1356-62. Epub 2006 Mar 23. &lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16556691" target="_blank"&gt;&lt;STRONG&gt;[PubMed] &lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;4. Smyth A, Tan K H-V, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once vs. three times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet 2005; 365 (9459):573-8. &lt;STRONG&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15708100" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/STRONG&gt; &lt;A name=5&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;5. Antibiotic Treatment for Cystic Fibrosis - Report on the UK Cystic Fibrosis Trust Antibiotic Group (Third Edition, In Press, expected early 2009). &lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;B&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;&lt;B&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P align=center&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311641</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311641]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Major publications for CF in recent years</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Major publications for CF in recent years&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;by Dr Jim Littlewood, Chairman - Cystic Fibrosis Trust&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There have been a number of significant changes in management and new treatments. Guidelines, Standards, Consensus Documents and Cochrane Systematic Reviews now provide a formidable source of information; the internet has made the information readily available for professionals and patients. &lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;General care of people with CF&lt;/B&gt;&lt;BR&gt;All agree people with CF should have some contact with a Specialist CF Centre – for adults for all their care and children for either full or shared care [&lt;A href="#1"&gt;1,2&lt;/A&gt;]. Appropriate immunisation recommendations have been agreed [&lt;A href="#3"&gt;3&lt;/A&gt;]. Mutation analysis and antenatal diagnosis are now available and the entitlement of high risk individuals [&lt;A href="#4"&gt;4,5&lt;/A&gt;] as are detailed guidelines for management of pregnancy in women with CF [&lt;A href="#6"&gt;6&lt;/A&gt;]. Neonatal screening is country wide in UK since 2007 and policies for screening [&lt;A href="#7"&gt;7&lt;/A&gt;], early management [&lt;A href="#8"&gt;8&lt;/A&gt;] and for situations where the diagnosis is in doubt [&lt;A href="#9"&gt;9&lt;/A&gt;] are available. Criteria for diagnosis [&lt;A href="#10"&gt;10&lt;/A&gt;] have been revised to include newborns [&lt;A href="#11"&gt;11&lt;/A&gt;] and atypical patients [&lt;A href="#12"&gt;12&lt;/A&gt;]. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Respiratory Tract&lt;/B&gt;&lt;BR&gt;Clinic and ward routines require a strict infection control policy and appropriate patient segregation according to microbiological status [&lt;A href="#13"&gt;13,14&lt;/A&gt;] with strict segregation of patients infected with Burkholderia cepacia complex [&lt;A href="#15"&gt;15&lt;/A&gt;], also for those infected with so-called ‘highly transmissible’ strains of Pseudomonas aeruginosa [&lt;A href="#16"&gt;16-19&lt;/A&gt;]. There is evidence that cross-infection with P. aeruginosa in people with CF is a common occurrence [&lt;A href="#20"&gt;20,21&lt;/A&gt;]. Also MRSA is a problem for some [&lt;A href="#22"&gt;22&lt;/A&gt;] &lt;/P&gt;
&lt;P&gt;Physiotherapy remains an established part of treatment [&lt;A href="#23"&gt;23&lt;/A&gt;] and was reviewed recently [&lt;A href="#24"&gt;24,25&lt;/A&gt;]. The Vest, so popular in North America is still little used in the UK but comparable in effect with standard techniques [&lt;A href="#26"&gt;26&lt;/A&gt;]. The need for daily physiotherapy in healthy CF infants is not agreed [&lt;A href="#27"&gt;27&lt;/A&gt;] although most would avoid the head down position [&lt;A href="#28"&gt;28&lt;/A&gt;]. &lt;/P&gt;
&lt;P&gt;Antibiotics remain the mainstay of treatment. Routine use of prophylactic anti-staphylococcal antibiotics (flucloxacillin) for the first 2 years is recommended in the UK [&lt;A href="#29"&gt;29,&lt;/A&gt;&lt;A href="#37"&gt;37,38&lt;/A&gt;]. Nebulised antibiotics for early eradication treatment of Pseudomonas aeruginosa is now routine practice in European clinics [&lt;A href="#30"&gt;30&lt;/A&gt;] recently with more evidence to support the practice from N. America [&lt;A href="#31"&gt;31-33&lt;/A&gt;]. Nebulised antibiotics are also used for most patients with chronic infection [&lt;A href="#34"&gt;34&lt;/A&gt;] with courses of two intravenous antibiotics for exacerbations either in hospital or at home [&lt;A href="#35"&gt;35-38&lt;/A&gt;]. A special preparation of tobramycin for inhalation (TOBI) became available in the Nineties [&lt;A href="#39"&gt;39&lt;/A&gt;]. Long term azithromycin is used by many patients with chronic P. aeruginosa infection, possibly for its anti-inflammatory properties [&lt;A href="#40"&gt;40&lt;/A&gt;] and of proven clinical benefit [&lt;A href="#41"&gt;41,42&lt;/A&gt;]. &lt;/P&gt;
&lt;P&gt;Recombinant human DNase (Pulmozyme) was the first really effective mucolytic, [&lt;A href="#43"&gt;43,44&lt;/A&gt;] and now used by many patients [&lt;A href="#34"&gt;34&lt;/A&gt;] – even some with mild chest involvement [&lt;A href="#45"&gt;45&lt;/A&gt;]. Inhaled hypertonic saline was confirmed to be of significant benefit [&lt;A href="#46"&gt;46,&lt;/A&gt;&lt;A href="#34"&gt;34&lt;/A&gt;]. Bronchodilators remain of proven benefit [&lt;A href="#47"&gt;47,&lt;/A&gt;&lt;A href="#34"&gt;34&lt;/A&gt;]. &lt;/P&gt;
&lt;P&gt;Existing treatments were improved and revaluated – once daily intravenous tobramycin replaced three-times daily dosing [&lt;A href="#48"&gt;48&lt;/A&gt;]. Inhaled steroids, although undoubtedly helpful for some, were used more sparingly when it was shown that many patients were deriving no benefit [&lt;A href="#49"&gt;49&lt;/A&gt;]. Ibuprofen had been the subject of a large CF Foundation trial in 1995 [&lt;A href="#50"&gt;50&lt;/A&gt;] but continued to remained unpopular. &lt;/P&gt;
&lt;P&gt;Organ transplantation, particularly double lung transplantation for people with CF is well established [&lt;A href="#51"&gt;51&lt;/A&gt;] but there is still a chronic lack of donor organs. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Gastroenterology and Nutrition&lt;/B&gt;&lt;BR&gt;There are recent reviews of classification and measurement of the nutritional state [&lt;A href="#52"&gt;52,53&lt;/A&gt;] and general management of nutrition including vitamin supplementation, and more invasive measures such as enteral feeding [&lt;A href="#54"&gt;54-57&lt;/A&gt;]. There are recent detailed reviews of the treatment of malabsorption [&lt;A href="#58"&gt;58&lt;/A&gt;], also in younger patients [&lt;A href="#59"&gt;59&lt;/A&gt;]. In the early Nineties the new high strength pancreatic enzymes were increasingly used and a rare complication, fibrosing colonopathy was observed first in Liverpool [&lt;A href="#60"&gt;60&lt;/A&gt;]. Fortunately this disappeared following advice from the Committee on the Safety of Medicines to use equivalent of not more than 10,000 IU /kg/day of lipase [&lt;A href="#61"&gt;61&lt;/A&gt;] and the use of only Creon preparations. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Other &lt;/B&gt;&lt;BR&gt;With increasing survival, problems related to CF included diabetes mellitus [&lt;A href="#62"&gt;62,63&lt;/A&gt;], liver disease [&lt;A href="#64"&gt;64&lt;/A&gt;] for which ursodeoxycholic acid has proved a useful treatment [&lt;A href="#65"&gt;65&lt;/A&gt;] as has liver transplantation [&lt;A href="#66"&gt;66&lt;/A&gt;]. Osteoporosis became more common with increasing age [&lt;A href="#67"&gt;67&lt;/A&gt;]. Pregnancy [&lt;A href="#6"&gt;6&lt;/A&gt;] and male infertility [&lt;A href="#68"&gt;68&lt;/A&gt;] were increasing challenges. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Overall reviews&lt;/B&gt;&lt;BR&gt;There are concise, excellent reviews of the years 2007 [&lt;A href="#69"&gt;69&lt;/A&gt;] and 2009 [&lt;A href="#70"&gt;70&lt;/A&gt;] that can be recommended.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR align=center width="75%" SIZE=2&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;B&gt;References:&lt;/B&gt;&lt;BR&gt;1. &lt;A name=1&gt;&lt;/A&gt;Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK The CF Trust Clinical Standards and Accreditation Group. London. Cystic Fibrosis Trust, May 2001. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_3000Standards_of_Care.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;2. &lt;A name=2&gt;&lt;/A&gt;Kerem E, Conway S, Elborn S, Heijerman H. For the Consensus Committee. Standards of care for patients with cystic fibrosis: A European consensus. J Cyst Fibros 2005; 4:7-26. &lt;B&gt;&lt;A href="http://www.elsevier.com/framework_products/promis_misc/2005.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;3. &lt;A name=3&gt;&lt;/A&gt;Malfroot A, Adam G, Coif O, Doring G, Knoop C, Lang AB, et al. for the ECFS Vaccination Group. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4:77-87. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15978534" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;4. &lt;A name=4&gt;&lt;/A&gt;Castellani C, Cuppens H, Macek Jr M, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008; 7:179-196. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18456578" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;5. &lt;A name=5&gt;&lt;/A&gt;Dequeker E, Stuhrmann M, Morris MA, Casals T, Castellani C, Claustres M, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendations. Eur J Hun Genet 2009; 17:51-65. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18685558" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;6. &lt;A name=6&gt;&lt;/A&gt;Edenborough FP, Borgo G, Knoop C, Lannefors L, Mackenzie WE, Madge S, et al. Guidelines for the management of pregnancy in women with cystic fibrosis. J Cyst Fibros 2008: S2-S32. &lt;B&gt;&lt;A href="http://www.sciencedirect.com/science?_ob=PublicationURL&amp;amp;_tockey=%23TOC%237268%232008%23999929999.8998%23677240%23FLA%23&amp;amp;_cdi=7268&amp;amp;_pubType=J&amp;amp;_auth=y&amp;amp;_acct=C000050221&amp;amp;_version=1&amp;amp;_urlVersion=0&amp;amp;_userid=10&amp;amp;md5=27f7934bc8d3a9335a414ac71614790b" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;7. &lt;A name=7&gt;&lt;/A&gt;Castellani C, Southern KW, Brownlee K, Dankert-Roelse J, Duff A, Farrell M, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009; In press. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19246252" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;8. &lt;A name=8&gt;&lt;/A&gt;Mayell SJ, Sermet I, Southern KW and the ECFS Consensus Group. Guidelines on early (first year of life) management of infants identified with cystic fibrosis identified by newborn screening. J Cyst Fibros 2009. In press. &lt;/P&gt;
&lt;P&gt;9. &lt;A name=9&gt;&lt;/A&gt;Mayell SJ, Munck A, Craig JV, Sermet I, Brownlee KG, Schwarz MJ, et al. European Cystic Fibrosis Society Working Group. A European consensus for evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009; 8:71-78. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18957277" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;10. &lt;A name=10&gt;&lt;/A&gt;Rosenstein BJ, Cutting GR for the Cystic Fibrosis Consensus Panel. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132:589- 595. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9580754" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;11. &lt;A name=11&gt;&lt;/A&gt;Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153:S4-S14. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18639722" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;12. &lt;A name=12&gt;&lt;/A&gt;De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, et al. Diagnostic Working Group. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61:627-635. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16384879" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;13. &lt;A name=13&gt;&lt;/A&gt;Saiman L, Macdonald N, Burns JL, Hoiby N, Speert DP, Weber D. Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am J Infect Contr 2000; 28:381-385. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11029140" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;14. &lt;A name=14&gt;&lt;/A&gt;Zhou J, Garber E, Saiman L. Survey of infection control policies for patients with cystic fibrosis in the &lt;?xml:namespace prefix = st1 /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;United States&lt;/st1:place&gt;&lt;/st1:country-region&gt;. Am J Infect Contr 2008; 36:220 -222. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18371519" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;15. &lt;A name=15&gt;&lt;/A&gt;The Burkholderia cepacia Complex - Suggestions for Prevention and Infection Control. Cystic Fibrosis Trust Infection Control Group. Second edition. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, September 2004. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Burkholderia_cepacia_Sep_2004.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;16. &lt;A name=16&gt;&lt;/A&gt;Jones AM, Govan JR, Doherty CJ, Dodd ME, Isalska BJ, &lt;st1:place&gt;&lt;st1:City&gt;Stanbridge&lt;/st1:City&gt; &lt;st1:State&gt;TN&lt;/st1:State&gt;&lt;/st1:place&gt;, &lt;st1:place&gt;&lt;st1:City&gt;Webb&lt;/st1:City&gt; &lt;st1:State&gt;AK&lt;/st1:State&gt;&lt;/st1:place&gt;. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 2001; 358:557-558. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11520529" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;17. &lt;A name=17&gt;&lt;/A&gt;Jones AM, Dodd ME, Doherty CJ, Govan JR, &lt;st1:place&gt;&lt;st1:City&gt;Webb&lt;/st1:City&gt; &lt;st1:State&gt;AK&lt;/st1:State&gt;&lt;/st1:place&gt;. Increased treatment requirements of patients with cystic fibrosis who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002; 57:924-925. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12403871" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;18. &lt;A name=18&gt;&lt;/A&gt;McCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Walshaw MJ. Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 2001; 358:558-560. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11520530" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;19. &lt;A name=19&gt;&lt;/A&gt;2003 Robinson P, Carzino R, Armstrong D, Olinsky A. Pseudomonas cross-infection from cystic fibrosis patients to non-cystic fibrosis patients: implications for inpatient care of respiratory patients. J Clin Microbiol 2003; 41: 5741. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14662972" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;20. &lt;A name=20&gt;&lt;/A&gt;Pseudomonas aeruginosa infection in people with cystic fibrosis. Cystic Fibrosis Infection Control Group. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, November 2004. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_Pseudomonas_aeruginosa_Nov_04.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;21. &lt;A name=21&gt;&lt;/A&gt;Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in &lt;st1:country-region&gt;&lt;st1:place&gt;England&lt;/st1:place&gt;&lt;/st1:country-region&gt; and &lt;st1:country-region&gt;&lt;st1:place&gt;Wales&lt;/st1:place&gt;&lt;/st1:country-region&gt;. J Med Microbiol 2004; 53:609-615. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15184530" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;22. &lt;A name=22&gt;&lt;/A&gt;Methicillin–resistant Staphylococcus aureus (MRSA). Cystic Fibrosis Trust Infection Control Group. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, April 2008. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/MRSA_1st_Edition_Final_web.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;23. &lt;A name=23&gt;&lt;/A&gt;Clinical Guidelines for Physiotherapy Management of Cystic Fibrosis. Association of Chartered Physiotherapists in Cystic Fibrosis. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, January 2002. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_3400Physiotherapy.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;24. &lt;A name=24&gt;&lt;/A&gt;Dodd ME. Prasad SA. Physiotherapy management of cystic fibrosis. Chron Respir Dis 2005; 2:139-149. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16281437" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;25. &lt;A name=25&gt;&lt;/A&gt;Bradley JM, Moran FM, Elborn JS. Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Resp Med 2006; 100:191-201. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16412951" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;26. &lt;A name=26&gt;&lt;/A&gt;&lt;st1:City&gt;&lt;st1:place&gt;Warwick&lt;/st1:place&gt;&lt;/st1:City&gt; WJ. High-frequency chest compression. In: Button B, Mcllwaine M (Eds) Airway clearance Techniques Training Class. North American Cystic Fibrosis Conference, 2005. &lt;/P&gt;
&lt;P&gt;27. &lt;A name=27&gt;&lt;/A&gt;Prasad SA, Main E, Dodd ME. Association of Chartered Physiotherapists. Finding consensus on the physiotherapy management of asymptomatic infants with cystic fibrosis. Pediatr Pulmonol 2008; 43:236-244. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18214945" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;28. &lt;A name=28&gt;&lt;/A&gt;Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinsky. Chest physiotherapy, gastro-oesophageal reflux and arousal in infants with cystic fibrosis. Arch Dis Child 2004; 89:435-439. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15102635" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;29. &lt;A name=29&gt;&lt;/A&gt;Weaver LT, Green MG, Nicholson K, Mills J, Heeley ME, Kuzemko JA, et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994; 70:84-89. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8129449" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;30. &lt;A name=30&gt;&lt;/A&gt;Hansen CR, Pressler T, Hoiby N. Early eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7:523-530. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18693078" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;31. &lt;A name=31&gt;&lt;/A&gt;Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoyd KS, Shell R, et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001; 139:572-577. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11598606" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;32. &lt;A name=32&gt;&lt;/A&gt;Gibson RL, Emerson J, McNamara S Burns LL, Rosenfield M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Resp Crit Care Med 2003; 167:841-849. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12480612" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;33. &lt;A name=33&gt;&lt;/A&gt;Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42:610-623. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17534969" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;34. &lt;A name=34&gt;&lt;/A&gt;Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB ,et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Resp Crit Care Med 2007; 176:957-969. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17761616" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;35. &lt;A name=35&gt;&lt;/A&gt;Doring G, Conway SP, Heijerman HGH, Hodson ME, Hoiby N, Smyth A, Touw DJ, for the Consensus Committee. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European Consensus. Eur Respir J 2000; 16:749-767. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11106223" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;36. &lt;A name=36&gt;&lt;/A&gt;Doring G, Hoiby N, for Consensus Group. Early intervention and prevention of lung disease in cystic fibrosis. A European consensus. J Cyst Fibros 2004; 3:67-92. &lt;B&gt;&lt;A href="http://www.elsevier.com/framework_products/promis_misc/2004.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;37. &lt;A name=37&gt;&lt;/A&gt;Antibiotic Treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. Second edition. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, September 2002. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_3200Antibiotic_Treatment.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;38. &lt;A name=38&gt;&lt;/A&gt;Antibiotic Treatment for Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. Third Edition. Cystic Fibrosis Trust. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;, 2009. In press &lt;/P&gt;
&lt;P&gt;39. &lt;A name=39&gt;&lt;/A&gt;Ramsey BW, Pepe MS, Quann JM, Otto KL, &lt;st1:place&gt;&lt;st1:City&gt;Montgomery&lt;/st1:City&gt; &lt;st1:State&gt;AB&lt;/st1:State&gt;&lt;/st1:place&gt;, Williams-Warren J, et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Eng J Med 1999; 340:23-30. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9878641" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;40. &lt;A name=40&gt;&lt;/A&gt;Everard ML, Sly P, Brenan S, Ryan G. Macrolides antibiotics in diffuse panbronchiolitis and in cystic fibrosis. Eur Respir J 1997; 10:2926. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9493687" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;41. &lt;A name=41&gt;&lt;/A&gt;Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-784. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12383667" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;42. &lt;A name=42&gt;&lt;/A&gt;Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290:1749-1756. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14519709" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;43. &lt;A name=43&gt;&lt;/A&gt;Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase 1 reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci 1990; 87:9188-9192. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/2251263" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;44. &lt;A name=44&gt;&lt;/A&gt;Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637-642. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7503821" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;45. &lt;A name=45&gt;&lt;/A&gt;Quan JM, Tiddens HAWM, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, et al. Pulmozyme Early Intervention Trial Study Group. A two-year randomised placebo controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139:813-820. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11743506" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;46. &lt;A name=46&gt;&lt;/A&gt;Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. National Hypertonic Saline in Cystic Fibrosis Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Eng J Med 2006; 354:229-240. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16421364" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;47. &lt;A name=47&gt;&lt;/A&gt;Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Sys Rev 2005; 4:CD003428. &lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD003428.pub2" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;48. &lt;A name=48&gt;&lt;/A&gt;Smyth A, Tan KH, Hyman-Taylor P, Mulheran, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis – the TOPIC study: a randomised controlled trial. Lancet 2005; 365:373-378. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15708100" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;49. &lt;A name=49&gt;&lt;/A&gt;Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, &lt;st1:place&gt;&lt;st1:PlaceName&gt;Flather&lt;/st1:PlaceName&gt; &lt;st1:PlaceName&gt;M&lt;/st1:PlaceName&gt; &lt;st1:PlaceName&gt;et al.&lt;/st1:PlaceName&gt; &lt;st1:PlaceType&gt;Multicenter&lt;/st1:PlaceType&gt;&lt;/st1:place&gt; randomised controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Resp Crit Care Med 2006; 173:1356-1362. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16556691" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;50. &lt;A name=50&gt;&lt;/A&gt;Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high dose ibuprofen in patients with cystic fibrosis. N Eng J Med 1995; 332:848-854. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7503838" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;51. &lt;A name=51&gt;&lt;/A&gt;Corris PA. Lung transplantation for cystic fibrosis. Curr Opin Organ Tran 2008; 13:484-488. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19060530" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;52. &lt;A name=52&gt;&lt;/A&gt;Wiedemann B, Paul KD, Stern M, Wagner TO, Hirche TO. German CFQA Group. Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. Eur J Clin Nutr 2007; 61:759-68. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17213872" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;53. &lt;A name=53&gt;&lt;/A&gt;Lai HJ, Shoff SM. Classification of malnutrition in cystic fibrosis: implications for evaluating and benchmarking clinical practice performance. Am J Clin Nutr2008; 88:161-166. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18614737" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;54. &lt;A name=54&gt;&lt;/A&gt;Nutritional Management of Cystic Fibrosis. Report of the UK Cystic Fibrosis Trust Nutrition Working Group. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, April 2002. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C_3500Nutritional_Management.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt;(PDF) &lt;/P&gt;
&lt;P&gt;55. &lt;A name=55&gt;&lt;/A&gt;Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HGM, Roberecht E, Döring G. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002; 1: 67-91. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15463811" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;56. &lt;A name=56&gt;&lt;/A&gt;Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Clinical Practice Guidelines on Growth and Nutrition Subcommittee. Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108:832-839. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18442507" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;57. &lt;A name=57&gt;&lt;/A&gt;Conway SP. Morton A. Wolfe S. Enteral tube feeding for cystic fibrosis.[update of Cochrane Database Syst Rev. 2000;(2):CD001198; PMID: 10796753]. Cochrane Database of Systematic Reviews. (2):CD001198, 2008. &lt;B&gt;&lt;A href="http://dx.doi.org/10.1002/14651858.CD001198.pub2" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;58. &lt;A name=58&gt;&lt;/A&gt;Littlewood JM, Wolfe SP, Conway SP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol 2006; 41:35-49. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16288483" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;59. &lt;A name=59&gt;&lt;/A&gt;Munck A, Duhamel JF, Lamireau T, Le Luyer B, Le Tallec C, Bellon G, et al. Pancreatic enzyme replacement therapy for young cystic fibrosis patients. J Cyst Fibros 2009; 8:14-18. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18718819" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;60. &lt;A name=60&gt;&lt;/A&gt;Smyth RL, van Velzen D, &lt;st1:place&gt;&lt;st1:City&gt;Smyth&lt;/st1:City&gt; &lt;st1:State&gt;AR&lt;/st1:State&gt;&lt;/st1:place&gt;, Lloyd DA, Heaf DP. Strictures of the ascending colon in cystic fibrosis and high strength pancreatic enzymes. Lancet 1994; 343:85-86. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7903780" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;61. &lt;A name=61&gt;&lt;/A&gt;Littlewood JM. Update on intestinal strictures. J R Soc Med 1999; 92(Suppl 37):41-49. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10472252" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;62. &lt;A name=62&gt;&lt;/A&gt;Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and management. Pediatr Diabetes 2000; 1:41-48. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15016241" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;63. &lt;A name=63&gt;&lt;/A&gt;Management of cystic fibrosis related diabetes mellitus. Cystic Fibrosis Trust Diabetes Working Group. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, June 2004. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/diabetes.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;64. &lt;A name=64&gt;&lt;/A&gt;Sokol RJ, Durie PR for the CFF Hepatobiliary Disease Consensus Group. Recommendations for the management of liver and biliary disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 1999; 28(Suppl 1):S1-S13. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9934970" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;65. &lt;A name=65&gt;&lt;/A&gt;Colombo C, Battezatti PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double blind multicentre trial. Hepatology 1996; 23:1484-1490. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8675168" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;66. &lt;A name=66&gt;&lt;/A&gt;Melzi ML, Kelly DA, Colombo C, Jara P, Manzanares J, Colledan M, et al. EGSLTCF, European Liver Transplant Association (ELTA), European Cystic Fibrosis Society (ECFS). Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transplant International 2006; 19:726- 731. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16918533" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;67. &lt;A name=67&gt;&lt;/A&gt;Bone mineralisation in Cystic Fibrosis. Cystic Fibrosis Trust Bone Mineralisation Working Group. First Edition. &lt;st1:City&gt;&lt;st1:place&gt;London&lt;/st1:place&gt;&lt;/st1:City&gt;. Cystic Fibrosis Trust, February 2007. &lt;B&gt;&lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/Bone-Mineral-Booklet.pdf" target="_blank"&gt;[Full text]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;68. &lt;A name=68&gt;&lt;/A&gt;Hubert D, Patrat C, Guibert J, Thiounn N, Bienvenu T, Viot G, Jouannet P, Epelboin S. Results of assisted reproductive technique in men with cystic fibrosis. Hum Repro 2006; 21:1232-1236. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16431902" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;69. &lt;A name=69&gt;&lt;/A&gt;Accurso FJ. Update in Cystic Fibrosis 2007. Am J Respir Crit Care Med 2008; 177:1058-1061. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18460460" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P&gt;70. &lt;A name=70&gt;&lt;/A&gt;Ratjen F. Update in Cystic Fibrosis 2008. Am J Respir Crit Care Med 2009; 179:445-448. &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19264980" target="_blank"&gt;[PubMed]&lt;/A&gt;&lt;/B&gt; &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 6pt 0cm 0pt; LINE-HEIGHT: 150%"&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;B&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;&lt;B&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311631</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311631]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Methodology</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;The Annual Evidence Update(AEU) for Cystic Fibrosis uses the document &lt;A href="http://www.elsevier.com/framework_products/promis_misc/2005.pdf" target="_blank"&gt;Standards of care for patients with cystic fibrosis: a European consensus (2005)&lt;/A&gt; as the starting document. &lt;BR&gt;&lt;BR&gt;In line with this document the search period was defined to be 1 January 2005 till May 2009. The searches were carried out over the period 15 April - 17 April 2009. Systematic reviews published in English language were only included for the AEU 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The databases searched were PubMed, Medline(OVID), Embase(OVID), and the Cochrane Database of Systematic Reviews. The Internet search engines Google, Ask.com, Intute, Yahoo were searched for relevant charities, organisations and consortiums.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;The following search filters were used:&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;PubMed&lt;/STRONG&gt; – The online search filter for Systematic Reviews &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query/static/clinical.shtml" target="_blank"&gt;http://www.ncbi.nlm.nih.gov/entrez/query/static/clinical.shtml&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Medline&lt;/STRONG&gt; - The OVID filter from SIGN was used &lt;A href="http://www.sign.ac.uk/methodology/filters.html#systematic" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html#systematic&lt;/A&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;1. Meta-Analysis as Topic/ &lt;BR&gt;2. meta analy$.tw. &lt;BR&gt;3. metaanaly$.tw. &lt;BR&gt;4. Meta-Analysis/ &lt;BR&gt;5. (systematic adj (review$1 or overview$1)).tw. &lt;BR&gt;6. exp Review Literature as Topic/ &lt;BR&gt;7. or/1-6 &lt;BR&gt;8. cochrane.ab. &lt;BR&gt;9. embase.ab. &lt;BR&gt;10. (psychlit or psyclit).ab. &lt;BR&gt;11. (psychinfo or psycinfo).ab. &lt;BR&gt;12. (cinahl or cinhal).ab. &lt;BR&gt;13. science citation index.ab. &lt;BR&gt;14. bids.ab. &lt;BR&gt;15. cancerlit.ab. &lt;BR&gt;16. or/8-15 &lt;BR&gt;17. reference list$.ab. &lt;BR&gt;18. bibliograph$.ab. &lt;BR&gt;19. hand-search$.ab. &lt;BR&gt;20. relevant journals.ab. &lt;BR&gt;21. manual search$.ab. &lt;BR&gt;22. or/17-21 &lt;BR&gt;23. selection criteria.ab. &lt;BR&gt;24. data extraction.ab. &lt;BR&gt;25. 23 or 24 &lt;BR&gt;26. Review/ &lt;BR&gt;27. 25 and 26 &lt;BR&gt;28. Comment/ &lt;BR&gt;29. Letter/ &lt;BR&gt;30. Editorial/ &lt;BR&gt;31. animal/ &lt;BR&gt;32. human/ &lt;BR&gt;33. 31 not (31 and 32) &lt;BR&gt;34. or/28-30,33 &lt;BR&gt;35. 7 or 16 or 22 or 27 &lt;BR&gt;36. 35 not 34 &lt;BR&gt;37. 36 and “cystic fibrosis”&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Embase&lt;/STRONG&gt; – The OVID filter from SIGN was used &lt;A href="http://www.sign.ac.uk/methodology/filters.html#systematic" target="_blank"&gt;http://www.sign.ac.uk/methodology/filters.html#systematic&lt;/A&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;1. exp Meta Analysis/ &lt;BR&gt;2. ((meta adj analy$) or metaanalys$).tw. &lt;BR&gt;3. (systematic adj (review$1 or overview$1)).tw. &lt;BR&gt;4. or/1-3 &lt;BR&gt;5. cancerlit.ab. &lt;BR&gt;6. cochrane.ab. &lt;BR&gt;7. embase.ab. &lt;BR&gt;8. (psychlit or psyclit).ab. &lt;BR&gt;9. (psychinfo or psycinfo).ab. &lt;BR&gt;10. (cinahl or cinhal).ab. &lt;BR&gt;11. science citation index.ab. &lt;BR&gt;12. bids.ab. &lt;BR&gt;13. or/5-12 &lt;BR&gt;14. reference lists.ab. &lt;BR&gt;15. bibliograph$.ab. &lt;BR&gt;16. hand-search$.ab. &lt;BR&gt;17. manual search$.ab. &lt;BR&gt;18. relevant journals.ab. &lt;BR&gt;19. or/14-18 &lt;BR&gt;20. data extraction.ab. &lt;BR&gt;21. selection criteria.ab. &lt;BR&gt;22. 20 or 21 &lt;BR&gt;23. review.pt. &lt;BR&gt;24. 22 and 23 &lt;BR&gt;25. letter.pt. &lt;BR&gt;26. editorial.pt. &lt;BR&gt;27. animal/ &lt;BR&gt;28. human/ &lt;BR&gt;29. 27 not (27 and 28) &lt;BR&gt;30. or/25-26,29 &lt;BR&gt;31. 4 or 13 or 19 or 24 &lt;BR&gt;32. 31 not 30 &lt;BR&gt;33. “cystic fibrosis” and 32&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;BR&gt;Limits for publication dates and English language were used across all databases.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Number of systematic reviews found:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;A total of 282 records were retrieved. Eliminating duplicates reduced this figure to 201. &lt;/P&gt;
&lt;P&gt;All citations found in the database searches were scanned by reading the titles and abstracts to identify potential systematic reviews relevant to cystic fibrosis. The final decision on whether to include a citation as being a valid systematic review of relevant to this Annual Evidence Update was taken by Dr Mark Everard, Clinical Lead for NHS Evidence – respiratory.&lt;/P&gt;
&lt;P&gt;A total of 73 references were included within this Annual Evidence Update.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;STRONG&gt;&lt;A href="nelh:311628:1" name=internalLink&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311642</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=311642]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis – Physiotherapy</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis – Physiotherapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;by S&amp;nbsp;Ammani Prasad, Cystic Fibrosis Unit, Great Ormond Street Hospital for Children NHS Trust&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Cystic fibrosis (CF) is the most frequent cause of suppurative lung disease in the younger Caucasian population. A depleted volume of the airway surface liquid (ASL) layer in the respiratory system leads to abnormal mucociliary clearance.[&lt;A href="#1"&gt;&lt;B&gt;1&lt;/B&gt;&lt;/A&gt;] A chronic cycle of infection and inflammation results in progressive suppurative bronchiectasis and lung damage. Although airway clearance continues to be an integral part of care, physical exercise, postural care and the need to address the unique complications which emerge as a result of improved longevity have significantly changed the nature of physiotherapy in CF. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Airway Clearance&lt;/B&gt; 
&lt;P&gt;&lt;B&gt;Is it effective?&lt;/B&gt;&lt;BR&gt;Despite several comparative studies of airway clearance techniques in CF, there continues to be a lack of robust evidence to support the long term benefits of intervention.[&lt;A href="#2"&gt;&lt;B&gt;2&lt;/B&gt;&lt;/A&gt;] A lack of evidence should however not necessarily be associated with a lack of benefit. Clinicians generally agree that airway clearance is likely to be beneficial in those with established respiratory disease.[&lt;A href="#3"&gt;&lt;B&gt;3&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;B&gt;Which technique?&lt;/B&gt;&lt;BR&gt;The physiological principles of airway clearance techniques have begun to be investigated in greater detail.[&lt;A href="#4"&gt;&lt;B&gt;4&lt;/B&gt;&lt;/A&gt;] Systematic reviews comparing the various airway clearance modalities have not identified a single technique as being superior to others.[&lt;A href="#5"&gt;&lt;B&gt;5-7&lt;/B&gt;&lt;/A&gt;] Some studies report a trend for patients to prefer therapies which are self administered.[&lt;A href="#7"&gt;&lt;B&gt;7,8&lt;/B&gt;&lt;/A&gt;] The performance of routine daily airway clearance require considerable time and can impose a significant burden on patients and families. Adherence to routine airway clearance continues to be reported as poor.[&lt;A href="#9"&gt;&lt;B&gt;9,10&lt;/B&gt;&lt;/A&gt;] The use of non-invasive ventilation as an adjunct to airway clearance may be useful in improving gas exchange during sleep in those with moderate to severe disease but its impact on disease progression remains unclear.[&lt;A href="#11"&gt;&lt;B&gt;11&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;B&gt;To tip or not to tip?&lt;/B&gt;&lt;BR&gt;The association of gasto-oesophageal reflux and postural drainage (PD) using a head down tipped position, particularly in babies with CF,[&lt;A href="#12"&gt;&lt;B&gt;12,13&lt;/B&gt;&lt;/A&gt;] has led to a significant change in practice internationally. Many centres now advocate only the use of modified PD (omitting a head down tip). The place of PD as a routine therapy has also been questioned in the absence of copious secretions, a situation no longer uncommon in the CF population. 
&lt;P&gt;&lt;B&gt;When should airway clearance be introduced?&lt;/B&gt;&lt;BR&gt;The primary aim is to prevent or delay the onset of bronchiectasis and lung damage. In infants, modified postural drainage and percussion remain widely used internationally but other techniques such as infant PEP and assisted AD along with physical activity have emerged as feasible alternatives. Newborn screening (NBS) for cystic fibrosis, now widely available internationally, has led to much earlier diagnosis and the emergence of a cohort of healthy infants who appear free of clinical symptoms and the role of routine airway clearance in “asymptomatic infants has recently been questioned.[&lt;A href="#14"&gt;&lt;B&gt;14&lt;/B&gt;&lt;/A&gt;] .There is however strong evidence for the presence of very early lung disease in terms of inflammation and infection,[&lt;A href="#15"&gt;&lt;B&gt;15&lt;/B&gt;&lt;/A&gt;] reduction in lung function[&lt;A href="#16"&gt;&lt;B&gt;16&lt;/B&gt;&lt;/A&gt;] and structural changes,[&lt;A href="#17"&gt;&lt;B&gt;17&lt;/B&gt;&lt;/A&gt;] even in “pre-symptomatic” infants. This issue continues to generate much debate internationally and opinions remain divided.[&lt;A href="#18"&gt;&lt;B&gt;18&lt;/B&gt;&lt;/A&gt;] Consensus methodology has been used by the Association of Chartered Physiotherapists in Cystic Fibrosis in the UK to develop guidelines for the physiotherapy management of asymptomatic infants with CF.[&lt;A href="#19"&gt;&lt;B&gt;19,20&lt;/B&gt;&lt;/A&gt;] A change in the traditional approach should not be interpreted as a withdrawal of physiotherapy from babies who are apparently well but as a new approach to intervention. 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Exercise&lt;/B&gt;&lt;BR&gt;The short and long term benefits of regular physical activity are well established and the importance of regular physical exercise as an essential part of the physiotherapy regimen is recognised. The effect of inspiratory muscle training in CF however remains unclear.[&lt;A href="#21"&gt;&lt;B&gt;21&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;B&gt;Habitual activity&lt;/B&gt;&lt;BR&gt;The measurement of habitual activity and its relationship to clinical status has also received attantion.[&lt;A href="#22"&gt;&lt;B&gt;22-24&lt;/B&gt;&lt;/A&gt;] A recent study reported no significant differences in habitual activity between prepubescent children with CF and controls,[&lt;A href="#24"&gt;&lt;B&gt;24&lt;/B&gt;&lt;/A&gt;] but pubescent children with moderate to severe disease were less active than controls. Gender differences were only apparent after the onset of puberty with boys being significantly more active than girls with the same degree of disease severity. 
&lt;P&gt;&lt;B&gt;Muscle Function&lt;/B&gt;&lt;BR&gt;Attention has also recently focussed on the quality of muscle in CF and whether there is a disease specific defect within the muscles.[&lt;A href="#25"&gt;&lt;B&gt;25,26&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Musculoskeletal Issues&lt;/B&gt; 
&lt;P&gt;&lt;B&gt;Low bone mineral density&lt;/B&gt;&lt;BR&gt;Low bone mineral density is a recognised problem in CF.[&lt;A href="#28"&gt;&lt;B&gt;28&lt;/B&gt;&lt;/A&gt;] Altered bone mineralisation is also reduced in children, particularly those with poor lung function ref Weight bearing exercises are thought to enhance bone accrual in healthy children and therefore it can be hypothesised that regular, weight-bearing exercise will significantly enhance bone accrual in healthy children. Very few studies have examined the potential for exercise to improve bone accrual in the CF population.[&lt;A href="#29"&gt;&lt;B&gt;29,30&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;B&gt;Posture&lt;/B&gt;&lt;BR&gt;The postural and respiratory musculature are inextricably linked. Altered respiratory mechanics due to an increased work of breathing, hyperinflation and coughing contribute to soft tissue tightening and muscle imbalance which in turn lead to postural abnormalities, pain and poor quality of life.[&lt;A href="#31"&gt;&lt;B&gt;31&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Urinary Incontinence&lt;/B&gt;&lt;BR&gt;Urinary incontinence is a well recognised problem in women with CF. More recently attention has been paid to its prevalence in young girls[&lt;A href="#32"&gt;&lt;B&gt;32,33&lt;/B&gt;&lt;/A&gt;]. In adults pelvic floor muscle exercises (PFME) have been reported as beneficial,[&lt;A href="#34"&gt;&lt;B&gt;34,35&lt;/B&gt;&lt;/A&gt;] particularly in terms of improving muscle endurance. Adding regular PFME to the physiotherapy regimen adds to the burden of treatment and long term adherence may well be poor. Paediatric as well as adult CF teams should be sensitive to the high prevalence of UI in the young female population. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;References:&lt;/B&gt; 
&lt;P&gt;&lt;A name=1&gt;&lt;/A&gt;1. Mall M, Boucher RC Pathogenesis of pulmonary disease in cystic fibrosis. In: Bush A, Alton EWF, Davies JC, Griesenback U, Jaffe A (Eds) Cystic Fibrosis in the 21st century Progress in Respiratory Research Karger, Basel 2006; 34:116-121 
&lt;P&gt;&lt;A name=2&gt;&lt;/A&gt;2. van der Schans CP, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No.: CD001401. DOI: 10.1002/14651858.CD001401.[&lt;A href="http://dx.doi.org/10.1002/14651858.CD001401" target="_blank"&gt;&lt;B&gt;Full text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=3&gt;&lt;/A&gt;3. Flume PA, Robinson K, O’Sullivan B, Finder JD&amp;lt; Vender FL, Willey-Courand D, White TB, Marshall BC &amp;amp; The Clinical Practice Guidelines Committee. Cystic Fibrosis Pulmonary Guidelines: Airway Clearance therapies. Resp Care 2009;54:522-537[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19327189" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=4&gt;&lt;/A&gt;4. McCarren B, Alison JA. Physiological effects of vibration in subjects with cystic fibrosis. European Respiratory Journal 2006; 27:1204-1209[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16455834" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=5&gt;&lt;/A&gt;5. Main E, Prasad SA, van der Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. The Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD002011. DOI: 10.1002/14651858.CD002011.pub2.[&lt;A href="http://dx.doi.org/10.1002/14651858.CD002011.pub2" target="_blank"&gt;&lt;B&gt;Full text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=6&gt;&lt;/A&gt;6. Elkins M, Jones A, van der Schans CP. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003147. DOI: 10.1002/14651858.CD003147.pub3.[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003147.pub3" target="_blank"&gt;&lt;B&gt;Full text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=7&gt;&lt;/A&gt;7. Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD006842. DOI: 10.1002/14651858.CD006842.pub2[&lt;A href="http://dx.doi.org/10.1002/14651858.CD006842.pub2" target="_blank"&gt;&lt;B&gt;Full text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=8&gt;&lt;/A&gt;8. Pryor JA. A comparison of five airway clearance techniques in the treatment of people with cystic fibrosis. Thesis submitted for the degree of Doctor of Philosophy, Imperial College London 2005 
&lt;P&gt;&lt;A name=9&gt;&lt;/A&gt;9. Bucks RS, Hawkins K, Skinner TC, Horn S, Seddon P, Horne R. Adherence to Treatment in Adolescents with Cystic Fibrosis: The Role of Illness Perceptions and Treatment Beliefs. J Pediatr Psychol 2009 [Epub ahead of print] [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19196850" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=10&gt;&lt;/A&gt;10. Arias Llorente RP, Bousoño García C, Díaz Martín JJ.Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008;7:359-67 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18304896" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=11&gt;&lt;/A&gt;11. Moran F, Bradley JM, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2007;4:CD002769 [&lt;A href="http://dx.doi.org/10.1002/14651858.CD002769.pub3" target="_blank"&gt;&lt;B&gt;Full text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=12&gt;&lt;/A&gt;12. Button BM, Heine RG, Catto-Smith AG, Olinsky A, Phelan PD, Ditchfield MR, Story I. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. Pediatr Pulmonol. 2003;35:208-13 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12567389" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=13&gt;&lt;/A&gt;13. Button BM, Heine RG, Catto-Smith AG, Phelan PD, Olinsky A. Chest physiotherapy, gastro-oesophageal reflux, and arousal in infants with cystic fibrosis. Arch Dis Child. 2004;89:435-9 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15102635" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=14&gt;&lt;/A&gt;14. Pryor JA, Main E, Agent P, Bradley JM. Physiotherapy. In: Bush A, Alton E, Griesenbach U, Jaffe A (Eds). Cystic Fibrosis in the 21st century Progress in Respiratory Research Karger, Basel 2006;301-309 
&lt;P&gt;&lt;A name=15&gt;&lt;/A&gt;15. Brennan S, Gangell C, Wainwright C, Sly PD. Disease surveillance using bronchoalveolar lavage. Paediatr Resp Rev 2009;9:151-159 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18694706" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=16&gt;&lt;/A&gt;16. Ranganathan S, Linnane B, Nolan G, Gangell G, Hall G. Early Detection of Lung Disease in Children with Cystic Fibrosis Using Lung Function. Paeditr Resp Rev 2008;9:160-167 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17121870" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=17&gt;&lt;/A&gt;17. Linnane B, Robinson P, Ranganathan S, Stick S, Murray C. Role of high-resolution computed tomography in the detection of early cystic fibrosis lung disease. Paeditr Resp Rev 2008;9:168-175 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18694708" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=18&gt;&lt;/A&gt;18. Prasad SA, Main E. Routine airway clearance in asymptomatic infants and babies with cystic fibrosis in the UK: obligatory or obsolete? Physical Therapy Reviews 2006;11:11-20 
&lt;P&gt;&lt;A name=19&gt;&lt;/A&gt;19. Prasad SA, Main E, Dodd ME. Finding consensus on the physiotherapy management of asymptomatic infants with cystic fibrosis. Pediatr Pulmonl 2008;43:236-244 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18214945" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=20&gt;&lt;/A&gt;20. Association of Chartered Physiotherapists in Cystic Fibrosis. Clinical guidance for the physiotherapy management of screened infants with Cystic fibrosis. ACPCF Physiotherapy Guidance Paper no. 4. [&lt;A href="http://www.interactivecsp.org.uk/uploads/documents/CompletedACPCFinfantguidelineOctober2008.pdf" target="_blank"&gt;&lt;B&gt;Full Text&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=21&gt;&lt;/A&gt;21. Reid WD, Geddes EL, O'Brien K, Brooks D, Crowe J. Effects of inspiratory muscle training in cystic fibrosis: a systematic review. Clin Rehabil. 2008;2:1003-1013 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18955432" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=22&gt;&lt;/A&gt;22. Wells GD, Wilkes DL, Schneiderman-Walker J, Elmi M, Tullis E, Lands LC, Ratjen F, Coates AL. Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis. Pediatr Pulmonol. 2008;43:345-53 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18306334" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=23&gt;&lt;/A&gt;23. Schneiderman-Walker J, Wilkes DL, Strug L, Lands LC, Pollock SL, Selvadurai HC, Hay J, Coates AL, Corey M. Sex differences in habitual physical activity and lung function decline in children with cystic fibrosis. J Pediatr. 2005;147:321-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16182669" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=24&gt;&lt;/A&gt;24. Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP. Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child 2004;89:928-933 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15383436" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=25&gt;&lt;/A&gt;25. Sahlberg M, Svantesson U, Magnusson Thomas E, Andersson BA, Saltin B, Strandvik B. Muscular strength after different types of training in physically active patients with cystic fibrosis.Scand J Med Sci Sports. 2008;18:756-764 [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Muscular%20strength%20after%20different%20types%20of%20training%20in%20physically%20active%20patients%20with%20cystic%20fibrosis" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=26&gt;&lt;/A&gt;26. Rosenthal M, Narang I, Edwards L, Bush A. Non-invasive assessment of exercise performance in children with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis: is there a CF specific muscle defect? Pediatr Pulmonol. 2009;44:222-230 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19206180" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=27&gt;&lt;/A&gt;27. Buntain HM, Greer RM, Schluter PJ, Wong JC, Batch JA, Potter JM, Lewindon PJ, Powell E, Wainwright CE, Bell SC. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax. 2004;59:149-155 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14760157" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=28&gt;&lt;/A&gt;28. Hind K, Truscott JG, Conway SP. Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis-related low bone mineral density? Exercise for bone health in children with cystic fibrosis. J Cyst Fibros 2008;7:270-276 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18378195" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=29&gt;&lt;/A&gt;29. Dodd JD, Barry SC, Barry RB, Cawood TJ, McKenna MJ, Gallagher CG. Bone mineral density in cystic fibrosis: benefit of exercise capacity. J Clin Densitom. 2008;11:537-42 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18619882" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=30&gt;&lt;/A&gt;30. Massery M Musculoskeletal and neuromuscular interventions: a physical approach to cystic fibrosis. J Royal Soc Med 2005;98 (Suppl 45):55-66 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16025768" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=31&gt;&lt;/A&gt;31. Blackwell K, Malone PS, Denny A, Connett G, Maddison J.The prevalence of stress urinary incontinence in patients with cystic fibrosis: an under-recognized problem. J Pediatr Urol. 2005;1:5-9 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18947528" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=32&gt;&lt;/A&gt;32. Prasad SA, Balfour-Lynn IM, Carr SB, Madge SL. A comparison of the prevalence of urinary incontinence in girls with cystic fibrosis, asthma and healthy controls. Pediatr Pulmonol 2006; 41:1065-1068 [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16988998" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=33&gt;&lt;/A&gt;33. McVean RJ, Orr A, Webb AK, Bradbury A, Kay L, Philips E, Dodd ME. Treatment of urinary incontinence in cystic fibrosis. J Cyst Fibros 2003;2:171-176 [&lt;A href="https://rmsadmin.library.nhs.uk/admin/wizards/articles/Treatment%20of%20urinary%20incontinence%20in%20cystic%20fibrosis" target="_blank"&gt;&lt;B&gt;PubMed&lt;/B&gt;&lt;/A&gt;] 
&lt;P&gt;&lt;A name=34&gt;&lt;/A&gt;34. Button BM, Sherburn M, Chase J, Stillman B, Wilson J. Effect of a three months physiotherapeutic intervention on incontinence in women with cystic fibrosis and COPD. Pediatr Pulmonol 2005:40 (Suppl 28):A369 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P align=center&gt;&lt;B&gt;&lt;A href="nelh:311628:0" name=internalLink&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>314091</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=314091]]&gt;</url>
    <title>2009 Annual Evidence Update on Cystic Fibrosis - Supporting Resources</title>
    <publicationDate>2009-05-11T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CYSTIC FIBROSIS,CHRONIC SUPPURATIVE DISEASES,2009 CF AEU]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2009 Annual Evidence Update on Cystic Fibrosis - Supporting Resources&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;B&gt;Cystic Fibrosis Trust&lt;BR&gt;&lt;/B&gt;The Cystic Fibrosis Trust is the UK's only national charity dedicated to all aspects of Cystic Fibrosis.&lt;BR&gt;&lt;A href="mailto:enquiries@cftrust.org.uk" target="_blank"&gt;enquiries@cftrust.org.uk&lt;/A&gt; &lt;BR&gt;&lt;A href="http://www.cftrust.org.uk/" target="_blank"&gt;http://www.cftrust.org.uk/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;European Cystic Fibrosis Society (ECFS) &lt;BR&gt;&lt;/B&gt;Mission Statement: The European Cystic Fibrosis Society (ECFS) aims to achieve the best possible treatment and the highest quality of life for the patient with cystic fibrosis by the development and distribution of knowledge in the field of cystic fibrosis. The ECFS provides an international forum on all aspects of CF with membership of the society open to all actively engaged in CF research or clinical care.&lt;BR&gt;&lt;A href="mailto:info@ecfs.eu" target="_blank"&gt;info@ecfs.eu&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.ecfs.eu/" target="_blank"&gt;http://www.ecfs.eu/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;British Thoracic Society&lt;BR&gt;&lt;/B&gt;Our objective is to improve the standards of care of people who have respiratory diseases.&lt;BR&gt;&lt;A href="mailto:bts@brit-thoracic.org.uk" target="_blank"&gt;bts@brit-thoracic.org.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;http://www.brit-thoracic.org.uk/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;European Respiratory Society&lt;BR&gt;&lt;/B&gt;Aims to alleviate suffering from respiratory disease and to promote lung health through research, knowledge sharing, medical and public education. &lt;BR&gt;&lt;A href="mailto:info@ersnet.org" target="_blank"&gt;info@ersnet.org&lt;/A&gt;&lt;BR&gt;&lt;A href="http://dev.ersnet.org/10-overview.htm" target="_blank"&gt;http://dev.ersnet.org/10-overview.htm&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Cystic Fibrosis Nurses: the international specialist group&lt;BR&gt;&lt;/B&gt;&lt;A href="http://www.cfnurses.net/" target="_blank"&gt;http://www.cfnurses.net/&lt;/A&gt;&lt;BR&gt;&lt;A href="mailto:valerie.hall@belfasttrust.hscni.net" target="_blank"&gt;valerie.hall@belfasttrust.hscni.net&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Association of Respiratory Nurse Specialists&lt;BR&gt;&lt;/B&gt;Aims to promote a higher level of respiratory nursing practice through leadership, education and professional development and to influence the direction of respiratory nursing care.&lt;BR&gt;&lt;A href="mailto:info@arns.co.uk" target="_blank"&gt;info@arns.co.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.arns.co.uk/" target="_blank"&gt;http://www.arns.co.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;Cochrane Cystic Fibrosis and Genetic Disorders Group&lt;BR&gt;&lt;/B&gt;The Cochrane Cystic Fibrosis &amp;amp; Genetic Disorders Review Group comprises an international network of health care professionals, researchers and consumers preparing, maintaining, and disseminating systematic reviews of randomised control trials in the treatment of cystic fibrosis and other genetic disorders.&lt;BR&gt;&lt;A href="mailto:traceyr@liverpool.ac.uk" target="_blank"&gt;traceyr@liverpool.ac.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.cfgd.cochrane.org/en/index.html" target="_blank"&gt;http://www.cfgd.cochrane.org/en/index.html&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;UK&lt;/B&gt;&lt;B&gt; Cystic Fibrosis Gene Therapy Consortium &lt;BR&gt;&lt;/B&gt;The UK Cystic Fibrosis Gene Therapy Consortium (UK CFGTC) is the unified research programme of the three leading gene therapy groups in the UK.&lt;BR&gt;&lt;A href="mailto:administrator@cfgenetherapy.org.uk" target="_blank"&gt;administrator@cfgenetherapy.org.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.cfgenetherapy.org.uk/" target="_blank"&gt;http://www.cfgenetherapy.org.uk/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;UK&lt;/B&gt;&lt;B&gt; Cystic Fibrosis Microbiology Consortium &lt;BR&gt;&lt;/B&gt;It brings together scientists and clinicians with internationally recognised experience of CF lung disease and complementary expertise.&lt;BR&gt;&lt;A href="mailto:cfmbcomments@ed.ac.uk" target="_blank"&gt;cfmbcomments@ed.ac.uk&lt;/A&gt;&lt;BR&gt;&lt;A href="http://www.cfmicrobiology.org.uk/" target="_blank"&gt;http://www.cfmicrobiology.org.uk/&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;B&gt;NHS Choices - Cystic Fibrosis&lt;BR&gt;&lt;/B&gt;&lt;A href="http://www.nhs.uk/conditions/Cystic-fibrosis/Pages/Introduction.aspx" target="_blank"&gt;http://www.nhs.uk/conditions/Cystic-fibrosis/Pages/Introduction.aspx&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;B&gt;&lt;A href="nelh:311628:0" name=internalLink&gt;&lt;B&gt;Home Page&lt;BR&gt;2009 Annual Evidence Update on Cystic Fibrosis&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394010</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=394010]]&gt;</url>
    <title>2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Home Page</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Home Page&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Welcome to the 2010Annual Evidence Update for COPD. We have presented the latest evidence published in the 12 months, to build on those updates from previous years.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;&lt;A href="nelh:394012:1" name=internalLink&gt;
&lt;P&gt;2010 Annual Evidence Update for Chronic Obstructive Pulmonary Disease (COPD)&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:394011:1" name=internalLink&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;Methodology&lt;/P&gt;&lt;/A&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394011</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=394011]]&gt;</url>
    <title>2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Methodology</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A literature search was carried out to identify systematic reviews on COPD published in the last 12 months, since the searches were carried out for the 2009 AEU on COPD.&lt;/P&gt;
&lt;P&gt;The searches were carried out on 25 October 2010, using the following terms:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;COPD&lt;BR&gt;chronic obstructive pulmonary disease&lt;BR&gt;chronic bronchitis&lt;BR&gt;emphysema&lt;BR&gt;chronic obstructive airway disease&lt;BR&gt;chronic airflow limitation&lt;BR&gt;chronic obstructive respiratory disease&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Sources searched:&lt;/STRONG&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;PubMed - using the &lt;A href="http://www.ncbi.nlm.nih.gov/corehtml/query/static/clinical.shtml" target="_blank"&gt;PubMed clinical queries systematic review filter&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Cochrane Database of Systematic Reviews&lt;/P&gt;
&lt;P&gt;NHS Evidence - respiratory&lt;/P&gt;
&lt;P&gt;NHS Evidence - searching Medline, AMED, CINAHL, BNI and PsychInfo&lt;BR&gt;&amp;nbsp;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&lt;STRONG&gt;Timeframe&lt;/STRONG&gt;&lt;BR&gt;Where possible sources were searched from June 2009 to include reviews that may not have been indexed in time for the 2009 AEU on COPD. Where it was not possible to search over within such a defined time period, sources were searched from the beginning of 2009.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;/STRONG&gt;&lt;BR&gt;Results from the searches were collated and duplicates removed. They were also compared with the 2009 AEU on COPD, and those citations presented last year were also removed. Citations were hand searched to identify systematic reviews for inclusion, with the final results approved by Dr Mark Everard, clinical lead for NHS Evidence - respiratory&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="nelh:394010:1" name=internalLink&gt;&lt;STRONG&gt;&lt;A href="nelh:394010:1" name=internalLink&gt;&lt;STRONG&gt;&lt;STRONG&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=328903" target="_blank"&gt;COPD Annual Evidence Update Home Page&lt;/A&gt;&lt;/STRONG&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>394012</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=394012]]&gt;</url>
    <title>2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Results</title>
    <publicationDate>2010-11-15T00:00:00</publicationDate>
    <publisher>NHS Evidence - respiratory</publisher>
    <publicationType>ANNUAL EVIDENCE UPDATE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;2010 Annual Evidence Update on Chronic Obstructive Pulmonary Disease - Results&lt;/pageTitle&gt;&lt;pageBody&gt;Links are provided to PubMed Abstracts for all citations, and to the full text where these are freely available. 
&lt;P&gt;&lt;B&gt;Lung function&lt;/B&gt; 
&lt;P&gt;Abramson,M.J.; Schattner,R.L.; Sulaiman,N.D.; Birch,K.E.; Simpson,P.P.; Del Colle,E.A.; Aroni,R.A.; Wolfe,R.; Thien,F.C. Do spirometry and regular follow-up improve health outcomes in general practice patients with asthma or COPD? A cluster randomised controlled trial. Medical Journal of Australia, 2010, 193, 2, 104-109. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20642418" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Management of exacerbations&lt;/B&gt; 
&lt;P&gt;Agarwal,R.; Aggarwal,A.N.; Gupta,D.; Jindal,S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest, 2010, 137, 2, 318-325. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19783669" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Burns,K.E.; Adhikari,N.K.; Keenan,S.P.; Meade,M.O. Noninvasive positive pressure ventilation as a weaning strategy for intubated adults with respiratory failure. Cochrane Database Systematic Reviews, 2010, (8), 8, CD004127. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14584005" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD004127/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Hoogendoorn,M.; Hoogenveen,R.T.; Rutten-van Molken,M.P.; Vestbo,J.; Feenstra,T.L. Case-fatality of COPD exacerbations: a meta-analysis and statistical modeling approach. European Respiratory Journal, 2010. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20595157" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Kliber,A.; Lynd,L.D.; Sin,D.D. The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respiratory Research, 2010, 11, 56. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20459831" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Lim,B.L.; Kelly,A.M. A meta-analysis on the utility of peripheral venous blood gas analyses in exacerbations of chronic obstructive pulmonary disease in the emergency department. European Journal of Emergency Medicine, 2010, 17, 5, 246-248. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19996974" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Rothberg,M.B.; Pekow,P.S.; Lahti,M.; Brody,O.; Skiest,D.J.; Lindenauer,P.K Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Journal of Hospital Medicine, 2010, 5, 5, 261-267. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20533570" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Drug Therapy&lt;/B&gt; 
&lt;P&gt;Cazzola,M.; Floriani,I.; Page,C.P. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulmonary Pharmacology and Therapeutics, 2010, 23, 2, 135-144. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19854285" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Celli,B.; Decramer,M.; Leimer,I.; Vogel,U.; Kesten,S.; Tashkin,D.P. Cardiovascular safety of tiotropium in patients with COPD. Chest, 2010, 137, 1, 20-30. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19592475" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Kaplan,A. Effect of tiotropium on quality of life in COPD: a systematic review. Primary Care Respiratory Journal, 2010. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/21042697" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Loke,Y.K.; Kwok,C.S.; Singh,S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. European Respiratory Journal , 2010, 35, 5, 1003-1021. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19926743" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Mauskopf,J.A.; Baker,C.L.; Monz,B.U.; Juniper,M.D. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. Journal of Medical Economics, 2010, 13, 3, 403-417. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20608887" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Singh,S.; Loke,Y.K. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 2010, 5, 189-195. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20714372" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Weatherall,M.; Clay,J.; James,K.; Perrin,K.; Shirtcliffe,P.; Beasley,R. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta- analysis. Respirology, 2009, 14, 7, 983-990. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19740259" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Welsh,E.J.; Cates,C.J.; Poole,P. Combination inhaled steroid and long-acting beta2- agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews, 2010, (5), 5, CD007891. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19740259" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007891/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Physiotherapy&lt;/B&gt; 
&lt;P&gt;Cross,J.; Elender,F.; Barton,G.; Clark,A.; Shepstone,L.; Blyth,A.; Bachmann,M.; Harvey,I.; MATREX Research Group. A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX). Health Technology Assessments, 2010, 14, 23, 1-147, iii-iv. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20487638" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Hill,K.; Patman,S.; Brooks,D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. Chronic Respiratory Disease, 2010, 7, 1, 9-17. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19819912" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Tang,C.Y.; Taylor,N.F.; Blackstock,F.C. Chest physiotherapy for patients admitted to hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD): a systematic review. Physiotherapy, 2010, 96, 1, 1-13. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20113757" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Thomas,M.J.; Simpson,J.; Riley,R.; Grant,E. The impact of home-based physiotherapy interventions on breathlessness during activities of daily living in severe COPD: a systematic review. Physiotherapy, 2010, 96, 2, 108-119. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20420957" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Smoking cessation &lt;/B&gt;
&lt;P&gt;Hoogendoorn,M.; Feenstra,T.L.; Hoogenveen,R.T.; Rutten-van Molken,M.P. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax, 2010, 65, 8, 711-718. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20685746" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Miscellaneous Interventions&lt;/B&gt; 
&lt;P&gt;Al-Ghimlas,F.; Todd,D.C. Creatine supplementation for patients with COPD receiving pulmonary rehabilitation: a systematic review and meta-analysis. Respirology, 2010, 15, 5, 785-795. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20497386" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Baraniak,A.; Sheffield,D. The efficacy of psychologically based interventions to improve anxiety, depression and quality of life in COPD: A systematic review and meta- analysis. Patient Education and Counseling, 2010. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20447795" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Bartoli,L.; Zanaboni,P.; Masella,C.; Ursini,N. Systematic review of telemedicine services for patients affected by chronic obstructive pulmonary disease (COPD). Telemedicine journal and e-health, 2009, 15, 9, 877-883. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19919194" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Bolton,C.E.; Waters,C.S.; Peirce,S.; Elwyn,G. Insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. Journal of Evaluation in Clinical Practice, 2010. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20846317" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Frei,A.; Svarin,A.; Steurer-Stey,C.; Puhan,M.A. Self-efficacy instruments for patients with chronic diseases suffer from methodological limitations--a systematic review. Health and Quality of Life Outcomes, 2009, 7, 86. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19781095" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Gotzsche,P.C.; Johansen,H.K. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Systematic Reviews, 2010, (7), 7, CD007851. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20614465" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007851/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Hunt,T.; Williams,M.T.; Frith,P.; Schembri,D. Heliox, dyspnoea and exercise in COPD. European Respiratory Review, 2010, 19, 115, 30-38. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20956163" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Janaudis-Ferreira,T.; Hill,K.; Goldstein,R.; Wadell,K.; Brooks,D. Arm exercise training in patients with chronic obstructive pulmonary disease: a systematic review. Journal of cardiopulmonary rehabilitation and prevention, 2009, 29, 5, 277-283. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19935139" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Polisena,J.; Tran,K.; Cimon,K.; Hutton,B.; McGill,S.; Palmer,K.; Scott,R.E. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta- analysis. Journal of Telemedicine and Telecare, 2010, 16, 3, 120-127. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20197355" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Poole,P.; Black,P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews, 2010, (2), 2, CD001287. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16855965" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD001287/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;Walters,J.A.; Turnock,A.C.; Walters,E.H. ; Wood-Baker,R. Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews, 2010, (5), 5, CD005074. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20464737" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] [ &lt;B&gt;&lt;A href="http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD005074/frame.html" target="_blank"&gt;Full Text&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Exercise&lt;/B&gt; 
&lt;P&gt;Beauchamp,M.K.; Nonoyama,M.; Goldstein,R.S.; Hill,K.; Dolmage,T.E.; Mathur,S.; Brooks,D. Interval versus continuous training in individuals with chronic obstructive pulmonary disease-a systematic review. Thorax, 2010, 65, 2, 157-164. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/19996334" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ]&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;B&gt;Adherence&lt;/B&gt; 
&lt;P&gt;Charles,M.S.; Blanchette,C.M.; Silver,H.; Lavallee,D.; Dalal,A.A.; Mapel,D. Adherence to controller therapy for chronic obstructive pulmonary disease: a review. Current Medical Research and Opinion, 2010, 26, 10, 2421-2429. [ &lt;B&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/20815661" target="_blank"&gt;PubMed Abstract&lt;/A&gt;&lt;/B&gt; ] 
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P align=center&gt;&lt;BR&gt;&lt;B&gt;&lt;A href="nelh:394010:1" name=internalLink&gt;&lt;B&gt;COPD Annual Evidence Update Home Page&lt;/B&gt;&lt;/A&gt;&lt;/B&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>312760</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/qof_os_final.pdf]]&gt;</url>
    <title>A guide to the Quality and Outcomes Framework for respiratory disease</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It aims to explain the changes to the respiratory elements of the QOF for 2006, advise clinicians on how to achieve these objectives, and attempt to suggest what further changes should come over the next few years.&lt;/P&gt;
&lt;P&gt;GPIAG Primary Care Respiratory Society UK Opinion Sheet No. 6.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>154711</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/13/73/77/04137377.pdf]]&gt;</url>
    <title>A Review of services for allergy: The epidemiology, demand for and provision of treatment and effectiveness of clinical interventions</title>
    <publicationDate>2006-07-20T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,ASTHMA,PUBLICATIONS,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published by the Department of Health&amp;nbsp;sets out the findings of a review of allergy services, which the Government undertook to carry out in its response to a House of Commons Health Committee inquiry. It identifies actions that can be taken, both at local and at national levels, to improve services.&lt;/P&gt;
&lt;P&gt;The review report draws on the views of stakeholders and summarises the evidence.&amp;nbsp; It identifies good practice in the NHS, across the wide range of services available for people with allergies, and the spectrum of skills and competences of clinicians involved in their care.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;However, the review has also revealed some gaps in the knowledge and skills of clinical staff dealing with allergy (especially in diagnosis), in systematic planning and commissioning of services for allergy, in baseline data on NHS services for allergy, relevant service capacity and costs, and workforce, and in research.&lt;/P&gt;
&lt;P&gt;The report acknowledges that, although incomplete, the evidence is sufficient for recommendations to be made for action over the next few years in order to improve services for allergy.&amp;nbsp; It identifies three areas in which initial action will be of key importance:&lt;/P&gt;
&lt;DIV class=block100&gt;
&lt;DIV class=leftFloat100&gt;
&lt;UL&gt;
&lt;LI&gt;local commissioners to establish levels of need for services for allergy in their health community 
&lt;LI&gt;SHA workforce planners to work with Deans and providers to explore the scope for creating additional training places for allergists 
&lt;LI&gt;the Department of Health to consider the options for commissioning the development of NICE guidelines for allergy, and work with the Royal Colleges on guidance for referral and care pathways.&lt;/LI&gt;&lt;/UL&gt;&lt;/DIV&gt;
&lt;P&gt;&lt;A title="" href="http://www.dh.gov.uk/assetRoot/04/13/73/78/04137378.pdf" target="_blank"&gt;Download supporting information on the epidemiology (PDF, 753K)&lt;/A&gt; &lt;/P&gt;
&lt;DIV class=linkContainer&gt;&lt;A title="" href="http://www.dh.gov.uk/assetRoot/04/13/73/79/04137379.pdf" target="_blank"&gt;Download supporting information on clinical interventions (PDF, 2183K)&lt;/A&gt;&amp;nbsp; &lt;/DIV&gt;
&lt;DIV class=linkContainer&gt;&amp;nbsp;&lt;/DIV&gt;
&lt;DIV class=linkContainer&gt;&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4137365" target="_blank"&gt;Click here&lt;/A&gt; to link to this document in the Department of Health website&lt;/DIV&gt;&lt;/DIV&gt;]]&gt;</body>
  </document>
  <document>
    <id>77831</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1196942154040]]&gt;</url>
    <title>A Winter's Tale - Coming to Terms with Winter Respiratory Illnesses</title>
    <publicationDate>2005-01-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (HPA)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,VIRAL,PUBLICATIONS,BRONCHITIS - ACUTE,INFECTIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This Health Protection Agency report examines winter infections from the following perspectives: 
&lt;UL&gt;
&lt;LI&gt;Community 
&lt;LI&gt;General practice 
&lt;LI&gt;Hospital 
&lt;LI&gt;Impact on mortality 
&lt;LI&gt;Laboratory 
&lt;LI&gt;Issues for health services 
&lt;LI&gt;Surveillance&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Revised May 2005.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325782</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/allergic_rhinitis_final.pdf]]&gt;</url>
    <title>Allergic Rhinitis</title>
    <publicationDate>2008-09-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>One of a range of easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at those working in primary care</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;This opinion sheet details the diagnosis and treatments of rhitinis. &lt;/P&gt;
&lt;P&gt;Opinion Sheets on other related topics are available from the GPIAG website&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gpiag.org/pubs/opinionsheets.php" target="_blank"&gt;http://www.gpiag.org/pubs/opinionsheets.php&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;&lt;A href="http://www.gpiag.org/opinions/allergic_rhinitis_final.pdf" target="_blank"&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>124657</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/asthma_and_ar_opinione3_final.pdf]]&gt;</url>
    <title>Allergic Rhinitis and Asthma</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ENT AND AUDIOLOGY,ASTHMA,RESPIRATORY,NOSE &amp; SINUS DISORDERS,ALLERGY,CONDITIONS,IMMUNOLOGICALLY BASED DISORDERS,RHINITIS,HAYFEVER,RHINOSINUSITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It details the evidence that allergic rhinitis and asthma are inter-linked, the evidence that treating allergic rhinitis improves asthma outcomes, the diagnosis and management of allergic rhinitis and asthma.&lt;/P&gt;
&lt;P&gt;GPIAG Primary Care Respiratory Society UK Opinion Sheet No. 3.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124657</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/asthma_and_ar_opinione3_final.pdf]]&gt;</url>
    <title>Allergic Rhinitis and Asthma</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ENT AND AUDIOLOGY,ASTHMA,RESPIRATORY,NOSE &amp; SINUS DISORDERS,ALLERGY,CONDITIONS,IMMUNOLOGICALLY BASED DISORDERS,RHINITIS,HAYFEVER,RHINOSINUSITIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It details the evidence that allergic rhinitis and asthma are inter-linked, the evidence that treating allergic rhinitis improves asthma outcomes, the diagnosis and management of allergic rhinitis and asthma.&lt;/P&gt;
&lt;P&gt;GPIAG Primary Care Respiratory Society UK Opinion Sheet No. 3.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125059</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125059]]&gt;</url>
    <title>Allergic Rhinitis and Asthma</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ENT AND AUDIOLOGY,RESPIRATORY,ASTHMA,NOSE &amp; SINUS DISORDERS,THERAPEUTIC INTERVENTIONS,DRUG TREATMENTS,IMMUNOTHERAPY,STEROIDS,CONDITIONS,HAYFEVER,RHINITIS,RHINOSINUSITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Allergic Rhinitis and Asthma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Dr Glenis Scadding&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 -&amp;nbsp;26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;ENT surgeons deal with upper respiratory tract problems, whilst below the larynx chest physicians are involved. Yet there is evidence that the respiratory tract should be considered&amp;nbsp; and treated as one organ.&lt;A href="#refs"&gt;[1]&lt;/A&gt; Allergic rhinitis and allergic asthma are chronic inflammatory conditions that frequently co-exist, both with hallmark eosinophils. The main evidence for this united airways approach is based not only on&amp;nbsp; histopathology but also on epidemiology, natural history, hyperreactivity, trigger factors and on the effects of rhinitis treatment upon asthma.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Epidemiology and Natural History&lt;/STRONG&gt;&lt;BR&gt;Rhinitis and asthma occur worldwide, with similar high prevalence in Westernised societies. A prospective study by Linneberg et al&lt;A href="#refs"&gt;[2]&lt;/A&gt; suggests that allergic rhinitis and asthma are manifestations of the same disease entity, with allergic rhinitis either preceding or developing concurrently with allergic asthma. Rhinitis, whether allergic or skin prick test negative, carries a three- fold relative&amp;nbsp; risk&amp;nbsp; for the development of future asthma. Furthermore, occupational asthma studies usually report that allergic rhinitis either precedes or accompanies asthma development. The severity and extent of rhinitis is frequently paralleled by that of asthma, with upper airway changes usually occurring first&lt;A href="#refs"&gt;[3,4]&lt;/A&gt;.The majority of asthmatics have rhinitis.&amp;nbsp; Rhinitis&amp;nbsp; exacerbates and increases the costs of current asthma, with increased need for visits for medical care.&lt;A href="#refs"&gt;[5,6]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Bronchial Hyperreactivity&lt;/STRONG&gt;&lt;BR&gt;A population- based study confirms previous observations that rhinitis is associated with bronchial hyper-reactivity. Treatment of seasonal rhinitis with topical nasal corticosteroids or sodium cromoglicate, was associated with a reduction in bronchial hyper-reactivity and asthma symptoms.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Triggers&lt;/STRONG&gt; &lt;BR&gt;Trigger factors are similar for both conditions: allergens, infection and pollution- and are&amp;nbsp; synergistic. Most exacerbations of asthma begin in the nose- with viral rhinitis precipitating asthma exacerbations in approximately 80% of children and 60% of adults.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Mechanisms&lt;/STRONG&gt;&lt;BR&gt;Absence of nasal air-conditioning or the dripping of infected or cytokine and mediator-rich postnasal secretions have been assumed to be the major exacerbating mechanisms by which rhinitis can worsen asthma. However, recent observations demonstrate several other possibilities: including&amp;nbsp; nerve reflexes, nitric oxide and systemic links. Allergen contact in one part of the respiratory tract leads to inflammatory changes in both upper and lower airways via a systemic activation of eosinophil precursors from the bone marrow . These travel via the bloodstream to the site of allergen contact, but also to other parts of the respiratory tract. Further work is required to try and clearly demonstrate a direct link between upper and lower airways through any of these mechanisms.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Rhinitis treatment&lt;/STRONG&gt;&lt;BR&gt;The ARIA (Allergic Rhinitis and its Impact on Asthma) document&lt;A href="#refs"&gt;[1]&lt;/A&gt; recognises the pathophysiological similarities between asthma and rhinitis, their frequent co-existence, and provides evidence-based guidelines for treatment based on a new classification of rhinitis as being intermittent, or persistent, and mild or moderate-to-severe. It states that patients with persistent rhinitis should be examined for asthma and vice versa. Treatment should consider both conditions. For both asthma and rhinitis first line therapy for anything more than mild intermittent symptoms is locally applied corticosteroid, however there are likely to be difficulties with this approach with respect to safety and concordance.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The BTS/ SIGN asthma guidelines state that there is no evidence that treating rhinitis benefits asthma&lt;A href="#refs"&gt;[7]&lt;/A&gt; but there are several suggestive strands of evidence to suggest that there may be some benefit as follows. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Topical intranasal corticosteroid use reduced the overall relative risk for an emergency department visit/hospitalisation for asthma in three separate retrospective studies involving thousands of patients&lt;A href="#refs"&gt;[8-10]&lt;/A&gt;. Anti- histamines used alone were less effective, but the combination of intranasal steroid and anti- histamine reduced asthma exacerbations more than either alone, suggesting the possible benefit of a systemic component to therapy&lt;A href="#refs"&gt;[10]&lt;/A&gt;. Leukotriene receptor antagonists have proved effective in both asthma and rhinitis in separate clinical trials. Post hoc analysis of the COMPACT study&lt;A href="#refs"&gt;[11]&lt;/A&gt; demonstrates that asthma in patients with associated rhinitis benefits more from addition of montelukast than from a doubling of inhaled steroid (an increase in budesonide 400mcg to 800 mcg daily), again hinting at the need for rhinitis treatment and possibly for systemic therapy.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It is clearly important to treat the morbidity associated with allergic rhinitis in asthmatic subjects. The nature and extent of any benefit on the severity of asthmatic symptoms still needs to be clarified.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Future management&lt;/STRONG&gt;&lt;BR&gt;Evidence exists that subcutaneous immunotherapy (SIT) modifies the natural course of allergic disease as well as reducing symptoms. Both Johnstone&lt;A href="#refs"&gt;[12]&lt;/A&gt; and Möller&lt;A href="#refs"&gt;[13]&lt;/A&gt;&amp;nbsp;observed that young patients with rhinitis receiving SIT were less likely to develop subsequent asthma or new allergic sensitivities. SIT is thought to redirect&amp;nbsp; CD-4 positive T-lymphocytes towards TH-1 or TH-0 immune responses probably via the generation of regulatory T cells. Effectiveness is maintained at least 3 years after discontinuation. Subcutaneous immunotherapy is not suitable for widespread use, however safer and simpler alternatives such as sublingual immunotherapy are under investigation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The ARIA recommendations – that patients with perennial rhinitis should be investigated for asthma and vice versa – need to be applied both in general practice and in chest and ENT clinics, where joint clinics with physicians and surgeons are probably optimal. &lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the authors. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via&amp;nbsp;PubMed)&amp;nbsp;of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bousquet J, Van Cauwenberge P, Khaltaev N et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-334. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11707753&amp;amp;query_hl=24&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Linneberg A, Henrik Nielsen N, Frolund L et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57: 969-971. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12359002&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Kapsali T, Horowitz E, Diemer F et al. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol 1997; 99: S138.&lt;/LI&gt;
&lt;LI&gt;ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem MA, Sterk PJ, Rabe KF, Bel EH.Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002 Apr;109(4):621-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11941310&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Yawn BP, Yunginger JW, Wollan PC et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999; 103:54-59. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9893185&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005 Jan;115(1):129-34.&lt;A href="http://pediatrics.aappublications.org/cgi/content/full/115/1/129" target="_blank"&gt; [Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Higgins BG, Douglas JG. The new BTS/SIGN asthma guidelines: where evidence leads the way. Thorax. 2003 Feb; 58(2):98-9.&amp;nbsp;&lt;A href="http://thorax.bmjjournals.com/cgi/content/full/58/2/98" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST.&amp;nbsp; Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002; 109: 636–642. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11941313&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Crystal-Peters J, Neslusan C., Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalization and emergency department visits. J Allergy Clin. Immunol 2002; 109: 57-62. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Abstract&amp;amp;list_uids=21657213" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004 Mar;113(3):415-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15007339&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.&lt;BR&gt;Thorax. 2003 Mar;58(3):211-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12612295&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://thorax.bmjjournals.com/cgi/content/full/58/3/211" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Johnstone DE. A study of the natural history of bronchial asthma in children. Am J Dis Child 1968; 115: 213-216. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=5636498&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: 251-256.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11842293&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://rms.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D29991" target="_blank"&gt;Allergic rhinitis&lt;/A&gt;, PRODIGY, last revised July 2005. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004460/frame.html" target="_blank"&gt;Capsaicin for allergic rhinitis in adults, &lt;/A&gt;The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=238082&amp;amp;tabID=289" target="_blank"&gt;Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis&lt;/A&gt; The Cochrane Library 2003, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=242967&amp;amp;tabID=289" target="_blank"&gt;Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=242794&amp;amp;tabID=289" target="_blank"&gt;Management of allergic and nonallergic rhinitis&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gpiag.org/opinions/asthma_and_ar_opinione3_final.pdf" target="_blank"&gt;GPIAG Opinion No 3. Allergic Rhinitis and Asthma&amp;nbsp;&lt;/A&gt;(PDF). General Practice Airways Group (GPIAG) Opinions, March 2006.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.statistics.gov.uk/children/downloads/asthma.pdf" target="_blank"&gt;The health of children and young people - Asthma and allergic diseases&amp;nbsp;&lt;/A&gt;(PDF). Office for National Statistics, March 2004.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.lunguk.org/allergy.asp" target="_blank"&gt;Allergy, &lt;/A&gt;British Lung Foundation (BLF).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cks.library.nhs.uk/patient_information_leaflet/rhinitis" target="_blank"&gt;Rhinitis&lt;/A&gt;, Clinical Knowledge Summaries (CKS).&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=hyperlink&gt;&lt;SPAN class=hyperlink&gt;&lt;A class=hyperlink href="http://www.labtestsonline.org.uk/understanding/analytes/allergy/glance.html" target="_blank"&gt;Allergy Test (RAST)&lt;/A&gt;&lt;/SPAN&gt;, Lab Tests Online UK.&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>125059</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125059]]&gt;</url>
    <title>Allergic Rhinitis and Asthma</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ ENT AND AUDIOLOGY,RESPIRATORY,ASTHMA,NOSE &amp; SINUS DISORDERS,THERAPEUTIC INTERVENTIONS,DRUG TREATMENTS,IMMUNOTHERAPY,STEROIDS,CONDITIONS,HAYFEVER,RHINITIS,RHINOSINUSITIS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Allergic Rhinitis and Asthma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Dr Glenis Scadding&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 -&amp;nbsp;26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Introduction&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;ENT surgeons deal with upper respiratory tract problems, whilst below the larynx chest physicians are involved. Yet there is evidence that the respiratory tract should be considered&amp;nbsp; and treated as one organ.&lt;A href="#refs"&gt;[1]&lt;/A&gt; Allergic rhinitis and allergic asthma are chronic inflammatory conditions that frequently co-exist, both with hallmark eosinophils. The main evidence for this united airways approach is based not only on&amp;nbsp; histopathology but also on epidemiology, natural history, hyperreactivity, trigger factors and on the effects of rhinitis treatment upon asthma.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Epidemiology and Natural History&lt;/STRONG&gt;&lt;BR&gt;Rhinitis and asthma occur worldwide, with similar high prevalence in Westernised societies. A prospective study by Linneberg et al&lt;A href="#refs"&gt;[2]&lt;/A&gt; suggests that allergic rhinitis and asthma are manifestations of the same disease entity, with allergic rhinitis either preceding or developing concurrently with allergic asthma. Rhinitis, whether allergic or skin prick test negative, carries a three- fold relative&amp;nbsp; risk&amp;nbsp; for the development of future asthma. Furthermore, occupational asthma studies usually report that allergic rhinitis either precedes or accompanies asthma development. The severity and extent of rhinitis is frequently paralleled by that of asthma, with upper airway changes usually occurring first&lt;A href="#refs"&gt;[3,4]&lt;/A&gt;.The majority of asthmatics have rhinitis.&amp;nbsp; Rhinitis&amp;nbsp; exacerbates and increases the costs of current asthma, with increased need for visits for medical care.&lt;A href="#refs"&gt;[5,6]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Bronchial Hyperreactivity&lt;/STRONG&gt;&lt;BR&gt;A population- based study confirms previous observations that rhinitis is associated with bronchial hyper-reactivity. Treatment of seasonal rhinitis with topical nasal corticosteroids or sodium cromoglicate, was associated with a reduction in bronchial hyper-reactivity and asthma symptoms.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Triggers&lt;/STRONG&gt; &lt;BR&gt;Trigger factors are similar for both conditions: allergens, infection and pollution- and are&amp;nbsp; synergistic. Most exacerbations of asthma begin in the nose- with viral rhinitis precipitating asthma exacerbations in approximately 80% of children and 60% of adults.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Mechanisms&lt;/STRONG&gt;&lt;BR&gt;Absence of nasal air-conditioning or the dripping of infected or cytokine and mediator-rich postnasal secretions have been assumed to be the major exacerbating mechanisms by which rhinitis can worsen asthma. However, recent observations demonstrate several other possibilities: including&amp;nbsp; nerve reflexes, nitric oxide and systemic links. Allergen contact in one part of the respiratory tract leads to inflammatory changes in both upper and lower airways via a systemic activation of eosinophil precursors from the bone marrow . These travel via the bloodstream to the site of allergen contact, but also to other parts of the respiratory tract. Further work is required to try and clearly demonstrate a direct link between upper and lower airways through any of these mechanisms.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Rhinitis treatment&lt;/STRONG&gt;&lt;BR&gt;The ARIA (Allergic Rhinitis and its Impact on Asthma) document&lt;A href="#refs"&gt;[1]&lt;/A&gt; recognises the pathophysiological similarities between asthma and rhinitis, their frequent co-existence, and provides evidence-based guidelines for treatment based on a new classification of rhinitis as being intermittent, or persistent, and mild or moderate-to-severe. It states that patients with persistent rhinitis should be examined for asthma and vice versa. Treatment should consider both conditions. For both asthma and rhinitis first line therapy for anything more than mild intermittent symptoms is locally applied corticosteroid, however there are likely to be difficulties with this approach with respect to safety and concordance.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The BTS/ SIGN asthma guidelines state that there is no evidence that treating rhinitis benefits asthma&lt;A href="#refs"&gt;[7]&lt;/A&gt; but there are several suggestive strands of evidence to suggest that there may be some benefit as follows. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Topical intranasal corticosteroid use reduced the overall relative risk for an emergency department visit/hospitalisation for asthma in three separate retrospective studies involving thousands of patients&lt;A href="#refs"&gt;[8-10]&lt;/A&gt;. Anti- histamines used alone were less effective, but the combination of intranasal steroid and anti- histamine reduced asthma exacerbations more than either alone, suggesting the possible benefit of a systemic component to therapy&lt;A href="#refs"&gt;[10]&lt;/A&gt;. Leukotriene receptor antagonists have proved effective in both asthma and rhinitis in separate clinical trials. Post hoc analysis of the COMPACT study&lt;A href="#refs"&gt;[11]&lt;/A&gt; demonstrates that asthma in patients with associated rhinitis benefits more from addition of montelukast than from a doubling of inhaled steroid (an increase in budesonide 400mcg to 800 mcg daily), again hinting at the need for rhinitis treatment and possibly for systemic therapy.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It is clearly important to treat the morbidity associated with allergic rhinitis in asthmatic subjects. The nature and extent of any benefit on the severity of asthmatic symptoms still needs to be clarified.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Future management&lt;/STRONG&gt;&lt;BR&gt;Evidence exists that subcutaneous immunotherapy (SIT) modifies the natural course of allergic disease as well as reducing symptoms. Both Johnstone&lt;A href="#refs"&gt;[12]&lt;/A&gt; and Möller&lt;A href="#refs"&gt;[13]&lt;/A&gt;&amp;nbsp;observed that young patients with rhinitis receiving SIT were less likely to develop subsequent asthma or new allergic sensitivities. SIT is thought to redirect&amp;nbsp; CD-4 positive T-lymphocytes towards TH-1 or TH-0 immune responses probably via the generation of regulatory T cells. Effectiveness is maintained at least 3 years after discontinuation. Subcutaneous immunotherapy is not suitable for widespread use, however safer and simpler alternatives such as sublingual immunotherapy are under investigation.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The ARIA recommendations – that patients with perennial rhinitis should be investigated for asthma and vice versa – need to be applied both in general practice and in chest and ENT clinics, where joint clinics with physicians and surgeons are probably optimal. &lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the authors. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via&amp;nbsp;PubMed)&amp;nbsp;of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bousquet J, Van Cauwenberge P, Khaltaev N et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-334. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=11707753&amp;amp;query_hl=24&amp;amp;itool=pubmed_DocSum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Linneberg A, Henrik Nielsen N, Frolund L et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57: 969-971. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12359002&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Kapsali T, Horowitz E, Diemer F et al. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol 1997; 99: S138.&lt;/LI&gt;
&lt;LI&gt;ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem MA, Sterk PJ, Rabe KF, Bel EH.Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002 Apr;109(4):621-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11941310&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Yawn BP, Yunginger JW, Wollan PC et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999; 103:54-59. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9893185&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005 Jan;115(1):129-34.&lt;A href="http://pediatrics.aappublications.org/cgi/content/full/115/1/129" target="_blank"&gt; [Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Higgins BG, Douglas JG. The new BTS/SIGN asthma guidelines: where evidence leads the way. Thorax. 2003 Feb; 58(2):98-9.&amp;nbsp;&lt;A href="http://thorax.bmjjournals.com/cgi/content/full/58/2/98" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST.&amp;nbsp; Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002; 109: 636–642. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11941313&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Crystal-Peters J, Neslusan C., Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalization and emergency department visits. J Allergy Clin. Immunol 2002; 109: 57-62. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;dopt=Abstract&amp;amp;list_uids=21657213" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol. 2004 Mar;113(3):415-9. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15007339&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.&lt;BR&gt;Thorax. 2003 Mar;58(3):211-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12612295&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&amp;nbsp;&lt;A href="http://thorax.bmjjournals.com/cgi/content/full/58/3/211" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Johnstone DE. A study of the natural history of bronchial asthma in children. Am J Dis Child 1968; 115: 213-216. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=5636498&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109: 251-256.&amp;nbsp; &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11842293&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://rms.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D29991" target="_blank"&gt;Allergic rhinitis&lt;/A&gt;, PRODIGY, last revised July 2005. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004460/frame.html" target="_blank"&gt;Capsaicin for allergic rhinitis in adults, &lt;/A&gt;The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=238082&amp;amp;tabID=289" target="_blank"&gt;Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis&lt;/A&gt; The Cochrane Library 2003, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=242967&amp;amp;tabID=289" target="_blank"&gt;Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=242794&amp;amp;tabID=289" target="_blank"&gt;Management of allergic and nonallergic rhinitis&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gpiag.org/opinions/asthma_and_ar_opinione3_final.pdf" target="_blank"&gt;GPIAG Opinion No 3. Allergic Rhinitis and Asthma&amp;nbsp;&lt;/A&gt;(PDF). General Practice Airways Group (GPIAG) Opinions, March 2006.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.statistics.gov.uk/children/downloads/asthma.pdf" target="_blank"&gt;The health of children and young people - Asthma and allergic diseases&amp;nbsp;&lt;/A&gt;(PDF). Office for National Statistics, March 2004.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.lunguk.org/allergy.asp" target="_blank"&gt;Allergy, &lt;/A&gt;British Lung Foundation (BLF).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cks.library.nhs.uk/patient_information_leaflet/rhinitis" target="_blank"&gt;Rhinitis&lt;/A&gt;, Clinical Knowledge Summaries (CKS).&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=hyperlink&gt;&lt;SPAN class=hyperlink&gt;&lt;A class=hyperlink href="http://www.labtestsonline.org.uk/understanding/analytes/allergy/glance.html" target="_blank"&gt;Allergy Test (RAST)&lt;/A&gt;&lt;/SPAN&gt;, Lab Tests Online UK.&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>5962</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://ajrccm.atsjournals.org/]]&gt;</url>
    <title>American Journal of Respiratory and Critical Care Medicine</title>
    <publicationDate></publicationDate>
    <publisher>American Thoracic Society</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,ICU]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An official journal of the American Thoracic Society. Articles consist predominantly of original research either clinically based or of a basic science nature.&lt;/P&gt;
&lt;P&gt;Papers solely or predominantly based in cell and molecular biology are published in the companion journal of the American Thoracic Society, the American Journal of Respiratory Cell and Molecular Biology.&lt;/P&gt;
&lt;P&gt;The Journal also seeks to publish review articles on areas of interest in several forms. &lt;/P&gt;
&lt;P&gt;Published twice a month&lt;BR&gt;ISSN: 1073-449x 
&lt;P&gt;&lt;STRONG&gt;Access through the publisher's website&lt;/STRONG&gt;:&lt;BR&gt;Access to full text is via subscription. Non subscribers can access some full text articles, tables of contents and abstracts from January 1994 plus additional features.&lt;BR&gt;&lt;A href="http://ajrccm.atsjournals.org/" target="_blank"&gt;http://ajrccm.atsjournals.org/&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5967</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://ajrcmb.atsjournals.org/]]&gt;</url>
    <title>American Journal of Respiratory Cell and Molecular Biology</title>
    <publicationDate></publicationDate>
    <publisher>American Thoracic Society</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An official journal of the American Thoracic Society. Publishes papers that report significant and original observations in the area of pulmonary biology.&lt;/P&gt;
&lt;P&gt;The focus includes, but is not confined to, cellular, biochemical, molecular, developmental, genetic, and immunologic studies of lung cells and molecules. &lt;/P&gt;
&lt;P&gt;Published 12 times a year&lt;BR&gt;ISSN: 1044-1549&amp;nbsp;&amp;nbsp; 
&lt;P&gt;&lt;STRONG&gt;Access through the publisher's website&lt;/STRONG&gt;:&lt;BR&gt;Access to full text is via subscription. Non subscribers can access some full text articles, tables of contents and abstracts from January 1994 plus additional features.&lt;BR&gt;&lt;A href="http://ajrcmb.atsjournals.org/" target="_blank"&gt;http://ajrcmb.atsjournals.org/&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5979</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://oberon.annallergy.org/vl=1594784/cl=21/nw=1/rpsv/home.htm]]&gt;</url>
    <title>Annals of Allergy, Asthma and Immunology</title>
    <publicationDate></publicationDate>
    <publisher>National Library of Medicine - MEDLINE Abstracts</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Official publication of the American College of Allergy, Asthma, and Immunology. Aims to be an objective, scientific forum for the allergy/immunology specialist to keep up-to-date on clinical research in the field. The emphasis is on providing information that is applicable to both the clinician and the researcher. Opportunites are provided to participate in accredited continuing medical education activities to enhance overall clinical proficiency. 
&lt;P&gt;Published 12 times a year.&lt;BR&gt;ISSN: 1081-1206 
&lt;P&gt;&lt;STRONG&gt;Access through the publisher's website&lt;/STRONG&gt;:&lt;BR&gt;Access to full text is via subscription. Non subscribers can access some full text articles, tables of contents and abstracts from 1996 plus additional features.&lt;BR&gt;&lt;A href="http://allergy.edoc.com/" target="_blank"&gt;http://allergy.edoc.com/&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6000</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://ats.ctsnetjournals.org/]]&gt;</url>
    <title>Annals of Thoracic Surgery</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Annals of Thoracic Surgery provides original coverage of recent progress in chest and cardiovascular surgery and related fields.&amp;nbsp;The official journal of two of the largest American associations in its specialty - the Society of Thoracic Surgeons and the Southern Thoracic Surgical Association. 
&lt;P&gt;A clinically oriented resource, The Annals of Thoracic Surgery is committed to providing a place for all thoracic surgeons to relate experiences which will help improve patient care. 
&lt;P&gt;Published 12 times a year.&lt;BR&gt;ISSN: 0003-4975 
&lt;P&gt;Access to full text is via subscription, with free access for non subscribers to tables of contents from 1965 onwards, abstracts from 1975 onwards and some full text articles plus additional features&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>298651</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=298651]]&gt;</url>
    <title>Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008</title>
    <publicationDate>2008-11-17T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,RESPIRATORY,EMERGENCY CARE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Welcome to the 2008 Annual Evidence Update for Chronic Obstructive Pulmonary Disease (COPD) - 17-21 November 2008.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;This update aims to build on the National Knowledge Week for COPD published earlier in 2008, that presented the evidence base used to inform the NSF for COPD. The Annual Evidence update (AEU) presents the latest published systematic reviews in COPD. It is published in the same week as &lt;A href="http://www.goldcopd.com/WCDIndex.asp" target="_blank"&gt;World COPD Day &lt;/A&gt;(19 November 2008). There is also further information available from the &lt;A href="http://www.lunguk.org/media-and-campaigning/campaigns/worldcopdday.htm" target="_blank"&gt;British Lung Foundation&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;There are no invited commentaries with AEU due to the close proximity to the publication of the NSF for COPD. Further information (including that prior to 2008) is available within the &lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=288&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;COPD section of the library&lt;/A&gt;.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=298637&amp;amp;tabID=289&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE&amp;amp;catID=5880" target="_blank"&gt;Evidence Base for COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=298643&amp;amp;tabID=290&amp;amp;summaries=true&amp;amp;resultsPerPage=10&amp;amp;sort=TITLE&amp;amp;catID=5880" target="_blank"&gt;Methodology for Annual Evidence Update of COPD&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>298637</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=298637]]&gt;</url>
    <title>Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008 - Evidence Base</title>
    <publicationDate>2008-11-17T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008 - Evidence Base&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;A comprehensive literature search was carried out to identify systematic reviews published in COPD in 2008. This aims to build on the &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278340&amp;amp;tabID=290&amp;amp;catID=5880" target="_blank"&gt;evidence based&lt;/A&gt; published in February 2008 that was used to inform the COPD NSF. Full details of the search strategy are available on the methodology page.&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Bausewein C, Booth S, Gysels M, Higginson I.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;SPAN lang=DA style="mso-ansi-language: DA"&gt;Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005623.&lt;/SPAN&gt;&lt;SPAN lang=DA&gt; &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005623" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0000ff&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:place&gt;&lt;st1:City&gt;Bentley&lt;/st1:City&gt; &lt;st1:State&gt;AR&lt;/st1:State&gt;&lt;/st1:place&gt;, Emrani P, Cassano PA.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Genetic Variation and Gene Expression in Antioxidant-Related Enzymes and Risk of Chronic Obstructive Pulmonary Disease: A Systematic Review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Thorax. 2008 Jun 19. [Epub ahead of print] &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18566111?ordinalpos=23&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;st1:place&gt;&lt;st1:City&gt;Coventry&lt;/st1:City&gt; &lt;st1:State&gt;PA&lt;/st1:State&gt;&lt;/st1:place&gt;, Gellatly JL.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Improving outcomes for COPD patients with mild-to-moderate anxiety and depression: a systematic review of cognitive behavioural therapy.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Br J Health Psychol. 2008 Sep;13(Pt 3):381-400. Epub 2007 Apr 18. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17535503?ordinalpos=73&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Thorax. 2008 May;63(5):415-22. Epub 2008 Jan 30. Review. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18234905?ordinalpos=53&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Drug Saf. 2008;31(5):409-14. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18422381?ordinalpos=34&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=DE style="mso-ansi-language: DE"&gt;&lt;FONT face=Arial&gt;Fagevik Olsén M, Westerdahl E.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Positive Expiratory Pressure in Patients with Chronic Obstructive Pulmonary Disease - A Systematic Review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Respiration. 2008 Oct 9. [Epub ahead of print] &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18843173?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;J Antimicrob Chemother. 2008 Sep;62(3):442-50. Epub 2008 May 8. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18467303?ordinalpos=28&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Geddes EL, O'Brien K, Reid WD, Brooks D, Crowe J.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Inspiratory muscle training in adults with chronic obstructive pulmonary disease: An update of a systematic review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Respir Med. 2008 Aug 15. [Epub ahead of print] &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18708282?ordinalpos=12&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Hu G, Shi Z, Hu J, Zou G, Peng G, Ran P.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Association between polymorphisms of microsomal epoxide hydrolase and COPD: results from meta-analyses.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Respirology. 2008 Nov;13(6):837-50. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18811882?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Lacasse Y, Martin S, Lasserson TJ, Goldstein RS.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Eura Medicophys. 2007 Dec;43(4):475-85. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18084170?ordinalpos=60&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Lin K, Watkins B, Johnson T Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O'Donnell D, Fitzgerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.&lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp; &lt;/SPAN&gt;Thorax. 2008 Feb;63(2):122-8. Epub 2007 Aug 16. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17702790?ordinalpos=72&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;O'Brien K, Geddes EL, Reid WD, Brooks D, Crowe J.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;J Cardiopulm Rehabil Prev. 2008 Mar-Apr;28(2):128-41. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18360190?ordinalpos=38&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Peytremann-Bridevaux I, Staeger P, Bridevaux &lt;st1:place&gt;PO&lt;/st1:place&gt;, &lt;st1:place&gt;&lt;st1:City&gt;Ghali&lt;/st1:City&gt; &lt;st1:State&gt;WA&lt;/st1:State&gt;&lt;/st1:place&gt;, Burnand B.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Effectiveness of chronic obstructive pulmonary disease-management programs: systematic review and meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Am J Med. 2008 May;121(5):433-443.e4. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18456040?ordinalpos=30&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=DE style="mso-ansi-language: DE"&gt;&lt;FONT face=Arial&gt;Puhan MA, Vollenweider D, Steurer J, Bossuyt PM, Ter Riet G.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;BMC Med. 2008 Oct 10;&lt;st1:time Hour="6" Minute="28"&gt;6:28&lt;/st1:time&gt;. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18847478?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=SV style="mso-ansi-language: SV"&gt;&lt;FONT face=Arial&gt;Quon BS, Gan WQ, Sin DD.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Chest. 2008 Mar;133(3):756-66. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18321904?ordinalpos=42&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=SV style="mso-ansi-language: SV"&gt;&lt;FONT face=Arial&gt;Rizkallah J, Man SF, Sin DD.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Prevalence of Pulmonary Embolism in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Chest. 2008 Sep 23. [Epub ahead of print] &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812453?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Safety of long-acting beta-agonists in stable COPD: a systematic review.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Chest. 2008 May;133(5):1079-87. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18460518?ordinalpos=29&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Singh S, &lt;st1:place&gt;&lt;st1:City&gt;Loke&lt;/st1:City&gt; &lt;st1:State&gt;YK&lt;/st1:State&gt;&lt;/st1:place&gt;, Furberg CD.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;JAMA. 2008 Sep 24;300(12):1439-50. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18812535?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Sobieraj DM, White CM, Coleman CI.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Clin Ther. 2008 Aug;30(8):1416-25. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18803985?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Steele BG, Belza B, Cain KC, Coppersmith J, Lakshminarayan S, Howard J, Haselkorn JK.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Arch Phys Med Rehabil. 2008 Mar;89(3):404-12. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18295615?ordinalpos=48&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;Zwar N, Hermiz O, Hasan I, Comino E, Middleton S, Vagholkar S, Marks G.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;FONT face=Arial&gt;A cluster randomised controlled trial of nurse and GP partnership for care of chronic obstructive pulmonary disease.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;BMC Pulm Med. 2008 Jun 3;8:8. &lt;B&gt;&lt;SPAN style="FONT-SIZE: 10pt"&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18519003?ordinalpos=25&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum" target="_blank"&gt;&lt;SPAN style="TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT color=#0000ff&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/B&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/B&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;The following articles were also selected for inclusion:&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&lt;/FONT&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;&lt;o:p&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;SPAN style="COLOR: windowtext; TEXT-DECORATION: none; text-underline: none"&gt;British Thoracic Society Standards of Care Committee.&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;st1:PersonName&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;BTS&lt;/SPAN&gt;&lt;/st1:PersonName&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt; statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN&gt;Thorax. 2008 Mar;63 Suppl 1:i1-i16. &lt;A href="http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Good%20Clinical%20Practice/hospreferalthorax.pdf" target="_blank"&gt;&lt;U&gt;&lt;STRONG&gt;[FULL TEXT]&lt;/STRONG&gt;&lt;/U&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;SPAN style="COLOR: windowtext; TEXT-DECORATION: none; text-underline: none"&gt;U.S. Preventive Services Task Force.&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=SV style="FONT-FAMILY: Tahoma; mso-ansi-language: SV"&gt;Ann Intern Med. 2008 Apr 1;148(7):529-34. Epub 2008 Mar 3.&lt;/SPAN&gt;&lt;SPAN&gt; &lt;A href="http://www.ahrq.gov/clinic/uspstf08/copd/copdrs.htm" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;&lt;STRONG&gt;[FULL TEXT]&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;&lt;SPAN style="COLOR: windowtext; TEXT-DECORATION: none; text-underline: none"&gt;Lin K, Watkins B, Johnson T, Rodriguez JA, Barton MB; U.S. Preventive Services Task Force.&lt;/SPAN&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; LINE-HEIGHT: 15pt"&gt;&lt;SPAN style="FONT-FAMILY: Tahoma"&gt;Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN&gt;Ann Intern Med. 2008 Apr 1;148(7):535-43. Epub 2008 Mar 3. &lt;A href="http://www.annals.org/cgi/content/full/148/7/529" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;&lt;STRONG&gt;[FULL TEXT]&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>298643</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=298643]]&gt;</url>
    <title>Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008 - Methodology</title>
    <publicationDate>2008-11-17T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Annual Evidence Update for Chronic Obstructive Pulmonary Disease 2008 - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A literature search was carried out to identify systematic reviews on COPD published in 2008. This aims to build on the evidence base published in February 2008 that was used to inform the COPD NSF.&lt;/P&gt;
&lt;P&gt;The seraches were carried out on 6-7 November 2008, using the following terms:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9.5pt; FONT-FAMILY: Verdana; mso-bidi-font-family: 'Times New Roman'"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;COPD&lt;BR&gt;chronic obstructive pulmonary disease&lt;BR&gt;chronic bronchitis&lt;BR&gt;emphysema&lt;BR&gt;chronic obstructive airway disease&lt;BR&gt;chronic airflow limitation&lt;BR&gt;chronic obstructive respiratory disease&lt;BR&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;&lt;STRONG&gt;Sources searched:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;PubMed - using the &lt;A href="http://www.nlm.nih.gov/bsd/pubmed_subsets/sysreviews_strategy.html" target="_blank"&gt;PubMed clinical queries systematic review filter&lt;/A&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;Ovid Medline - using the SIGN Medline systematic review filter&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;1&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Meta-Analysis/ (16778)&lt;BR&gt;2&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; meta analy$.tw. (19124)&lt;BR&gt;3&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; metaanaly$.tw. (658)&lt;BR&gt;4&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; meta analysis.pt. (16778)&lt;BR&gt;5&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (systematic adj (review$1 or overview$1)).tw. (14864)&lt;BR&gt;6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; exp Review Literature/ (866631)&lt;BR&gt;7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; or/1-6 (883349)&lt;BR&gt;8&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; cochrane.ab. (10052)&lt;BR&gt;9&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; embase.ab. (7766)&lt;BR&gt;10&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (psychlit or psyclit).ab. (721)&lt;BR&gt;11&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (psychinfo or psycinfo).ab. (2121)&lt;BR&gt;12&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; (cinahl or cinhal).ab. (3097)&lt;BR&gt;13&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; science citation index.ab. (827)&lt;BR&gt;14&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; bids.ab. (200)&lt;BR&gt;15&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; cancerlit.ab. (392)&lt;BR&gt;16&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; or/8-15 (14980)&lt;BR&gt;17&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; reference list$.ab. (4043)&lt;BR&gt;18&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; bibliograph$.ab. (5295)&lt;BR&gt;19&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; hand-search$.ab. (1830)&lt;BR&gt;20&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; relevant journals.ab. (316)&lt;BR&gt;21&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; manual search$.ab. (924)&lt;BR&gt;22&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; or/17-21 (11023)&lt;BR&gt;23&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; selection criteria.ab. (9158)&lt;BR&gt;24&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; data extraction.ab. (4094)&lt;BR&gt;25&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 23 or 24 (12448)&lt;BR&gt;26&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; review.pt. (865345)&lt;BR&gt;27&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 25 and 26 (8890)&lt;BR&gt;28&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; comment.pt. (273026)&lt;BR&gt;29&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; letter.pt. (325169)&lt;BR&gt;30&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; editorial.pt. (145583)&lt;BR&gt;31&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; animal/ (1742045)&lt;BR&gt;32&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; human/ (4701885)&lt;BR&gt;33&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 31 not (31 and 32) {No Related Terms} (562)&lt;BR&gt;34&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; or/28-30,33 (520446)&lt;BR&gt;35&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 7 or 16 or 22 or 27 (886297)&lt;BR&gt;36&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 35 not 34 (864981)&lt;BR&gt;37&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; copd {No Related Terms} (1023)&lt;BR&gt;38&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; chronic obstructive pulmonary disease {No Related Terms} (1330)&lt;BR&gt;39&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; chronic bronchitis {No Related Terms} (527)&lt;BR&gt;40&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; emphysema {No Related Terms} (580)&lt;BR&gt;41&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; chronic obstructive airway disease {No Related Terms} (84)&lt;BR&gt;42&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; chronic airflow limitation {No Related Terms} (508)&lt;BR&gt;43&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; chronic obstructive respiratory disease {No Related Terms} (663)&lt;BR&gt;44&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; or/37-43 (4223)&lt;BR&gt;45&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 36 and 44 (1878)&lt;BR&gt;46&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; limit 45 to (english language and yr="2008") (135)&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;Respiratory Specialist Library&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;&lt;STRONG&gt;Identification of Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P class=MsoNormal dir=ltr style="MARGIN: 0cm 0cm 0pt"&gt;Results from the searches were collated and duplicates removed. Citations were hand searched by reading titles and abstracts to identify systematic reviews for inclusion. All results were approved by the clinical lead for the Respiratory Specialist Library, Dr Mark Everard.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>308801</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;HPAwebStandard/HPAweb_C/1225268885969?p=1158945066450]]&gt;</url>
    <title>Annual Report on Tuberculosis Surveillance in the UK 2008</title>
    <publicationDate>2008-10-01T00:00:00</publicationDate>
    <publisher>Health Protection Agency (HPA)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;The report details the distribution and current trends of tuberculosis in &lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; highlighting issues concerning drug resistance and treatment. The report also provides the research &amp;amp; development work carried out by the Health Protection agency along with its partners. &lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;The Health Protection Agency &lt;/A&gt;is an independent &lt;st1:country-region&gt;&lt;st1:place&gt;UK&lt;/st1:place&gt;&lt;/st1:country-region&gt; organisation that was set up by the government in 2003 to protect the public from threats to their health from infectious diseases and environmental hazards.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;It does this by providing advice and information to the general public, to health professionals such as doctors and nurses, and to national and local government &lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.hpa.org.uk/webw/HPAweb&amp;amp;Page&amp;amp;HPAwebContentAreaLanding/Page/1153822623886?p=1153822623886" target="_blank"&gt;Click here &lt;/A&gt;to view other publications by The Health Protection Agency (HPA)&lt;o:p&gt;&lt;/o:p&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79829</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/collection/asthma]]&gt;</url>
    <title>Asthma</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since February 1998 relevant to asthma. &lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>251358</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=251358]]&gt;</url>
    <title>Asthma - Sources of Information</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,RESPIRATORY,SPECIALTIES,ASTHMA,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Asthma - Sources of Information&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Asthma is the commonest chronic disease of childhood and a major cause of morbidity in adults.&amp;nbsp; The &lt;A href="http://www.sign.ac.uk/guidelines/fulltext/101/index.html" target="_blank"&gt;SIGN/BTS guideline&amp;nbsp;&lt;/A&gt;first published in 2003 is a ‘living’ [regularly updated] guideline that covers all the major topics in the care of patients with asthma.&amp;nbsp; A major revision was published on 6 May 2008. The guideline highlights the difficulties in diagnosis due to the lack of a confirmatory test and that the diagnosis is a clinical one sometime corroborated by suggestive changes in lung function. Assessing the response to a trial of treatment and on going assessment including review of the diagnosis is emphasised.&amp;nbsp; Other topics covered include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;non-pharmacological management&lt;/LI&gt;
&lt;LI&gt;pharmacological management&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;inhaler devices&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;acute asthma&lt;/LI&gt;
&lt;LI&gt;pregnancy&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;occupational asthma&lt;/LI&gt;
&lt;LI&gt;organisation of care&lt;/LI&gt;
&lt;LI&gt;patient education and self management&lt;/LI&gt;
&lt;LI&gt;compliance&amp;nbsp;&lt;/LI&gt;
&lt;LI&gt;outcomes and audit&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This guideline incorporates data from many sources including systematic reviews.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://cks.library.nhs.uk/asthma" target="_blank"&gt;Clinical Knowledge Summaries (CKS)&lt;/A&gt; also provide guidelines based on the SIGN/BTS guidelines.&lt;/P&gt;
&lt;P&gt;NICE guidance is available for &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=29736&amp;amp;tabID=288&amp;amp;catID=5872" target="_blank"&gt;inhalers for the under 5’s&amp;nbsp;&lt;/A&gt;and &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=30203&amp;amp;tabID=288&amp;amp;catID=5872" target="_blank"&gt;5-15 years olds&lt;/A&gt;.&amp;nbsp; This emphasises that while holding chambers and pMDIs are the cheapest option clinicians can prescribe other delivery systems for inhaled steroids in older children if the a clinician believes that it is so unlikely that an individual child will use the pMDI &amp;amp; spacer properly that his or her asthma control may be affected. Further technology appraisals addressing the use of &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11892" target="_blank"&gt;inhaled steroids in children&lt;/A&gt; [2007] and &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11945" target="_blank"&gt;adults &lt;/A&gt;[2008], and &lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11894" target="_blank"&gt;Omalizumab for severe persistent allergic asthma&lt;/A&gt; [2007]&amp;nbsp;have been published.&lt;/P&gt;
&lt;P&gt;There are a large number of &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/cochrane_search_fs.html?mode=startsearch&amp;amp;products=all&amp;amp;unitstatus=none&amp;amp;opt1=OR&amp;amp;Query2=&amp;amp;zones2=article-title&amp;amp;opt2=AND&amp;amp;Query3=&amp;amp;zones3=author&amp;amp;opt3=AND&amp;amp;Query4=&amp;amp;zones4=abstract&amp;amp;opt4=AND&amp;amp;Query5=&amp;amp;zones5=tables&amp;amp;FromYear=&amp;amp;ToYear=&amp;amp;Query1=asthma&amp;amp;zones1=keywords" target="_blank"&gt;Cochrane reviews &lt;/A&gt;addressing various aspects of management.&amp;nbsp; The list of available reviews are listed.&amp;nbsp; These will have been considered as part of the SIGN/BTS methodology.&amp;nbsp; Other sources of information include HTA and DARE, which are available within the &lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?catID=5872" target="_blank"&gt;Evidence &lt;/A&gt;section of the library.&lt;/P&gt;
&lt;P&gt;A number of general patient information sheets can be obtained from &lt;A href="http://cks.library.nhs.uk/asthma#-276015" target="_blank"&gt;CKS&lt;/A&gt;, the &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=51443&amp;amp;tabID=292&amp;amp;catID=5872" target="_blank"&gt;British Thoracic Society&lt;/A&gt; and the &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79452&amp;amp;tabID=292&amp;amp;catID=5872" target="_blank"&gt;British Lung Foundation&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The charity providing more detailed patient information and a national helpline is &lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;Asthma UK&lt;/A&gt;.&amp;nbsp; The major training centres for nurses and health care professionals are the &lt;A href="http://www.educationforhealth.org.uk/" target="_blank"&gt;Education for Health&amp;nbsp;&lt;/A&gt;and &lt;A href="http://www.respiratoryeduk.com/" target="_blank"&gt;Respiratory Education UK&lt;/A&gt;.&amp;nbsp; The &lt;A href="http://www.gpiag.org/" target="_blank"&gt;General Practice Airways Group (GPIAG)&lt;/A&gt; provides a focus for primary care physicians with an interest in asthma.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>325787</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/asthma_special_situations_final.pdf]]&gt;</url>
    <title>Asthma - Special Situations</title>
    <publicationDate>2009-07-23T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>One of a range of easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at those working in primary care</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;This opinion sheet provides an overview of the managemen of asthma in special situations; these include asthma in pregnancy, asthma on holiday, and occupational asthma&lt;/P&gt;
&lt;P&gt;Opinion Sheets on other related topics are available from the GPIAG website &lt;BR&gt;&lt;A href="http://www.gpiag.org/pubs/opinionsheets.php" target="_blank"&gt;http://www.gpiag.org/pubs/opinionsheets.php&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125010</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125010]]&gt;</url>
    <title>Asthma Inhaler Devices</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Asthma Inhaler Devices&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Sue Gray&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 - 26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Asthma is a common disease of the airway and lungs, which is reversible and causes inflammation, bronchial hyper-reactivity and in turn narrowing of the airway&lt;A href="#refs"&gt;[1]&lt;/A&gt;. A key component of the management of this condition involves inhalation of medication, which delivers the drug directly to the airways. The speed of onset for drugs such as &lt;SPAN style="FONT-FAMILY: Symbol; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;b&lt;/SPAN&gt; agonists is much more rapid than when taken orally while the systemic side effects of drugs such as &lt;SPAN style="FONT-FAMILY: Symbol; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA"&gt;b&lt;/SPAN&gt; agonists and corticosteroids can be minimised. &lt;/P&gt;
&lt;P&gt;There is a confusing array of inhaler devices and drug/device combinations available, which can make it difficult for a clinician to make informed prescribing decisions about all the possible permutations&lt;A href="#refs"&gt;[2]&lt;/A&gt;. The best guide to choosing an inhaler is to use a device the patient can use effectively [as demonstrated in the clinic] and which they will use effectively at home. There is little point supplying a patient with a pressurised metered dose inhaler and spacer for an inhaled corticosteroids [ICS] if the subject will not use the spacer at home.&amp;nbsp; It is particularly important to choose a device that the patient will use effectively for ICS as there is no feedback from the drugs in terms of immediate effect. Devices for ICS should also minimise upper airways deposition to minimise the potential for local side effects such as hoarseness and oro-pharyngeal candidiasis and to reduce the absorption of drugs such as beclomethasone from the GI tract.&lt;/P&gt;
&lt;P&gt;When choosing the dose of an inhaled steroid the best guide is to use the lowest dose that works.&lt;/P&gt;
&lt;P&gt;The pressurised metered-dose inhaler (MDI), developed in 1956, is still the most widely prescribed inhaler device and is used by over 75% of patients. Studies show that over 50% of patients do not use MDI’s correctly&lt;A href="#refs"&gt;[3,4]&lt;/A&gt;. Other factors may influence the patient’s ability to co-ordinate their MDI, e.g. no further re-instruction of technique or stress. Health professionals may also have problems demonstrating inhaler technique and require training in order to teach patients correctly&lt;A href="#refs"&gt;[5]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;A patient’s use of their inhaler device should be checked at every consultation, as inappropriate device selection or inadequate training can result in inefficient drug delivery and treatment failure&lt;A href="#refs"&gt;[6]&lt;/A&gt;. A patient’s attitudes and abilities to asthma therapy, for example education, experiences, physical ability and effective teaching of technique will affect their device use, therefore, this should be considered when selecting the most appropriate device&lt;A href="#refs"&gt;[7]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Colour coding of devices&lt;BR&gt;&lt;/STRONG&gt;Drug classes can be identified by colour e.g.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;BLUE: Reliever – short-acting Beta-agonist.&lt;/LI&gt;
&lt;LI&gt;BROWN/ORANGE/BURGUNDY: Preventers – Corticosteroid.&lt;/LI&gt;
&lt;LI&gt;GREEN: long-acting Beta-agonist.&lt;/LI&gt;
&lt;LI&gt;PURPLE/RED and WHITE: long-acting Beta-agonist/Corticosteroid combination.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Types of Inhalers&lt;/STRONG&gt;&lt;BR&gt;There are three main categories of inhalers:&lt;/P&gt;
&lt;P&gt;1.&amp;nbsp;Metered dose inhalers (MDI) can be subdivided into un-adapted and adapted e.g. spacer devices, and breath-actuated devices.&lt;A href="#refs"&gt;[8]&lt;/A&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;Spacer devices:&lt;BR&gt;Volumatic, Aerochamber, Pocket chamber, Spacehaler&lt;/P&gt;
&lt;P&gt;&amp;nbsp;Breath-actuated:&lt;BR&gt;&amp;nbsp;Easy-Breathe, Autohaler&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;2.&amp;nbsp;Dry powder inhalers&lt;BR&gt;These can be single or multi-dose inhalers&lt;A href="#refs"&gt;[9]&lt;/A&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Accuhaler&lt;/LI&gt;
&lt;LI&gt;Diskhaler&lt;/LI&gt;
&lt;LI&gt;Turbohaler&lt;/LI&gt;
&lt;LI&gt;Easyhaler&lt;/LI&gt;
&lt;LI&gt;Clickhaler&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;3. Nebulisers&lt;BR&gt;There is considerable evidence that in mild to moderate exacerbations of asthma b agonists delivered via pressurised metered dose inhaler and spacer can be as effective as nebulised therapy.&amp;nbsp; The use of nebulisers is increasingly being confined to the treatment of more severe exacerbations or situations where the patient is not able to use any other form of inhaler device such as the the elderly with cognitive or physical problems. There are two main types: compressor driven or ultrasonic&lt;A href="#refs"&gt;[10]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Teaching&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Jargon should be avoided and language the patient easily understands should be used.&lt;/LI&gt;
&lt;LI&gt;At each consultation the nurse should take the opportunity to repeat instructions and check the patient’s understanding and technique.&lt;/LI&gt;
&lt;LI&gt;There should be an agreed device check protocol to ensure all team members are giving the same instructions.&lt;/LI&gt;
&lt;LI&gt;Patient device technique should be recorded at each visit.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Acceptability&lt;/STRONG&gt; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;If a patient can not use a particular device a different one should be tried.&lt;/LI&gt;
&lt;LI&gt;In children and adolescents peer pressure may affect acceptance of their device.&lt;/LI&gt;
&lt;LI&gt;With any patient/parent/carer it is important to involve them in the selection. &lt;/LI&gt;
&lt;LI&gt;In adults, a device’s acceptability may depend on convenience and whether they see it as an embarrassment. In older people it is important to assess their mental and physical capabilities as this may affect their ability to learn how to use a device[6].&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Best Practice&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Choose a device the patient finds easy to use effectively. It is crucial the patient is involved in the decision making process in the choice of device&lt;A href="#refs"&gt;[11]&lt;/A&gt;.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Encourage the patient to bring their inhaler to clinic for inhaler technique check. This should be checked at each clinic visit and is essential to facilitate the patient’s acceptance and their understanding of how to use the device. It also reduces the problems of cleaning placebo inhalers&lt;A href="#refs"&gt;[12,13]&lt;/A&gt;.&lt;/LI&gt;
&lt;LI&gt;Good communication between patient and health professional is vital to successful asthma management. It should involve history-taking, discussion of the condition, an understanding of the patient’s attitude to asthma and its management, and an insight into the patient’s lifestyle.&lt;/LI&gt;
&lt;LI&gt;Patient’s should also be taught how to tell their inhalers are empty, cleaning of them and about good oral hygiene measures. This will reduce the incidence of oral side-effects.&lt;/LI&gt;&lt;/UL&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the management of Asthma. Thorax 2003;&amp;nbsp;58: Suppl. 1, 1-94. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=30346&amp;amp;tabID=288&amp;amp;catID=5872" target="_blank"&gt;[Full Text - available online as the latest edition published in 2005]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Inhaler devices for asthma. Drug Therapeutic Bulletin 2000; 38:9–13. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10829349&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Hilton, S. An audit of inhaler technique among asthma patients of 34 general practitioners. British Journal of General Practice 1990; 40:505-506. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2282229&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Pearce, L. KNOW HOW Asthma inhalers. Nursing Times 2000. &lt;A href="http://www.nursingtimes.net/" target="_blank"&gt;www.nursingtimes.net&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Barnes, G, Booker, R, Brown, F. et al. Devices under discussion: A report from the National Asthma and Respiratory Training Centre. Cookham: Direct Publishing Solutions: 1997.&lt;/LI&gt;
&lt;LI&gt;Lenney, J. et al. Inappropriate inhaler use: assessment of patient use and preference of seven inhalation devices. Respiratory Medicine 2000; 94:496–500. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10868714&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Wright, J, Brocklebank, D, Ram, F. Inhaler devices for the management of asthma and COPD. Effective Health Care 2003; 8:1. &lt;A href="http://www.york.ac.uk/inst/crd/ehc81.htm" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ram, F, Brocklebank, D, White, J. et al. Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma (Cochrane Review). The Cochrane Library 2002; Issue 2. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=237527&amp;amp;tabID=289" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Koskela, T, Hedman, J, Ekroos, H, et al. Equivalence of two steroid-containing inhalers: Easyhaler multidose powder inhaler compared with conventional aerosol with large volume spacer. Respiration 2000; 67:194–202. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10773793&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cates, C, J. Comparison of holding chambers and nebulisers for beta-agonists in acute asthma. American&amp;nbsp; Journal of Respiratory and Critical Care Medicine 1997; 155:(4) 531.&lt;/LI&gt;
&lt;LI&gt;McFadden, jr, E. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. Journal of Allergy and Clinical Immunology 1995; 96:(2) 278-283. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7636071&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;British Thoracic Society and the National Respiratory Training Centre. Practical recommendations for the use of Placebo Inhalers.&amp;nbsp;British Thoracic Society Website; 2005.&amp;nbsp;&lt;A href="http://www.brit-thoracic.org.uk/c2/uploads/placeboinhalersfinal.pdf" target="_blank"&gt;[Full Text]&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Clancy, K. 2003, Cross infection and the use and decontamination of placebo inhalers. British Journal of Nursing 2003; 12:(13) 778–783. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12920455&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://rms.nelh.nhs.uk/respiratory/viewResource.asp?categoryID=5872&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D29736" target="_blank"&gt;Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma&lt;/A&gt; NICE, August 2000.&amp;nbsp;Guideline published more than 5 years ago, but publisher has confirmed the guideline's continued validity (March 2006).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://rms.nelh.nhs.uk/respiratory/viewResource.asp?categoryID=5872&amp;amp;uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D30203" target="_blank"&gt;Inhaler devices for routine treatment of chronic asthma in older children aged 5-15 years&lt;/A&gt; NICE, March 2002.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=239198&amp;amp;tabID=289" target="_blank"&gt;Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=236332&amp;amp;tabID=289" target="_blank"&gt;Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=237320&amp;amp;tabID=289" target="_blank"&gt;Holding chambers versus nebulisers for inhaled steroids in chronic asthma&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.pier.org.uk/Cal/Asthmanew/index.htm" target="_blank"&gt;Inhaler Device Technique&lt;/A&gt;, Teaching Package, Sheffield Children's Hospital September 2003&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://www.asthma.org.uk/all_about_asthma/medicines_treatments/reliever.html" target="_blank"&gt;Reliever inhalers &lt;/A&gt;(Asthma UK).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.asthma.org.uk/all_about_asthma/medicines_treatments/preventer.html" target="_blank"&gt;Preventer inhalers&lt;/A&gt; (Asthma UK).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.asthma.org.uk/all_about_asthma/medicines_treatments/using_your.html" target="_blank"&gt;Using your inhalers&lt;/A&gt; (Asthma UK).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.asthma.org.uk/all_about_asthma/medicines_treatments/spacers.html" target="_blank"&gt;Spacers&lt;/A&gt; (Asthma UK).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.asthma.org.uk/all_about_asthma/medicines_treatments/nebulisers.html" target="_blank"&gt;Nebulisers &lt;/A&gt;(Asthma UK).&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>312014</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/asthma_review_final.pdf]]&gt;</url>
    <title>Asthma Review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It details the key components of an asthma review and describes a practical approach to the provision of asthma reviews in primary care.&lt;/P&gt;
&lt;P&gt;GPIAG Opinon No 23&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250552</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Asthma/index.htm]]&gt;</url>
    <title>Asthma: Long-acting B2 agonists</title>
    <publicationDate>2007-02-19T00:00:00</publicationDate>
    <publisher>Medicines and Healthcare products Regulatory Agency (MHRA)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Section from the MHRA website which provides information on the treatment of asthma, in particular the use and safety of long-acting B2 agonists.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Section from the MHRA website which provides information on the treatment of asthma, in particular the use and safety of long-acting ß2 agonists.&lt;/P&gt;
&lt;P&gt;The content was last reviewed / modified on 07-Feb-2008&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>112923</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/infections/topics_az/influenza/avian/default.htm]]&gt;</url>
    <title>Avian Influenza, Bird Flu</title>
    <publicationDate></publicationDate>
    <publisher>Health Protection Agency (HPA)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CLINICAL LIBRARY,MAJOR INCIDENT,EMERGENCY CARE,RESPIRATORY,VIRAL,RESPIRATORY,CONTINGENCY,INFECTIONS,INFLUENZA,INFECTIONS,PANDEMIC INFLUENZA,SEASONAL INFLUENZA,PANDEMIC INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This webpage produced by the Health Protection Agency (HPA)&amp;nbsp;provides a wealth of information and advice on the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Frequently asked questions 
&lt;LI&gt;Background information 
&lt;LI&gt;Current travel advice 
&lt;LI&gt;Related websites (covering seasonal, avian and pandemic influenza websites)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Other&amp;nbsp;resouces include recent updates such as&amp;nbsp; epidemiological data, detailed guidance, laboratory information and further contact details.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>126699</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/AboutUs/MinistersAndDepartmentLeaders/ChiefMedicalOfficer/Features/FeaturesArticle/fs/en?CONTENT_ID=4102997&amp;chk=OcYuEL]]&gt;</url>
    <title>Bird flu and pandemic influenza: what are the risks?</title>
    <publicationDate>2008-06-30T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,VIRAL,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;A severe form of avian influenza or ‘bird flu’ – called H5N1 – has affected poultry flocks and other birds in several countries since 2003. &lt;/P&gt;
&lt;P class=teaserText&gt;As of&amp;nbsp;05&amp;nbsp;February 2007, 271 people have also caught the infection, as a result of close and direct contact with infected birds. One hundred and&amp;nbsp;sixty-five of these have subsequently died. &lt;/P&gt;
&lt;P class=teaserText&gt;There is no firm evidence that H5N1 has acquired the ability to pass easily from person to person. However, concern remains that the virus might develop this ability, or that it might mix with human flu viruses to create a new virus. It is this ability of avian influenza, to change and to mix, that has given rise to the fear of a new human flu pandemic. &lt;/P&gt;
&lt;P class=teaserText&gt;This regularly updated feature explains the background to the disease, and assesses the nature of the risk to people living in the UK.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>144202</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.erpho.org.uk/Download/Public/15381/1/BurdenLungDisease2006.pdf]]&gt;</url>
    <title>Burden of Lung Disease 2006 - 2nd Edition</title>
    <publicationDate>2006-06-28T00:00:00</publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,INFECTIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The second edition of a statistics report from the British Thoracic Society on over 30 lung conditions. It also details the numbers of people affected and the cost to the NHS.]]&gt;</body>
  </document>
  <document>
    <id>282779</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.csrt.com/en/publications/journal.asp]]&gt;</url>
    <title>Canadian Journal of Respiratory Therapy</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Society of Respiratory Therapists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the journal of the Canadian Society of Respiratory Therapists, and represents the interests of respiratory therapists nationally in Canada and internationally. Along with articles of information, CSRT news and events, the CJRT also publishes scientific articles and abstracts of interest to those in the RT profession.&lt;/P&gt; &lt;P&gt;&lt;BR&gt;Full text is available online for the past year&lt;/P&gt; &lt;P&gt;&lt;BR&gt;Published&amp;nbsp;4 times a year&lt;BR&gt;ISSN: 0831-2478 &lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access to the full text of this journal:&lt;BR&gt;&lt;/STRONG&gt;NHS staff can access full text from 2004 onwards with an Athens user name and password at:&lt;/P&gt; &lt;P&gt;&lt;A href="http://search.ebscohost.com/direct.asp?db=c8h&amp;amp;jid=IO7&amp;amp;scope=site&amp;amp;authtype=athens" target="_blank"&gt;http://search.ebscohost.com/direct.asp?db=c8h&amp;amp;jid=IO7&amp;amp;scope=site&amp;amp;authtype=athens&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Athens access:&lt;BR&gt;&lt;/STRONG&gt;NHS staff wishing to access licensed resources need a (free) Athens username and password which can be arranged at any local NHS Library or online at: &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;.&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282779</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.csrt.com/en/publications/journal.asp]]&gt;</url>
    <title>Canadian Journal of Respiratory Therapy</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Society of Respiratory Therapists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This is the journal of the Canadian Society of Respiratory Therapists, and represents the interests of respiratory therapists nationally in Canada and internationally. Along with articles of information, CSRT news and events, the CJRT also publishes scientific articles and abstracts of interest to those in the RT profession.&lt;/P&gt; &lt;P&gt;&lt;BR&gt;Full text is available online for the past year&lt;/P&gt; &lt;P&gt;&lt;BR&gt;Published&amp;nbsp;4 times a year&lt;BR&gt;ISSN: 0831-2478 &lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Access to the full text of this journal:&lt;BR&gt;&lt;/STRONG&gt;NHS staff can access full text from 2004 onwards with an Athens user name and password at:&lt;/P&gt; &lt;P&gt;&lt;A href="http://search.ebscohost.com/direct.asp?db=c8h&amp;amp;jid=IO7&amp;amp;scope=site&amp;amp;authtype=athens" target="_blank"&gt;http://search.ebscohost.com/direct.asp?db=c8h&amp;amp;jid=IO7&amp;amp;scope=site&amp;amp;authtype=athens&lt;/A&gt;&lt;/P&gt; &lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Athens access:&lt;BR&gt;&lt;/STRONG&gt;NHS staff wishing to access licensed resources need a (free) Athens username and password which can be arranged at any local NHS Library or online at: &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;.&lt;/P&gt; &lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282979</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://search.ebscohost.com/direct.asp?db=c8h&amp;jid=IO7&amp;scope=site&amp;authtype=athens]]&gt;</url>
    <title>Canadian Journal of Respiratory Therapy</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Society of Respiratory Therapists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS,ICU,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Published&amp;nbsp;5 times a year&lt;BR&gt;ISSN: 1205-9838 &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to the full text of this journal:&lt;BR&gt;&lt;/STRONG&gt;NHS staff can access full text from January&amp;nbsp;2004 onwards through&amp;nbsp;EBSCO as part of the NHS Core Content Collection. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Athens access:&lt;BR&gt;&lt;/STRONG&gt;NHS staff wishing to access licensed resources need a (free) Athens username and password which can be arranged at any local NHS Library or online at: &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282979</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://search.ebscohost.com/direct.asp?db=c8h&amp;jid=IO7&amp;scope=site&amp;authtype=athens]]&gt;</url>
    <title>Canadian Journal of Respiratory Therapy</title>
    <publicationDate></publicationDate>
    <publisher>Canadian Society of Respiratory Therapists</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS,ICU,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Published&amp;nbsp;5 times a year&lt;BR&gt;ISSN: 1205-9838 &lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access to the full text of this journal:&lt;BR&gt;&lt;/STRONG&gt;NHS staff can access full text from January&amp;nbsp;2004 onwards through&amp;nbsp;EBSCO as part of the NHS Core Content Collection. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Athens access:&lt;BR&gt;&lt;/STRONG&gt;NHS staff wishing to access licensed resources need a (free) Athens username and password which can be arranged at any local NHS Library or online at: &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>122891</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.advisorybodies.doh.gov.uk/comeap/expertreview.HTM]]&gt;</url>
    <title>Cardiovascular Disease and Air Pollution - A report by the Committee on the Medical Effects of Air Pollutants</title>
    <publicationDate>2006-02-28T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report published by the Committee on the Medical Effects of Air Pollution, recognises the link between air pollution and heart disease.&lt;/P&gt;
&lt;P&gt;The main findings of the report are that “outdoor air pollutants are likely to be associated with increased deaths and hospital admissions for cardiovascular related disease. This association is not as large as factors such as family history, smoking and hypertension.” The Committe could not identify the exact mechanisms by which air pollution affects the cardiovascular system, but suggests two possible mechanisms:&lt;/P&gt;
&lt;P&gt;• Inhalation of particles in the air causes chemical reactions in the body which increase the likelihood of blood to clot and/or atheromatous plaque to rupture, leading to heart attack. &lt;BR&gt;• Particles subtly affect the control of heart rhythm.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.advisorybodies.doh.gov.uk/comeap/statementsreports/CardioDisease.pdf" target="_blank"&gt;Click here to view the full report (pdf version)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.advisorybodies.doh.gov.uk/comeap/statementsreports/CardioDisease_appen.pdf" target="_blank"&gt;Click here to view the report appendices (pdf version)&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5971</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.chestjournal.org/]]&gt;</url>
    <title>CHEST</title>
    <publicationDate></publicationDate>
    <publisher>American College of Chest Physicians</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Formerly: Diseases of the Chest</description>
    <body>&lt;![CDATA[ &lt;P&gt;CHEST is the official publication of the &lt;A href="http://www.chestnet.org/journal/index.php" target="_blank"&gt;American College of Chest Physicians&lt;/A&gt;. Each month it features cutting edge clinical investigations in the multidisciplinary specialties of chest medicine, such as pulmonology, cardiology, thoracic surgery, transplantation, sleep and breathing, airways disease, and more. CHEST also features basic science, special reports, case reports, board review questions, and more. Editorials and communications to the editor explore controversial issues and encourage further discussion by physicians dealing with chest medicine. 
&lt;P&gt;Published 12 times a year&lt;BR&gt;ISSN: 0012-3692 
&lt;P&gt;&lt;STRONG&gt;Access through the publisher's website:&lt;BR&gt;&lt;/STRONG&gt;Access to full text is via subscription. Non subscribers can access some full text articles, tables of contents and abstracts from 1970 plus additional features. &lt;A href="http://www.chestjournal.org/" target="_blank"&gt;http://www.chestjournal.org/&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>144395</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.cqc.org.uk/_db/_documents/COPD_report1_200607272728.pdf]]&gt;</url>
    <title>Clearing the air: A national study of chronic obstructive pulmonary disease</title>
    <publicationDate>2006-07-01T00:00:00</publicationDate>
    <publisher>Care Quality Commission</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The Care Quality Commission has carried out a national study of the care and treatment available for people with COPD in England.</description>
    <body>&lt;![CDATA[ &lt;P class=intro minmax_bound="true"&gt;The Healthcare Commission has carried out a national study of the care and treatment available for people with COPD in England. The study is part of a wider programme of work, which focuses on promoting improvement in services for people with long term conditions or chronic disease.&lt;/P&gt;
&lt;P minmax_bound="true"&gt;COPD is the term now used to describe a range of chronic chest conditions, including chronic bronchitis and emphysema. It is an incurable long term condition, which is diagnosed in at least 900,000 people in the UK and places a significant burden on the NHS.&lt;/P&gt;
&lt;P minmax_bound="true"&gt;The following report presents the detailed findings of&amp;nbsp;the Healthcare Commission&amp;nbsp;national study of COPD. It provides an overview of the experiences of people with COPD and relevant Government policy and guidelines. It aims to improve understanding and awareness of COPD among healthcare professionals and the public, and highlight the impact of this condition on the NHS.&lt;/P&gt;
&lt;P minmax_bound="true"&gt;The report provides recommendations for the Department of Health and those responsible for providing healthcare services locally. It also provides details of further activities by the Healthcare Commission in relation to the care and treatment of people with COPD and other long term conditions.&lt;/P&gt;
&lt;P minmax_bound="true"&gt;The Healthcare Commission have also produced a &lt;A href="http://www.healthcarecommission.org.uk/_db/_documents/COPD_factsheet.pdf" target="_blank"&gt;COPD summary factsheet (pdf 42kb).&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82823</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.clinicalmolecularallergy.com/home/]]&gt;</url>
    <title>Clinical and Molecular Allergy</title>
    <publicationDate></publicationDate>
    <publisher>Biomed Central</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Clinical and Molecular Allergy is an Open Access, peer-reviewed journal that addresses clinical and molecular aspects of allergic disease. The publication includes reviews, case reports and research studies.&lt;/P&gt;
&lt;P&gt;This journal is published monthly.&lt;BR&gt;ISSN: 1476-7961&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>105089</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4121753]]&gt;</url>
    <title>Clinical Guidelines for Patients with an Influenza like illness during an Influenza Pandemic</title>
    <publicationDate>2006-06-06T00:00:00</publicationDate>
    <publisher>Crown; British Thoracic Society; British Infection Society;Health Protection Agency</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,VIRAL,PUBLICATIONS,GUIDELINES,INFECTIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;This document contains guidance for health professionals regarding the treatment of pandemic influenza, agreed by experts from the British Thoracic Society, the British Infection Society and the Health Protection Agency. It is published as official UK guidance by the Department of Health in England and covers treatment in hospitals and the community, of both adults and children.&lt;/P&gt;
&lt;P&gt;It is intended for use in the UK in event that the World Health Organisation declares that an influenza pandemic has started, and the Department of Health in England (UK-wide lead agency on pandemic influenza, including the devolved administrations) has declared UK Pandemic Alert Level 2 (cases of pandemic influenza identified within the UK).&lt;/P&gt;
&lt;P&gt;&lt;A class=internalLink href="http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4135811.pdf" target="_blank"&gt;Download guidelines (PDF, 1067K)&lt;/A&gt; &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>197442</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=197442]]&gt;</url>
    <title>COPD and palliative and supportive care</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;COPD and palliative and supportive care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Professor Sam H Ahmedzai, University of Sheffield, Academic Unit of Supportive Care&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Three main points are important to consider:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;The physical and psychosocial burden of COPD has largely been ignored&lt;/LI&gt;
&lt;LI&gt;Palliative care has ignored COPD to the extent that this patient group has been excluded from hospice and community care&lt;/LI&gt;
&lt;LI&gt;A supportive care approach offers a new way to include these patients&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;In contrast to advanced cancer, which has developed considerable resources for patients, end-stage non-malignant respiratory disease has largely been ignored by the health service and its professions &lt;A href="#refs"&gt;[1, 2]&lt;/A&gt;. Although a few patients receive intensive medical and nursing care at the end of life with artificial ventilation, most die slowly in hospital wards, at home or in nursing homes.&amp;nbsp; The scale of suffering for patients and their family carers is beginning to emerge &lt;A href="#refs"&gt;[3, 4]&lt;/A&gt; and palliative care services are becoming aware of non-cancer patients’ needs at the end of life &lt;A href="#refs"&gt;[5, 6, 7]&lt;/A&gt;. However, it is unclear if current palliative care services are equipped to meet these additional demands. &lt;/P&gt;
&lt;P&gt;It is useful to compare and contrast COPD with cancer &lt;A href="#refs"&gt;[8]&lt;/A&gt; from the patients’ viewpoint:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Common physical symptoms: &lt;A href="#refs"&gt;[9]&lt;/A&gt; e.g. pain, dyspnoea, cough, anorexia, emesis and constipation are comparable with those of lung cancer patients.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Psychosocial symptoms: &lt;A href="#refs"&gt;[10]&lt;/A&gt; Low mood is found to the same extent as, or often is worse than, in cancer.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Quality of life measurement: &lt;A href="#refs"&gt;[11]&lt;/A&gt; COPD patients suffer as much as most lung cancer patients, but because COPD patients remain ill for longer, the total amount of their suffering could be argued to be greater. &lt;/LI&gt;
&lt;LI&gt;Communication of terminal disease: &lt;A href="#refs"&gt;[12]&lt;/A&gt; Is less open with COPD patients than with cancer patients.&lt;/LI&gt;
&lt;LI&gt;Mobility: As with many cancer patients, patients with long-term non-malignant disease are liable to lose mobility and become house-bound &lt;/LI&gt;
&lt;LI&gt;Home-based care: COPD patients and carers are less likely to receive terminal care in their homes from district nurses and specialist palliative care nurses. &lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Although the overall degree of physical and psychosocial hardship is similar between cancer and non-malignant lung disease, cancer patients are currently better cared for in the British health care system – especially if the independent hospice movement is included. The best current knowledge about managing physical symptoms should be easily transferred from cancer to non-cancer. But unfortunately the use of analgesic and sedating drugs is still associated with myths and some fears exist in the minds of the public and many professionals. Randomised controlled trials of symptom control in end-stage COPD are scarce. Morphine has been shown to palliate breathlessness in end-stage lung disease and modern synthetic opioids are known to offer advantages over codeine and morphine for pain and breathlessness control &lt;A href="#refs"&gt;[13]&lt;/A&gt;.&lt;BR&gt;Transferring the palliative care knowledge based on the experience with cancer to COPD faces two important barriers:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Reluctance of palliative care services to adapt to and embrace non-cancer patients.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Healthcare professionals’ wariness about referring patients to palliative care services such as hospices and hospital teams because of difficulty judging prognosis.&lt;BR&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;To surmount these barriers it may help to use a new approach towards the care of COPD patients and their carers.&amp;nbsp; The approach of ‘supportive care’ is not restricted to the end of life but instead is determined by physical, psychosocial, information, rehabilitation and existential needs – from the time of diagnosis, and regardless of prognosis.&amp;nbsp; Supportive care embraces palliative care for the terminal stages, but if offered from the onset of a chronic illness, more patients may benefit from seamless and holistic care &lt;A href="#refs"&gt;[14]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Gott CM, Ahmedzai SH, Wood C.&amp;nbsp; How many inpatients at an acute hospital have palliative care needs? Comparing the perspectives of medical and nursing staff. Palliative Medicine 2001; 15:451–60. &lt;A href="http://pmj.sagepub.com/cgi/reprint/15/6/451" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Skilbeck J, Small N, Ahmedzai SH.&amp;nbsp; Nurses’ perception of specialist palliative care in an acute hospital.&amp;nbsp; International Journal of Palliative Nursing 1999 5:110–15.&lt;/LI&gt;
&lt;LI&gt;Lynn J, Ely E, Wesley E et al. Living and dying with chronic obstructive pulmonary disease.&amp;nbsp; Journal of the American Geriatric Society 2000 48(5):S910–S1000. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10809462&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Weiss SC, Emmanuel LL, Fairclough DL et al. Understanding the experience of pain in terminally ill patients. Lancet 2001 357:1311–15. &lt;A href="http://linkinghub.elsevier.com/retrieve/pii/S0140673600045153" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Coventry PA.&amp;nbsp; Grande GE.&amp;nbsp; Richards DA.&amp;nbsp; Todd CJ. Prediction of appropriate timing of palliative care for older adults with non-malignant life-threatening disease: a systematic review.&amp;nbsp; Age &amp;amp; Ageing 2005&amp;nbsp;&amp;nbsp; 34(3):218-27. &lt;A href="http://ageing.oxfordjournals.org/cgi/content/abstract/34/3/218" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Skilbeck J, Mott L, Page H et al. Palliative care in chronic obstructive airways disease: a needs assessment. Palliative Medicine 1998 12:245–54. &lt;A href="http://pmj.sagepub.com/cgi/reprint/12/4/245" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Freeman D.&amp;nbsp; Price D. ABC of chronic obstructive pulmonary disease. Primary care and palliative care. British Medical Journal. 2006 333(7560):188-90.&lt;/LI&gt;
&lt;LI&gt;Edmonds P, Karlson S, Khan S et al. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001 15:287–95. [&lt;A href="http://pmj.sagepub.com/cgi/reprint/15/4/287" target="_blank"&gt;FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Booth S.&amp;nbsp; Wade R.&amp;nbsp; Johnson M.&amp;nbsp; Kite S.&amp;nbsp; Swannick M.&amp;nbsp; Anderson H.&amp;nbsp; Expert Working Group of the Scientific Committee of the Association of Palliative Medicine. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respiratory Medicine 2004 98(1):66-77. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=14959816&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt; [erratum appears in Respiratory Medicine. 2004 May;98(5):476].&lt;/LI&gt;
&lt;LI&gt;Elkington H.&amp;nbsp; White P.&amp;nbsp; Addington-Hall J.&amp;nbsp; Higgs R.&amp;nbsp; Pettinari C. The last year of life of COPD: a qualitative study of symptoms and services.&amp;nbsp; Respiratory Medicine 2004 98(5):439-45. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15139573&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Guthrie SJ, Hill KM, Muers MF. Living with severe COPD.&amp;nbsp; A qualitative exploration of the experience of patients in Leeds. Respiratory Medicine 2001; 95:196–204. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11266237&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Curtis JR.&amp;nbsp; Engelberg RA.&amp;nbsp; Wenrich MD.&amp;nbsp; Au DH. Communication about palliative care for patients with chronic obstructive pulmonary disease. Journal of Palliative Care 2005 21(3):157-64. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;amp;cmd=Retrieve&amp;amp;dopt=AbstractPlus&amp;amp;list_uids=16334970&amp;amp;query_hl=9&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Jennings AL.&amp;nbsp; Davies AN.&amp;nbsp; Higgins JP.&amp;nbsp; Gibbs JS.&amp;nbsp; Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002 57(11):939-44. &lt;A href="http://thorax.bmj.com/cgi/reprint/57/11/939" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ahmedzai SH, Walsh TD. Palliative medicine and modern cancer care. Seminars in Oncology 2000 27:1-6. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10697016&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=left&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?catID=5880&amp;amp;tabID=292" target="_blank"&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>312085</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/copd_review_final.pdf]]&gt;</url>
    <title>COPD Review</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It aims to provide a practical approach to reviewing people with COPD.&lt;/P&gt;
&lt;P&gt;GPIAG Opinon No 25&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82824</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://ccforum.com/]]&gt;</url>
    <title>Critical Care</title>
    <publicationDate></publicationDate>
    <publisher>Biomed Central</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,ICU]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Critical Care is a peer-reviewed, clinical medical journal which aims to improve the care of critically ill patients by acquiring, discussing, distributing, and promoting evidence-based information relevant to professionals in the intensive care field.&lt;/P&gt;
&lt;P&gt;This is an open access journal and free to everyone.&lt;/P&gt;
&lt;P&gt;This journal is published 6 times a year.&lt;BR&gt;ISSN: 1364-8535&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79831</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/collection/cystic_fibrosis]]&gt;</url>
    <title>Cystic fibrosis</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,RESPIRATORY,CYSTIC FIBROSIS,SPECIALTIES,CYSTIC FIBROSIS,PUBLICATIONS,STAFF USE,JOURNALS,CHRONIC SUPPURATIVE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since April 1999 relevant to cystic fibrosis. &lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>293470</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=293470]]&gt;</url>
    <title>Cystic Fibrosis - Introductory Article</title>
    <publicationDate>2008-09-02T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ GENETIC CONDITIONS A-Z,RESPIRATORY,CYSTIC FIBROSIS,GENETIC CONDITIONS,SYSTEMS &amp; SYMPTOMS,CYSTIC FIBROSIS (CF),CONDITIONS C,CHRONIC SUPPURATIVE DISEASES,BLOOD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description>Cochrane Cystic Fibrosis &amp; Genetic Disorders Review Group.</description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Cystic Fibrosis - Introductory Article&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Cystic fibrosis is the most common life-limiting autosomal recessive genetic disorder in Caucasians, with respiratory disease being the major cause of mortality and morbidity. The UK Cystic Fibrosis Trust has published a series of consensus documents aimed at clinicians and allied health professionals involved in treating patients with cystic fibrosis. They are written by cystic fibrosis experts in a range of specialist areas, and provide guidance in some of the most important topics in cystic fibrosis treatment and care, such as Standards of care, Burkholderia cepacia, Pseudomonas aeruginosa, Nursing, Physiotherapy, Nutrition, Antibiotics and CF related diabetes.&amp;nbsp; The following documents are available via the UK &lt;A href="http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/" target="_blank"&gt;CF Trust website&lt;/A&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Addendum for Bone Mineralisation in Cystic Fibrosis. 2007.&lt;/LI&gt;
&lt;LI&gt;The Burkholderia cepacia Complex - Suggestions for Prevention and Infection Control. Second edition. 2004.&lt;/LI&gt;
&lt;LI&gt;Standards of Care - Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK 2001. 2001. &lt;/LI&gt;
&lt;LI&gt;Pseudomonas aeruginosa infection in people with Cystic Fibrosis. Suggestions for Prevention and Infection Control. Second Edition. 2004. &lt;/LI&gt;
&lt;LI&gt;National Consensus Standards for the Nursing Management of Cystic Fibrosis. 2001.&lt;/LI&gt;
&lt;LI&gt;Clinical Guidelines for the Physiotherapy Management of Cystic Fibrosis. 2002.&lt;/LI&gt;
&lt;LI&gt;Nutritional Management of Cystic Fibrosis. 2002. &lt;/LI&gt;
&lt;LI&gt;Antibiotic Treatment for Cystic Fibrosis. Second edition. 2002. &lt;/LI&gt;
&lt;LI&gt;Addendum for Antibiotic Treatment for Cystic Fibrosis. Second edition. 2002 &lt;/LI&gt;
&lt;LI&gt;Management of Cystic Fibrosis-related Diabetes Mellitus. 2004.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The European Cystic Fibrosis Society has also published a series of consensus reports on a number of aspects of cystic fibrosis. Published consensus reports are listed below, some of which are available free of charge from the &lt;A href="http://www.ecfs.eu/publications/consensus_reports" target="_blank"&gt;ECFS website&lt;/A&gt;:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008.&lt;/LI&gt;
&lt;LI&gt;Clinical Trials in Cystic Fibrosis. 2007.&lt;/LI&gt;
&lt;LI&gt;Immunisation in the current management of cystic fibrosis patients. 2005.&lt;/LI&gt;
&lt;LI&gt;Standards of care for patients with cystic fibrosis: A European consensus. 2005.&lt;/LI&gt;
&lt;LI&gt;Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. 2005.&lt;/LI&gt;
&lt;LI&gt;Nutrition inpatients with cystic fibrosis: a European consensus. 2002.&lt;/LI&gt;
&lt;LI&gt;Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. 2000.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These documents incorporate data from many sources including Cochrane systematic reviews. While there are currently no NICE guidelines available, there are a large number of &lt;A href="http://www.cochrane.org/reviews/en/topics/55.html" target="_blank"&gt;Cochrane Reviews &lt;/A&gt;addressing the wide range of interventions available for the treatment of this multi-system disease. As well as informing current guidelines, Cochrane Reviews are also used to determine the future research agenda, evidence from which will then feedback into the development of future guidelines.&lt;/P&gt;
&lt;P&gt;Other sources of information include HTA and DARE, which are available within the &lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=289&amp;amp;catID=5883&amp;amp;" target="_blank"&gt;Evidence &lt;/A&gt;section of the library.&lt;/P&gt;
&lt;P&gt;Furthermore, a number of general patient information sheets can be obtained from the UK &lt;A href="http://www.cftrust.org.uk/aboutcf/publications/factsheets/" target="_blank"&gt;Cystic Fibrosis Trust&lt;/A&gt;. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>286714</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Managingyourorganisation/Commissioning/Commissioningspecialisedservices/Specialisedservicesdefinition/DH_4001675]]&gt;</url>
    <title>Cystic Fibrosis - Specialised Services National Definition Set</title>
    <publicationDate>2007-02-08T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CYSTIC FIBROSIS,PUBLICATIONS,CHRONIC SUPPURATIVE DISEASES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Cystic fibrosis (CF) affects all races but, in particular, is the commonest recessively inherited disease of Caucasians affecting 1/2500 live births. 
&lt;DIV class="subContent first"&gt;
&lt;P&gt;It is a multi-system disease affecting the exocrine glands, principally the lung and digestive systems. It is estimated that a population of 250,000 is likely to have 35 residents with CF, 15 of which will be adults. For those born since 1990 it is expected that 50% will live beyond 40 years. As it is a progressive condition with an improving prognosis, there is a rapidly increasing number of adult patients with inevitably more severe problems, whilst the paediatric population is relatively static.&lt;/P&gt;
&lt;P&gt;As a multi-system disease, a specialist centre requires a multi-disciplinary team approach to care. This team comprises experienced clinician, specialist nurse, respiratory physiotherapist, dietician, clinical psychologist and ideally, social worker, all of whom spend a substantial part of their working time dealing with CF.&lt;/P&gt;
&lt;P&gt;Patient care is delivered by a hub and spoke arrangement with the specialist centre at the hub supervising but sharing care with local hospitals and primary care teams. Whilst details of the model may vary between patients and areas, the key is that specialist supervision oversees local provision with the patient seen centrally at diagnosis for initial assessment and then at minimum, annually for review. Currently, most provision for adults is only at specialist centres, whereas the hub and spoke arrangement is common for children.&lt;/P&gt;
&lt;P&gt;The definition of a specialist centre is not rigid and is based on a combination of patient treatment services, numbers attending there, the presence of the multi-disciplinary team outlined above, the ability to manage the more unusual manifestations of the condition and the additional functions it carries out such as research, education and standard setting.&lt;/P&gt;
&lt;P&gt;Specialised services for adults and children are not the same and should be commissioned separately but with regard to each other and in particular, services should be arranged to ensure a smooth transition from paediatric to adult care. Paediatric services should be provided in a paediatric setting where there are appropriate paediatric support services.&lt;/P&gt;
&lt;P&gt;It is the nature of the service that is specialised not its physical location. All care for CF patients whether within the specialist hospital or the shared care facility should be regarded as specialised. In fact, any care provided by the CF team, which may include support given in a patient's home will come within the remit of this definition.&lt;/P&gt;&lt;/DIV&gt;
&lt;DIV class=subContent&gt;
&lt;UL class=subLinks&gt;
&lt;LI&gt;&lt;A class=internalLink title="complete definition document" href="http://www.dh.gov.uk/en/Managingyourorganisation/Commissioning/Commissioningspecialisedservices/Specialisedservicesdefinition/DH_4001675?IdcService=GET_FILE&amp;amp;dID=15333&amp;amp;Rendition=Web" target="_blank"&gt;Download complete definition document (PDF, 30K)&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;&lt;/DIV&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>374852</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.impressresp.com/Portals/0/IMPRESS/DeliveringRespCare_Final.pdf]]&gt;</url>
    <title>Delivering respiratory care closer to home by improving the way respiratory outpatient care is provided</title>
    <publicationDate>2008-08-15T00:00:00</publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report&amp;nbsp; highlights the main opportunities and challenges in moving patients' care closer to hom.]]&gt;</body>
  </document>
  <document>
    <id>312017</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/diagnosis_of_asthma_final.pdf]]&gt;</url>
    <title>Diagnosis of Asthma</title>
    <publicationDate>2005-05-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It provides short summary intended to assist clinicians in making a diagnosis of asthma in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet No. 15.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325792</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/diagnosis_asthma_adults_final.pdf]]&gt;</url>
    <title>Diagnosis of Asthma in Adults</title>
    <publicationDate>2009-06-23T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>One of a range of easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at those working in primary care.</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;Opinion Sheets on other related topics are available from the GPIAG website &lt;BR&gt;&lt;A href="http://www.gpiag.org/pubs/opinionsheets.php" target="_blank"&gt;http://www.gpiag.org/pubs/opinionsheets.php&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262201</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/atrial/merec_extra_no28.htm]]&gt;</url>
    <title>Does TORCH shed light on COPD management?</title>
    <publicationDate>2007-05-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,MEREC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>MeReC Extra, Issue No. 28, May 2007.</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/atrial/resources/merec_extra_no28.pdf" target="_blank"&gt;Click here to view this document (PDF version)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This is one of a series of briefings published by the National Prescribing Centre six times a year. The briefing was published in May 2007 and focuses on whether TORCH sheds light on COPD management.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.npc.co.uk/MeReC_Extra/2007/pdfs/MeReC_Extra_No27.pdf" target="_blank"&gt;&amp;nbsp;&lt;/P&gt;&lt;/A&gt;]]&gt;</body>
  </document>
  <document>
    <id>344015</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.theipcrg.org/resources/ipcrg_copd_opinion_5.pdf]]&gt;</url>
    <title>Early Diagnosis of COPD does help!</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>International Primary Care Respiratory Group (IPCRG)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Opinion sheet published by the IPCRG</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the International Primary Care Respiratory Group, IPCRG (formaly GPIAG), aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;This opinion sheet reviews the evidence for the benefits of early diagnosis of COPD and gives some tools that can be used to make changes in practice to improve health outcomes for patients.&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6005</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://ejcts.ctsnetjournals.org/]]&gt;</url>
    <title>European Journal of Cardio-Thoracic Surgery</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The primary aim of the European Journal of Cardio-Thoracic Surgery is to provide a medium for the publication of high-quality original scientific reports documenting progress in cardiac and thoracic surgery. The journal publishes reports of significant clinical and experimental advances related to surgery of the heart, the great vessels and the chest. Special emphasis is placed on contribution from the European countries. Selected papers from the annual meetings of the European Association for Cardio-Thoracic Surgery are printed in the journal. 
&lt;P&gt;Published 12 times a year.&lt;BR&gt;ISSN: 1010-7940 
&lt;P&gt;Access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts from 1987 onwards, some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>102927</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.erj.ersjournals.com/]]&gt;</url>
    <title>European Respiratory Journal</title>
    <publicationDate></publicationDate>
    <publisher>European Respiratory Society (ERS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The official journal of the &lt;A href="http://www.ersnet.org/" target="_blank"&gt;European Respiratory Society&lt;/A&gt;. This peer reviewed journal features:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;clinical and experimental work in the field of respiratory medicine 
&lt;LI&gt;original articles 
&lt;LI&gt;series 
&lt;LI&gt;editorials 
&lt;LI&gt;correspondence 
&lt;LI&gt;short reports and case studies.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Access is available to abstracts and table of contents, with free full text access to articles over 18 months old.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325741</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://err.ersjournals.com/]]&gt;</url>
    <title>European Respiratory Review</title>
    <publicationDate></publicationDate>
    <publisher>European Respiratory Society (ERS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The &lt;STRONG&gt;European Respiratory Review&lt;/STRONG&gt; publishes reviews, updates, editorials and case reports on current topical issues in respiratory medicine, science and surgery. Currently, it is published quarterly&lt;/P&gt;
&lt;P&gt;This is an open access journal. All content can be viewed free of charge through their website - &lt;A href="http://err.ersjournals.com/" target="_blank"&gt;http://err.ersjournals.com/&lt;/A&gt;&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187250</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187250]]&gt;</url>
    <title>Evidence-based drug therapy</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,THERAPEUTIC INTERVENTION,SMOKING,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Evidence-based drug therapy&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr David Halpin, Consultant Physician &amp;amp; Honorary Senior Clinical Lecturer, Royal Devon &amp;amp; Exeter Hospital&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Patients with COPD experience a variety of symptoms reflecting the multi-dimensional nature of the condition.&amp;nbsp; The NICE guideline groups these into 8 broad problem areas, each of which may require drug therapy: smoking, breathlessness, exacerbations, respiratory failure, cor pulmonale, weight loss, chronic productive cough, and anxiety and depression.&amp;nbsp; Most patients seek medical help because of breathlessness, and this and reduction in exacerbation frequency are the areas were most of the recent developments have occurred.&amp;nbsp; Oxygen therapy and diuretics are effective treatments for respiratory failure and cor-pulmonale, and anti-depressants improve anxiety and depression. &lt;/P&gt;
&lt;P&gt;Mild intermittent breathlessness can be treated using as needed short-acting beta-agonists such as salbutamol or terbutaline, or the short-acting anticholinergic ipratropium.&amp;nbsp; Short-acting beta agonists and anticholinergics can be combined to give greater symptomatic benefit, but there is now good evidence that long-acting bronchodilators such as tiotropium, salmeterol or formoterol, offer significant benefits over the short-acting drugs in terms of reduced symptoms, improved lung function and exercise capacity, better health related quality of life and also reduced exacerbation rates.&amp;nbsp; These drugs should be used in patients with persistent symptoms.&amp;nbsp; Just as with the short-acting drugs, there is emerging evidence that combining a long-acting beta agonist, such as formoterol or salmeterol, with the long-acting anticholinergic tiotropium offers greater benefits than either drug alone.&lt;/P&gt;
&lt;P&gt;Inhaled steroids do not abolish the airway inflammation present in patients with COPD but they do have an important role in reducing exacerbation rates in patients.&amp;nbsp; Current guidelines recommend their use in patients with an FEV1 less than 50% who have had 2 or more exacerbations requiring antibiotics or oral steroids in a twelve month period.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Combining inhaled steroids with long-acting beta agonists can augment the effects of the beta agonist on breathlessness, exercise capacity and lung function and can lead to a greater reduction in exacerbation frequency.&amp;nbsp; The number needed to treat (NNT) with combination therapy to prevent an exacerbation is extremely low (between 2-3). New data, as yet only published in abstract form suggest that these combinations may also reduce mortality in COPD and they appear to be effective across the spectrum of severity.&lt;/P&gt;
&lt;P&gt;Theophylline and its derivatives are also effective at improving lung function, but their effects on breathlessness, exercise capacity and preventing exacerbations are less clear.&amp;nbsp; Their usefulness is limited by the need to monitor plasma levels and their potential for interaction with other medication.&amp;nbsp; Thus, they tend to be used only in patients who have already tried long-acting bronchodilators or who are unable to use inhaled therapy.&lt;/P&gt;
&lt;P&gt;The devices used to deliver drugs to the lungs are, in many respects, as important as the drugs themselves.&amp;nbsp; If the device is inefficient at delivering the drugs to the lungs or is difficult for patients to learn, or remember how to use then the effectiveness of the therapy will be reduced.&amp;nbsp; Elderly patients with cognitive impairment may have particular difficulty learning and remembering how to use an inhaler.&amp;nbsp; The NICE guideline recommends that inhalers should be prescribed only after patients have received training in the use of the device and have demonstrated satisfactory technique.&lt;/P&gt;
&lt;P&gt;Long term oxygen therapy LTOT aims to improve survival in patients with COPD who have severe hypoxaemia as well as reducing the incidence of polycythaemia, reducing the progression of pulmonary hypertension and improving neuropsychological health.&amp;nbsp; LTOT is indicated in patients with COPD who have a PaO2 &amp;lt; 7.3 kPa when stable, or a PaO2 &amp;gt; 7.3 and &amp;lt; 8 kPa when stable and one of: secondary polycythaemia, nocturnal hypoxaemia (SaO2 less than 90% for more than 30% of the time), peripheral oedema or pulmonary hypertension.&amp;nbsp; The NICE guideline points out that patients require specialist assessment for LTOT therapy because the respiratory drive of some patients with COPD depends on their degree of hypoxia rather than the usual dependence on hypercapnia.&amp;nbsp; Thus uncontrolled oxygen therapy can result in suppression of respiratory drive, carbon dioxide narcosis and ultimately respiratory arrest.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Some patients with COPD only become hypoxaemic on exercise and oxygen has been used to try to improve exercise capacity and reduce disability in these individuals.&amp;nbsp; The new home oxygen service in England contains specific recommendations on the process necessary to determine if the patient requires ambulatory oxygen therapy.&amp;nbsp; Oxygen is also used to provide symptomatic relief of breathlessness.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;If patients with COPD continue to smoke the NICE guideline recommends that they should be encouraged to stop at every opportunity, whatever their age, and offered help to do so.&amp;nbsp; The guidelines recommend that unless contraindicated, bupropion or nicotine replacement therapy combined with an appropriate support programme should be used to optimise quit rates.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188181&amp;amp;tabID=289" target="_blank"&gt;Antibiotics for acute bronchitis&lt;/A&gt;&amp;nbsp;The Cochrane Library 2004, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190290&amp;amp;tabID=289" target="_blank"&gt;Antibiotics for exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Libray 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=189735&amp;amp;tabID=289" target="_blank"&gt;Cardioselective beta-blockers for chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2005, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190159&amp;amp;tabID=289" target="_blank"&gt;Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2004, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=114008&amp;amp;tabID=289" target="_blank"&gt;Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190829&amp;amp;tabID=289" target="_blank"&gt;Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=122223&amp;amp;tabID=289" target="_blank"&gt;Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta analysis&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2006.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188607&amp;amp;tabID=289" target="_blank"&gt;Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=125481&amp;amp;tabID=289" target="_blank"&gt;Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2006.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=112317&amp;amp;tabID=289" target="_blank"&gt;The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2005.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=112321&amp;amp;tabID=289" target="_blank"&gt;The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of published studies&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2005.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=189329&amp;amp;tabID=289" target="_blank"&gt;Tiotropium for stable chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2005, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>331020</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108948]]&gt;</url>
    <title>Exercise peak practice: national summary</title>
    <publicationDate>2009-11-23T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ HEALTH MANAGEMENT,RESPIRATORY,QUALITY AND MONITORING,RISK MANAGEMENT,VIRAL,PUBLICATIONS,INFECTIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report of Exercise Peak Practice is a national summary providing an overview of the ten regional exercises, and documents the high-level areas for further action identified by the delegates who attended.&amp;nbsp;Nationally, Exercise Peak Practice reaffirmed the extent and depth of planning that had already taken place in the NHS in readiness for an influenza pandemic and demonstrated considerable leadership, commitment and planning undertaken by both clinical and managerial staff across the NHS.]]&gt;</body>
  </document>
  <document>
    <id>6008</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/elu?cookieSet=1]]&gt;</url>
    <title>Experimental Lung Research</title>
    <publicationDate></publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Experimental Lung Research publishes articles in all fields of respiratory tract anatomy, biology, developmental biology, toxicology, and pathology. Emphasis is placed on investigations concerned with molecular, biochemical, and cellular mechanisms of normal function, pathogenesis, and responses to injury. The journal publishes reports on important methodological advances on new experimental modes. Also published are invited reviews on important and timely research advances, as well as proceedings of specialized symposia. 
&lt;P&gt;Published 10 times a year.&lt;BR&gt;ISSN: 1521-0499 (online)&amp;nbsp; 
&lt;P&gt;Access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts, some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79191</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/12/17/49/04121749.pdf]]&gt;</url>
    <title>Explaining Pandemic Flu: A guide from the Chief Medical Officer: October 2005 Edition</title>
    <publicationDate>2005-10-19T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ VIRAL,INFECTIONS,OUTCOMES,RISK FACTORS,ENVIRONMENTAL,RESPIRATORY DISORDERS,INFLUENZA,POPULATION BASED &amp; PREVENTATIVE SERVICES,INFECTION CONTROL,MONTHLY ADDITIONS,RESPIRATORY,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SERVICES,HEALTH SERVICES,HEALTHCARE &amp; HEALTH SERVICES,MARCH 2010]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=teaserText&gt;Provides professionals and members of the public with a better understanding of pandemic flu, its likely impact on the UK and their country's plans to respond.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>197299</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=197299]]&gt;</url>
    <title>Facts about COPD</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Facts about COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following information is reproduced with the kind permission of the &lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;British Thoracic Society&lt;/A&gt;.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;COPD kills 30,000 people a year in England and Wales . It is the 5th biggest killer in the UK [1] and the 5th biggest killer worldwide [2] &lt;/LI&gt;
&lt;LI&gt;COPD is an umbrella term for a group of lung diseases which include chronic bronchitis, emphysema and small airways disease. Lung damage over a long period of time impairs the flow of air in and out of the lungs and causes breathlessness &lt;/LI&gt;
&lt;LI&gt;COPD is the only major cause of death whose incidence is on the increase [3] &lt;/LI&gt;
&lt;LI&gt;There are an estimated 3 million people with COPD in the UK [4] , although only an estimated 900,000 are correctly diagnosed [5] . &lt;/LI&gt;
&lt;LI&gt;In the UK, the rate of COPD has been increasing nearly three times faster amongst women than men [6] &lt;/LI&gt;
&lt;LI&gt;COPD kills around 12,000 UK women every year [7]&amp;nbsp;&amp;nbsp;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;References: &lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;National Statistics (2006) Health Statistics Quarterly 30 &lt;A href="http://www.statistics.gov.uk/downloads/theme_health/HSQ30.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;A Practice Nurse Supplement: Nov 2003 &lt;/LI&gt;
&lt;LI&gt;Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349 1498-504 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;amp;db=pubmed&amp;amp;list_uids=9167458&amp;amp;dopt=medline" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Stang P, Lydick E, Silberman C et al. The Prevalence of COPD: Using smoking rates to estimate disease frequency in the general population. Chest 2000; 117: 354S-359S &lt;A href="http://www.chestjournal.org/cgi/content/full/117/5_suppl_2/354S" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Lung Report III (2003), British Lung Foundation &lt;A href="http://www.lunguk.org/downloads/Lung_Report_III_WEB.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt; (PDF)&lt;/LI&gt;
&lt;LI&gt;Breathing Fear - The COPD Effect, Allen &amp;amp; Hanburys 2003 &lt;/LI&gt;
&lt;LI&gt;British Lung Foundation (2005) - Femme Fatality: The rise and rise of COPD in women &lt;A href="http://www.lunguk.org/download.asp?tb=news&amp;amp;id=164" target="_blank"&gt;[FULL TEXT]&lt;/A&gt; (PDF)&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>124004</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=124004]]&gt;</url>
    <title>Free Journals</title>
    <publicationDate>2006-03-29T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Free Journals&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman'; mso-fareast-language: EN-US; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA"&gt;&lt;SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Verdana; mso-fareast-language: EN-US; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA; mso-bidi-font-size: 12.0pt; mso-bidi-font-family: 'Times New Roman'"&gt;The specialist library has put together a list of free journals online&amp;nbsp;relating to the respiratory speciality and&amp;nbsp;including some&amp;nbsp;general medical journals. We have divided them into those that are free to everyone, and those that are part of the NLH Core Content Collection and free to&amp;nbsp;NHS healthcare professionals via their Athens account. You can learn more about what an Athens account is by &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;&lt;FONT color=#3399cc&gt;clicking here&lt;/FONT&gt;&lt;/A&gt;.&amp;nbsp;&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Free to everyone&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ajplung.physiology.org/" target="_blank"&gt;American Journal of Physiology – Lung Cellular and Molecular Physiology&lt;/A&gt; (free after one year)&lt;/P&gt;&lt;STRONG&gt;
&lt;P&gt;&lt;/STRONG&gt;&lt;A href="http://ajrccm.atsjournals.org/" target="_blank"&gt;American Journal of Respiratory and Critical Care Medicine&lt;/A&gt; (free one year after publication)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ajrcmb.atsjournals.org/" target="_blank"&gt;American Journal of Respiratory Cell and Molecular Biology&lt;/A&gt; (free one year after publication)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://journals.elsevierhealth.com/periodicals/ymas" target="_blank"&gt;Asthma Magazine&lt;/A&gt; (2002 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.biomedcentral.com/bmcpulmmed/" target="_blank"&gt;BMC Pulmonary Medicine&lt;/A&gt; (2001 – present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://bmj.bmjjournals.com/" target="_blank"&gt;BMJ&lt;/A&gt; (original research papers free: other content free one year after publication)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chestjournal.org/" target="_blank"&gt;CHEST&lt;/A&gt; (free one year after publication)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.cdc.gov/nccdphp/publications/cdnr/" target="_blank"&gt;Chronic Disease Notes and Reports&lt;/A&gt; (1996 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.clinicalmolecularallergy.com/" target="_blank"&gt;Clinical and Molecular Allergy&lt;/A&gt; (2003 – present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.coughjournal.com/" target="_blank"&gt;Cough&lt;/A&gt; (2005 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ccforum.com/" target="_blank"&gt;Critical Care&lt;/A&gt; (1997 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.allergysa.org/journal.htm" target="_blank"&gt;Current Allergy &amp;amp; Clinical Immunology&lt;/A&gt; (2003 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://jama.ama-assn.org/" target="_blank"&gt;JAMA&lt;/A&gt; (articles free after 6 months, users will need to register as a guest)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://content.nejm.org/" target="_blank"&gt;New England Journal of Medicine&lt;/A&gt; (original articles free after 6 months)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gpiag.org/journ/" target="_blank"&gt;Primary Care Respiratory Journal&lt;/A&gt; (1997 – 2000 available freely via GPIAG website, subsequent issues available via subscription)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.chestnet.org/education/online/pccu/index.php" target="_blank"&gt;Pulmonary and Critical Care Update&lt;/A&gt; (2003 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://respiratory-research.com/home/" target="_blank"&gt;Respiratory Research&lt;/A&gt; (2000 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://ukpmc.ac.uk/tocrender.cgi?journal=379&amp;amp;action=archive" target="_blank"&gt;SLEEP&lt;/A&gt; (2007)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.sro.org/srolow/default.html" target="_blank"&gt;Sleep Research Online&lt;/A&gt; (1998 – the present)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://thorax.bmjjournals.com/contents-by-date.0.shtml" target="_blank"&gt;Thorax&lt;/A&gt; (free after one year)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://tc.bmjjournals.com/contents-by-date.0.shtml" target="_blank"&gt;Tobacco Control&lt;/A&gt; (free after one year)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.who.int/tobacco/" target="_blank"&gt;Tobacco Free Initiative&lt;/A&gt; (WHO information resource)&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Free to NHS Athens account holders&lt;/STRONG&gt; (NHS staff &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;click here&lt;/A&gt; for an Athens account)&lt;/P&gt;
&lt;P&gt;&lt;A href="http://search.ebscohost.com/direct.asp?db=c8h&amp;amp;jid=IO7&amp;amp;scope=site&amp;amp;authtype=athens" target="_blank"&gt;Canadian Journal of Respiratory Therapy&lt;/A&gt; (1996 - present)&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284184</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Lung%20Cancer/WTSTPBTSfinal210408.pdf]]&gt;</url>
    <title>Giving Information to Lung Cancer Patients - Guidance for Healthcare Professionals Discussing Options for Patients on The Lung Cancer Pathway</title>
    <publicationDate>2008-04-01T00:00:00</publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>CARE GUIDELINE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG CANCER,MALIGNANT DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The British Thoracic Society Lung Cancer and Mesothelioma Specialist Advisory Group has produced a guidance document, &lt;STRONG&gt;Giving Information to Lung Cancer Patients&lt;/STRONG&gt;, to assist healthcare professionals in discussion of options for patients on the lung cancer pathway.&lt;/P&gt;
&lt;P&gt;This document covers the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Rationale 
&lt;LI&gt;When to provide information 
&lt;LI&gt;Discusssion after MDT review 
&lt;LI&gt;Being positive 
&lt;LI&gt;Prognosis 
&lt;LI&gt;Non small cell lung cancer 
&lt;LI&gt;Small cell lung cancer 
&lt;LI&gt;Documentation 
&lt;LI&gt;Summary 
&lt;LI&gt;Further information and resources&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>258868</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdhyper/merec_extra_no27_suppl.htm]]&gt;</url>
    <title>Grazax sublingual immunotherapy against grass pollen allergy</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>MeReC Extra, Issue No. 27 (supplement), March 2007</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/cdhyper/resources/merec_extra_no27_suppl.pdf" target="_blank"&gt;Click here to view this document (PDF version)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This is one of a series of briefings published by the National Prescribing Centre six times a year. The briefing was published in March 2007 and focuses on &lt;SPAN class=subheader&gt;Grazax sublingual immunotherapy against grass pollen allergy&lt;/SPAN&gt;. &lt;/P&gt;
&lt;P&gt;The briefing concludes that published randomised clinical trial data suggest that Grazax is statistically significantly more effective than placebo in reducing rhinoconjunctivitis symptoms and the need for additional medication when given 16 weeks before, and continuously throughout, a single pollen season. Some benefit may be obtained if Grazax is initiated at least eight weeks before the season. However, in absolute terms the clinical benefits appear very modest in comparison with symptomatic treatment alone. Further information is required to establish the long-term safety and efficacy of Grazax when given over several seasons, and to identify whether or not there are significant benefits that justify its use ahead of subcutaneous immunotherapy.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270344</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.rcplondon.ac.uk/pubs/contents/e226ee0c-ccef-4dba-b62f-86f046371dfb.pdf]]&gt;</url>
    <title>Harm reduction in nicotine addiction: helping people who can't quit</title>
    <publicationDate>2007-10-01T00:00:00</publicationDate>
    <publisher>Royal College of Physicians (RCP)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ SMOKING,PUBLICATIONS,THERAPEUTIC INTERVENTION,OUTCOMES,ECONOMICS,INDUSTRY,RESPIRATORY DISORDERS,RESPIRATORY,PUBLIC HEALTH,REPORTS,DETERMINANTS,SOCIAL DETERMINANTS,LIFESTYLE,MANAGEMENT &amp; INTERVENTIONS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,HEALTH SERVICES,HEALTHCARE &amp; HEALTH SERVICES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This RCP report makes the case for harm reduction strategies to protect smokers. The report demonstrates that smokers smoke predominantly for nicotine, that nicotine itself is not especially hazardous, and that if nicotine could be provided in a form that is acceptable and effective as a cigarette substitute, millions of lives could be saved. The report also argues that the regulatory systems that currently govern nicotine products in most countries, including the UK, actively discourage the development, marketing and promotion of significantly safer nicotine products to smokers.]]&gt;</body>
  </document>
  <document>
    <id>6028</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://journals.elsevierhealth.com/periodicals/ymhl]]&gt;</url>
    <title>Heart and Lung: Journal of Acute and Critical Care</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Heart and Lung presents peer-reviewed articles on techniques, advances, investigations, and observations in acute and critical care.&lt;/P&gt;
&lt;P&gt;Other sections focus on infection control, neonatal nursing, advanced practice nursing, pharmacotherapy, ethical issues, and patient education. Many articles aim to provide nurses with a framework for applying research results in clinical practice. &lt;/P&gt;
&lt;P&gt;ISSN: 1527-3288&lt;BR&gt;Published 6 times a year. 
&lt;P&gt;Online access to full-text articles from September/October 1998 onwards is via subscription. Non subscribers can access tables of contents and abstracts from 1997 onwards. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>101817</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/documents/Helping%20Smokers%20Stop.doc]]&gt;</url>
    <title>Helping smokers to stop: advice for pharmacists in England</title>
    <publicationDate>2005-08-17T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence (NICE)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,SMOKING,GUIDELINES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document aims to support pharmacists and their teams to deliver smoking cessation treatment.&lt;/P&gt;
&lt;P&gt;The publication was commissioned by the Health Development Agency (HDA) in collaboration with the Royal Pharmaceutical Society of Great Britain and PharmacyHealthLink.&lt;/P&gt;
&lt;P&gt;This publication does not represent NICE guidance.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325786</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/high_risk_asthma_final.pdf]]&gt;</url>
    <title>High Risk Asthma</title>
    <publicationDate>2009-06-23T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>One of a range of easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at those working in primary care</description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;Opinion Sheets on other related topics are available from the GPIAG website &lt;BR&gt;&lt;A href="http://www.gpiag.org/pubs/opinionsheets.php" target="_blank"&gt;http://www.gpiag.org/pubs/opinionsheets.php&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>212772</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.homeoxygen.nhs.uk/1.php]]&gt;</url>
    <title>Home Oxygen Service</title>
    <publicationDate></publicationDate>
    <publisher>NHS Primary Care Contracting</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This website provides links to&amp;nbsp;three different&amp;nbsp;websites covering public, professional and NHS information.&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Public: patients, carers, public. 
&lt;LI&gt;Professionals: Healthcare Professionals involved in the clinical assesment and ongoing care of patients undergoing home oxygen therapy. 
&lt;LI&gt;NHS: for people involved in management of the Home Oxygen Service &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>312092</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/resources/os8_home_oxygen.pdf]]&gt;</url>
    <title>Home oxygen therapy</title>
    <publicationDate>2006-11-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It summarises the current guideline advice on assessing and treating patients who require oxygen therapy.&lt;/P&gt;
&lt;P&gt;GPIAG Opinon No 8&lt;/P&gt;
&lt;P&gt;Revised August 2009&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124953</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=124953]]&gt;</url>
    <title>Impact of SIGN/BTS Guidelines on Asthma Management</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Impact of SIGN/BTS Guidelines on Asthma Management&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Prof Martyn Partridge&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 -&amp;nbsp;26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The first British Guidelines on Asthma in Adults were published in 1990&lt;A href="#refs"&gt;[1,2]&lt;/A&gt;. They were revised in 1992 and 1995 and subsequently the British Thoracic Society worked with the Scottish Intercollegiate Guidelines Network using rigorous methodology to produce the new British Guideline on Asthma in 2003 and these are now updated, at least in part, annually. The next complete Revision in printed form will be in 2007. &lt;/P&gt;
&lt;P&gt;Since 1997 each revision of the Guidelines has been published with the help of a Dissemination Committee and the activities of these Committees have been fully reported in the literature &lt;A href="#refs"&gt;[3,4]&lt;/A&gt;. It is not possible to evaluate the extent to which these Guidelines have been implemented (i.e. led to a change in healthcare practice) but the Dissemination Committee does monitor the amount of material sent out, the quantity of materials requested by healthcare professionals and the number of copies of Guidelines and accompanying educational materials which are downloaded from the two organisations’ websites. &lt;/P&gt;
&lt;P&gt;When formal awareness studies have been undertaken, it’s clear that only some of the key dissemination messages are successfully spread with a tendency for there to be a greater awareness regarding therapeutic recommendations compared to issues concerning diagnosis, self management or organisation of care. This emphasises the fact that implementation depends on a large number of factors and there are many other influences. The presence of rigorously produced evidence-based Guidelines however permits all to sing from the same songsheet, and the process of producing the Guidelines has proved equally valuable in highlighting areas in need of further research.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A name=refs&gt;&lt;/A&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The references were supplied by the author. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Guidelines for management of asthma in adults: 1 – Chronic Persistent Asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, Kings Fund Centre, National Asthma Campaign. BMJ 1990; 301:651-3. &lt;/LI&gt;
&lt;LI&gt;Guidelines for management of asthma in adults: 2 - Acute Severe Asthma. Statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, Kings Fund Centre, National Asthma Campaign. BMJ 1990; 301:797-800.&lt;/LI&gt;
&lt;LI&gt;Partridge MR, Harrison BDW, Rudolph M, Bellamy D, Silverman M. The British Asthma Guidelines – their production, dissemination and implementation. An article for Respiratory Medicine on behalf of the British Asthma Guidelines Co-ordinating Committee. Resp. Med 1998; 92: 1046-52. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9893774&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Dennis SM, Edwards S, Partridge MR, Pinnock HJ,&amp;nbsp; Qureshi SJ.&amp;nbsp; The Dissemination of the British Guideline on the Management of Asthma 2003; Resp. Med 2004; 98: 832-837. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=15338794&amp;amp;query_hl=18&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/FONT&gt; 
&lt;P&gt;&lt;/P&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;BR&gt;&lt;/STRONG&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P align=left&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=left&gt;&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/63/index.html" target="_blank"&gt;British Guideline on the Management of Asthma&lt;/A&gt;, SIGN/BTS (last updated November 2005)&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>281358</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.impressresp.com/]]&gt;</url>
    <title>Improving and Integrating Respiratory Services in the NHS (IMPRESS)</title>
    <publicationDate></publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ORGANISATIONS,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PROFESSIONAL BODIES]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>A joint initiative between the two leading respiratory clinical societies in the UK: the Primary Care Respiratory Society and the British Thoracic Society</description>
    <body>&lt;![CDATA[ &lt;P&gt;IMPRESS is a joint initiative between the two leading respiratory clinical societies in the UK: the &lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;British Thoracic Society &lt;/A&gt;and the &lt;A href="http://www.pcrs-uk.org/" target="_blank"&gt;Primary Care Respiratory Society (PCRS)&lt;/A&gt; UK (previously the General Practice Airways Group, GPIAG).&lt;/P&gt;
&lt;P&gt;The site contains information&amp;nbsp;to commission or provide high quality patient-centred services, integrated between primary and secondary care. The focus is on long term conditions such as COPD, asthma and sleep apnoea because these are the conditions most likely to require a mix of primary and secondary care over a person's lifetime. The website is designed to equip commissioners with an understanding of the evidence-base, standards, workforce issues, and tricky issues such as interpreting data and coding correctly.&amp;nbsp; Equally, it offers clinicians practical tools; an appreciation of how their services might be commissioned in the future, and suggestions of how they best engage with the commissioning process.&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>98643</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.immunisation.nhs.uk/files/flu_factsheet.pdf]]&gt;</url>
    <title>Influenza: The disease and vaccine</title>
    <publicationDate>2005-06-22T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,VIRAL,PATIENT INFORMATION,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This factsheet discusses and describes&amp;nbsp;the disease, who is most at risk, when the flu season starts and ends, and why different types of flu change every year. The factsheet&amp;nbsp;further discusses the flu vaccine and what someone should do if they catch flu.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>258877</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/cardio/cdhyper/merec_extra_no27.htm]]&gt;</url>
    <title>Inhaled corticosteroids: children are at risk from high doses</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,RESPIRATORY,SPECIALTIES,ASTHMA,ASTHMA,STAFF USE,INVESTIGATIONS,THERAPEUTIC INTERVENTION,MEREC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>MeReC Extra, Issue No. 27, March 2007</description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;A href="http://www.npc.co.uk/ebt/merec/cardio/cdhyper/resources/merec_extra_no27.pdf" target="_blank"&gt;Click here to view this document (PDF version)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This is one of a series of briefings published by the National Prescribing Centre six times a year. The briefing was published in March 2007 and focuses on i&lt;SPAN class=subheader&gt;nhaled corticosteroids and&amp;nbsp;children who are at risk from high doses&lt;/SPAN&gt;.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312020</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/inhaler_devices_final.pdf]]&gt;</url>
    <title>Inhaler Devices</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the &lt;SPAN class=detail_dataText&gt;Primary Care Respiratory Society UK&lt;/SPAN&gt;, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It looks at the different types of inhalers available and patients use of them.&lt;/P&gt;
&lt;P&gt;&lt;SPAN class=detail_dataText&gt;Primary Care Respiratory Society UK&lt;/SPAN&gt; Opinion Sheet No 20.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6087</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.theunion.org/about-the-journal/about-the-journal.html]]&gt;</url>
    <title>International Journal of Tuberculosis and Lung Disease</title>
    <publicationDate></publicationDate>
    <publisher>International Union Against Tuberculosis and Lung Disease</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,SMOKING,JOURNALS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the International Union against Tuberculosis and Lung Disease.&lt;BR&gt;A peer reviewed reference for clinical research and epidemiological studies on tuberculosis.&lt;/P&gt;
&lt;P&gt;Covers lung health worldwide, including articles on TB/HIV and non-tuberculosis-related respiratory diseases such as asthma, acute respiratory infection, COPD, child lung health and the hazards of tobacco and pollution. &lt;/P&gt;
&lt;P&gt;ISSN 1027-3719, Online ISSN: 1815-7920 &lt;BR&gt;Published 12 times a year. 
&lt;P&gt;Online access to full text is available to subscribers&amp;nbsp;on the ingenta website:&lt;BR&gt;&lt;A href="http://www.ingenta.com/journals/browse/iuatld/ijtld" target="_blank"&gt;http://www.ingenta.com/journals/browse/iuatld/ijtld&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>275424</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/pdf/PreventingSmokingChildrenEvidence%20ReviewFullReport.pdf]]&gt;</url>
    <title>Interventions to Prevent the Uptake of Smoking in Children and Young People</title>
    <publicationDate>2007-11-22T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence (NICE)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,COMMUNITY CHILD HEALTH,RESPIRATORY,RESPIRATORY,HEALTH PROMOTION,SPECIALTIES,PUBLICATIONS,REPORTS,PUBLICATIONS,SMOKING,SMOKING,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NICE Rapid Review</description>
    <body>&lt;![CDATA[ &lt;P&gt;This review examines the effectiiveness of: (a) mass media interventions designed to prevent the uptake of smoking in children and young people and (b) interventions that are designed to prevent the illegal sale of tobacco&amp;nbsp;to children and young people. The review considers specific sub-questions related to the factors that might influence effectiveness, any differential effects for different audiences, and barriers and facilitators to implementation.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>280090</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.lunguk.org/NR/rdonlyres/E027CA18-B5C6-49AB-96FA-C4AF55E6F484/0/InvisibleLivesreport.pdf]]&gt;</url>
    <title>Invisible Lives - Chronic Obstructive Pulmonary Disease (COPD) - finding the missing millions</title>
    <publicationDate>2007-11-06T00:00:00</publicationDate>
    <publisher>British Lung Foundation (BLF)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This British Lung Foundation (BLF)&amp;nbsp;report which aims to draw public attention to the issue of lung disease.&lt;/P&gt;&lt;FONT face=FSAlbert-Light&gt;
&lt;P align=left&gt;Recent research suggests that there are an estimated 3.7 million people with COPD&lt;/FONT&gt;&lt;FONT face=FSAlbert-Light size=1&gt; &lt;/FONT&gt;&lt;FONT face=FSAlbert-Light&gt;in the UK, yet only 900,000 people have been diagnosed with the disease&lt;/FONT&gt;&lt;FONT face=FSAlbert-Light&gt;. This means that there are 2.8 million people who are currently unaware they have a condition which, if left untreated, could severely restrict their lives and eventually kill them. These are the ‘missing millions’ after which this report is named.&lt;/P&gt;
&lt;P align=left&gt;With this report the BLF believes it has identified specific communities throughout the UK where people are at high risk of hospital admission with COPD. Within these communities 1.9 million people live in postcode areas at high risk of COPD admissions.&amp;nbsp;BLF have also identified the best communication channels to reach and engage these people, making it possible for those at risk to be diagnosed and treated to ensure they have the potential to live longer, more productive lives.&lt;/P&gt;
&lt;P&gt;&lt;/FONT&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>98598</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/11/57/86/04115786.pdf]]&gt;</url>
    <title>It takes your breath away: The impact of Chronic Obstructive Pulmonary Disease</title>
    <publicationDate>2005-07-20T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,SMOKING,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Part of the Chief Medical Officer's annual report for 2004. The report looks at the costs and management of COPD, and makes a number of recommendations - including one recommending the formulation of a National Service Framework for COPD.]]&gt;</body>
  </document>
  <document>
    <id>6085</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.liebertpub.com/publication.aspx?pub_id=24]]&gt;</url>
    <title>Journal of Aerosol Medicine</title>
    <publicationDate></publicationDate>
    <publisher>Mary Ann Liebert Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,AEROSOL THERAPY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the International Society for Aerosols in Medicine. Contains peer-reviewed papers on studies involving inhalation of particles and gases in the respiratory tract. Covering the use of aerosols as tools to study basic physiological phenomena, their use as delivery systems for medication, the measurement of respiratory secretions and the toxic effects of inhaled agents. 
&lt;P&gt;ISSN: 0894-2684&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text is available to subscribers from June 2000 (Volume 13, 2) onwards on the ingenta website : &lt;A href="http://taddeo.ingentaselect.com/vl=1454830/cl=74/nw=1/rpsv/catchword/mal/08942684/" target="_blank"&gt;http://taddeo.ingentaselect.com/vl=1454830/cl=74/nw=1/rpsv/catchword/mal/08942684/&lt;/A&gt;&lt;BR&gt;Information about the journal and tables of contents can be freely accessed by non-subscribers through the journal homepage.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6092</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://informahealthcare.com/jas]]&gt;</url>
    <title>Journal of Asthma</title>
    <publicationDate></publicationDate>
    <publisher>Informa Healthcare</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the Association for the Care of Asthma. Discusses asthma from the perspectives of clinical immunology, allergy, pulmonary physiology, psychosomatics, pharmacology and other asthma-related clinical health trends. 
&lt;P&gt;ISSN: 1532-4303 (electronic) 0277-0903 (paper) &lt;BR&gt;Published&amp;nbsp;10 times a year. 
&lt;P&gt;Online access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts from May 2001 (Volume 38, 1) onwards, previews of full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6095</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.blackwellpublishing.com/journal.asp?ref=0962-1105]]&gt;</url>
    <title>Journal of Sleep Research</title>
    <publicationDate></publicationDate>
    <publisher>Blackwell Publishing</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the European Sleep Research Society. Publishes research papers and presenting new findings in the field of sleep and wakefulness (including biological rhythms and dreaming). Aims to reflect progress in the field and promote and international exchange of ideas between scientists. 
&lt;P&gt;Print ISSN: 0962-1105 Online ISSN: 1365-2869&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text, from March 1996 (Volume 5, 1) onwards, is via subscription, with free access for non subscribers to tables of contents and abstracts some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6004</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://jtcs.ctsnetjournals.org/]]&gt;</url>
    <title>Journal of Thoracic and Cardiovascular Surgery</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,TRANSPLANTATION,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of The American Association for Thoracic Surgery and The Western Thoracic Surgical Association. Presents articles on conditions of the chest, heart, lungs, and great vessels where surgical intervention is indicated. Focuses on techniques and developments in cardiac surgery, pacemaker insertion/removal, lung and esophageal surgeries, heart and lung transplantation, and other procedures. &lt;/P&gt;
&lt;P&gt;Published 12 times a year.&lt;BR&gt;Online ISSN: 01097-685X 
&lt;P&gt;Access to full text is via subscription, with free access for non subscribers to tables of contents from 1965 onwards, abstracts from 1975 onwards and some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6090</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thoracicimaging.com/]]&gt;</url>
    <title>Journal of Thoracic Imaging</title>
    <publicationDate></publicationDate>
    <publisher>Lippincott Williams &amp; Wilkins</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,IMAGING,PUBLICATIONS,JOURNALS,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Provides information on all aspects of the use of imaging techniques in the diagnosis of chest disease. Publishes original articles and analytical reviews concerning the use of conventional chest radiography, tomography, computed tomography, digitized radiography, ultrasound, nuclear medicine, magnetic resonance imaging, and all other promising techniques of thoracic radiology. 
&lt;P&gt;ISSN: 0883-5993&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts from July 2001 (Volume 16, 3) onwards, some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187257</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187257]]&gt;</url>
    <title>Living with COPD</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Living with COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Monica Fletcher, Chief Executive, Education for Health&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Chronic obstructive pulmonary disease (COPD) is characterised by slowly progressive, irreversible airflow obstruction&lt;A href="#refs"&gt;[1]&lt;/A&gt;. It produces progressively disabling symptoms that eventually impact on every aspect of a patient’s life. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Burden of disease&lt;/STRONG&gt;&lt;BR&gt;The burden of COPD on individuals, the health service and society as a whole is great. Compared to angina&lt;A href="#refs"&gt;[2]&lt;/A&gt; there are at least twice as many GP consultations for COPD&amp;nbsp; and of the total costs of managing COPD, 16.4% are for GP visits and a further 5.7% of the costs are for unscheduled visits to the GP or accident and emergency department&lt;A href="#refs"&gt;[3]&lt;/A&gt;. We should not forget that the main burden of this devastating disease falls on the patients and their families who live and cope with the disease every day. A key aim of COPD management is to keep patients functioning, as independently as possible in the community&lt;A href="#refs"&gt;[1]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Smoking cessation&lt;/STRONG&gt;&lt;BR&gt;The vast majority of patients with COPD are or have been smokers; there is a smaller percentage who have never smoked. It is also true to say that not all smokers will develop COPD. However for those who do smoke, stopping is the only thing that reduces the progression of COPD. Lost lung function cannot be regained, but stopping smoking reduces the rate of decline of lung function to that of a non-smoker&lt;A href="#refs"&gt;[4]&lt;/A&gt;. It is never too late to stop! All health professionals must encourage and support COPD patients to quit – at every opportunity. Nicotine replacement therapy or bupropion, together with active support, maximises the chance of success and should be encouraged&lt;A href="#refs"&gt;[5]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Exercise and breathlessness&lt;BR&gt;&lt;/STRONG&gt;Progressive breathlessness on exertion is a key feature of COPD. Even every day activities such as washing and dressing can cause disabling breathlessness. Often the response to such experiences is activity avoidance and this can lead to a downward deconditioning spiral whereby cardiovascular fitness decreases, skeletal muscle mass is lost and patients consequently become more breathless. Figure 1.&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID187257/nelhImp_0000_livingcopd.jpg" name=nelh_tempImage2&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;Fig 1: The downward spiral of breathlessness in COPD&amp;nbsp;&lt;/P&gt;
&lt;P&gt;For people with COPD breathlessness is not harmful although it is unpleasant and can provoke anxiety and panic.&amp;nbsp; Regular exercise improves cardiovascular fitness, maintains function and can reduce the sensation of breathlessness. It is important to encourage COPD patients (except when they have co-morbid cardiovascular disease when specialist advice should be sought) to maintain, and preferably increase their activity levels. &lt;/P&gt;
&lt;P&gt;The Medical Research Council Dyspnoea Score allows patients to assess how much their breathlessness interferes with their ability to undertake normal daily activities. The NICE guideline&lt;A href="#refs"&gt;[1]&lt;/A&gt; recommends its use during routine reviews.&lt;/P&gt;
&lt;P&gt;The MRC Dyspnoea Scale&lt;/P&gt;
&lt;P&gt;Grade&amp;nbsp;Degree of breathlessness related to activities&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Not troubled by breathlessness except on strenuous exercise&lt;/LI&gt;
&lt;LI&gt;Short of breath when hurrying on walking up a slight hill&lt;/LI&gt;
&lt;LI&gt;Walks slower than contemporaries on the level because of breathlessness, or has to stop for breath when walking at own pace&lt;/LI&gt;
&lt;LI&gt;Stops for breath after walking about 100m, or after a few minutes on the level&lt;/LI&gt;
&lt;LI&gt;Too breathless to leave the house, or breathless when dressing or undressing&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&lt;BR&gt;A Borg scale&lt;A href="#refs"&gt;[6]&lt;/A&gt;, allows patients to grade the intensity of their breathlessness during activity. It was developed as a tool for athletes and coaches to guide the intensity of sports training, but is equally applicable as a guide to increase exercise tolerance in COPD. The eventual aim should be to experience moderate breathlessness (Borg scale 3-5) for at least 20 minutes, three or four times a week&lt;A href="#refs"&gt;[7]&lt;/A&gt;. Exercise needs to be regular and simple exercise regimes that equate with normal daily activity, such as walking, cycling or stair climbing, are most likely to be adhered to. &lt;/P&gt;
&lt;P&gt;COPD patients usually use accessory muscles of respiration. These are less efficient and tire easily. Breathing techniques such as abdominal breathing and pursed lip breathing can improve respiratory efficiency and help patients gain a sense of control. Active cycle breathing may help expectoration&lt;A href="#refs"&gt;[9]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Pulmonary rehabilitation&lt;/STRONG&gt;&lt;BR&gt;Pulmonary Rehabilitation is the most cost effective intervention in the management of COPD, other than smoking cessation.&lt;/P&gt;
&lt;P&gt;Rehabilitation can&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;reduce breathlessness&lt;/LI&gt;
&lt;LI&gt;improve both functional and maximal exercise capacity, and &lt;/LI&gt;
&lt;LI&gt;improve quality of life&lt;A href="#refs"&gt;[8]&lt;/A&gt;. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;The NICE guideline&lt;A href="#refs"&gt;[1]&lt;/A&gt; recommends that it is offered to all suitable patients scoring 3 or more on the MRC Dyspnoea Scale.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Nutrition&lt;/STRONG&gt;&lt;BR&gt;Normal, healthy eating advice should form part of routine patient education in COPD&lt;A href="#refs"&gt;[1]&lt;/A&gt;. Obesity increases breathlessness and advice about weight reduction may be appropriate. In severe COPD, however, weight loss is common. The mechanisms behind weight loss are not fully understood but are likely to be a combination of systemic inflammation and a simple energy expenditure/intake imbalance&lt;A href="#refs"&gt;[10]&lt;/A&gt;. It is associated with a poor prognosis&lt;A href="#refs"&gt;[11]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Exacerbations&lt;/STRONG&gt;&lt;BR&gt;Exacerbations are distressing, disruptive and disabling; the effects can last up to four months&lt;A href="#refs"&gt;[12]&lt;/A&gt;. Frequent exacerbations increase disease progression&lt;A href="#refs"&gt;[13]&lt;/A&gt; and lead to significant loss of quality of life&lt;A href="#refs"&gt;[14]&lt;/A&gt;. Advice about how to avoid them (if possible), and how to manage them if they occur is therefore important. All COPD patients should be have annual influenza vaccine and should also be vaccinated against pneumococcal pneumonia. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Self-management plans&lt;/STRONG&gt;&lt;BR&gt;The vital components of a COPD self-management plan have yet to be determined and there is no evidence that asthma self-management plans are helpful&lt;A href="#refs"&gt;[15]&lt;/A&gt;. However, the NICE guideline&lt;A href="#refs"&gt;[1]&lt;/A&gt; suggests that self-management/exacerbation action plans look promising.&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Patients should be informed about the signs of an exacerbation so that they can respond promptly and appropriately. Such signs include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Increasing breathlessness and reduced exercise tolerance&lt;/LI&gt;
&lt;LI&gt;Increased sputum production or sputum purulence&lt;/LI&gt;
&lt;LI&gt;Increased cough, wheeze or chest tightness.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;These symptoms are often accompanied by upper airway symptoms such as a sore throat or blocked nose&lt;A href="#refs"&gt;[1]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The first line of therapy is to increase the frequency and/or dose of short acting bronchodilators or to add additional short acting agents to control breathlessness&lt;A href="#refs"&gt;[1]&lt;/A&gt;. Patients should be advised about how to do this safely. If the sputum becomes purulent antibiotics are indicated&lt;A href="#refs"&gt;[16]&lt;/A&gt;. If breathlessness interferes with activities of daily living and fails to respond to increased bronchodilators a short course of oral corticosteroids may be necessary&lt;A href="#refs"&gt;[17]&lt;/A&gt;. Some patients, particularly those experiencing frequent exacerbations, benefit from keeping ‘standby’ courses of antibiotics and corticosteroids at home so that they can initiate treatment.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Psychological problems and social isolation&lt;/STRONG&gt;&lt;BR&gt;Breathlessness saps energy and confidence, reduces independence and causes loss of role and self-esteem. It is hardly surprising that clinical depression in severe COPD is common&lt;A href="#refs"&gt;[17]&lt;/A&gt;. All health professionals caring for COPD patients need to be alert to the signs of depression.&lt;/P&gt;
&lt;P&gt;Maintaining normal social contacts helps reduce social isolation and depression and needs to be encouraged. Breathe Easy, the patient self-help groups supported by The British Lung Foundation, provide an ideal forum for patients and carers to socialise and gain valuable peer support, as well as being a useful source of practical advice and information. &lt;BR&gt;&amp;nbsp;&lt;BR&gt;&lt;STRONG&gt;Family and relationship problems&lt;/STRONG&gt;&lt;BR&gt;Long term illness places considerable strains on families and partners. Carers often suffer from anxiety and depression. The additional domestic burden they shoulder may produce feelings of resentment on their part and guilt on the part of the patient. COPD affects older people and a patient’s main carer may also be elderly and ill. COPD is a progressive, long-term and eventually terminal illness. The aim of treatment should be to enable patients not simply to live with COPD, but to have a life with it. With appropriate treatment and support it is possible to put quality back into their remaining years.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (Suppl 1): 1-232 &lt;A href="http://www.nice.org.uk/page.aspx?o=cg012" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Anderson RH, Esmail A, Hollowell J. Epidemiologically based needs assessment: Report 16: lower respiratory disease. 2003. London. Department of Health&lt;/LI&gt;
&lt;LI&gt;Britton M. the burden of COPD in the UK: results from the Confronting COPD Survey. Respir Med 2003; 97 (Suppl C): S71-79 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12647945&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Fletcher C, Peto R. The natural history of chronic airflow obstruction. British Medical Journal 1977;1: 1645-8 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;amp;db=PubMed&amp;amp;list_uids=871704&amp;amp;dopt=medline" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;National Institute for Clinical Excellence.&amp;nbsp; Guidance of the use of Nicotine Replacement Therapy&amp;nbsp; (NRT) and bupropion for smoking cessation. NICE Technology Appraisal Guidance No 39. 2002. London. National Institute for Clinical Excellence. &lt;A href="http://www.nice.org.uk/page.aspx?o=30590" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Borg GAV. Psychophysical bases of perceived exertion. Med. Sci. Sport. Ex. 1982; 14: 377-381 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7154893&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Singh SJ. Aerobic exercise training in patients with COPD. In: Practical Pulmonary Rehabilitation. 1997. London. Chapman &amp;amp; Hall. Pp 81-98&lt;/LI&gt;
&lt;LI&gt;Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library. Oxford. Update Software 2003; Issue 3. &lt;A href="http://dx.doi.org/10.1002/14651858.CD003793.pub2" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Booker R. Vital COPD. 2005. London. Class Health. Pp 77-78&lt;/LI&gt;
&lt;LI&gt;Agusti AG, Noguera A, Sauleda J, Sala E, Pous J, Busquet X .&amp;nbsp; Systemic effects of chronic obstructive pulmonary disease. European Respiratory Journal&amp;nbsp; 2003; 21(2): 347-360 &lt;A href="http://www.erj.ersjournals.com/cgi/content/abstract/21/2/347" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1999; 160: 1856-1861 &lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/160/6/1856" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000; 161: 1608-1613 &lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/161/5/1608?ijkey=2612cf233fb3dcbed4d1d16057fa4eaeac776041&amp;amp;keytype2=tf_ipsecsha" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852 &lt;A href="http://thorax.bmjjournals.com/cgi/content/abstract/57/10/847" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine1998; 157: 1418-1422 &lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/157/5/1418" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Monninkhof EM, van der Valk PDLPM, van der Palen J, Van Herwaarden CLA, Partridge MR, Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library. Oxford. Update Software 2003; Issue 3 &lt;A href="http://dx.doi.org/10.1002/14651858.CD002990" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Saint S, Bent S, Vittinghof E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations – a metaanalysis, Journal of the American Medical Association 1995; 273: 957-960 &lt;A href="http://jama.ama-assn.org/cgi/content/abstract/273/12/957" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). The Cochrane Library. Oxford: Update Software 2003; Issue 3 &lt;A href="http://dx.doi.org/10.1002/14651858.CD001288.pub2" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;&amp;nbsp;&lt;BR&gt;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Abdominal breathing&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Practice regularly so that it becomes habitual. &lt;/LI&gt;
&lt;LI&gt;Place one hand on the tummy and the other on the chest. &lt;/LI&gt;
&lt;LI&gt;Relax the tummy muscles and breathe in slowly for a count of two. &lt;/LI&gt;
&lt;LI&gt;Keep the hand on the chest still while the hand on the tummy moves outwards as you breathe in. &lt;/LI&gt;
&lt;LI&gt;Tighten the tummy muscles and breathe out for a count of four. &lt;/LI&gt;
&lt;LI&gt;Again, keep the hand on the chest still, while the hand on the tummy moves inwards.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&amp;nbsp;&lt;STRONG&gt;Pursed lip breathing&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Relax neck and shoulder muscles.&lt;/LI&gt;
&lt;LI&gt;Breathe in slowly through the nose for a count of two. &lt;/LI&gt;
&lt;LI&gt;Purse your lips and exhale gently through the mouth for a count of four. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Active cycle breathing&lt;/STRONG&gt;&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Sit comfortably and take three to five breaths using abdominal or pursed lip breathing. &lt;/LI&gt;
&lt;LI&gt;Take a normal breath in, a squeeze the air out through your open mouth using the chest and tummy muscles, making a ‘huff’ sound. &lt;/LI&gt;
&lt;LI&gt;Return to abdominal or pursed lip breathing. &lt;/LI&gt;
&lt;LI&gt;Repeat this four or five times with rests in between if necessary.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;&lt;STRONG&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>258914</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.cadth.ca/media/pdf/385_steroids_tr_e.pdf]]&gt;</url>
    <title>Long-acting ß2-agonists with or without corticosteroids for chronic obstructive pulmonary disease</title>
    <publicationDate>2007-03-01T00:00:00</publicationDate>
    <publisher>Canadian Agency for Drugs and Technologies in Health (CADTH)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;A href="http://www.cadth.ca/media/pdf/469_steroids_to_e.pdf" target="_blank"&gt;Click here to view 'Report in Brief' summary (pdf version)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The Canadian Agency for Drugs and Technologies in Health (CADTH) has published a review of long-acting ß2-agonists (LABA) plus corticosteroids (combined therapy; CT) versus LABA alone in treatment of chronic obstructive pulmonary disease (COPD). &lt;BR&gt;&lt;BR&gt;The authors carried out a systematic review of the literature and identified three relevant RCTs. The three-year and lifetime cost-effectiveness of CT compared with LABA alone was estimated for four disease-management strategies, as follows:&lt;BR&gt;&lt;BR&gt;• Strategy 1 (base case) = all patients were treated with LABA&lt;BR&gt;• Strategy 2 = in addition to the base case, ICS was given to patients with Stage 3 disease &lt;BR&gt;• Strategy 3 = in addition to the base case, ICS was given to patients with Stage 2 or 3 disease &lt;BR&gt;• Strategy 4 = in addition to the base case, ICS was given to all patients&lt;BR&gt;&lt;BR&gt;The authors summarised:&lt;BR&gt;&lt;BR&gt;• CT in all COPD stages is more effective than LABA alone&lt;BR&gt;&lt;BR&gt;Available evidence suggests that CT results in fewer overall exacerbations and improved quality of life measures, compared with treatment by LABA alone. There is no evidence to suggest that mortality differs with different strategies. &lt;BR&gt;&lt;BR&gt;• Different treatment strategies will vary in cost-effectiveness&lt;BR&gt;&lt;BR&gt;Each strategy is associated with an additional increase of 0.01 quality-adjusted life year (QALY) per patient. Strategies 2 and 3 may be perceived as cost-effective by those who are prepared to pay up to 50,000 Canadian dollars for a QALY.&lt;BR&gt;&lt;BR&gt;The review concluded:&lt;BR&gt;&lt;BR&gt;‘The results indicate that CT administered to moderate and severe COPD patients may be perceived as cost-effective, if the health system is prepared to pay up to 50,000 Canadian dollars for a QALY. The budgetary impact analysis indicates that additional resources would be required to realize the benefit of implementing our recommendations, but a reduction in the use of other health care resources could compensate for some of the difference’.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6084</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/505953/description]]&gt;</url>
    <title>Lung Cancer</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the International Association for the Study of Lung Cancer&lt;BR&gt;Aims to provide the most recent information on lung cancer. It publishes original research articles on clinical and basic science aspects of topics&amp;nbsp;related to&amp;nbsp;lung cancer.&lt;/P&gt;
&lt;P&gt;Short communications, technical notes and reviews may also be published.&lt;BR&gt;Also functions as a forum for those with an interest in the field. Containing news and reports from national and international groups working with lung cancer, book reviews and review articles.&lt;/P&gt;
&lt;P&gt;Each issue includes a reference section derived from the Excerpta Medica Database, with key abstracts covering the literature on lung cancer. &lt;/P&gt;
&lt;P&gt;ISBN: 0169-5002 &lt;BR&gt;Published 12 times a year 
&lt;P&gt;Online access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts plus additional features.&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>79855</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/collection/lung_function]]&gt;</url>
    <title>Lung Function</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,LUNG FUNCTION TESTING,PUBLICATIONS,JOURNALS,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since March 2000 relevant to lung function.&lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342010</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.european-lung-foundation.org/uploads/Document/WEB_CHEMIN_13411_1222853571.pdf]]&gt;</url>
    <title>Lung health in Europe - facts and figures</title>
    <publicationDate></publicationDate>
    <publisher>European Respiratory Society (ERS) and European Lung Foundation</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CYSTIC FIBROSIS,VIRAL,LUNG CANCER,MALIGNANT DISEASE,OBSTRUCTIVE SLEEP APNOEA,PNEUMONIA - COMMUNITY ACQUIRED,PNEUMONIA – IMMUNOSUPPRESSED PATIENT,SLEEP DISORDERED BREATHING,CHRONIC SUPPURATIVE DISEASES,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This brochure provides information about the impact of respiratory diseases on the the European Health Systems.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This brochure gives information about the impact of respiratory diseases on European health systems. It also includes facts about the economic impact of these respiratory diseases. &lt;/P&gt;
&lt;P&gt;The brochure describes the impact of the following major diseases&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Asthma 
&lt;LI&gt;COPD 
&lt;LI&gt;Cystic Fibrosis 
&lt;LI&gt;Lung Cancer 
&lt;LI&gt;Pneumonia 
&lt;LI&gt;Sleep Apnoea 
&lt;LI&gt;Tuberculosis&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This brochure has been published by the &lt;A href="http://www.ersnet.org/" target="_blank"&gt;European Respiratory Society&lt;/A&gt; and the &lt;A href="http://www.european-lung-foundation.org/index.php?id=1" target="_blank"&gt;European Lung foundation&lt;/A&gt;. This is an abridged version of the “European Lung White Book”&lt;/P&gt;
&lt;P&gt;The European Lung White Book is a 200-page report which includes data on the causes, means of prevention and treatment for a wide range of respiratory diseases, as well as epidemiological data collected from the 51 countries of the WHO Europe region. It also details the financial impact of respiratory disease in Europe and highlights the requirements to improve both research and patient care &lt;/P&gt;
&lt;P&gt;This report can be ordered for using the order form on the European Respiratory society website. &lt;A href="http://www.ersnet.org/ers/show/default.aspx?id_attach=6107" target="_blank"&gt;Click here &lt;/A&gt;to access the order form&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312045</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/management_of_childhood_asthma.pdf]]&gt;</url>
    <title>Management of asthma in children</title>
    <publicationDate>2006-03-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the &lt;SPAN class=detail_dataText&gt;Primary Care Respiratory Society UK&lt;/SPAN&gt;, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It provides a short summary of the latest guideline evidence on the management of paediatric asthma, with particular emphasis on the main areas of concern for parents - the diagnosis itself, the need for regular treatment including inhaled steroids, inhaler devices, lifestyle issues, and avoidance of trigger factors.&lt;/P&gt;
&lt;P&gt;GPIAG &lt;SPAN class=detail_dataText&gt;Primary Care Respiratory Society UK&lt;/SPAN&gt; Opinion Sheet&amp;nbsp;No. 4.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312100</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/acuteexacerbations_final.pdf]]&gt;</url>
    <title>Management of Exacerbations of Chronic Obstructive Pulmonary Disease in Primary Care</title>
    <publicationDate>2008-03-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It details a proactive approach to managing acute exacerbations of CODP in primary care.&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet No. 16.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312763</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/occupationallungdisease_final.pdf]]&gt;</url>
    <title>Management of occupational lung disease in primary care</title>
    <publicationDate>2007-12-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,OCCUPATIONAL LUNG DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It aims to to provide evidence-based advice concerning early identification of patients with occupational airways disease.&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet&amp;nbsp;No. 14.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312119</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/resources/os13_copd_stable.pdf]]&gt;</url>
    <title>Management of Stable Chronic Obstructive Pulmonary Disease in Primary Care</title>
    <publicationDate>2007-01-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It aims to provide concise advice, based on current international (GOLD) and UK guidelines, on the management of stable Chronic Obstructive Pulmonary Disease (COPD).&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet No. 13.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>342398</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&amp;dDocName=CON068569&amp;RevisionSelectionMethod=LatestReleased]]&gt;</url>
    <title>Medical Device Alert: T-piece connector incorporated into various breathing systems</title>
    <publicationDate>2010-01-28T00:00:00</publicationDate>
    <publisher>MHRA</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Medical Device Alert by MHRA</description>
    <body>&lt;![CDATA[ &lt;P&gt;This is a medical device alert published by MHRA regarding a T-piece connector incorporated into various breathing systems&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON068552?tabName=Device" target="_blank"&gt;http://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON068552?tabName=Device&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>250852</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_072348]]&gt;</url>
    <title>Mesothelioma Framework</title>
    <publicationDate>2007-02-27T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,MALIGNANT DISEASE,PUBLICATIONS,MESOTHELIOMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Advice for the NHS on how to organise services for Malignant Pleural Mesothelioma (MPM) patients to improve quality of care across the country.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Advice for the NHS on how to organise services for Malignant Pleural Mesothelioma (MPM) patients to improve quality of care across the country.&lt;/P&gt;
&lt;P&gt;This framework aims to provide Strategic Health Authorities (SHAs), cancer networks, Primary Care Trusts (PCTs) and NHS Trusts in England with advice on how to organise services for mesothelioma patients in order to improve quality of care to a uniformly high level across the country. It includes advice on:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Configuration of services; 
&lt;LI&gt;Raising Awareness; 
&lt;LI&gt;Clinical management; 
&lt;LI&gt;Underpinning programmes such as information, research and audit.&lt;/LI&gt;&lt;/OL&gt;]]&gt;</body>
  </document>
  <document>
    <id>124655</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/mucolytics_opinion3_final_v02.pdf]]&gt;</url>
    <title>Mucolytics</title>
    <publicationDate>2004-09-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It&amp;nbsp;details what are mucolytics, the evidence for their effectiveness, who should receive them and how they should be taken.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet No. 2.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>37138</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/SpecialisedServicesDefinition/SpecialisedServicesDefinitionArticle/fs/en?CONTENT_ID=4001681&amp;chk=9JuLUM]]&gt;</url>
    <title>National Heart and Lung Transplant Standards</title>
    <publicationDate></publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG TRANSPLANTATION,PUBLICATIONS,TRANSPLANTATION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This document has been issued following a consultation into the standards of heart and lung transplantation services. The resulting&amp;nbsp;standards are intended to ensure that patients receive services that match the evidence of the best care available, and that providers know how to develop such services. 
&lt;P&gt;These standards cover the following areas: 
&lt;UL&gt;
&lt;LI&gt;staffing levels 
&lt;LI&gt;staff qualifications 
&lt;LI&gt;retrieval arrangements 
&lt;LI&gt;outcomes (including survival and rejection rates)&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The document was published in September 2002.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312047</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/nice_ics_final.pdf]]&gt;</url>
    <title>National Institute for Health and Clinical Excellence (NICE) Guidelines for Inhaled Steroids for the treatment of chronic asthma</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It considers the key recommendations of the NICE guidance&amp;nbsp;and how they complement the recommendations of the 2008 British Thoracic Society (BTS)/ Scottish Intercollegiate Network(SIGN) Guideline for the Management of Asthma.&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet No. 24.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>125074</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125074]]&gt;</url>
    <title>National Knowledge Week for Asthma 2006 - Contributors</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2006 - Contributors&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Respiratory Specialist Library is extremely grateful to the following people, who&amp;nbsp;wrote the short articles forming the basis of the National Knowledge Week for Asthma 22 - 26 May 2006.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Prof Peter Barnes&lt;/STRONG&gt;&lt;BR&gt;Peter Barnes is Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities and&amp;nbsp;was appointed to his present post in 1987.&amp;nbsp;Peter has published over 1000 peer-review papers on asthma, COPD and related topics and has edited over 40 books. He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK over the last 20 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:124996:0" name=internalLink&gt;What's New in Asthma&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Prof Martyn Partridge&lt;/STRONG&gt;&lt;BR&gt;Martyn R. Partridge&amp;nbsp; M.D.,&amp;nbsp; F.R.C.P., is&amp;nbsp; Professor of Respiratory Medicine&amp;nbsp;at Imperial College London, NHLI Division based at Charing Cross Hospital and Honorary Consultant Respiratory Physician to Hammersmith Hospitals NHS Trust. His research interests are in the delivery of effective respiratory healthcare. &lt;/P&gt;
&lt;P&gt;Martyn&amp;nbsp;is (Honorary) Chief Medical Advisor to Asthma UK. He has been a member of the British Asthma Guidelines group since 1989 and is currently on the Executive and Steering Groups of the BTS/SIGN asthma guideline group.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:124953:0" name=internalLink&gt;The impact of the SIGN/BTS guidelines on asthma management&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;STRONG&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Sue Gray&lt;/STRONG&gt;&lt;BR&gt;Sue Gray, SRN, BSc (Hons), Non-Medical Prescriber, Dip. Asthma, &lt;BR&gt;COPD, Allergy &amp;amp; Immunology and Psychology of Asthma, qualified as a SRN in 1969. Sue has worked in respiratory care nursing since 1976, mainly in Asthma, COPD and Allergy. She&amp;nbsp;has developed an asthma care pathway and asthma action plans for primary and secondary care in Tameside. She is a committee member and Treasurer&amp;nbsp;of ARNS (The Association of Respiratory Nurse Specialists). &lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;/STRONG&gt;&lt;A href="nelh:125010:0" name=internalLink&gt;&lt;STRONG&gt;Asthma inhaler devices&lt;/STRONG&gt;&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;STRONG&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Dr Andy Robson&lt;/STRONG&gt;&lt;BR&gt;After obtaining a degree in Pharmacology in 1986 Andy has always worked in the field of Respiratory Medicine, either in research or in a clinical setting.&lt;/P&gt;
&lt;P&gt;Two years in the Department of Clinical Pharmacology, Cardiothoracic Institute (London) was followed by a move to the Department of Physiology, St George’s Hospital Medical School in south London where he completed his PhD in Respiratory Physiology. After leaving St George’s he moved to the Department of Respiratory Medicine, Royal Postgraduate Medical School to work on various aspects of nasal physiology with Professor Neil Pride. &lt;/P&gt;
&lt;P&gt;While working with Prof. Pride his interest in clinical work, especially in Respiratory Function was rekindled and Andy obtained a post as Clinical Scientist in the Lothian Area Respiratory Function Service in March 1995. As Clinical Scientist he has been involved in a number of changes to the Service over the years including changes to the results database and the implementation of new tests such as the incremental walking test and the hypoxic challenge test for patients wishing to fly. &lt;/P&gt;
&lt;P&gt;Andy has recently become Editor of Inspire, the Journal of the Association for Respiratory Physiology and Physiology (ARTP). Andy is also the ARTP representative on the Respiratory Specialist Library stakeholder group.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:125067:0" name=internalLink&gt;&lt;STRONG&gt;The role of respiratory function laboratories in asthma&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;STRONG&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Dr Glenis Scadding&lt;/STRONG&gt;&lt;BR&gt;Glenis is a Consultant in Rhinology Clinical Immunology and Allergy&lt;BR&gt;Royal National Throat, Nose and Ear Hospital, London.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:125059:0" name=internalLink&gt;Allergic rhinitis and asthma&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;STRONG&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Dr Hilary Pinnock&lt;/STRONG&gt;&lt;BR&gt;Hilary is Clinical Research Fellow in the Division of Community Health Sciences: GP Section at the&amp;nbsp;University of Edinburgh and also a Principal in General Practice at&amp;nbsp;Whitstable Medical Practice.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:124949:0" name=internalLink&gt;The management of asthma in primary care&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;STRONG&gt;
&lt;HR width="50%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Dr Anne Bruton and Dr Rachel Garrod&lt;/STRONG&gt;&lt;BR&gt;Anne is a physiotherapist and postdoctoral Research Fellow, University of Southampton. Rachel is a physiotherapist and Reader in Physiotherapy at the Department of Health and Social Care Sciences, St Georges University of London. Anne and Rachel are also representatives for the Association of Chartered Physiotherapists in Respiratory Care (ACPRC) on the Respiratory Specialist Library stakeholder group.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Topic: &lt;A href="nelh:124901:0" name=internalLink&gt;Physiotherapy practice and asthma&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>126226</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=126226]]&gt;</url>
    <title>National Knowledge Week for Asthma 2006 - Organisations</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2006 - Organisations&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The following organisations provide information and/or education on Asthma, and are stakeholders in the Respiratory Specialist Library.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;Asthma UK&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.lunguk.org/" target="_blank"&gt;British Lung Foundation (BLF)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.acprc.org/?" target="_blank"&gt;Association of Chartered Physiotherapists in Respiratory Care&amp;nbsp;(ACPRC)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.arns.co.uk/" target="_blank"&gt;Association of Respiratory Nurse Specialists (ARNS)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.artp.org.uk/?/" target="_blank"&gt;Association for Respiratory Technology and Physiology&amp;nbsp;(ARTP)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;British Thoracic Society (BTS)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.educationforhealth.org.uk/" target="_blank"&gt;Education for Health (formerly National Respiratory Training Centre)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.gpiag.org/" target="_blank"&gt;General Practice Airways Group (GPIAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.respiratoryetc.com/" target="_blank"&gt;Respiratory Education UK (Formerly RETC)&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>125045</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125045]]&gt;</url>
    <title>National Knowledge Week for Asthma 2006 - Topics</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2006 - Topics&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A number of topics within asthma were chosen to be covered in this national knowledge week, in consultation with the respiratory specialist library stakeholder group. Each topic has a short article written by an expert in that field, after which there are a number of links to the latest evidence based information published in that area. Links to high quality patient information have also been provided.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The topics are as follows:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="nelh:124996:0" name=internalLink&gt;What’s new in asthma?&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:124953:0" name=internalLink&gt;&lt;A href="nelh:124953:0" name=internalLink&gt;The impact of the SIGN/BTS guidelines on asthma management&lt;/A&gt;&lt;A href="nelh:124953:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:125010:0" name=internalLink&gt;Asthma inhaler devices&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:125067:0" name=internalLink&gt;The role of respiratory function laboratories in asthma&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:125059:0" name=internalLink&gt;&lt;A href="http://www.library.nhs.uk/respiratory/viewResource.aspx?resID=125059&amp;amp;code=275b9e477cc4bff4ee1323e94139744a" target="_blank"&gt;Allergic rhinitis and asthma&lt;/A&gt;&lt;A href="nelh:124657:0" name=internalLink&gt;&lt;/A&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:124949:0" name=internalLink&gt;The management of asthma in primary care&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:124901:0" name=internalLink&gt;Physiotherapy practice and asthma&lt;/A&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284300</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=284300]]&gt;</url>
    <title>National Knowledge Week for Asthma 2008</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,NKW ASTHMA,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;The Annual Evidence Update (AEU) for Asthma aims to highlight new evidence in the field of asthma. It is held during the week 5 – 9 May 2008 to coincide with &lt;/FONT&gt;&lt;A href="http://www.ginasthma.com/WADIndex.asp" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;World Asthma Day&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;FONT face=Arial&gt; on 6 May 2008. &lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;The AEU is a comprehensive literature search for published evidence between 1 January 2006 to mid-April 2008. Information published before or after these dates can be found in the &lt;/FONT&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=288&amp;amp;catID=5872&amp;amp;" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;Asthma&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;FONT face=Arial&gt; section of the library. Full details of the search strategy used in the AEU can be found on the &lt;A href="nelh:284301:0" name=internalLink&gt;Methodology &lt;/A&gt;page and the results on the &lt;A href="nelh:284284:0" name=internalLink&gt;Annual Evidence Update &lt;/A&gt;page. &lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;The Complementary and Alternative Medicine Specialist Library have also carried out an &lt;/FONT&gt;&lt;A href="http://www.library.nhs.uk/cam/viewResource.aspx?resid=283492&amp;amp;code=f5cb23c0adcbb7f2740a0d958b39355f" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;Annual Evidence Update on CAM for Asthma 2008&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;FONT face=Arial&gt;.&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;There is also a page on supporting information that links to some of the key documents and patient information.&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:284284:0" name=internalLink&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;Annual Evidence Update&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&lt;A href="nelh:284301:0" name=internalLink&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;Methodology&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&amp;nbsp;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="nelh:284321:0" name=internalLink&gt;&lt;FONT face=Arial&gt;&lt;STRONG&gt;Supporting Information&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/A&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/STRONG&gt;&lt;/FONT&gt;&lt;/BLOCKQUOTE&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284284</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=284284]]&gt;</url>
    <title>National Knowledge Week for Asthma 2008 - Annual Evidence Update</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,NKW ASTHMA,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2008 - Annual Evidence Update&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;The Annual Evidence Update presents the results of the literature search, as detailed in the &lt;A disabled href="nelh:284301:0" name=internalLink&gt;methodology &lt;/A&gt;section. It also includes links to the British Asthma Guideline and recently published NICE Guidance.&lt;/P&gt;
&lt;P&gt;Where possible we have linked to the full text or PubMed abstracts of the articles available on the internet. Users may have access to full text of the articles listed with just abstracts via Athens or local library/university subscriptions.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/63/index.html" target="_blank"&gt;British Guideline on the Management of Asthma&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;NICE Guidance:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11892" target="_blank"&gt;Asthma (in children) - corticosteroids (November 2007)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11945" target="_blank"&gt;Asthma (in adults) - corticosteroids (March 2008)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;o=11894" target="_blank"&gt;Asthma (uncontrolled) - omalizumab (November 2007)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Cochrane Reviews:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ADAMS, N., LASSERSON, T.J., CATES, C.J. and JONES, P.W., 2007. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(4)&lt;/B&gt;(4), pp. CD002310. &lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17943772?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ADAMS, N., LASSERSON, T.J., CATES, C.J. and JONES, P.W., 2007. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(4)&lt;/B&gt;(4), pp. CD002310.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD002310.pub4" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;AL SAYYAD, J.J., FEDOROWICZ, Z., ALHASHIMI, D. and JAMAL, A., 2007. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(1)&lt;/B&gt;(1), pp. CD003163.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003163.pub4" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;&lt;/P&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ARNOLD, E., CLARK, C.E., LASSERSON, T.J. and WU, T., 2008. Herbal interventions for chronic asthma in adults and children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(1)&lt;/B&gt;(1), pp. CD005989.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005989.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;ADAMS, N.P. and JONES, P.W., 2006. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. &lt;I&gt;Respiratory medicine, &lt;/I&gt;&lt;B&gt;100&lt;/B&gt;(8), pp. 1297-1306.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16806876?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BHOGAL, S., ZEMEK, R. and DUCHARME, F.M., 2006. Written action plans for asthma in children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;3&lt;/B&gt;, pp. CD005306.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005306.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;CHANG, A.B., TAYLOR, B., MASTERS, I.B., LAIFOO, Y. and BROWN, A.D., 2007. Indigenous healthcare worker involvement for Indigenous adults and children with asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(4)&lt;/B&gt;(4), pp. CD006344.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD006344.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;DUCHARME, F.M., LASSERSON, T.J. and CATES, C.J., 2006. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(4)&lt;/B&gt;(4), pp. CD003137.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003137.pub3" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;GUEVARA, J.P., DUCHARME, F.M., KEREN, R., NIHTIANOVA, S. and ZORC, J., 2006. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(2)&lt;/B&gt;(2), pp. CD003558.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003558.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;KOH, M.S., TEE, A., LASSERSON, T.J. and IRVING, L.B., 2007. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(3)&lt;/B&gt;(3), pp. CD002739.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD002739.pub3" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;LASSERSON, T.J., CATES, C.K., JONES, A.B., STEELE, E.H. and WHITE, J., 2006. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(2)&lt;/B&gt;(2), pp. CD005309.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005309.pub3" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;PETSKY, H.L., KYNASTON, J.A., TURNER, C., LI, A.M., CATES, C.J., LASSERSON, T.J. and CHANG, A.B., 2007. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(2)&lt;/B&gt;(2), pp. CD005603.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005603.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;RODRIGO, G., POLLACK, C., RODRIGO, C. and ROWE, B.H., 2006. Heliox for nonintubated acute asthma patients. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(4)&lt;/B&gt;(4), pp. CD002884.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD002884.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ROWE, B.H., SPOONER, C.H., DUCHARME, F.M., BRETZLAFF, J.A. and BOTA, G.W., 2007. Corticosteroids for preventing relapse following acute exacerbations of asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(3)&lt;/B&gt;(3), pp. CD000195.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD000195.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;SRIDHAR, A.V. and MCKEAN, M., 2006. Nedocromil sodium for chronic asthma in children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;3&lt;/B&gt;, pp. CD004108.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD004108.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;TAPP, S., LASSERSON, T.J. and ROWE, B., 2007. Education interventions for adults who attend the emergency room for acute asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(3)&lt;/B&gt;(3), pp. CD003000.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003000.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;TEE, A.K., KOH, M.S., GIBSON, P.G., LASSERSON, T.J., WILSON, A.J. and IRVING, L.B., 2007. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(3)&lt;/B&gt;(3), pp. CD001281.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD001281.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;VUILLERMIN, P., SOUTH, M. and ROBERTSON, C., 2006. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;3&lt;/B&gt;, pp. CD005311.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD005311.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;WALKER, S., MONTEIL, M., PHELAN, K., LASSERSON, T.J. and WALTERS, E.H., 2006. Anti-IgE for chronic asthma in adults and children. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(2)&lt;/B&gt;(2), pp. CD003559.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD003559.pub3" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;WALTERS, E.H., GIBSON, P.G., LASSERSON, T.J. and WALTERS, J.A., 2007. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. &lt;I&gt;Cochrane database of systematic reviews (Online), &lt;/I&gt;&lt;B&gt;(1)&lt;/B&gt;(1), pp. CD001385.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://dx.doi.org/10.1002/14651858.CD001385.pub2" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;FULL TEXT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;BR&gt;&lt;STRONG&gt;Other Systematic Reviews&lt;/STRONG&gt;&lt;/P&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;ALVAREZ, G.G. and FITZGERALD, J.M., 2007. A systematic review of the psychological risk factors associated with near fatal asthma or fatal asthma. &lt;I&gt;Respiration; international review of thoracic diseases, &lt;/I&gt;&lt;B&gt;74&lt;/B&gt;(2), pp. 228-236.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17139165?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BAGER, P., WOHLFAHRT, J. and WESTERGAARD, T., 2008. Caesarean delivery and risk of atopy and allergic disease: meta-analyses. &lt;I&gt;Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, &lt;/I&gt;&lt;B&gt;38&lt;/B&gt;(4), pp. 634-642.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18266879?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BALICER, R.D., GROTTO, I., MIMOUNI, M. and MIMOUNI, D., 2007. Is childhood vaccination associated with asthma? A meta-analysis of observational studies. &lt;I&gt;Pediatrics, &lt;/I&gt;&lt;B&gt;120&lt;/B&gt;(5), pp. e1269-77.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17974720?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BEACH, J., RUSSELL, K., BLITZ, S., HOOTON, N., SPOONER, C., LEMIERE, C., TARLO, S.M. and ROWE, B.H., 2007. A systematic review of the diagnosis of occupational asthma. &lt;I&gt;Chest, &lt;/I&gt;&lt;B&gt;131&lt;/B&gt;(2), pp. 569-578.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17296663?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BEUTHER, D.A. and SUTHERLAND, E.R., 2007. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. &lt;I&gt;American journal of respiratory and critical care medicine, &lt;/I&gt;&lt;B&gt;175&lt;/B&gt;(7), pp. 661-666.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17234901?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BOLUYT, N., VAN DER LEE, J.H., MOYER, V.A., BRAND, P.L. and OFFRINGA, M., 2007. State of the evidence on acute asthma management in children: a critical appraisal of systematic reviews. &lt;I&gt;Pediatrics, &lt;/I&gt;&lt;B&gt;120&lt;/B&gt;(6), pp. 1334-1343.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18055684?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;BUSSEY-SMITH, K.L. and ROSSEN, R.D., 2007. A systematic review of randomized control trials evaluating the effectiveness of interactive computerized asthma patient education programs. &lt;I&gt;Annals of Allergy, Asthma &amp;amp; Immunology : Official Publication of the American College of Allergy, Asthma, &amp;amp; Immunology, &lt;/I&gt;&lt;B&gt;98&lt;/B&gt;(6), pp. 507-16; quiz 516, 566.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17601262?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;CALAMITA, Z., SACONATO, H., PELA, A.B. and ATALLAH, A.N., 2006. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. &lt;I&gt;Allergy, &lt;/I&gt;&lt;B&gt;61&lt;/B&gt;(10), pp. 1162-1172.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16942563?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;CHIDA, Y., HAMER, M. and STEPTOE, A., 2008. A bidirectional relationship between psychosocial factors and atopic disorders: a systematic review and meta-analysis. &lt;I&gt;Psychosomatic medicine, &lt;/I&gt;&lt;B&gt;70&lt;/B&gt;(1), pp. 102-116.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18158379?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;COFFMAN, J.M., CABANA, M.D., HALPIN, H.A. and YELIN, E.H., 2008. Effects of asthma education on children's use of acute care services: a meta-analysis. &lt;I&gt;Pediatrics, &lt;/I&gt;&lt;B&gt;121&lt;/B&gt;(3), pp. 575-586.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18310208?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;COLEBOURN, C.L., BARBER, V. and YOUNG, J.D., 2007. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. &lt;I&gt;Anaesthesia, &lt;/I&gt;&lt;B&gt;62&lt;/B&gt;(1), pp. 34-42.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17156225?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;DOMBROWSKI, M.P., SCHATZ, M. and ACOG COMMITTEE ON PRACTICE BULLETINS-OBSTETRICS, 2008. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. &lt;I&gt;Obstetrics and gynecology, &lt;/I&gt;&lt;B&gt;111&lt;/B&gt;(2 Pt 1), pp. 457-464.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18238988?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;DYER, M.J., HALPIN, D.M. and STEIN, K., 2006. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. &lt;I&gt;BMC family practice, &lt;/I&gt;&lt;B&gt;7&lt;/B&gt;, pp. 34.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16753053?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;FISK, W.J., LEI-GOMEZ, Q. and MENDELL, M.J., 2007. Meta-analyses of the associations of respiratory health effects with dampness and mold in homes. &lt;I&gt;Indoor air, &lt;/I&gt;&lt;B&gt;17&lt;/B&gt;(4), pp. 284-296.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17661925?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;GIBSON, P.G., POWELL, H. and DUCHARME, F.M., 2007. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. &lt;I&gt;The Journal of allergy and clinical immunology, &lt;/I&gt;&lt;B&gt;119&lt;/B&gt;(2), pp. 344-350.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17291852?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;HAVEMANN, B.D., HENDERSON, C.A. and EL-SERAG, H.B., 2007. The association between gastro-oesophageal reflux disease and asthma: a systematic review. &lt;I&gt;Gut, &lt;/I&gt;&lt;B&gt;56&lt;/B&gt;(12), pp. 1654-1664.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17682001?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;JAAKKOLA, J.J., AHMED, P., IEROMNIMON, A., GOEPFERT, P., LAIOU, E., QUANSAH, R. and JAAKKOLA, M.S., 2006. Preterm delivery and asthma: a systematic review and meta-analysis. &lt;I&gt;The Journal of allergy and clinical immunology, &lt;/I&gt;&lt;B&gt;118&lt;/B&gt;(4), pp. 823-830.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17030233?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;JARTTI, T., 2008. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? &lt;I&gt;European journal of pediatrics &lt;/I&gt;.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18214538?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;JOINT TASK FORCE ON PRACTICE PARAMETERS, AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY, AMERICAN COLLEGE OF ALLERGY, ASTHMA AND IMMUNOLOGY and JOINT COUNCIL OF ALLERGY, ASTHMA AND IMMUNOLOGY, 2007. Allergen immunotherapy: a practice parameter second update. &lt;I&gt;The Journal of allergy and clinical immunology, &lt;/I&gt;&lt;B&gt;120&lt;/B&gt;(3 Suppl), pp. S25-85.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17765078?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;KOH, G.C., SHEK, L.P., GOH, D.Y., VAN BEVER, H. and KOH, D.S., 2007. Eosinophil cationic protein: is it useful in asthma? A systematic review. &lt;I&gt;Respiratory medicine, &lt;/I&gt;&lt;B&gt;101&lt;/B&gt;(4), pp. 696-705.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17034998?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;LAMONTAGNE, A.D., RADI, S., ELDER, D.S., ABRAMSON, M.J. and SIM, M., 2006. Primary prevention of latex related sensitisation and occupational asthma: a systematic review. &lt;I&gt;Occupational and environmental medicine, &lt;/I&gt;&lt;B&gt;63&lt;/B&gt;(5), pp. 359-364.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16469822?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;LEONARDI-BEE, J., PRITCHARD, D. and BRITTON, J., 2006. Asthma and current intestinal parasite infection: systematic review and meta-analysis. &lt;I&gt;American journal of respiratory and critical care medicine, &lt;/I&gt;&lt;B&gt;174&lt;/B&gt;(5), pp. 514-523.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16778161?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;LI, H.T., ZHANG, T.T., ZHOU, H., QU, X.J., WU, W.M. and HUANG, J., 2007. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. &lt;I&gt;Respiration; international review of thoracic diseases, &lt;/I&gt;&lt;B&gt;74&lt;/B&gt;(1), pp. 33-43.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17008769?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;MACDONALD, C., STERNBERG, A. and HUNTER, P.R., 2007. A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma. &lt;I&gt;Environmental health perspectives, &lt;/I&gt;&lt;B&gt;115&lt;/B&gt;(12), pp. 1691-1695.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18087584?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;MOHAMMED, S. and GOODACRE, S., 2007. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. &lt;I&gt;Emergency medicine journal : EMJ, &lt;/I&gt;&lt;B&gt;24&lt;/B&gt;(12), pp. 823-830.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18029512?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;PASSALACQUA, G., BOUSQUET, P.J., CARLSEN, K.H., KEMP, J., LOCKEY, R.F., NIGGEMANN, B., PAWANKAR, R., PRICE, D. and BOUSQUET, J., 2006. ARIA update: I--Systematic review of complementary and alternative medicine for rhinitis and asthma. &lt;I&gt;The Journal of allergy and clinical immunology, &lt;/I&gt;&lt;B&gt;117&lt;/B&gt;(5), pp. 1054-1062.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16675332?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;PETERS, J., PICKVANCE, S., WILFORD, J., MACDONALD, E. and BLANK, L., 2007. Predictors of delayed return to work or job loss with respiratory ill-health: a systematic review. &lt;I&gt;Journal of Occupational Rehabilitation, &lt;/I&gt;&lt;B&gt;17&lt;/B&gt;(2), pp. 317-326.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17295061?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;POURESLAMI, I.M., ROOTMAN, I., BALKA, E., DEVARAKONDA, R., HATCH, J. and FITZGERALD, J.M., 2007. A systematic review of asthma and health literacy: a cultural-ethnic perspective in Canada. &lt;I&gt;MedGenMed : Medscape general medicine, &lt;/I&gt;&lt;B&gt;9&lt;/B&gt;(3), pp. 40.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18092046?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;RACHIOTIS, G., SAVANI, R., BRANT, A., MACNEILL, S.J., NEWMAN TAYLOR, A. and CULLINAN, P., 2007. Outcome of occupational asthma after cessation of exposure: a systematic review. &lt;I&gt;Thorax, &lt;/I&gt;&lt;B&gt;62&lt;/B&gt;(2), pp. 147-152.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17040933?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;RAHIMI, R., NIKFAR, S. and ABDOLLAHI, M., 2006. Meta-analysis finds use of inhaled corticosteroids during pregnancy safe: a systematic meta-analysis review. &lt;I&gt;Human &amp;amp; experimental toxicology, &lt;/I&gt;&lt;B&gt;25&lt;/B&gt;(8), pp. 447-452.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16937916?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;REISMAN, J., SCHACHTER, H.M., DALES, R.E., TRAN, K., KOURAD, K., BARNES, D., SAMPSON, M., MORRISON, A., GABOURY, I. and BLACKMAN, J., 2006. Treating asthma with omega-3 fatty acids: where is the evidence? A systematic review. &lt;I&gt;BMC complementary and alternative medicine, &lt;/I&gt;&lt;B&gt;6&lt;/B&gt;, pp. 26.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16854238?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;RING, N., MALCOLM, C., WYKE, S., MACGILLIVRAY, S., DIXON, D., HOSKINS, G., PINNOCK, H. and SHEIKH, A., 2007. Promoting the use of Personal Asthma Action Plans: a systematic review. &lt;I&gt;Primary care respiratory journal : journal of the General Practice Airways Group, &lt;/I&gt;&lt;B&gt;16&lt;/B&gt;(5), pp. 271-283.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17710351?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;RODRIGO, G.J., 2006. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. &lt;I&gt;Chest, &lt;/I&gt;&lt;B&gt;130&lt;/B&gt;(5), pp. 1301-1311.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17099004?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;SALPETER, S.R., BUCKLEY, N.S., ORMISTON, T.M. and SALPETER, E.E., 2006. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. &lt;I&gt;Annals of Internal Medicine, &lt;/I&gt;&lt;B&gt;144&lt;/B&gt;(12), pp. 904-912.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16754916?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;SANDERS, D.L. and ARONSKY, D., 2006. Biomedical informatics applications for asthma care: a systematic review. &lt;I&gt;Journal of the American Medical Informatics Association : JAMIA, &lt;/I&gt;&lt;B&gt;13&lt;/B&gt;(4), pp. 418-427.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16622164?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;SMITH, J.R., MUGFORD, M., HOLLAND, R., NOBLE, M.J. and HARRISON, B.D., 2007. Psycho-educational interventions for adults with severe or difficult asthma: a systematic review. &lt;I&gt;The Journal of asthma : official journal of the Association for the Care of Asthma, &lt;/I&gt;&lt;B&gt;44&lt;/B&gt;(3), pp. 219-241.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17454342?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;THAVAGNANAM, S., FLEMING, J., BROMLEY, A., SHIELDS, M.D. and CARDWELL, C.R., 2008. A meta-analysis of the association between Caesarean section and childhood asthma. &lt;I&gt;Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, &lt;/I&gt;&lt;B&gt;38&lt;/B&gt;(4), pp. 629-633.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18352976?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;VAN DER HULST, A.E., KLIP, H. and BRAND, P.L., 2007. Risk of developing asthma in young children with atopic eczema: a systematic review. &lt;I&gt;The Journal of allergy and clinical immunology, &lt;/I&gt;&lt;B&gt;120&lt;/B&gt;(3), pp. 565-569.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17655920?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;VORK, K.L., BROADWIN, R.L. and BLAISDELL, R.J., 2007. Developing asthma in childhood from exposure to secondhand tobacco smoke: insights from a meta-regression. &lt;I&gt;Environmental health perspectives, &lt;/I&gt;&lt;B&gt;115&lt;/B&gt;(10), pp. 1394-1400.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17938726?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;VUILLERMIN, P.J., ROBERTSON, C.F. and SOUTH, M., 2007. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children: systematic review. &lt;I&gt;Journal of paediatrics and child health, &lt;/I&gt;&lt;B&gt;43&lt;/B&gt;(6), pp. 438-442.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17535172?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;WILLEMS, D.C., JOORE, M.A., HENDRIKS, J.J., WOUTERS, E.F. and SEVERENS, J.L., 2006. Cost-effectiveness of self-management in asthma: a systematic review of peak flow monitoring interventions. &lt;I&gt;International Journal of Technology Assessment in Health Care, &lt;/I&gt;&lt;B&gt;22&lt;/B&gt;(4), pp. 436-442.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16984676?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;WLODARCZYK, J.H., GIBSON, P.G. and CAESER, M., 2008. Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. &lt;I&gt;Annals of Allergy, Asthma &amp;amp; Immunology : Official Publication of the American College of Allergy, Asthma, &amp;amp; Immunology, &lt;/I&gt;&lt;B&gt;100&lt;/B&gt;(1), pp. 23-30.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18254478?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;YORKE, J., FLEMING, S.L. and SHULDHAM, C., 2007. A systematic review of psychological interventions for children with asthma. &lt;I&gt;Pediatric pulmonology, &lt;/I&gt;&lt;B&gt;42&lt;/B&gt;(2), pp. 114-124.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16757162?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;YORKE, J., FLEMING, S.L. and SHULDHAM, C., 2007. Psychological interventions for adults with asthma: a systematic review. &lt;I&gt;Respiratory medicine, &lt;/I&gt;&lt;B&gt;101&lt;/B&gt;(1), pp. 1-14.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17186533?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ZEMEK, R.L., BHOGAL, S.K. and DUCHARME, F.M., 2008. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? &lt;I&gt;Archives of Pediatrics &amp;amp; Adolescent Medicine, &lt;/I&gt;&lt;B&gt;162&lt;/B&gt;(2), pp. 157-163.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/18250241?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#800080&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;BR&gt;
&lt;P style="LINE-HEIGHT: 120%"&gt;&lt;SPAN lang=EN-US style="FONT-FAMILY: Arial"&gt;ZOLLNER, E.W., 2007. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)--the risk as determined by gold standard adrenal function tests: a systematic review. &lt;I&gt;Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, &lt;/I&gt;&lt;B&gt;18&lt;/B&gt;(6), pp. 469-474.&lt;SPAN style="mso-spacerun: yes"&gt; &lt;/SPAN&gt;&lt;SPAN style="mso-spacerun: yes"&gt;&lt;/SPAN&gt;[&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17680905?dopt=abstract" target="_blank"&gt;&lt;U&gt;&lt;FONT color=#0066cc&gt;PUBMED ABSTRACT&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;]&lt;/SPAN&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284301</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=284301]]&gt;</url>
    <title>National Knowledge Week for Asthma 2008 - Methodology</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,NKW ASTHMA,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2008 - Methodology&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;The reference document used to provide the starting point for this search was the SIGN guideline ‘&lt;/FONT&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=266961&amp;amp;tabID=288" target="_blank"&gt;&lt;B&gt;&lt;SPAN style="COLOR: black; TEXT-DECORATION: none; text-underline: none"&gt;&lt;FONT face=Arial&gt;British guideline on the management of asthma&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/A&gt;&lt;FONT face=Arial&gt;’ (01 July 2007). &lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;The search date ran from 2006 to the present.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;All the searches were carried out on 14 and 15 April 2008.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;Sources Searched&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;The following sources were searched: &lt;BR style="mso-special-character: line-break"&gt;&lt;BR style="mso-special-character: line-break"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;UL style="MARGIN-TOP: 0cm" type=disc&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; COLOR: black; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;PUBMED using the PUBMED Clinical Queries systematic review filter and “asthm*” as free text search term, limited to references published in the last 2 year and in the English language.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; COLOR: black; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;Cochrane Library, using “asthm*” as a free text search term and limited to reviews from dates to 2006 – 2008.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/LI&gt;
&lt;LI class=MsoNormal style="MARGIN: 0cm 0cm 0pt; COLOR: black; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt"&gt;&lt;SPAN lang=EN style="mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;Selected NLH Healthcare Databases (AMED, BNI, EMBASE, MEDLINE, PsycINFO, CINAHL) using the search terms “asthm*” and “systematic review” combined, and limiting to references from 2006 - 2008.&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;BR&gt;&lt;FONT face=Arial&gt;Details of the PUBMED Clinical Queries systematic review filter and its validation can be found via the following link:&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query/static/clinical.shtml" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#0066cc&gt;http://www.ncbi.nlm.nih.gov/entrez/query/static/clinical.shtml&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;FONT face=Arial&gt; &lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: center" align=center&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;Identification of systematic reviews&lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;All citations found in the database searches were hand sifted for duplicates, and abstracts read to identify systematic reviews and potential systematic reviews relevant to Asthma. &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;&amp;nbsp; &lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;To determine systematic reviews, the definition of a systematic review from the &lt;/FONT&gt;&lt;A href="http://www.cochrane.org/resources/glossary.htm" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#0066cc&gt;Glossary of Cochrane Collaboration Terms&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&lt;FONT face=Arial&gt; on the Cochrane Collaboration website was used:&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;“A review of a clearly formulated question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies.”&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN lang=EN style="COLOR: black; mso-ansi-language: EN"&gt;&lt;FONT face=Arial&gt;The final decisions on whether to include a citation as relevant to the topic and being a systematic review was made at the final editing stage by Dr Mark Everard, Clinical Lead for the NLH Child Health and Paediatrics Specialist Library.&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/SPAN&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>284321</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=284321]]&gt;</url>
    <title>National Knowledge Week for Asthma 2008 - Supporting Information</title>
    <publicationDate>2008-05-05T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,NKW ASTHMA,2008]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 2008 - Supporting Information&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/101/index.html" target="_blank"&gt;British Guideline on the Management of Asthma&lt;/A&gt;&amp;nbsp;(Latest update published 6 May 2008)&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;This is a ‘living’ guideline which is reviewed every year and updated if necessary to take into account new evidence and information. Originally published in 2003, details of all updates to the guideline are also available together with a range of supporting materials including case studies, educational slides and posters.&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.sign.ac.uk/guidelines/fulltext/63/index.html" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.sign.ac.uk/guidelines/published/support/guideline63/index.html#tables" target="_blank"&gt;Evidence tables for Pharmalogical Management of Asthma&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;Asthma UK&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.asthma.org.uk/how_we_help/world_asthma_day/index.html" target="_blank"&gt;Asthma UK page for World Asthma Day 2008&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;British Thoracic Society&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.occupationalasthma.com/" target="_blank"&gt;Occupational Asthma&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.occupationalasthma.com/" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;o:p&gt;&lt;FONT face=Arial&gt;&amp;nbsp;&lt;/FONT&gt;&lt;/o:p&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;B style="mso-bidi-font-weight: normal"&gt;&lt;FONT face=Arial&gt;Patient Information&lt;o:p&gt;&lt;/o:p&gt;&lt;/FONT&gt;&lt;/B&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;Asthma UK&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.lunguk.org/you-and-your-lungs/diagnosis-and-treatment/diagnosing-childhood-asthma.htm" target="_blank"&gt;British Lung Foundation Asthma Pages&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;A href="http://www.lunguk.org/you-and-your-lungs/diagnosis-and-treatment/diagnosing-childhood-asthma.htm" target="_blank"&gt;&lt;U&gt;&lt;FONT face=Arial color=#800080&gt;&lt;/FONT&gt;&lt;/U&gt;&lt;/A&gt;&amp;nbsp;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;FONT face=Arial&gt;&lt;A href="http://www.brit-thoracic.org.uk/ClinicalInformation/Asthma/PatientInformationAsthma/tabid/161/Default.aspx" target="_blank"&gt;BTS Patient Information on Asthma&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>125034</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125034]]&gt;</url>
    <title>National Knowledge Week for Asthma 22 - 26 May 2006</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Asthma 22 - 26 May 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P align=center&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID125034/nelhImp_0000_Image1.jpg" name=nelh_tempImage0&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage2 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID125034/nelhImp_0001_Image3.jpg" name=nelh_tempImage2&gt;&amp;nbsp;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID125034/nelhImp_0002_Image2.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;The aim of these pages is to present the latest available evidence and information within the topics chosen in Asthma. A short article was written for each topic by experts representing the different professional groups involved in respiratory medicine and healthcare. Each topic is accompanied by supporting evidence and patient information, and in the majority of cases a list of references provided by the author. The supporting evidence has been limited to that published in the last two years – there may be further information available within the &lt;A href="http://rms.nelh.nhs.uk/respiratory/searchResponse.asp?categoryID=5872" target="_blank"&gt;Asthma &lt;/A&gt;section of the library.&lt;/P&gt;
&lt;P&gt;The topics were chosen in consultation with the Respiratory Specialist Library stakeholder group.&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;&lt;A href="nelh:125045:0" name=internalLink&gt;&lt;FONT size=+1&gt;Topics&lt;/FONT&gt; &lt;/A&gt;– &lt;FONT size=+1&gt;&lt;A href="nelh:125074:0" name=internalLink&gt;&lt;FONT size=+1&gt;Contributors&lt;/FONT&gt; &lt;/A&gt;&lt;/FONT&gt;– &lt;FONT size=+1&gt;&lt;A href="nelh:126226:0" name=internalLink&gt;&lt;FONT size=+1&gt;Organisations&lt;/FONT&gt;&lt;/A&gt;&lt;/FONT&gt;&lt;/P&gt;&lt;BR&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278340</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278340]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;This information within the National Knowledge Week for COPD has been prepared by members of the COPD National Service Framework External Reference Group, as part of their work in developing advice for Ministers on the content of a National Service Framework for people with COPD.&lt;/P&gt;
&lt;P&gt;It is based on a review of the evidence base undertaken by Kleijnen Systematic Reviews. The evidence base is published in a separate document within the National Knowledge Week, and where possible we have linked to full text or abstracts.&lt;/P&gt;
&lt;P&gt;The advice from the COPD External Reference Group will be presented to Ministers in February 2008.&amp;nbsp; During 2008 the Department of Health will be carrying out an economic assessment of the recommendations and writing the National Service Framework, which will be published at the end of 2008.&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278341:0" name=internalLink&gt;&lt;STRONG&gt;Raising Awareness of Lung Disease&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278342:0" name=internalLink&gt;&lt;STRONG&gt;Risk Factors for COPD&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278343:0" name=internalLink&gt;&lt;STRONG&gt;Preventing COPD&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278344:0" name=internalLink&gt;&lt;STRONG&gt;Access to Stop Smoking Services&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278345:0" name=internalLink&gt;&lt;STRONG&gt;Diagnosing COPD&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278346:0" name=internalLink&gt;&lt;STRONG&gt;Exercise&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278347:0" name=internalLink&gt;&lt;STRONG&gt;Psychological Interventions&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278348:0" name=internalLink&gt;&lt;STRONG&gt;Nutrition&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278349:0" name=internalLink&gt;&lt;STRONG&gt;Surgical Interventions for COPD&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278354:0" name=internalLink&gt;&lt;STRONG&gt;COPD Exacerbations&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;A href="nelh:278356:0" name=internalLink&gt;&lt;STRONG&gt;Evidence Base&lt;/STRONG&gt;&lt;/A&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;Further information can be obtained at &lt;A href="http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/DH_4138532" target="_blank"&gt;http://www.dh.gov.uk/en/Policyandguidance/Healthandsocialcaretopics/DH_4138532&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Or email &lt;A href="mailto:copd_nsf@dh.gsi.gov.uk" target="_blank"&gt;copd_nsf@dh.gsi.gov.uk&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278344</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278344]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Access to Stop Smoking Services</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,SMOKING,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Access to Stop Smoking Services&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;If people do smoke then stopping is the single most effective, and cost effective, way to reduce the risk of getting COPD. Quitting smoking can prevent or delay the development of airflow limitation, or reduce its progression &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#61" target="_blank"&gt;[61]&lt;/A&gt;, and can have a substantial effect on subsequent mortality. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#62" target="_blank"&gt;[62]&lt;/A&gt; All smokers, those who may be at risk for COPD as well as those who already have the disease, should be offered the most intensive stop smoking intervention feasible. Stop smoking interventions are effective in both sexes, in all racial and ethnic groups, and in pregnant women. Age influences quit rates, with young people less likely to quit, but never-the-less stop smoking programs can be effective in all age groups &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=58808#8" target="_blank"&gt;[8]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Stop smoking services need to offer a long-term programme that is flexible enough to deal with an individual’s needs. It can take as many as seven or eight attempts for a smoker to successfully quit, therefore programmes need to take this into account and have robust systems for following up those that have used their service and offering further help if needed.&lt;/P&gt;
&lt;P&gt;Access to behavioural support and pharmacotherapies that greatly increase the chances of stopping smoking needs to be improved. Currently, although available, there are widespread variations in accessibility and quality of both support and treatments throughout the UK. &lt;/P&gt;
&lt;P&gt;The extensive literature on stop smoking interventions demonstrates that success rates increase with the intensity of the intervention provided, ranging from 2% (abstinence for 6 months or longer) for brief opportunistic advice from a GP to 13-19% for intensive behavioural support plus pharmacotherapy (NRT or Bupropion). The advent of varenicline as a NICE approved stop smoking treatment may further enhance rates at the top end of the scale, given that it has higher efficacy rates than Bupropion. &lt;/P&gt;
&lt;P&gt;Stop smoking services should also take into account other smoked substances that may have an impact on lung health, such as cannabis. Local Stop Smoking Services should link with local drug teams to address this issue. Other inhaled illicit substances, such as crack cocaine and heroin, are also likely to have a detrimental effect on lung health &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#63" target="_blank"&gt;[63]&lt;/A&gt; and local drug teams and healthcare professionals should work together to address this.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Stop Smoking Services&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Every organisation should have an accessible, long-term, structured, non-judgmental, stop smoking programme offering a complete range of stop smoking aids individualised to the patient, including behavioural aids as well as pharmacotherapy, that includes follow-up and measures quit rates at 4 weeks and 12 months. All possible treatments should be offered before the intervention is considered complete. Therefore a patient commencing on NRT, who fails in their quit attempt should then be considered, as appropriate, for the next step up in pharmacotherapy, for example bupropion or varenicline. Stop Smoking programmes should be set up to reflect the needs of individual populations. There should be national outcome measures of smoking quit rates for COPD patients and local measures to assess the success rate of the service offered and compared to the national figure. Annual assessments of smoking status should be performed. If relapse occurs but patients remain motivated to quit continual support should be offered. &lt;/P&gt;
&lt;P&gt;Although there is no extensive research into the value of such programmes specifically in COPD patients outside of clinical trails, the health gains achieved by stopping smoking are indisputable. These gains are not just in COPD itself, where stopping smoking is of proven benefit, but also on other pre-existing conditions such as cancer, cardiovascular disease, diabetes and osteoporosis. &lt;/P&gt;
&lt;P&gt;A formal stop smoking programme should not be simply informing a patient of the health hazards of continuing smoking or giving advice to stop smoking. This has value in general but it is not sufficiently effective to constitute a programme. A programme should be a 'treatment paradigm' starting with the simplest effective treatment and progressing to the most 'aggressive' if success is not achieved at the previous level. &lt;/P&gt;
&lt;P&gt;There have been many trials with different strategies or interventions but most have shown low, unproven or a nil success rate. Therefore only strategies with proven success should be promoted. It should also be recognised that the difficulty involved in stopping smoking means that an individual will go through, on average, six attempts to quit before success is achieved. Thus follow up and 'retreatment' and recognition of this need is required and should be an integral part of the programme. &lt;/P&gt;
&lt;P&gt;The starting point should be a formal programme with continued support, either one to one or in a group, with education and with or without nicotine replacement therapy. This has been demonstrated to be effective, but note the success rate is still under 10%. &lt;/P&gt;
&lt;P&gt;Therefore approximately 90% of subjects should be offered and enter the next level of treatment which requires pharmacotherapy. Here the success rate in trials rises to 15 -30%. &lt;/P&gt;
&lt;P&gt;In all these treatment pathways there will be failures and relapses requiring further intervention. The arithmetic therefore implies a large number of subjects should be receiving pharmacotherapy but prescribing data does not suggest this is happening on a sufficiently large scale. There is an added risk that the more educated, informed and articulate will be more able to access this higher level of treatment. This inequality would not be an efficient use of resources since this is the group with the lowest health impact of smoking. Or, to consider the situation the other way round, the group needing the most aggressive intervention could become the least likely to receive it. &lt;/P&gt;
&lt;P&gt;A formula could be devised as to what a reasonable basic level of prescribing should be and this should also be flexible. Areas of low income, industrial areas, for example, should be expected to be showing higher rates than high income areas. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278354</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278354]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - COPD Exacerbations</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,THERAPEUTIC INTERVENTION,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - COPD Exacerbations&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Prompt presentation for treatment has been shown to improve outcomes &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#141" target="_blank"&gt;[141]&lt;/A&gt;. Thus, it is important that patients who develop exacerbations, together with their carers, are able to understand and recognise exacerbation symptoms. &lt;/P&gt;
&lt;P&gt;COPD exacerbations are associated with worse quality of life &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#142" target="_blank"&gt;[142]&lt;/A&gt;, faster disease progression &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#143" target="_blank"&gt;[143,144]&lt;/A&gt; and increased mortality &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#145" target="_blank"&gt;[145]&lt;/A&gt;. They are also a significant cause of hospital admission, readmission and considerable healthcare cost &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#146" target="_blank"&gt;[146]&lt;/A&gt;. Some COPD patients are prone to frequent exacerbations [&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#142" target="_blank"&gt;142]&lt;/A&gt; and these are the group of patients at most risk of hospital admission. &lt;/P&gt;
&lt;P&gt;Most COPD exacerbations can be managed and assessed in the community; some exacerbations may be mild and self-limiting and only require an increase in regular inhaled medication. However, most exacerbations require therapy with either antibiotics and/or corticosteroids, depending on their severity and effect on the patients’ daily activities. Patients with more severe exacerbations will require access to specialist care to undergo investigations such as measurement of arterial blood gases, chest radiograph and assessment of therapy. The severity of an exacerbation is also affected by other co-morbidities that are commonly found in this COPD patient group and need to be recognised &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#147" target="_blank"&gt;[147]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;COPD exacerbations account for 15.9% of all medical emergency admissions with an average length of stay of nine days &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#148" target="_blank"&gt;[148]&lt;/A&gt; and just over 20% presenting with acidotic respiratory failure &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#149" target="_blank"&gt;[149]&lt;/A&gt;. Non-invasive ventilation (NIV) through a nasal or face mask has been shown to reduce mortality, tracheal intubation and complications associated with invasive ventilation &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#150" target="_blank"&gt;[150]&lt;/A&gt;. The use of NIV has also been shown to be highly cost-effective &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#151" target="_blank"&gt;[151]&lt;/A&gt;. COPD patients with acute respiratory failure must be identified and investigated promptly and treated with NIV and controlled oxygen therapy usually as the first choice of therapy according to guidelines &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#152" target="_blank"&gt;[152]&lt;/A&gt;. In view of the dangers of hypercapnia in these patients, any supplemental oxygen therapy must be controlled during transfer to hospital and admission&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#153" target="_blank"&gt;[153]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Respiratory physiotherapy during an acute exacerbation should be available for airway clearance, reducing the work of breathing and restoring functional status and may include using the active cycle of breathing techniques &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#154" target="_blank"&gt;[154]&lt;/A&gt;, the positive expiratory pressure mask&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#155" target="_blank"&gt;[155]&lt;/A&gt;, positioning &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#156" target="_blank"&gt;[156]&lt;/A&gt;, pursed lip breathing &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#157" target="_blank"&gt;[157]&lt;/A&gt;, inspiratory muscle training &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#158" target="_blank"&gt;[158]&lt;/A&gt; and rehabilitation early after onset of exacerbation &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#159" target="_blank"&gt;[159]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;A hospital admission with a COPD exacerbation is an important event in the natural history of the condition and thus during the admission, the opportunity should be provided for patient education and review of COPD management. Following hospital admission for an exacerbation, 30% of COPD patients are likely to be readmitted within a three month period &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#160" target="_blank"&gt;[160]&lt;/A&gt;). The reasons for readmission are complex and thus after hospital admission, patients require regular follow up with review of both their medical condition, pre-existing conditons and psychosocial needs. In a community COPD study, 22% of patients developed another exacerbation within 50 days &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#161" target="_blank"&gt;[161]&lt;/A&gt; and thus it is important that patients who have been admitted to hospital should be reviewed early.&lt;BR&gt;&lt;BR&gt;There are various models of care available for patients presenting with exacerbations, including self-management, avoidance of hospital admission with schemes such as hospital at home and supported discharge &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#162" target="_blank"&gt;[162]&lt;/A&gt;. These hospital at home and supported discharge schemes have been shown to be effective with similar rates of hospital readmission, but preferred by patients and cheaper than usual care &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#162" target="_blank"&gt;[162]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Chronic Care&lt;/P&gt;
&lt;P&gt;The patient’s knowledge of COPD is a pre-requisite for self-management and concordance with medical treatment. To be effective, the educational needs should be addressed from the patient’s perspective and delivered in a receptive format. The key educational topics are disease education, management of breathlessness, pharmacological treatments, exacerbation management, psychological support and benefits guidance. &lt;/P&gt;
&lt;P&gt;A structured approach to the management of COPD will have some of the benefits that have been seen in other chronic diseases such as diabetes, heart failure and asthma. At present, care is directed primarily towards the management of the acute exacerbation. In order to move away from this existing reactive provision it is necessary to have an organized, multi disciplinary approach to COPD management. &lt;/P&gt;
&lt;P&gt;Self-management is the term applied to the educational programme that teaches the skills required for concordance with medical treatment, encouragement to change behaviour, provide emotional support and promote an active lifestyle. Self-management skills can be taught within a formal rehabilitation programme or separately by interview or manual. Recent reviews of this subject suggest that this approach is beneficial in reducing hospital admissions. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278345</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278345]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Diagnosing COPD</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,COUGH,IMAGING,LUNG FUNCTION TESTING,WHEEZE,SMOKING,DIAGNOSIS AND MONITORING,SYMPTOMS,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Diagnosing COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;COPD is a common condition, but one for which the causes are not fully understood. Currently COPD is usually detected late in the disease or not diagnosed at all. Spirometrically defined COPD is present in 13% of the population over 35 years in the U.K., but 80% of cases are undiagnosed. Even in moderate to severe disease (GOLD 3 - 4) less than half had a prior diagnosis &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#64" target="_blank"&gt;[64]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Many people, both symptomatic and asymptomatic are unaware of the presence of COPD and that they can take steps to improve outcomes and progression. For these reasons, patients often present late when the potential benefits of intervention are reduced. &lt;/P&gt;
&lt;P&gt;There is evidence that a major cause of COPD is smoking, but it is likely that a range of factors, including occupation, environmental factors, family history, asthma, health events in childhood and genetic susceptibility, may also have a role &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#65" target="_blank"&gt;[65]&lt;/A&gt;. Therefore, in order to find people who have, or will develop COPD, different approaches are needed that focus on general lung health in young adults, as well as looking for COPD in certain groups, such as smokers. The advantage of such a multi pronged approach is that as well as identifying cases of COPD, other common lung diseases may be detected at an earlier stage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Case finding&lt;/STRONG&gt;&lt;BR&gt;Features suggestive of COPD include exposures such as current or previous smoking, chronic asthma, occupational exposure to dust, gases and vapours, and low education/income, over 40s. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#66" target="_blank"&gt;[66]&lt;/A&gt; Additional features include wheeze, cough, phlegm, and breathlessness, and the presence of co-morbidities. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#67" target="_blank"&gt;[67-74]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;Targeting people who fall into these categories and have these early signs of COPD will lead to earlier diagnosis of those with mild COPD. There is evidence that those with symptomatic airflow obstruction benefit from treatment, self management education and lifestyle modification and that the earlier these steps are taken the better the outcomes in terms of quality of life and healthcare consumption. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#75" target="_blank"&gt;[75]&lt;/A&gt; &lt;/P&gt;
&lt;P&gt;This approach will also help to identify other common co-morbidities, such as heart disease, osteoporosis, type 2 diabetes, anxiety and depression, and lung cancer. It will also rule out common conditions that mimic COPD, such as asthma, bronchiectasis, thrombo-embolic disease, heart failure, and anaemia.&lt;/P&gt;
&lt;P&gt;The National Service Framework for COPD will be investigating further ways of identifying COPD at an earlier stage.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Confirming the diagnosis of COPD&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;In order to identify people with COPD at an early stage more widespread testing using symptom questionnaires and screening spirometry will be required. Those suspected of having respiratory disease even though spirometry is normal should be referred for comprehensive assessment to confirm the diagnosis and severity and ensure instigation of appropriate therapies.&lt;/P&gt;
&lt;P&gt;For the purposes of detecting airflow obstruction, screening spirometry may be performed using a simple device that measures FEV&lt;SUB&gt;1&lt;/SUB&gt;. The purpose is not to make a diagnosis but those with a positive test should be referred for further assessment when diagnosis and its nature may be confirmed. The standard of training and equipment is lower for a screening test than for a diagnostic test, and screening tests may be performed by a range of professionals in a range of settings with the aim of encouraging more widespread testing of lung function.&lt;/P&gt;
&lt;P&gt;The widespread use of CT scanning as part of the diagnosis of COPD and also to aid in the identification of lung cancer, is not currently recommended but further research and feasibility testing in this area is needed as a way of complementing physiological testing and characterising the structural damage due to COPD.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278356</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278356]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Evidence Base</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Evidence Base&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;A comprehensive literature search of the evidence base was undertaken by Kleijnen Systematic Reviews for the COPD NSF. This was carried out up to the end of December 2007.&lt;/P&gt;
&lt;P&gt;Where possible we have linked to the full text or abstracts of the articles available on the internet. Users may have access to full text of the articles listed with just abstracts via Athens or local library/university subscriptions.&lt;/P&gt;
&lt;P&gt;&lt;/P&gt;
&lt;OL&gt;&lt;A name=1&gt;&lt;/A&gt;
&lt;LI&gt;Voelkel NF. Raising awareness of COPD in primary care. Chest 2000; 117(5 Suppl 2):372S-375S. [&lt;A href="http://www.chestjournal.org/cgi/reprint/117/5_suppl_2/372S" target="_blank"&gt;FULL TEXT, PDF&lt;/A&gt;]&lt;/LI&gt;&lt;A name=2&gt;&lt;/A&gt;
&lt;LI&gt;Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004; 98(10):932-937. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15481268?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=3&gt;&lt;/A&gt;
&lt;LI&gt;Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Jr. et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005; 118(12):1415. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16378794?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=4&gt;&lt;/A&gt;
&lt;LI&gt;British Lung Foundation. Lost in translation: Bridging the communication gap in COPD. British Lung Foundation 2006. [&lt;A href="http://www.lunguk.org/OneStopCMS/Core/CrawlerResourceServer.aspx?resource=A9AA7512-A460-4A8E-99DC-4F3CBB015998&amp;amp;mode=link&amp;amp;guid=e4ebca89467541589a0feb72abf45c31" target="_blank"&gt;FULLTEXT, PDF&lt;/A&gt;]&lt;/LI&gt;&lt;A name=5&gt;&lt;/A&gt;
&lt;LI&gt;Georgopoulas D, Anthonisen NR. Symptoms and signs of COPD. In: Cherniack NS, ed. Chronic obstructive pulmonary disease. Toronto: WB Saunders Co; 1991:357-63.&lt;/LI&gt;&lt;A name=6&gt;&lt;/A&gt;
&lt;LI&gt;Celli BR, Rassulo J, Make BJ. Dyssynchronous breathing during arm but not leg exercise in patients with chronic airflow obstruction. N Engl J Med 1986;314(23):1485-90. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/3702963?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=7&gt;&lt;/A&gt;
&lt;LI&gt;Wouters EFM. Economic analysis of the Confronting COPD survey: an overview of results. Respiratory Medicine 2003;97:S3-S14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12647938?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=8&gt;&lt;/A&gt;
&lt;LI&gt;Department of Health. Coronary Heart Disease 10 years on. 2007. [&lt;A href="http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074238" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=9&gt;&lt;/A&gt;
&lt;LI&gt;Patel BD, Luben RN, Welch AA, Bingham SA, Khaw KT, Day NE, et al. Childhood smoking is an independent risk factor for obstructive airways disease in women. Thorax 2004 Aug;59(8):682-6. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15282389?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=10&gt;&lt;/A&gt;
&lt;LI&gt;Jaakkola JJ, Jaakkola MS. Effects of environmental tobacco smoke on the respiratory health of children. Scand J Work Environ Health 2002;28 Suppl 2:71-83. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12058805?rdinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=11&gt;&lt;/A&gt;
&lt;LI&gt;Cook DG, Strachan DP, Carey IM. Health effects of passive smoking. 9. Parental smoking and spirometric indices in children. Thorax 1998 Oct;53(10):884-93. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10193379?rdinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=12&gt;&lt;/A&gt;
&lt;LI&gt;Cook DG, Strachan DP. Health effects of passive smoking-10: Summary of effects of parental smoking on the respiratory health of children and implications for research. Thorax 1999 Apr;54(4):357-66. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10092699?rdinalpos=38&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=13&gt;&lt;/A&gt;
&lt;LI&gt;Strachan DP, Cook DG. Health effects of passive smoking. 1. Parental smoking and lower respiratory illness in infancy and early childhood. Thorax 1997 Oct;52(10):905-14. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9404380?rdinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=14&gt;&lt;/A&gt;
&lt;LI&gt;Surgeon General T. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Atlanta, Ga.; 2006. [&lt;A href="http://www.surgeongeneral.gov/library/secondhandsmoke/report/executivesummary.pdf" target="_blank"&gt;FULLTEXT, PDF&lt;/A&gt;]&lt;/LI&gt;&lt;A name=15&gt;&lt;/A&gt;
&lt;LI&gt;GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. December 2007 [&lt;A href="http://www.goldcopd.com/GuidelineItem.asp?intId=989" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=16&gt;&lt;/A&gt;
&lt;LI&gt;Prescott E, Godtfredsen N, Vestbo J, Osler M. Social position and mortality from respiratory diseases in males and females. Eur Respir J 2003 May;21(5):821-6. [&lt;A href="http://erj.ersjournals.com/cgi/content/full/21/5/821" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=17&gt;&lt;/A&gt;
&lt;LI&gt;O’Dwyer, L. Baum, F. Kavanagh, A, Macdougall, C. Do area-based interventions to reduce health inequalities work? A systematic review of evidence. Critical Public Health, December 2007; 17 (4): 317-335.&lt;/LI&gt;&lt;A name=18&gt;&lt;/A&gt;
&lt;LI&gt;American Thoracic Society. American Thoracic Society Statement: Occupational contribution to the burden of airway disease. (2003) Am J Respir Crit Care Med 167:787-97. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/167/5/787" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=19&gt;&lt;/A&gt;
&lt;LI&gt;Trupin L, et al. (2003) The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 22:462-469. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/14516136?ordinalpos=28&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=20&gt;&lt;/A&gt;
&lt;LI&gt;Hnizdo E, Sullivan P, Bang K, Wagner G (2002) Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 156:738-746. [&lt;A href="http://aje.oxfordjournals.org/cgi/content/full/156/8/738" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=21&gt;&lt;/A&gt;
&lt;LI&gt;Nurminen M, Karjalainen A (2001) Epidemiological estimate of the proportion of fatalities related to occupational factors in Finland. Scand J Work Environ Health 27:161-213.&lt;/LI&gt;&lt;A name=22&gt;&lt;/A&gt;
&lt;LI&gt;HSE. &lt;A href="http://www.hse.gov.uk/copd/" target="_blank"&gt;Chronic obstructive Pulmonary Disease&lt;/A&gt;&lt;/LI&gt;&lt;A name=23&gt;&lt;/A&gt;
&lt;LI&gt;HSE. &lt;A href="http://www.hse.gov.uk/statistics/2002/swc95.pdf" target="_blank"&gt;Self-reported working conditions in 1995: Results from a household survey&lt;/A&gt; (PDF)&lt;/LI&gt;&lt;A name=24&gt;&lt;/A&gt;
&lt;LI&gt;HSE. &lt;A href="http://www.hse.gov.uk/statistics/pdf/whassw1.pdf" target="_blank"&gt;Workplace health and safety survey programme: 2005 Worker survey first findings report&lt;/A&gt; (PDF)&lt;/LI&gt;&lt;A name=25&gt;&lt;/A&gt;
&lt;LI&gt;HSE &lt;A href="http://www.hse.gov.uk/statistics/pdf/whasse1.pdf" target="_blank"&gt;Workplace health and safety survey programme: 2005 Employer survey&lt;/A&gt; (PDF)&lt;/LI&gt;&lt;A name=26&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.workingforhealth.gov.uk/" target="_blank"&gt;Health, Work and Wellbeing website&lt;/A&gt;&lt;/LI&gt;&lt;A name=27&gt;&lt;/A&gt;
&lt;LI&gt;Palmer KT and Pearson S in Fitness for work: The medical aspects: Oxford University Press. Oxford 2007 Eds Palmer KT Cox RA and Brown I&lt;/LI&gt;&lt;A name=28&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.healthandsafety.co.uk/haswa.htm" target="_blank"&gt;Health &amp;amp; Safety at Work etc Act 1974 &lt;/A&gt;&lt;/LI&gt;&lt;A name=29&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.opsi.gov.uk/SI/si2002/20022677.htm" target="_blank"&gt;Control of Substances Hazardous to Health Regulations (as amended) 2002 &lt;/A&gt;&lt;/LI&gt;&lt;A name=30&gt;&lt;/A&gt;
&lt;LI&gt;Hnizdo E, Yu L, Freyder L, Attfield M, Lefante J, Glindmeyer HW. (2005) The precision of longitudinal lung function measurements: monitoring and interpretation. Occup Environ Med 62: 695-701. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16169915?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=31&gt;&lt;/A&gt;
&lt;LI&gt;HSE. &lt;A href="http://www.hse.gov.uk/pubns/guidance/g401.pdf" target="_blank"&gt;COSHH essentials: general guidance&lt;/A&gt; (PDF)&lt;/LI&gt;&lt;A name=32&gt;&lt;/A&gt;
&lt;LI&gt;Tarlo SM, Liss GM. Diisocyanate-induced asthma: diagnosis, prognosis, and effects of medical surveillance measures. Appl Occup Environ Hyg. 2002 Dec;17(12):902-8. Review. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12495601?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=33&gt;&lt;/A&gt;
&lt;LI&gt;Brant A, Nightingale S, Berriman J, Sharp C, Welch J, Newman Taylor AJ, Cullinan P. Supermarket baker's asthma: how accurate is routine health surveillance? Occup Environ Med. 2005 Jun;62(6):395-9. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15901887?ordinalpos=41&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=34&gt;&lt;/A&gt;
&lt;LI&gt;Hnizdo E, Yu L, Freyder L, Attfield M, Lefante J, Glindmeyer HW. The precision of longitudinal lung function measurements: monitoring and interpretation. Occup Environ Med. 2005 Oct;62(10):695-701. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16169915?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=35&gt;&lt;/A&gt;
&lt;LI&gt;Hnizdo E, Sircar K, Yan T, Harber P, Fleming J, Glindmeyer HW. Limits of longitudinal decline for the interpretation of annual changes in FEV1 in individuals. Occup Environ Med. 2007 May 3; [Epub ahead of print]. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17478573?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=36&gt;&lt;/A&gt;
&lt;LI&gt;Holland WW, Reid DD. The urban factor in chronic bronchitis. Lancet 1965; 1: 445-8. 70.&lt;/LI&gt;&lt;A name=37&gt;&lt;/A&gt;
&lt;LI&gt;Schikowski T, Sugiri D, Ranft U, Gehring U, Heinrich J, Wichmann HE, Kramer U: Long-term air pollution exposure and living close to busy roads are associated with COPD in women. Respir Res 2005, 6:152. [&lt;A href="http://respiratory-research.com/content/6/1/152" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=38&gt;&lt;/A&gt;
&lt;LI&gt;Gaudermann et al, 2004&lt;/LI&gt;&lt;A name=39&gt;&lt;/A&gt;
&lt;LI&gt;Anderson et al, 1997&lt;/LI&gt;&lt;A name=40&gt;&lt;/A&gt;
&lt;LI&gt;Brunekreef, 2005&lt;/LI&gt;&lt;A name=41&gt;&lt;/A&gt;
&lt;LI&gt;&lt;A href="http://www.defra.gov.uk/" target="_blank"&gt;DEFRA website &lt;/A&gt;&lt;/LI&gt;&lt;A name=42&gt;&lt;/A&gt;
&lt;LI&gt;Osman et al, 2007&lt;/LI&gt;&lt;A name=43&gt;&lt;/A&gt;
&lt;LI&gt;Eisner et al, 2006.&lt;/LI&gt;&lt;A name=44&gt;&lt;/A&gt;
&lt;LI&gt;Chapman et al, 2005&lt;/LI&gt;&lt;A name=45&gt;&lt;/A&gt;
&lt;LI&gt;(Sandford (NSR, 2002)&lt;/LI&gt;&lt;A name=46&gt;&lt;/A&gt;
&lt;LI&gt;Lomas DA. The selective advantage of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2006 May 15;173(10):1072-7). [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/173/10/1072" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=47&gt;&lt;/A&gt;
&lt;LI&gt;Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr. 1997 Jan;86(1):37-40. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/9116423?ordinalpos=47&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=48&gt;&lt;/A&gt;
&lt;LI&gt;Thelin T, Sveger T, McNeil TF: Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr 1996 Oct; 85(10): 1207-12. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/8922085?ordinalpos=32&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=49&gt;&lt;/A&gt;
&lt;LI&gt;Sveger, N Engl J Med. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200000 infants. 1976 Jun 10;294(24):1316-21&lt;/LI&gt;&lt;A name=50&gt;&lt;/A&gt;
&lt;LI&gt;Bernspång et al, Respir Med. 2007 Sep;101(9):1971-6. Epub 2007 May 25&lt;/LI&gt;&lt;A name=51&gt;&lt;/A&gt;
&lt;LI&gt;Acta Paediatr. 2000 Jun;89(6):628-31).&lt;/LI&gt;&lt;A name=52&gt;&lt;/A&gt;
&lt;LI&gt;Bull World Health Organ. 1997;75(5):397-415&lt;/LI&gt;&lt;A name=53&gt;&lt;/A&gt;
&lt;LI&gt;Carpenter et al, Ann Behav Med. 2007 Feb;33(1):22-8&lt;/LI&gt;&lt;A name=54&gt;&lt;/A&gt;
&lt;LI&gt;Silverman et al, Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1770-8. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/157/6/1770" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=55&gt;&lt;/A&gt;
&lt;LI&gt;McCloskey et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1419-24. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/164/8/1419" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=56&gt;&lt;/A&gt;
&lt;LI&gt;Sowden AJ, Arblaster L. Mass media interventions for preventing smoking in young people. Cochrane Database Syst Rev 1998;(2):CD001006. [&lt;A href="http://www.cochrane.org/reviews/en/ab001006.html" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=57&gt;&lt;/A&gt;
&lt;LI&gt;Sowden A, Arblaster L, Stead L. Community interventions for preventing smoking in young people. Cochrane Database Syst Rev 2003;(1):CD001291. [&lt;A href="http://www.cochrane.org/reviews/en/ab001291.html" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=58&gt;&lt;/A&gt;
&lt;LI&gt;Grimshaw GM, Stanton A. Tobacco cessation interventions for young people. Cochrane Database Syst Rev 2006;(4):CD003289. [&lt;A href="http://www.cochrane.org/reviews/en/ab003289.html" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=59&gt;&lt;/A&gt;
&lt;LI&gt;Grimshaw GM, Stanton A. Tobacco cessation interventions for young people. Cochrane Database Syst Rev 2006;(4):CD003289. [&lt;A href="http://www.cochrane.org/reviews/en/ab003289.html" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=60&gt;&lt;/A&gt;
&lt;LI&gt;Lumley J, Oliver SS, Chamberlain C, Oakley L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2004;(4):CD001055. [&lt;A href="http://www.cochrane.org/reviews/en/ab001055.html" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=61&gt;&lt;/A&gt;
&lt;LI&gt;Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-505. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/7966841?ordinalpos=51&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=62&gt;&lt;/A&gt;
&lt;LI&gt;Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of smoking cessation intervention on 14.5 year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233- 9. [&lt;A href="http://www.annals.org/cgi/reprint/142/4/233.pdf" target="_blank"&gt;FULL TEXT, PDF&lt;/A&gt;]&lt;/LI&gt;&lt;A name=63&gt;&lt;/A&gt;
&lt;LI&gt;Tashkin, D P. Airway effects of marijuana, cocaine and other inhaled illicit agents. Current Opinion in Pulmonary Medicine 7 (2):43-61, 2001. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11224724?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=64&gt;&lt;/A&gt;
&lt;LI&gt;Shahab, L., M. J. Jarvis, et al. (2006). "Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample." Thorax.Vol.59(11)()(pp 960-965), 2004. 61(12): 1043-1047. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/17040932?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=65&gt;&lt;/A&gt;
&lt;LI&gt;National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 Suppl 1:1-232. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15041752?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=66&gt;&lt;/A&gt;
&lt;LI&gt;Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94. [&lt;A href="http://erj.ersjournals.com/cgi/content/full/17/5/982" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=67&gt;&lt;/A&gt;
&lt;LI&gt;National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care." Thorax 2004; 59 suppl 1: 1-232. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/15041752?ordinalpos=7&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=68&gt;&lt;/A&gt;
&lt;LI&gt;Freeman D, Nordyke RJ, Isonaka S, Nonikov DV, Maroni JM, Price D, Halbert RJ. Questions for COPD diagnostic screening in a primary care setting. Respir Med. 2005 Oct;99(10):1311. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16140231?ordinalpos=3&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=69&gt;&lt;/A&gt;
&lt;LI&gt;Geijer, R. M. M., A. P. E. Sachs, et al. (2006). "Are patient characteristics helpful in recognizing mild COPD (GOLD I) in daily practice?" Scandinavian Journal of Primary Health Care 24(4): 237-242. [&lt;A href="http://www.informaworld.com/smpp/content?content=10.1080/02813430601016894" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=70&gt;&lt;/A&gt;
&lt;LI&gt;Price, D. B., D. G. Tinkelman, et al. (2006). "Symptom-based questionnaire for identifying COPD in smokers." Respiration 73(3): 285-95. [&lt;A href="http://content.karger.com/produktedb/produkte.asp?typ=fulltext&amp;amp;file=000090142" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=71&gt;&lt;/A&gt;
&lt;LI&gt;Price, D. B., D. G. Tinkelman, et al. (2006). "Scoring system and clinical application of COPD diagnostic questionnaires." Chest 129(6): 1531-9. [&lt;A href="http://www.chestjournal.org/cgi/content/full/129/6/1531?ck=nck" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=72&gt;&lt;/A&gt;
&lt;LI&gt;Tinkelman, D. G., D. B. Price, et al. (2006). "Symptom-based questionnaire for differentiating COPD and asthma." Respiration 73(3): 296-305. [&lt;A href="http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowFulltext&amp;amp;ArtikelNr=90141&amp;amp;Ausgabe=231763&amp;amp;ProduktNr=224278" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=73&gt;&lt;/A&gt;
&lt;LI&gt;Van Schayck CP,Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002 Jun 8;324(7350):1370. [&lt;A href="http://www.bmj.com/cgi/content/full/324/7350/1370" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=74&gt;&lt;/A&gt;
&lt;LI&gt;van Schayck, C. P., R. J. Halbert, et al. (2005). "Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting." Respirology 10(3): 323-33.[&lt;A href="http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1843.2005.00720.x" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=75&gt;&lt;/A&gt;
&lt;LI&gt;Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. [&lt;A href="http://jama.ama-assn.org/cgi/content/abstract/272/19/1497" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=76&gt;&lt;/A&gt;
&lt;LI&gt;Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population-based cohort study. Thorax 2006;61:772–778 [&lt;A href="http://thorax.bmj.com/cgi/content/full/61/9/772" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=77&gt;&lt;/A&gt;
&lt;LI&gt;Nici L, Donner C, Wouters E et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. American Journal of Respiratory &amp;amp; Critical Care Medicine 2006;173:1390-1413. [&lt;A href="http://www.ersnet.org/ers/LR/browse/viewPDF.aspx?id_attach=14674" target="_blank"&gt;FULL TEXT, PDF&lt;/A&gt;] &lt;/LI&gt;&lt;A name=78&gt;&lt;/A&gt;
&lt;LI&gt;Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary Rehabilitation: Joint ACCP/ AACVPR Evidence-Based Clinical Practice Guidelines. [Review] [211 refs]. Chest 2007;131:Suppl-42S. [&lt;A href="http://www.guideline.gov/summary/summary.aspx?ss=15&amp;amp;doc_id=10856&amp;amp;nbr=5669" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=79&gt;&lt;/A&gt;
&lt;LI&gt;Lacasse Y, Goldstein R, Lasserson TJ et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. [update of Cochrane Database Syst Rev. 2002;(3):CD003793; PMID: 12137716]. [Review] [253 refs]. Cochrane Database of Systematic Reviews 2006;CD003793. [&lt;A href="http://dx.doi.org/10.1002/14651858.CD003793.pub2" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=80&gt;&lt;/A&gt;
&lt;LI&gt;Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation. Lancet 2000;355:362–8. [&lt;A href="http://ebm.bmj.com/cgi/content/extract/5/5/140" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=81&gt;&lt;/A&gt;
&lt;LI&gt;Ries AL, Kaplan RM, Limberg TM, Prewitt L. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995; 122: 823-832. [&lt;A href="http://www.annals.org/cgi/content/full/122/11/823" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=82&gt;&lt;/A&gt;
&lt;LI&gt;Wedzicha JA, Bestall J, Garnham R, Garrod R, Paul EA, Jones PW. Randomised controlled trial of pulmonary rehabilitation in patients with severe chronic obstructive pulmonary disease stratified for disability. Eur Resp J 1998; 2: 363-9 [&lt;A href="http://www.erj.ersjournals.com/cgi/content/abstract/12/2/363" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=83&gt;&lt;/A&gt;
&lt;LI&gt;Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary Rehabilitation: Joint ACCP/ AACVPR Evidence-Based Clinical Practice Guidelines. [Review] [211 refs]. Chest 2007;131:Suppl-42S.&lt;/LI&gt;&lt;A name=84&gt;&lt;/A&gt;
&lt;LI&gt;Sewell L , Singh S J, Williams J E A, Collier R, and Morgan M D L How long should outpatient pulmonary rehabilitation be? A randomised controlled trial of 4 weeks versus 7 weeks. Thorax, September 1, 2006; 61:767 - 771. [&lt;A href="http://thorax.bmj.com/cgi/content/abstract/61/9/767" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=85&gt;&lt;/A&gt;
&lt;LI&gt;Mann W., Polkey M., Donaldson N. at al (2004).Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled trial BMJ 329: 1209 [&lt;A href="http://www.bmj.com/cgi/content/full/329/7476/1209" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=86&gt;&lt;/A&gt;
&lt;LI&gt;Murphy N., Bell C. and Costello R. (2005).Extending a home from hospital care programme for COPD exacerbations to include Pulmonary Rehabilitation. Respiratory Medicine 99: 1297 – 1302 [&lt;A href="http://linkinghub.elsevier.com/retrieve/pii/S0954611105000715" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=87&gt;&lt;/A&gt;
&lt;LI&gt;Bond JC, Prime H, Vincent EE et al 2006. In-patient rehabilitation during acue exacerbation of chronic obstructive pulmonary disease:immediate effects on health status and exercise capacity. Spoken session (SO98), published in Thorax 2006; 61 (supplement 2): ii3-ii56 [&lt;A href="http://thorax.bmj.com/cgi/content/full/61/suppl_2/ii3" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=88&gt;&lt;/A&gt;
&lt;LI&gt;Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary Rehabilitation: Joint ACCP/ AACVPR Evidence-Based Clinical Practice Guidelines. [Review] [211 refs]. Chest 2007;131:Suppl-42S. [&lt;A href="http://www.guideline.gov/summary/summary.aspx?ss=15&amp;amp;doc_id=10856&amp;amp;nbr=5669" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=89&gt;&lt;/A&gt;
&lt;LI&gt;Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease. Am J Respir Crit Care Med 2003;167:880–888. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/167/6/880" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=90&gt;&lt;/A&gt;
&lt;LI&gt;Rochester D F, Braun N M T, Laine S. Diaphragmatic energy expenditure in chronic respiratory failure the effect of assisted ventilation with body respirators. Am J Med, 1977,63:223 232 &lt;/LI&gt;&lt;A name=91&gt;&lt;/A&gt;
&lt;LI&gt;Landers MR, McWhorter JW, Filibeck D et al. Does sitting posture in chronic obstructive pulmonary disease really matter? An analysis of 2 sitting postures and their affect on pulmonary function. Journal of Cardiopulmonary Rehabilitation 2006;26:405-409. [&lt;A href="http://www.jcrjournal.com/pt/re/jcardiorehab/abstract.00008483-200611000-00011.htm" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=92&gt;&lt;/A&gt;
&lt;LI&gt;Sharp JT, Druz WS, Moisan T et al. Postural relief of dyspnoea in severe chronic obstructive pulmonary disease. American Review of Respiratory Disease 1980;122:201-211.&lt;/LI&gt;&lt;A name=93&gt;&lt;/A&gt;
&lt;LI&gt;Druz WS, Sharp JT, Druz WS et al. Electrical and mechanical activity of the diaphragm accompanying body position in severe chronic obstructive pulmonary disease. American Review of Respiratory Disease 1982;125:275-280. [&lt;A href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;amp;uid=7065537&amp;amp;cmd=showdetailview" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=94&gt;&lt;/A&gt;
&lt;LI&gt;LaPier TK, Donovan C. Sitting and standing position affect pulmonary function in patients with COPD: A preliminary study. Cardiopulmonary Physical Therapy Journal 1999;1-7.&lt;/LI&gt;&lt;A name=95&gt;&lt;/A&gt;
&lt;LI&gt;Barach AL. Chronic obstructive lung disease: postural relief of dyspnea. Arch Phys Med Rehabil 1974;55:494-504.&lt;/LI&gt;&lt;A name=96&gt;&lt;/A&gt;
&lt;LI&gt;Probst, V. S., T. Troosters, I. Coosemans, M. A. Spruit, F. O. Pitta, M. Decramer, and R. Gosselink. 2004. Mechanisms of Improvement in Exercise Capacity Using a Rollator in Patients With COPD. Chest 126:1102-1107. [&lt;A href="http://www.chestjournal.org/cgi/content/abstract/126/4/1102" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=97&gt;&lt;/A&gt;
&lt;LI&gt;Yohannes, A. M. and M. J. Connolly. 2003. Early mobilization with walking aids following hospital admission with acute exacerbation of chronic obstructive pulmonary disease. Clin.Rehabil. 17:465-471. [&lt;A href="http://cre.sagepub.com/cgi/content/refs/17/5/465" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=98&gt;&lt;/A&gt;
&lt;LI&gt;Dechman G, Wilson CR. Evidence Underlying Breathing Retraining in People With Stable Chronic Obstructive Pulmonary Disease. PHYS THER 2004;84:1189-1197. [&lt;A href="http://www.physther.net/cgi/content/full/84/12/1189" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=99&gt;&lt;/A&gt;
&lt;LI&gt;Bott,J. Physiotherapy. In: Morgan MDL, Singh SJ, eds. Practical Pulmonary Rehabilitation. London: Chapman and Hall 1997.&lt;/LI&gt;&lt;A name=100&gt;&lt;/A&gt;
&lt;LI&gt;BTS Guidelines on Respiratory Physiotherapy for the adult patient, [in preparation 2008].&lt;/LI&gt;&lt;A name=101&gt;&lt;/A&gt;
&lt;LI&gt;Velloso M, Jardim JR, . Study of energy expenditure during activities of daily living using and not using body position recommended by energy conservation techniques in patients with COPD. Chest 2006;130:126-132. [&lt;A href="http://www.chestjournal.org/cgi/content/abstract/130/1/126" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=102&gt;&lt;/A&gt;
&lt;LI&gt;Mortensen J, Jensen C, Groth S et al. The effect of forced expirations on mucociliary clearance in patients with chronic bronchitis and in healthy subjects. Clin Physiol 1991;11:439-450. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/1934940?ordinalpos=119&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=103&gt;&lt;/A&gt;
&lt;LI&gt;van der Schans CP, Goldstein RS, Bach JR. Airway secretion management and oxygen therapy. Physical Medicine and Rehabilitation Clinics of North America 1996;7:277-298.&lt;/LI&gt;&lt;A name=104&gt;&lt;/A&gt;
&lt;LI&gt;Clarke SW. Management of mucus hypersecretion. Eur J Respir Dis Suppl 1987;153:136-144.&lt;/LI&gt;&lt;A name=105&gt;&lt;/A&gt;
&lt;LI&gt;Savci S, Ince DI, Arikan H. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. Journal of Cardiopulmonary Rehabilitation 2000;Jan-Feb; 20:37-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10680096" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=106&gt;&lt;/A&gt;
&lt;LI&gt;Hess DR. The evidence for secretion clearance techniques. Respir Care 2001;46:1276-1293.&lt;/LI&gt;&lt;A name=107&gt;&lt;/A&gt;
&lt;LI&gt;Hess DR. The evidence for secretion clearance techniques. Cardiopulmonary physical Therapy 2002;13:7-22.&lt;/LI&gt;&lt;A name=108&gt;&lt;/A&gt;
&lt;LI&gt;Halpin D. NICE guidance for COPD. Thorax 2004;59:181-182.&lt;BR&gt;[&lt;A href="http://www.nice.org.uk/guidance/index.jsp?action=byID&amp;amp;r=true&amp;amp;o=10938" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=109&gt;&lt;/A&gt;
&lt;LI&gt;Bellone A, Spagnolatti L, Massobrio M et al. Short-term effects of expiration under positive pressure in patients with acute exacerbation of chronic obstructive pulmonary disease and mild acidosis requiring non-invasive positive pressure ventilation. Intensive Care Med 2002;28:581-585. [&lt;A href="http://www.springerlink.com/content/1tc7023q3tq73utx/" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=110&gt;&lt;/A&gt;
&lt;LI&gt;Kirsch I, Moore T, Scoboria A, Nicholls S. The Emperor's New Drugs: An Analysis of Antidepressant Medication Data Submitted to the U.S. Food and Drug Administration. Prevention &amp;amp; Treatment. 2002;5(23). [&lt;A href="http://content.apa.org/journals/pre/5/1/23" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=111&gt;&lt;/A&gt;
&lt;LI&gt;Hyland, ME. A Tale of Two Therapies: Psychotherapy and Complementary and Alternative Medicine (CAM) and the Human Effect. Clinical Medicine 2005; 5: 361-367. [&lt;A href="http://www.ingentaconnect.com/content/rcop/cm/2005/00000005/00000004/art00016" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=112&gt;&lt;/A&gt;
&lt;LI&gt;Hollon, S. D., Shelton, R. C., &amp;amp; Loosen, P. T. (1991). Cognitive therapy and pharmacotherapy for depression. Journal of Consulting &amp;amp; Clinical Psychology, 59, 88-99. [&lt;A href="http://content.apa.org/journals/ccp/59/1/88" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=113&gt;&lt;/A&gt;
&lt;LI&gt;Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. American Psychologist 1977; 32: 752-760.&lt;/LI&gt;&lt;A name=114&gt;&lt;/A&gt;
&lt;LI&gt;Wampold BE, Mondin GW, Moody M, Stich F, Benson K, Ahn H. A meta-analysis of outcome studies comparing bona fide psychotherapies: Empirically, “All must have prizes.” Psychological Bulletin 1997; 122:204-215. [&lt;A href="http://www.personal.kent.edu/~dfresco/CRM_Readings/Wampold_Dodo_1997_1.pdf" target="_blank"&gt;FULL TEXT, PDF&lt;/A&gt;] &lt;/LI&gt;&lt;A name=115&gt;&lt;/A&gt;
&lt;LI&gt;Wampold BE. The great psychotherapy debate: models, methods, and findings. Mahwah, NJ: Lawrence Erlbaum, 2001. &lt;/LI&gt;&lt;A name=116&gt;&lt;/A&gt;
&lt;LI&gt;Luborsky L, Rosenthal R, Diguer L, Andrusyna TP, Berman JS, Levitt JT, Seligman DA, Krause ED. The dodo bird verdict is alive and well – mostly. Clinical Psychology: Science and Practice 2002; 9: 2-12. [&lt;A href="http://www.csun.edu/~gk45683/Lester_Luborsky.pdf" target="_blank"&gt;FULL TEXT, PDF&lt;/A&gt;] &lt;/LI&gt;&lt;A name=117&gt;&lt;/A&gt;
&lt;LI&gt;Rosenzweig S. Some implicit common factors in divers methods of psychotherapy: “At last the Dodo said, ‘Everybody has won and all must have prizes.’” American Journal of Orthopsychiatry 1936; 6: 412-415. [&lt;A href="http://content.apa.org/journals/int/12/1/5.html" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=118&gt;&lt;/A&gt;
&lt;LI&gt;Moyer CA, Rounds J, Hannum JW. A meta-analysis of massage therapy research. Psychological Bulletin 2004;130: 3-18. [&lt;A href="http://content.apa.org/journals/bul/130/1/3" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=119&gt;&lt;/A&gt;
&lt;LI&gt;Hyland, ME. Whalley, B, Geraghty, AWA. Dispositional predictors of placebo responding: a motivational interpretation of flower essence and gratitude therapy. Journal of Psychosomatic Research 2007; 62:331-340. [&lt;A href="http://linkinghub.elsevier.com/retrieve/pii/S0022399906004582" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=120&gt;&lt;/A&gt;
&lt;LI&gt;Schols AMWJ, Fredrix EWHM, Soeters PB, Westerterp KP, Wouters EFM. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 1991;54:983–987.&lt;BR&gt;[&lt;A href="http://www.ajcn.org/cgi/content/abstract/54/6/983?ck=nck" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=121&gt;&lt;/A&gt;
&lt;LI&gt;Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Marin JG. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:961–966. &lt;BR&gt;[&lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/153/3/961" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=122&gt;&lt;/A&gt;
&lt;LI&gt;Schols AM, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791–1797. &lt;BR&gt;[&lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/157/6/1791" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=123&gt;&lt;/A&gt;
&lt;LI&gt;Landbo C, Prescott E, Lange P, Vestbo J, Almdal T. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–1861. &lt;BR&gt;[&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/160/6/1856" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=124&gt;&lt;/A&gt;
&lt;LI&gt;Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002;20:539–544. [&lt;A href="http://erj.ersjournals.com/cgi/content/full/20/3/539" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=125&gt;&lt;/A&gt;
&lt;LI&gt;Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sorensen TI, Lange P. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006;173:79–83.&lt;BR&gt;[&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/173/1/79" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=126&gt;&lt;/A&gt;
&lt;LI&gt;Mokhlesi B, Tulaimat, A Recent advances in obesity hypoventilation syndrome. Chest. 2007;132:1322-36. [&lt;A href="http://www.chestjournal.org/cgi/content/abstract/132/4/1322" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=127&gt;&lt;/A&gt;
&lt;LI&gt;Fishman, A., F. Martinez, K. Naunheim, S. Piantadosi, R. Wise, A. Ries, G. Weinmann, and D.E. Wood, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med, 2003. 348: 2059-73. [&lt;A href="http://content.nejm.org/cgi/content/full/348/21/2059" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=128&gt;&lt;/A&gt;
&lt;LI&gt;Geddes, D., M. Davies, H. Koyama, D. Hansell, U. Pastorino, J. Pepper, P. Agent, P. Cullinan, S.J. MacNeill, and P. Goldstraw, Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med, 2000. 343: 239-45. [&lt;A href="http://content.nejm.org/cgi/content/full/343/4/239?ck=nck" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=129&gt;&lt;/A&gt;
&lt;LI&gt;Criner, G.J., F.C. Cordova, S. Furukawa, A.M. Kuzma, J.M. Travaline, V. Leyenson, and G.M. O'Brien, Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1999. 160: 2018-27. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/160/6/2018" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=130&gt;&lt;/A&gt;
&lt;LI&gt;Miller, J.D., R.A. Malthaner, C.H. Goldsmith, R. Goeree, D. Higgins, P.G. Cox, L. Tan, and J.D. Road, A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada. Ann Thorac Surg, 2006. 81: 314-20; discussion 320-1. [&lt;A href="http://ats.ctsnetjournals.org/cgi/content/abstract/81/1/314" target="_blank"&gt;ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=131&gt;&lt;/A&gt;
&lt;LI&gt;Ramsey, S.D., K. Berry, R. Etzioni, R.M. Kaplan, S.D. Sullivan and D.E. Wood, Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med, 2003. 348: 2092-102. [&lt;A href="http://content.nejm.org/cgi/content/full/348/21/2092" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=132&gt;&lt;/A&gt;
&lt;LI&gt;Lim, E., A. Ali, N. Cartwright, I. Sousa, A. Chetwynd, M. Polkey, D. Geddes, J. Pepper, P. Diggle, and P. Goldstraw, Effect and duration of lung volume reduction surgery: mid term results of the Brompton trial. Thorac cardiovasc Surg 2006. 54: 188-92 [&lt;A href="http://www.thieme-connect.com/DOI/DOI?10.1055/s-2005-872953" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=133&gt;&lt;/A&gt;
&lt;LI&gt;Shah, S.S. and P. Goldstraw, Surgical treatment of bullous emphysema: experience with the Brompton technique. Ann Thorac Surg, 1994. 58: 1452-6. [&lt;A href="http://ats.ctsnetjournals.org/cgi/content/abstract/58/5/1452" target="_blank"&gt;ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=134&gt;&lt;/A&gt;
&lt;LI&gt;Venn, G.E., P.R. Williams and P. Goldstraw, Intracavity drainage for bullous, emphysematous lung disease: experience with the Brompton technique. Thorax, 1988. 43: 998-1002. [&lt;A href="http://thorax.bmj.com/cgi/content/abstract/43/12/998" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=135&gt;&lt;/A&gt;
&lt;LI&gt;O'Donnell, D.E., K.A. Webb, J.C. Bertley, L.K. Chau and A.A. Conlan, Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest, 1996. 110: 18-27. [&lt;A href="http://www.chestjournal.org/cgi/content/abstract/110/1/18" target="_blank"&gt;ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=136&gt;&lt;/A&gt;
&lt;LI&gt;Toma, T.P., N. Hopkinson, J. Hillier, D.M. Hansell, C. Morgan, P.G. Goldstraw, M.I. Polkey, and D.M. Geddes, Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet, 2003. 361: 931-3. [&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140673603127626/abstract" target="_blank"&gt;ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=137&gt;&lt;/A&gt;
&lt;LI&gt;Hopkinson, N.S., T.P. Toma, D.M. Hansell, P. Goldstraw, J. Moxham, D.M. Geddes, and M.I. Polkey, Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med, 2005. 171: 453-60.&lt;BR&gt;[&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/171/5/453" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=138&gt;&lt;/A&gt;
&lt;LI&gt;Wan, I.Y., T.P. Toma, D.M. Geddes, G. Snell, T. Williams, F. Venuta, and A.P. Yim, Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients. Chest, 2006. 129: 518-26. [&lt;A href="http://www.chestjournal.org/cgi/content/full/129/3/518" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=139&gt;&lt;/A&gt;
&lt;LI&gt;Lausberg, H.F., K. Chino, G.A. Patterson, B.F. Meyers, P.D. Toeniskoetter and J.D. Cooper, Bronchial fenestration improves expiratory flow in emphysematous human lungs. Ann Thorac Surg, 2003. 75: 393-7; discussion 398. [&lt;A href="http://ats.ctsnetjournals.org/cgi/content/full/75/2/393" target="_blank"&gt;FULL TEXT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=140&gt;&lt;/A&gt;
&lt;LI&gt;Macklem, P.T., Collateral ventilation. N Engl J Med, 1978. 298: 49-50&lt;/LI&gt;&lt;A name=141&gt;&lt;/A&gt;
&lt;LI&gt;Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Impact of Reporting and Early Therapy on Outcome of Exacerbations of COPD. Am J Respir Crit Care Med 2004: 169: 1298-130. [&lt;A href="http://ajrccm.atsjournals.org/cgi/reprint/169/12/1298" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=142&gt;&lt;/A&gt;
&lt;LI&gt;Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA.Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;157(5):1418-22. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/157/5/1418" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=143&gt;&lt;/A&gt;
&lt;LI&gt;Kanner RE, Anthonisen, NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive lung disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001; 164(3): 358-64. [&lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/164/3/358" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=144&gt;&lt;/A&gt;
&lt;LI&gt;Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002: 57(10): 847-52. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12324669?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=145&gt;&lt;/A&gt;
&lt;LI&gt;Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925-931. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16055622?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=146&gt;&lt;/A&gt;
&lt;LI&gt;Garcia-Aymerich, E Farrero, M A Félez, J Izquierdo, R M Marrades, and J M Antó. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58(2): 100 – 105. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/12554887?ordinalpos=6&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=147&gt;&lt;/A&gt;
&lt;LI&gt;Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005 128(4):2005-11. [&lt;A href="http://www.chestjournal.org/cgi/content/full/128/4/2005" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=148&gt;&lt;/A&gt;
&lt;LI&gt;British Thoracic Society (BTS) Burden of Lung Disease Report 2nd edition 2006 Available at [&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=144202&amp;amp;tabID=290" target="_blank"&gt;FULLTEXT AVAILABLE via RESPIRATORY SL&lt;/A&gt;]&lt;/LI&gt;&lt;A name=149&gt;&lt;/A&gt;
&lt;LI&gt;Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration Thorax, Jul 2000; 55(7): 550 - 554. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10856313?ordinalpos=13&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=150&gt;&lt;/A&gt;
&lt;LI&gt;Lightowler JVJ, Wedzicha JA, Elliott MW, Ram FSF. Non-invasive positive pressure ventilation for the treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease: a Cochrane systematic review and meta-analysis. BMJ 2003; 326:185-7. [&lt;A href="http://www.bmj.com/cgi/content/full/326/7382/185" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=151&gt;&lt;/A&gt;
&lt;LI&gt;Plant PK, Owen JL, Elliott MW. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. BMJ 2003;326(7396):956. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=12727767" target="_blank"&gt;PUBMED CENTRAL FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=152&gt;&lt;/A&gt;
&lt;LI&gt;BTS Guidelines: Non-invasive ventilation in acute respiratory failure Thorax, Mar 2002; 57(3): 192 - 211. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11867822?ordinalpos=4&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=153&gt;&lt;/A&gt;
&lt;LI&gt;BTS Acute Oxygen guidelines Thorax to be submitted later this year&lt;/LI&gt;&lt;A name=154&gt;&lt;/A&gt;
&lt;LI&gt;Savci S, Ince DI, Arikan H. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. Journal of Cardiopulmonary Rehabilitation 2000, Jan-Feb, 20, 37-43. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10680096?ordinalpos=1&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=155&gt;&lt;/A&gt;
&lt;LI&gt;Bellone A, Lascioli R, Raschi S et al. Chest physical therapy in patients with acute exacerbation of chronic bronchitis: effectiveness of three methods. Arch Phys Med Rehabil 2000, 81(5), 558 – 560. &lt;BR&gt;001, 120, 748-756. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/10807091?ordinalpos=2&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=156&gt;&lt;/A&gt;
&lt;LI&gt;O'Neill S &amp;amp; McCarthy D S. Postural relief of dyspnoea in severe chronic airflow limitation: relationship to respiratory muscle strength. Thorax 1983, 38 (8) 595-600. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/6612651?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=157&gt;&lt;/A&gt;
&lt;LI&gt;Garrod R, Dallimore K, Cook J et al. An evaluation of the acute impact of pursed lips breathing on walking distance in nonspontaneous pursed lips breathing chronic obstructive pulmonary disease patients. Chron Respir Dis 2005, 2 (2), 67-72. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/16279153?ordinalpos=9&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;PUBMED ABSTRACT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=158&gt;&lt;/A&gt;
&lt;LI&gt;Sanchez-Riera H., Montemayor RT, Ortega RF et al. Inspiratory muscle training in patients with COPD: effect on dyspnoea, exercise performance, and quality of life. Chest 2001; Sep;120(3):748-56. [&lt;A href="http://www.chestjournal.org/cgi/content/full/120/3/748" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=159&gt;&lt;/A&gt;
&lt;LI&gt;Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk fo readmission and mortality – a systematic review . Respir Res 2005; 6:54. [&lt;A href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;amp;pubmedid=15943867" target="_blank"&gt;FULL TEXT via PUBMED CENTRAL&lt;/A&gt;]&lt;/LI&gt;&lt;A name=160&gt;&lt;/A&gt;
&lt;LI&gt;Roberts CM. D Lowe, C E Bucknall, I Ryland, Y Kelly, M G Pearson. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002;57(2):137-41. [&lt;A href="http://www.ncbi.nlm.nih.gov/pubmed/11828043?ordinalpos=5&amp;amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum" target="_blank"&gt;ABSTRACT&lt;/A&gt;] &lt;/LI&gt;&lt;A name=161&gt;&lt;/A&gt;
&lt;LI&gt;Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Müllerova H, Donaldson GC, Wedzicha JA.. Inflammatory changes and recurrence at COPD exacerbations Eur Resp J 2007; 29(3):527-34. [&lt;A href="http://erj.ersjournals.com/cgi/content/full/29/3/527" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;A name=162&gt;&lt;/A&gt;
&lt;LI&gt;British Thoracic Society Guideline Development Group Intermediate care—Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline Thorax 2007; 62(3): 200-210. [&lt;A href="http://thorax.bmj.com/cgi/content/full/62/3/200" target="_blank"&gt;FULL TEXT&lt;/A&gt;]&lt;/LI&gt;&lt;/OL&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278346</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278346]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Exercise</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,THERAPEUTIC INTERVENTION,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Exercise&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;People with COPD develop progressive and irreversible airways narrowing that is associated with peripheral muscle weakness, causing breathlessness and reduced capacity for activity, resulting in considerable respiratory disability, especially in those with more severe disease. People with COPD who undertake regular physical activity have been shown to have reduced mortality and lower risk of hospital admission &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#76" target="_blank"&gt;[76]&lt;/A&gt;. Thus all patients with COPD need to be provided with advice and encouraged to improve and maintain levels of activity in their daily lives in a manner that is appropriate and acceptable for that individual. &lt;/P&gt;
&lt;P&gt;People with a very mild degree of disability only may be referred to a local facility for exercise training, supervised by fitness instructors trained in the issues relating to exercise and disability in COPD. However at present there is no evidence from controlled studies that this model of exercise training is effective. For most people with COPD, a structured programme, pulmonary rehabilitation, provided by healthcare professionals experienced in assessment and management of disability associated with COPD, has been shown to provide optimal benefit. It is the most popular and requested intervention by patients.&lt;/P&gt;
&lt;P&gt;Pulmonary rehabilitation (PR) refers to a combination of supervised exercise training with a comprehensive educational programme and psychosocial support. The European Respiratory Society and American Thoracic Respiratory Society have jointly created the following definition of PR: “an evidence-based multidisciplinary and comprehensive intervention for patients with chronic respiratory disease who are symptomatic and often have decreased daily life activities. Integrated into the individualized treatment of the patient, PR is designed to reduce symptoms, optimize functional status, increase participation, and reduce health care costs through stabilising or reversing systemic manifestations of the disease” &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#77" target="_blank"&gt;[77]&lt;/A&gt;. There are a significant number of randomised controlled trials demonstrating evidence of benefits of pulmonary rehabilitation for patients with COPD, with several systematic reviews and international organisational statements and guidelines supporting its use &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#78" target="_blank"&gt;[78,79]&lt;/A&gt;. PR has proven benefits on exercise tolerance, breathlessness and health-related quality of life, as well as improvements in health care utilisation including reduced length of hospital stay &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#80" target="_blank"&gt;[80]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;A number of studies have shown that exercise training is a vital component of the programme and that the combination of exercise and education increases exercise capacity and quality of life more than education alone &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#81" target="_blank"&gt;[81.82]&lt;/A&gt;. The exercise component should include aerobic endurance) and resistive (strength) training and flexibility. A programme of exercise training for the muscles of walking is recommended as a mandatory component of PR for people with COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#83" target="_blank"&gt;[83]&lt;/A&gt;. Exercise and activity should be prescribed from a validated and practised assessment, according to current guidance and of sufficient intensity to produce a measurable and documented improvement against a national benchmark, where available. Assessment of the need for mobility aids and/or ambulatory oxygen should be integrated. &lt;/P&gt;
&lt;P&gt;Most supervised UK programmes run twice weekly for 6 to 12 weeks but shorter programmes at 4 weeks may also be effective &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#84" target="_blank"&gt;[84]&lt;/A&gt;. Participants are encouraged to add sessions at home in between. PR should be made available to all appropriate patients with COPD with emerging evidence on the importance of instituting exercise as soon after exacerbation as possible &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#85" target="_blank"&gt;[85-87]&lt;/A&gt;. In addition, there is some evidence to support the fact that longer term rehabilitation and maintenance strategies are beneficial &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#88" target="_blank"&gt;[88]&lt;/A&gt;, although there is no consensus on how maintenance of the improvements gained by a pulmonary rehabilitation programme should be organized. Various strategies have been tried including monthly interventions, but it is important to note that effect wears off with discontinuation &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#89" target="_blank"&gt;[89]&lt;/A&gt;, so provision for maintenance of exercise and physical activity on an ongoing basis is essential&lt;/P&gt;
&lt;P&gt;Although physical training is the central focus of the programme, this needs to be accompanied by disease education and self-management advice. This usually takes the form of delivered talks and group discussions around the topics. Patients indicate that written material is necessary to support the education as well as self-management plans and home training diaries. Since rehabilitation should be seen as part of the integrated management of COPD the opportunity can be taken to provide specific physiotherapy, dietetic, occupational therapy or psychological advice where required.&lt;/P&gt;
&lt;P&gt;People with COPD adopt a breathing pattern which puts them at a mechanical disadvantage, whereby the respiratory muscles need more oxygen &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#90" target="_blank"&gt;[90]&lt;/A&gt;. People with COPD therefore need to be taught how to breathe and use their respiratory muscles effectively without increasing oxygen consumption. Correct body positioning can produce improvements in lung function &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#91" target="_blank"&gt;[91]&lt;/A&gt; and relief of breathlessness &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#92" target="_blank"&gt;[92]&lt;/A&gt; as well as reduction in the work of breathing, &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#93" target="_blank"&gt;[93]&lt;/A&gt; without any worsening of the arterial blood gases &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#94" target="_blank"&gt;[94]&lt;/A&gt; and can reverse unhelpful paradoxical abdominal wall motion &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#95" target="_blank"&gt;[95]&lt;/A&gt;. Arm support on a frame or rollator has been shown to increase ventilatory capacity in patients with severe COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#96" target="_blank"&gt;[96]&lt;/A&gt; and early mobilisation using these aids to be helpful following hospital admission with acute exacerbation &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#97" target="_blank"&gt;[97]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;The breathing techniques for which there is any level of published evidence are Diaphragmatic Breathing (DB) and Pursed Lips Breathing (PLB). Two systematic reviews of breathing exercises in COPD conclude that PLB should be included in breathing retraining but not diaphragmatic breathing &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#98" target="_blank"&gt;[98]&lt;/A&gt;. There are various other breathing techniques, grounded in physiological theory, with only scant published evidence to support or refute them, but strongly endorsed by patients, who report that breathing retraining is one of the most valuable parts of rehabilitation. The techniques are commonly taught by physiotherapists to help patients cope with breathlessness and are often an integral part of the rehabilitation process, which includes management of patients admitted with acute exacerbations. People with COPD are advised to practice them when well and resting, so that they can be used when active and getting breathless. They are also advocated for acute dyspnoeic episodes. These techniques are: Breathing Control, Relaxed Slow Deep Breathing, ‘Blow as you go!’ (exhalation on effort) and Paced Breathing. &lt;/P&gt;
&lt;P&gt;Good positioning, the breathing techniques above, relaxation and other strategies may be employed to ameliorate anxiety and panic associated with breathlessness. Although there is no published evidence in COPD, this strategy is strongly endorsed by our patient representatives &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#99" target="_blank"&gt;[99,100]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Energy conservation techniques (ECTs) facilitate a reduction in the energy expenditure of a task, such as activities of daily living (ADL), by organisation and pacing of tasks, as well as alternative ways to undertake them &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#101" target="_blank"&gt;[101]&lt;/A&gt;. This may be via a change in posture or arm position, eg teaching support of the upper limb undertaking tasks such as shaving or hairbrushing, sitting down to do simple chores, such as washing up. It also includes the use of appropriate home adaptations, such as a seat or hand rail, the lowering or raising of objects, or the use of small aids to reduce or eliminate high effort movement, eg., a ‘helping hand’ to reach for high objects or a sock ‘inserter’. ECTs should be combined with breathing techniques. &lt;/P&gt;
&lt;P&gt;Techniques to assist in the removal of phlegm or sputum may be instituted where required and assessed for effectiveness. There are a wide variety of airway clearance techniques, including: the Active Cycle of Breathing Techniques (ACBT), the Forced Expiration Technique, Autogenic Drainage, Positive Expiratory Pressure (PEP) and oscillating PEP. Traditional techniques are postural drainage with chest wall percussion and vibration. The Forced Expiration Technique is effective in clearing sputum in patients with COPD, &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#102" target="_blank"&gt;[102,103]&lt;/A&gt; and when combined with postural drainage is more effective than coughing alone &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#104" target="_blank"&gt;[104]&lt;/A&gt;. In patients with COPD, ACBT and autogenic drainage produced statistically and clinically significant improvements in pulmonary function, arterial blood gases, exercise tolerance and dyspnoea scores, and were equally effective. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#106" target="_blank"&gt;[106,107]&lt;/A&gt; PEP and oscillating PEP have been shown to be equally effective to traditional chest physiotherapy techniques. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#108" target="_blank"&gt;[108]&lt;/A&gt; In one randomised controlled trial in patients with COPD and acute respiratory failure, cough plus PEP led to greater sputum production and a quicker weaning time from NIV compared to cough alone. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#109" target="_blank"&gt;[109]&lt;/A&gt; No difference in benefit has been shown between devices in aiding sputum clearance. There may be a patient preference for PEP devices, with or without an oscillatory function, over traditional methods of postural drainage and manual techniques, due to the convenience they offer to the patient. PEP however, has not been compared with other more modern techniques in COPD and its relative efficacy and acceptability to e.g. ACBT or autogenic drainage is therefore unknown.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278348</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278348]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Nutrition</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Nutrition&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;COPD is accompanied by important systemic effects with muscle wasting, and patients are prone to weight loss especially those with more progressive disease. An elevated metabolic rate is found in moderate to severe COPD with increase in total energy expenditure&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#120" target="_blank"&gt;[120]&lt;/A&gt;. COPD patients also have a decreased food intake as a result of breathlessness. There are now a number of studies that have shown that body mass index (BMI) is an important factor determining prognosis in patients with COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#121" target="_blank"&gt;[121-123]&lt;/A&gt;. If an underweight COPD patient can manage to increase their weight, the prognosis is improved &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#122" target="_blank"&gt;[122,124]&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;The body mass is composed of two separate components – the fat free mass (FFM), which is the metabolically active part and the fat mass that is less active &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#125" target="_blank"&gt;[125]&lt;/A&gt;. There is also evidence that patients with COPD are at risk of a low fat free mass (FFM) and a low FFM is a better predictor of COPD mortality than the BMI &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#125" target="_blank"&gt;[125]&lt;/A&gt;. Some patients with a normal BMI may have a reduced FFM and thus nutritional assessment should include measurement of both BMI and FFM. Systemic markers have also been shown to be higher in patients with a low FFM, suggesting that the systemic inflammatory response in COPD patients causes the loss of lean muscle mass &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#125" target="_blank"&gt;[125]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Some patients with COPD may also be overweight with a high BMI, exacerbated by the progressive decrease in their physical activity. A high BMI is also associated with increased mortality &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#124" target="_blank"&gt;[124]&lt;/A&gt; and will contribute to other pre-existing conditions in COPD patients such as diabetes and obstructive sleep apnoea. COPD patients with obesity are also at risk of nocturnal hypoventilation that will make them more susceptible to developing respiratory failure &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#126" target="_blank"&gt;[126]&lt;/A&gt;. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278343</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278343]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Preventing COPD</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Preventing COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Approximately 80% of COPD is caused by smoking. Therefore the best way to reduce the incidence of COPD is to reduce the overall prevalence of smoking . This can be done by reducing the number of people that take up smoking and increasing the number of those who stop. These targets are best achieved by delivery of the most effective methods of tobacco control and stop smoking services. There need to be agreed national standards for both tobacco control and stop smoking programmes. Campaigns aimed at current smokers need to emphasise the links between smoking and COPD and the fact that evidence based stop smoking with behavioural support and pharmacotherapy offers the best chance of stopping smoking and so avoiding or significantly reducing the impact of COPD. These campaigns also need to inform smokers about their local stop smoking service and how to access them as services remain under used.&lt;/P&gt;
&lt;P&gt;There is some evidence to support multi-component and mass media interventions to prevent smoking uptake amongst young people, but the evidence is not strong &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#56" target="_blank"&gt;[56-58]&lt;/A&gt;. Mass media campaigns aimed at the general population of smokers are part of national policy on tobacco control and will remain so, as it is recognised that they do have some effect on young people and that changes to how smoking is perceived in the adult population will have a knock-on effect on younger generations.&lt;/P&gt;
&lt;P&gt;There is some evidence that interventions aimed at helping adolescent smokers to quit can be successful &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#59" target="_blank"&gt;[59]&lt;/A&gt;. Interventions aimed at pregnant women can also be successful in reducing the proportion of women who continue to smoke during pregnancy and reduce low birth weight and pre-term births &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#60" target="_blank"&gt;[60]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;In terms of adolescents, there is evidence that simply having a smoke free home leads to less likelihood of taking up smoking in the first place. (Surgeon General 06)&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278347</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278347]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Psychological Interventions</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,THERAPEUTIC INTERVENTION,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Psychological Interventions&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Many patients with COPD have psychological problems including depression anxiety and PTSD. Psychological problems can be treated by a range of treatments, and the majority of this research is conducted on people who do not have COPD. The following treatments have all been claimed to be effective for people with depression: pharmacological treatments, psychological therapy, complementary medicine, exercise and nutrition. One of the problems in evaluating the efficacy (in contrast to the effectiveness) of non-pharmacological treatments is that valid placebos are difficult or controversial. Nevertheless, it seems likely that in all non-pharmacological treatments, psychological factors (sometimes called placebos) play a role. For example, it has been estimated that 80% of the effectiveness of SSRIs for depression is placebo mediated&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#110" target="_blank"&gt;[110]&lt;/A&gt;, and complementary medicine also appears to be effective largely or entirely through a psychologically mediated route &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#111" target="_blank"&gt;[111]&lt;/A&gt;. Psychological therapies appear to be equally effective as pharmacological treatment &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#112" target="_blank"&gt;[112]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;There are at least 200 different kinds of psychotherapy or ‘talking therapy’ and considerable research effort has been devoted to comparing their effectiveness. Findings from this research needs to be treated with caution because, irrespective of the type of therapy, researchers tend to find that their preferred therapy is more effective. The effect of therapist and researcher belief on outcome is known as an allegiance effect. Because of the existence of allegiance effects, the only sensible way to evaluate the relative effectiveness of different psychotherapies is through meta-analysis. There have been several meta-analyses &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#113" target="_blank"&gt;[113-117]&lt;/A&gt;, all of which support in general terms the hypothesis put forward by Resenzweig &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#117" target="_blank"&gt;[117]&lt;/A&gt; 70 years ago that psychotherapies produce roughly equivalent results. &lt;/P&gt;
&lt;P&gt;There are reasons for supposing that physical therapies such as massage work through psychological mechanisms similar to those of psychotherapy &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#118" target="_blank"&gt;[118]&lt;/A&gt;, and data supports the view that complementary and alternative medicine (CAM) works through a similar non-specific psychological mechanisms as psychotherapy&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#111" target="_blank"&gt;[111,119]&lt;/A&gt;. The implication from these findings is that patients respond well to therapies that they believe are effective and which ‘feels right’ in terms of underlying motivations.&lt;/P&gt;
&lt;P&gt;In providing a recommendation for the management of psychological distress of COPD patients, the data from depression in general suggest that the type of therapy is unimportant. What does matter is the therapist’s effectiveness and belief in the therapy (some therapists produce consistently better results than others) and the patient’s confidence in and liking for the therapy. It should be noted that cancer patients are often given an option of a range of psychological therapies including CAM, and these therapies palliate the psychological distress associated with the disease. COPD patients should also be provided with a range of therapeutic options so that the patient’s choices individualises the therapy for the patient. &lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278341</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278341]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Raising Awareness of Lung Disease</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Raising Awareness of Lung Disease&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;There is evidence that there is a widespread lack of knowledge about COPD amongst the general public and healthcare professionals. There is also evidence that some healthcare professionals are unaware of the definition of COPD, do not use diagnostic measures well, and see COPD as a self-inflicted condition to which they give little sympathy &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#1" target="_blank"&gt;[1,2,3,8]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Within the general public awareness of COPD is low, both in terms of what causes it, and the impact of having COPD. There needs to be more focus on raising awareness within the population, particularly in young people before they are exposed to some of the risk factors for COPD. This can be done through health promotion campaigns and the school curriculum.&lt;/P&gt;
&lt;P&gt;There is evidence that patients with COPD are confused about the various disease labels that are used to describe COPD, are often unaware of the link between smoking and COPD, and do not realise that stopping smoking will reduce the rate of further decline in lung function &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#4" target="_blank"&gt;[4]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;It is important to focus on the early common signs of COPD; breathlessness, cough and spit, especially in current or past long-term smokers, or those who work in hazardous environments. Chronic cough is often the first symptom of COPD to develop. It is often ignored by people as a normal consequence of smoking or other exposures, for example dust at work. The cough may start as intermittent, eventually being there everyday, throughout the whole day &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#5" target="_blank"&gt;[5]&lt;/A&gt;. &lt;BR&gt;&lt;BR&gt;Persistent and progressive breathlessness is a characteristic of COPD. COPD patients experience breathlessness at lower levels of exercise than unaffected people of the same age. At first, the breathlessness may only be noticed when doing strenuous exercise. This often leads to a change in behaviour so that strenuous exercise is avoided. As lung function deteriorates, breathlessness can become present during everyday activities (e.g., dressing, washing) or at rest &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#6" target="_blank"&gt;[6]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;People with COPD often produce small amounts of sputum or spit after coughing fits. Increased amounts over a long period of time may indicate a problem &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#8" target="_blank"&gt;[8]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;It is estimated that between 9% and 30% of patients are undiagnosed, despite having symptoms consistent with COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#7" target="_blank"&gt;[7]&lt;/A&gt;. By raising awareness of these symptoms and the link with COPD it is hoped that more people will seek professional help earlier, rather than modifying their behaviour to cope with the symptoms and therefore being more likely to present at a later stage of the disease. By raising awareness of these symptoms within the healthcare profession, it will also mean that COPD will be more likely to be considered as a possible diagnosis and the correct diagnostic tests offered. It is estimated that up to 65% of patients do not receive regular prescribed medication for their symptoms &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#16" target="_blank"&gt;[16]&lt;/A&gt;. These issues need to be embedded into the core training for healthcare professionals. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There is no published evidence that evaluates targeting lung health rather than COPD per se. However, there is evidence that there is confusion over what COPD is, and to address this there should be more emphasis on lung health as a whole as this is more easily understandable, and will also have wider health benefits. &lt;/P&gt;
&lt;P&gt;This is consistent with the approach that has been taken in other disease areas, for example coronary heart disease. The National Service Framework for coronary heart disease succeeded in uniting Government and clinical agendas to deliver improvements across the entire patient pathway. A national programme for improving heart health contributed to a reduction in mortality and significant improvements in care for patients with heart disease &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#8" target="_blank"&gt;[8]&lt;/A&gt;.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278342</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278342]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Risk Factors of COPD</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,OCCUPATIONAL LUNG DISEASE,SMOKING,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Risk Factors of COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Smoking&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;There is evidence that smoking during childhood leads to a greater risk of developing COPD in later life. This is in part due to an increase in the length of time that the person has been smoking for, but in women, childhood smoking leads to an increased risk of developing COPD regardless of the amount of time the person has smoked &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#9" target="_blank"&gt;[9]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Maternal smoking during pregnancy is associated with deficits in FEV&lt;SUB&gt;1&lt;/SUB&gt; in school-aged children. Maternal smoking in pregnancy also affects foetal development of the respiratory system and there is strong evidence that exposure in pregnancy may predict the development of asthma and reduced lung function later in life &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#10" target="_blank"&gt;[10]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;There is also an increased risk of acute lower respiratory infections and onset of childhood asthma when either parent has smoked &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#11" target="_blank"&gt;[11-14]&lt;/A&gt;. A history of severe childhood respiratory infection is associated with reduced lung function and increased respiratory symptoms in later life. There is also an association between low birth weight and decreased FEV&lt;SUB&gt;1&lt;/SUB&gt; in later life &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#15" target="_blank"&gt;[15]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Deprivation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Deprivation and high smoking rates, go hand in hand. Both are associated with a high prevalence of COPD , although deprivation appears to be a risk factor from COPD independently of smoking &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#16" target="_blank"&gt;[16]&lt;/A&gt;. There is a need for adequate provision of well funded, easily accessible, evidence based stop smoking services throughout England, but especially targeted in deprived areas. Areas with ethnic minorities with high smoking rates need specially designed Stop Smoking services that offer support in the appropriate language. &lt;/P&gt;
&lt;P&gt;Local Authorities need to be included in joint working with health care commissioners to address the wider determinants of health, particularly those that have an impact on COPD. There is some evidence that area-based interventions can have positive effects of health inequalities &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#17" target="_blank"&gt;[17]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Occupation&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Data from a number of surveys, in industrialised populations estimate that approximately 15% of the attributable risk of COPD arises from exposures to gases, dusts, vapours and fumes at work &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#18" target="_blank"&gt;[18-21]&lt;/A&gt;. None of these studies included a UK population but they are likely to be relevant to the occurrence of COPD here and previous data suggests that around 4000 COPD-related deaths each year are due to workplace exposures &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#22" target="_blank"&gt;[22]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;In 1995, 33% of males and 15% of females reported exposure to gases, dusts and/or fumes “always” or “nearly always” at work &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#23" target="_blank"&gt;[23]&lt;/A&gt;. In 2005, 29% of employees reported being “regularly” exposed to gases, dusts, fumes or vapours &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#24" target="_blank"&gt;[24]&lt;/A&gt; and 23% of employers acknowledged that a risk from them is present in their undertaking &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#25" target="_blank"&gt;[25]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;By being aware of the work done by their patients, healthcare professionals can aid in the early identification of cases of COPD caused by workplace risk factors. The resulting impact on lung health is likely to be comparable to stopping smoking.&lt;/P&gt;
&lt;P&gt;It is well recognised that being in employment confers many benefits including benefits to health &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#26" target="_blank"&gt;[26]&lt;/A&gt;. Minimising the impact of COPD on patients’ general health and fitness will help them remain in work. The fitness of individuals for the work they do will vary with circumstances, but guidance is available &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#27" target="_blank"&gt;[27]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Where a substance encountered at work is known to have an adverse effect on health there are legal obligations for employers, and those working for them, to prevent or, if that is not possible, then properly control exposure to it &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#28" target="_blank"&gt;[28,29]&lt;/A&gt;. In some circumstances employers will be obliged to undertake special measures (health surveillance) both to monitor and protect the health of individuals, and to provide feedback on the effectiveness of controls. Where serial lung function testing is required it is essential that this is done to appropriate standards if adverse effects are to be detected early&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#30" target="_blank"&gt;[30]&lt;/A&gt;. Where serial lung function tests are not required by law, they represent good practice &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#31" target="_blank"&gt;[31]&lt;/A&gt;. Where healthcare professionals are concerned about the possible role of work in causing an individual case of COPD they should consider the need for specialist advice in pursuing this, e.g. occupational heath advice, taking due note of the need to consult with the patient and gain consent before taking any action. Action to benefit the individual may benefit the health of others in the same workplace too.&lt;/P&gt;
&lt;P&gt;Access to workplace spirometry in the UK is variable, and there are no data currently assessing this provision. A diagnosis of COPD is made from a combination of clinical features and abnormal spirometry. If the latter is available in the workplace, this inherently will improve access for at risk workers to these measures. &lt;/P&gt;
&lt;P&gt;Application of a workplace based training and spirometry programme in Canada recently led to a reduction in observed cases of occupational lung disease due to isocyanates over a sustained period of time &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#32" target="_blank"&gt;[32]&lt;/A&gt;. Similarly, there are good data from other industry sectors suggesting that workplace-based spirometry is helpful in identifying occupational lung disease (specifically asthma) in, for example, bakers &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#33" target="_blank"&gt;[33]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Longitudinal change in spirometry has been used in workplace based monitoring programmes to identify those at risk of COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#34" target="_blank"&gt;[34,35]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Environment&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Environmental factors, which for this purpose we limit to air pollution both outdoor and indoor, can impact on COPD in two ways: initiation of disease (either alone or as a co-factor) and exacerbations. The evidence for exacerbations is much greater and is reasonably consistent although quantification of the true impact is difficult. This is ongoing work that the Department of Health is undertaking. &lt;/P&gt;
&lt;P&gt;Long term exposure to urban air pollution where the main source is coal burning or industry (such as was seen in the UK before the 1956 Clean Air Act) is associated with an increased risk of having chronic bronchitis &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#36" target="_blank"&gt;[36]&lt;/A&gt;. For contemporary air pollution, where vehicles are the major source, there is some evidence to suggest that long-term exposure is also associated with an increased risk of developing COPD. One study limited to women showed that living within 100m of a busy road conferred a 1.8 fold increased risk of developing COPD. In terms of lung function, for every 7µg/m3 rise in daily PM10 levels (particulate matter with an aerodynamic diameter of 10 micrometres), FEV&lt;SUB&gt;1&lt;/SUB&gt; was reduced by 5% and FVC by 3.7% &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#37" target="_blank"&gt;[37]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;There is some evidence that exposure to air pollution during childhood is associated with reduced lung growth &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#38" target="_blank"&gt;[38]&lt;/A&gt; although the overall effect size is small and to what extent this leads to an increased risk of COPD in adulthood is unknown. In addition these changes are at least partly reversible.&lt;/P&gt;
&lt;P&gt;There is clear evidence that on a day-to-day basis, exposure to outdoor air pollution increases the risk of death or hospital admission in COPD. In the European APHEA study, &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#39" target="_blank"&gt;[39]&lt;/A&gt; for every 10 µg/m3 rise in particle exposure, daily mortality in patients with COPD increased by 0.6% and for hospital admissions by 1%. It is likely that the smaller particles (PM2.5) are the major cause of these effects although the coarser particles may also be of importance for COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#40" target="_blank"&gt;[40]&lt;/A&gt;. This is important when considering interventions to control exposures but as other effects of air pollution on health, specifically cardiovascular effects, are more closely related to PM2.5 this should be the measure which is used as an assessment of success in control of outdoor air pollution exposure as is now used by the EU. In rural areas the secondary pollutant ozone may be as important as particles and is associated with mortality from COPD in time series studies.&lt;/P&gt;
&lt;P&gt;The UK has the tightest Air Quality Standards in the world and keeping PM and ozone levels down can be considered to be the best marker of impact on COPD mortality and exacerbations. These levels are enshrined in the Air Quality Strategy &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#41" target="_blank"&gt;[41]&lt;/A&gt; which has been developed by collaboration between DEFRA and the Department of Health. At local authority level, where responsibility for air pollution control lies, pressure should be maintained to reduce hot spots for air pollutant exposure using Air Quality Action Zones.&lt;/P&gt;
&lt;P&gt;Patients should be advised that when air pollution is high staying indoors would be advisable although the evidence to support this as an effective measure is lacking. Advice to patients with lung disease about what to do when air pollution increases is available on the &lt;A href="http://www.dh.gov.uk/" target="_blank"&gt;Department of Health website&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;For indoor pollution, environmental tobacco smoke (ETS) is the main source of concern in the UK but long term exposure to ETS does not appear to increase the risk of developing COPD or cause exacerbations in patients with pre-existing COPD. However, Quality of Life is significantly adversely affected by ETS exposure in patients with severe COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#42" target="_blank"&gt;[42]&lt;/A&gt; and there is a suggestion that severity of COPD may also relate to ETS exposure &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#43" target="_blank"&gt;[43]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Awareness of the detrimental effects of exposure to ETS is variable amongst the public but the specific effects in COPD have only just been identified. GPs should advise COPD patients about the risks of both ETS exposure as well as active smoking.&lt;/P&gt;
&lt;P&gt;Three billion people worldwide are exposed to biomass smoke which is known to be a cause of COPD in those exposed, particularly women. Levels of exposure are very high (hundreds or more times higher than indoor particle exposures in the UK) and interventions such as insertion of flued stoves has been shown to markedly reduce COPD prevalence &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#44" target="_blank"&gt;[44]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Genetic Factors&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;Alpha-1-antitrypsin deficiency is the only genetic factor that is widely accepted to predispose both smokers and non-smokers to COPD &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#45" target="_blank"&gt;[45,46]&lt;/A&gt;. The early detection of alpha1-antitrypsin deficiency results in increased awareness of the dangers of smoking and environmental pollution &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#47" target="_blank"&gt;[47]&lt;/A&gt;. Assessment of 61 individuals with PiZ alpha1-antitrypsin deficiency aged 18-20 years who had been identified in a neonatal screening programme revealed that 88% knew that they should avoid smoking to protect their lungs &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#48" target="_blank"&gt;[48]&lt;/A&gt;. Indeed the smoking rate was significantly less than that in control children in 61 PiZ alpha1-antitrypsin individuals from the cohort of 120 &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#49" target="_blank"&gt;[49]&lt;/A&gt; who were assessed at ages 18-20 and 107 of the cohort who were assessed at 30 years &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#50" target="_blank"&gt;[50]&lt;/A&gt;. All individuals advocated general screening for alpha1-antitrypsin deficiency preferably in the pre-adolescent period. The issues of pre-adolescent screening for alpha1-antitrypsin deficiency were addressed by Sveger and Thelin in a review in 2000 &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#51" target="_blank"&gt;[51]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The World Health Organisation recommended in 1997 that all people with a diagnosis of COPD and history of adult onset Asthma should be assessed for alpha1-antitrypsin deficiency &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#52" target="_blank"&gt;[52]&lt;/A&gt;. Those individuals with deficiency can then be assessed for liver disease and receive appropriate genetic counselling and screening of relatives. This would detect individuals earlier in the course of the disease and so facilitate advice on smoking cessation and the avoidance of occupational dusts so as to prevent the development of COPD. Affected relatives can also be monitored for the development of liver disease. There is evidence from a study of 199 smokers that a diagnosis of alpha1-antitrypsin deficiency (17 Z homozygotes) significantly increased the likelihood of reporting a 24-hr quit attempt (59%) with minimal smoking cessation intervention than those who did not have alpha1-antitrypsin deficiency (26%). MZ alpha1-antitrypsin heterozygotes (65 individuals) had a 34% quit attempt rate. Individuals with PiZ alpha1-antitrypsin deficiency were more likely than both heterozygotes and normals to seek information on treatment, use pharmacotherapy for smoking cessation, and report greater reductions in their smoking. However, there were no group differences in 3-month abstinence rates &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#53" target="_blank"&gt;[53]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;There is also evidence for an increased familial risk of COPD in siblings who do not have alpha1-antitrypsin deficiency &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#54" target="_blank"&gt;[54,55]&lt;/A&gt;. Therefore all first degree relatives should be offered assessment for COPD and strongly advised to abstain from smoking. &lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>278349</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=278349]]&gt;</url>
    <title>National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Surgical Interventions for COPD</title>
    <publicationDate>2008-02-04T00:00:00</publicationDate>
    <publisher>NLH Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,SURGERY,SURGERY,THORAX,LUNGS,NKW COPD,2007/8]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for Chronic Obstructive Pulmonary Disease 2008 - Surgical Interventions for COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;&lt;STRONG&gt;Lung Volume Reduction Surgery (LVRS)&lt;/STRONG&gt;&lt;BR&gt;With this approach non-functioning lung is removed by the surgeon to give the remaining lung ‘more room to work’ by reducing hyperinflation. Surgical technique has evolved but the usual approach is now by a VATS approach. The techniques is best suited to patients with severe exercise limitation and heterogenous disease (i.e. worse in the upper lobes) and where bilateral heterogenous disease is present a bilateral (often staged) procedure is favoured. Several prospective randomised studies &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#127" target="_blank"&gt;[127-130]&lt;/A&gt; have confirmed efficacy of the procedure in carefully selected patients (see below) and LVRS has been shown to be cost effective &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#131" target="_blank"&gt;[131]&lt;/A&gt;. Mortality rates for the procedure should be around 5% and despite ‘expert selection’ around 25% of patients fail to benefit. At present we expect patients to fare better than controls for at least 3 years. &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#132" target="_blank"&gt;[132]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Data on the relative preponderance of homogenous as opposed to heterogenous disease are sparse but, at least in UK clinical practice such patients constitute a minority of patients. Second, in order to reduce mortality and morbidity, most groups impose safety criteria so that patients who are too disabled are not eligible for LVRS. Thus for example at the Royal Brompton Hospital, patients must have a carbon monoxide gas transfer coefficient (TLCO) greater than 30% predicted and a shuttle walk distance more than 150m. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other Surgical Techniques&lt;BR&gt;&lt;/STRONG&gt;Alternative surgical techniques are used for occasional patients including the Monaldi procedure (where a catheter is used to decompress a large airspace) &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#133" target="_blank"&gt;[133,134]&lt;/A&gt; or bullectomy &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#135" target="_blank"&gt;[135]&lt;/A&gt;. Although case series suggest benefit these have not been subject to randomised controlled trials and are not likely to be performed in the future, given the small number of patients going forward for these procedures. &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Non surgical techniques&lt;BR&gt;&lt;/STRONG&gt;Future approaches are likely to include non-invasive techniques such as (a) endobronchial blockers (where a valve is placed within the airway with the aim of inducing collapse distal to the valve again allowing the remaining lung more room to work) &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#136" target="_blank"&gt;[136-138]&lt;/A&gt; and (b) extrapulmonary bypass (two approaches are presently being trialled to reduce hyperinflation by creating a direct connection between lung parenchyma and the atmosphere either through the main bronchi&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#139" target="_blank"&gt;[139]&lt;/A&gt; or through the skin &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=278356&amp;amp;tabID=290&amp;amp;catID=5880#140" target="_blank"&gt;[140]&lt;/A&gt;. Neither of these approaches is sufficiently far advanced to be recommended outside a research context at present, but it is anticipated that there will be future developments in these techniques.&lt;BR&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>187286</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187286]]&gt;</url>
    <title>National Knowledge Week for COPD 13-17 November 2006</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;National Knowledge Week for COPD 13-17 November 2006&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;P&gt;Welcome to the National Knowledge Week for COPD 13-17 November 2006.&lt;/P&gt;
&lt;P&gt;The aim of these pages is to present the latest available evidence and information within a number of topics&amp;nbsp;in Chronic Obstructive Pulmonary Disease (COPD). A short article was written for each topic by experts in respiratory medicine and healthcare. Each topic is accompanied by supporting evidence and patient information, and in the majority of cases a list of references provided by the author. The supporting evidence has been limited to that published in the last two years – there may be further information available within the COPD section of the library.&lt;/P&gt;
&lt;P&gt;The topics were chosen in consultation with stakeholders and experts in COPD. The topics are as follows:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;A href="nelh:187247:0" name=internalLink&gt;The burden of COPD in the UK&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187257:0" name=internalLink&gt;Living with COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187255:0" name=internalLink&gt;Setting standards for the delivery of integrated respiratory care (S-DIRC)&lt;/A&gt;&lt;A href="nelh:187255:0" name=internalLink&gt;&lt;/P&gt;
&lt;P&gt;&lt;/A&gt;&lt;A href="nelh:197439:0" name=internalLink&gt;Organisational change in primary care - impact on COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187248:0" name=internalLink&gt;Performing good quality spirometry&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187250:0" name=internalLink&gt;Evidence based drug therapy&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187253:0" name=internalLink&gt;The management of acute exacerbation in COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187254:0" name=internalLink&gt;Non-invasive ventilation&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:197364:0" name=internalLink&gt;The role of physical therapies in preventing exacerbation in COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187258:0" name=internalLink&gt;Role of the pharmacist in the management of COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187251:0" name=internalLink&gt;Pulmonary rehabilitation for COPD&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:197442:0" name=internalLink&gt;COPD and palliative and supportive care&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="nelh:187251:0" name=internalLink&gt;&amp;nbsp;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr&gt;&lt;/A&gt;In addition:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P dir=ltr&gt;&lt;A href="nelh:197299:0" name=internalLink&gt;Facts about COPD&lt;/A&gt;&lt;A href="nelh:197299:0" name=internalLink&gt;&lt;/P&gt;
&lt;P dir=ltr&gt;&amp;nbsp;&lt;/P&gt;&lt;/A&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>275292</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/Services/NCASP/Cancer/Lung%20cancer%202006.pdf]]&gt;</url>
    <title>National Lung Cancer Audit Report 2006</title>
    <publicationDate>2006-11-30T00:00:00</publicationDate>
    <publisher>The Information Centre for Health and Social Care, The Royal College of Physicians, and The Health Care Commission</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,MESOTHELIOMA,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Key findings about the quality of care for people with lung cancer in England incorporating headline and completeness data from Wales.
Report for the audit period 2005.</description>
    <body>&lt;![CDATA[ &lt;P&gt;The care provided for patients with lung cancer is described in this first report from new national data, published by The Information Centre for health and social care (The IC) in conjunction with the Royal College of Physicians on behalf of The Healthcare Commission. &lt;/P&gt;
&lt;P&gt;The lung cancer audit seeks to determine the extent to which the differences in survival can be explained by regional variations in: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;configuration of services 
&lt;LI&gt;management policies (including diagnosis, staging and treatment) 
&lt;LI&gt;the actual standards of specialist treatments (e.g. the availability of specialist thoracic surgeons and oncologists) 
&lt;LI&gt;casemix factors such as: stage at presentation; social deprivation (and its possible association with late presentation to medical care), co-morbidity and performance status. &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The first year of the audit covers data collected on the treatment of over 23,000 patients in 2005. Data is collected from 15 out of 34 English Cancer Networks and all 12 acute NHS trusts Wales. This represents 77 per cent of eligible hospitals submitting data, though more effort is needed to continue to recruit all trusts by the end of 2006. &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187254</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187254]]&gt;</url>
    <title>Non-invasive ventilation</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Non-invasive ventilation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr Mark Elliott&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P dir=ltr align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Non invasive ventilation (NIV) has been shown to be an effective treatment for ventilatory failure resulting from acute exacerbations of COPD in a number of randomised controlled trials. The studies showed that NIV is feasible in acute exacerbations of COPD and that the prevention of endotracheal intubation (ETI)&amp;nbsp; is advantageous. With NIV ventilation outside the ICU is an option; given the considerable pressure on ICU beds in most countries, the high costs and that for some patients admission to ICU is a distressing experience this is an attractive option. NIV can be instituted at an earlier stage in the natural history of the condition before mechanical ventilation would normally be considered necessary and should be seen primarily as a means of avoiding the need for intubation. &lt;/P&gt;
&lt;P&gt;NIV has also been compared directly with invasive ventilation in patients with an exacerbation of COPD and NIV was no worse than ETI and MV. In those who could be managed successfully with NIV there was an advantage both in the short term but also in the year after hospital discharge.&amp;nbsp; There are no absolute contraindications to NIV although a number have been suggested. In part, these “contraindications” have been determined by the fact that they were exclusion criteria for the controlled trials. It is therefore more correct to state that NIV is not proven in these circumstances rather than that it is contraindicated. When NIV can be successfully applied there are clear advantages, particularly a reduction in infectious complications and length of ICU and hospital stay, with an attendant reduction in costs. There is no convincing evidence to date that a failed trial of NIV is harmful. NIV has a role for weaning some patients, particularly those with COPD. NIV should be available in all patients admitting patients with acute exacerbations of COPD.&lt;/P&gt;
&lt;P&gt;The role of domiciliary NIV for patients with COPD is more controversial. There is no robust randomised controlled trial evidence to support the use of NIV. It would however be generally accepted that there is a role in patients with hypercapnia who can not tolerate oxygen despite careful attempts to titrate the flow rate. It may also benefit patients with recurrent exacerbations requiring NIV acutely but this needs to be confirmed. On the basis of current evidence domiciliary NIV should be considered for no more than a minority of patients with COPD.&lt;BR&gt;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Other Resources:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79830&amp;amp;tabID=290" target="_blank"&gt;Chronic obstructive airways disease&lt;/A&gt;&amp;nbsp;BMJ Topic Collection, August 1997 - 28 October 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=189966&amp;amp;tabID=289" target="_blank"&gt;Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2004, Issue 3. &lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=122221&amp;amp;tabID=289" target="_blank"&gt;Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2006.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>282017</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=80]]&gt;</url>
    <title>NPCi Blog - Informing smokers about their lung age may help them to stop smoking</title>
    <publicationDate>2008-03-14T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG FUNCTION TESTING,SMOKING,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Prescribing Centre (NPC) Blog, discussing the the following article published in BMJ Online.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.bmj.com/cgi/content/full/bmj.39503.582396.25v1" target="_blank"&gt;Parkes G, Greenhalgh T, Griffin M, et al. Effect on smoking quit rate of telling patients their lung age&amp;nbsp;: the Step2quit randomised controlled trial. BMJ Online first doi:10.1136/bmj.39503.582396.25 (published 6 March 2008)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;This study suggests that testing a smoker’s lung age with spirometry, and providing information in an understandable and visual way, is potentially an effective, brief intervention that helps more people to stop smoking.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>279503</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=53]]&gt;</url>
    <title>NPCi BLOG – Long-acting ß2 agonists (LABAs) for asthma: review by MHRA</title>
    <publicationDate>2008-01-10T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,RESPIRATORY,SPECIALTIES,ASTHMA,ASTHMA,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Prescribing Centre (NPC) Blog, discussing the &lt;A href="http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&amp;amp;nodeId=20" target="_blank"&gt;MHRA&lt;/A&gt; publication on findings of its review of LABAs (salmeterol and formoterol) in asthma, in the January issue of &lt;EM&gt;Drug Safety Update&lt;/EM&gt;&lt;U&gt; &lt;/U&gt;(7th January 2008).]]&gt;</body>
  </document>
  <document>
    <id>289128</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=43]]&gt;</url>
    <title>NPCi Blog - More data on the safety of salmeterol when added to inhaled corticosteroids in asthma</title>
    <publicationDate>2008-06-24T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Prescribing Centre (NPC) Blog, discussing&amp;nbsp;the need for more data on the safety of salmeterol when added to inhaled corticosteroids in asthma.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.annals.org/cgi/content/abstract/0000605-200807010-00229v1?papetoc" target="_blank"&gt;Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med&amp;nbsp; 2008; 149. Early online publication&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289692</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=159]]&gt;</url>
    <title>NPCi Blog - Mucolytics to prevent COPD exacerbations?</title>
    <publicationDate>2008-07-02T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Prescribing Centre (NPC) Blog, discussing&amp;nbsp;Carbocisteine reducing the mean frequency of exacerbations by a modest amount, from 1.35/patient-year to 1.01/patient-year, compared with placebo, in Chinese patients with chronic obstructive pulmonary disease (COPD).&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.thelancet.com/journals/lancet/article/PIIS0140673608608697/fulltext" target="_blank"&gt;Zheng J-P, Kang J, Huang S-G, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008;371:2013–8&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>270054</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=6]]&gt;</url>
    <title>NPCi BLOG - Observational data adds to concerns regarding inhaled steroids and pneumonia risk in patients with COPD</title>
    <publicationDate></publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PNEUMONIA - COMMUNITY ACQUIRED,INFECTIONS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;National Prescribing Centre (NPC) Blog, discussing inhaled steroid treatment and the risk of pneumonia&amp;nbsp;in patients with&amp;nbsp;Chronic Obstructive Pulmonary Disease (COPD).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>276966</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=51]]&gt;</url>
    <title>NPCi BLOG – Paediatric Cough Medicines – No help, some harm!</title>
    <publicationDate>2008-01-03T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,RESPIRATORY,COUGH,SPECIALTIES,COUGH,SYMPTOMS,THERAPEUTIC INTERVENTION,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Prescribing Centre (NPC) Blog, discussing an &lt;A href="http://content.nejm.org/cgi/content/full/357/23/2321" target="_blank"&gt;article&lt;/A&gt;&amp;nbsp;published by the &lt;A href="http://content.nejm.org/" target="_blank"&gt;New England Journal of Medicine&lt;/A&gt;&amp;nbsp;that gives an insight into recent concerns raised in the United States of America over the risk-benefit profile of children’s cough and cold medications.]]&gt;</body>
  </document>
  <document>
    <id>277600</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npci.org.uk/blog/?p=56]]&gt;</url>
    <title>NPCi BLOG - Varenicline compared with nicotine replacement therapy for smoking cessation</title>
    <publicationDate>2008-01-18T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ National Prescribing Centre (NPC) Blog, discussing Varenicline compared with nicotine replacement therapy for smoking cessation.]]&gt;</body>
  </document>
  <document>
    <id>197439</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=197439]]&gt;</url>
    <title>Organisational change in primary care- impact on COPD</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Organisational change in primary care- impact on COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr Rupert Jones, Respiratory Research Unit, Peninsula Medical School&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;The prominence of COPD has been rising over recent years, driven largely by the emerging understanding of the rising costs of the disease to the health service. COPD is underdiagnosed and undertreated in primary and secondary care. However, the old nihilism felt by clinicians is shifting as it becomes clear how much can be done for these long suffering patients.&lt;A href="#refs"&gt;[1]&lt;/A&gt; Early detection coupled with smoking cessation is effective in preventing decline into serious lung disease with its attendant costs to patients and the NHS. Most of the NHS costs relate to non-elective admissions. &lt;A href="#refs"&gt;[2]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Several key initiatives have delivered change to primary care. The first was the NICE guidelines for COPD&lt;A href="#refs"&gt;[3]&lt;/A&gt;, they again emphasised the now familiar please for:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Accurate diagnosis using spirometry in primary care. NICE calculates that opportunistic case finding primary care is cost effective. &lt;/LI&gt;
&lt;LI&gt;Smoking cessation&lt;/LI&gt;
&lt;LI&gt;Effective inhaled treatment&lt;/LI&gt;
&lt;LI&gt;Pulmonary rehabilitation for all who need it.&lt;/LI&gt;
&lt;LI&gt;Manage exacerbations&lt;/LI&gt;
&lt;LI&gt;Multidisciplinary working.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The quality and outcome framework of the GMS contract&lt;A href="#refs"&gt;[4]&lt;/A&gt; provided, the initial impetus for practices to get involved with COPD care. QoF provides financial inducements to diagnose using spirometry, keep a diagnostic register, record smoking cessation advice, check inhaler technique and influenza vaccination. The QoF targets were recently revised, but have changed little. The key points for practices is to have an accurate register, that exception reporting is important to meet high targets, reversibility testing is clinically useful in separating COPD from asthma (this is subject to debate). Asthma and COPD can co-exist, but only in a minority of patients. The QoF initiative has been criticised as it is about process not outcomes: recording of data is paramount, not outcomes like how many stop smoking. Furthermore the quality of spirometry for instance may be poor, but practices still get paid.&lt;/P&gt;
&lt;P&gt;NICE also recommends the management of exacerbations effectively. The strategy involves prevention, long acting bronchodilators, inhaled steroids and consideration of mucolytics. Pulmonary rehabilitation may also reduce exacerbations. Self management of the exacerbation is useful including recognition of the symptoms, and appropriate steps to take, such as antibiotics or oral steroids. Early intervention reduces the impact of exacerbations.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Healthcare commission (‘Clearing the Air – a national study on chronic obstructive pulmonary disease’ – report from the Healthcare Commission June 2006) has produced a lengthy report on COPD care and provides an insight as to how good care can help patients and&amp;nbsp; at the same time save the NHS money. In time, NHS providers will have to meet strict targets for their care of COPD patients. &lt;/P&gt;
&lt;P&gt;As the majority of healthcare costs come from exacerbations, especially admissions, exacerbation management is becoming critical. Furthermore several new policies have important implications for the way health care will be funded, commissioned and provided. Under Payment by Results, hospital tariff prices vary, but the average cost for a COPD admission is over £2,000.&amp;nbsp; With practice based commissioning, practices have an indicative budget for hospital care. If they manage to reduce their spend on hospital services, they can use the savings to support new services. Practice based commissioning is going to provide a major incentive to reduce admissions, but may have a detrimental effect on hospitals. In the meantime, effective systems of care such as early discharge schemes, community nursing services and pulmonary rehabilitation can be difficult to achieve. Many PCTs cannot afford them and new commissioning groups have not yet invested in them. To address this NICE is planning new commissioning guides. If that is not complicated enough, new providers can compete with current NHS providers for deliver of COPD care. Alternative providers (A –PMS) are private sector companies and include large health corporations; special providers (S- PMS) are NHS providers who become financially independent to run COPD services. Commissioners of healthcare, such as practices, can buy their services rather than using local hospital or community services.&lt;BR&gt;&amp;nbsp;&lt;BR&gt;Overall the importance of COPD has been recognised by the government. There is no simple fix, the NHS needs to address the prevention of new patients and management of existing patients. There is a plethora of policies from the Department of Health, which seem confusing, and at times contradictory, to address COPD care. A whole systems approach is needed, COPD now has its own National Service Framework to do just that. Building on the existing policy and guidance including the NICE guidelines and the Healthcare commissions work it will provide a patient orientated policy which will address all aspects of the disease. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Celli B. Chronic Obstructive Pulmonary Disease. From Unjustified Nihilism to Evidence-based Optimism. Proc Am Thorac Soc 2006;3:58-65. &lt;A href="http://pats.atsjournals.org/cgi/content/full/3/1/58" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir.Med 2003;97 Suppl C:S71-S79. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12647945&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;National Institute for Clinical Excellence. CG12 Chronic Obstructive Pulmonary Disease Clinical Guidelines.&amp;nbsp; 2004. London, Abba Litho Ltd.&amp;nbsp;&lt;A href="http://www.nice.org.uk/guidance/CG12" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;The NHS confederation, GMSC. Investing in general practice. New GMS contract.&amp;nbsp; 2003. London, The NHS confederation and the BMA. &lt;A href="http://www.bma.org.uk/ap.nsf/Content/investinggp" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&amp;nbsp;&amp;nbsp;Other Resources:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=34497&amp;amp;tabID=288" target="_blank"&gt;Chronic obstructive pulmonary disease : management of COPD in adults in primary and secondary care&lt;/A&gt;&amp;nbsp;NICE, February 2004.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=34136&amp;amp;tabID=288" target="_blank"&gt;The Management of Chronic Obstructive Pulmonary Disease (COPD) in General Practice&lt;/A&gt;&amp;nbsp;General Practice Airways Group (GPIAG), 2005.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=101444&amp;amp;tabID=288" target="_blank"&gt;The treatment and prevention of exacerbations in COPD: the role of primary care&lt;/A&gt;&amp;nbsp;British Lung Foundation (BLF), 2004.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>290198</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.myilibrary.com/Browse/open.asp?ID=28667]]&gt;</url>
    <title>Oxford Handbook of Respiratory Medicine</title>
    <publicationDate>2005-07-21T00:00:00</publicationDate>
    <publisher>Oxford University Press</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG FUNCTION TESTING,EDUCATION/CPD,PUBLICATIONS,DIAGNOSIS AND MONITORING,INFECTIONS,NHS CORE CONTENT EBOOKS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>NHS Core Content eBook</description>
    <body>&lt;![CDATA[ &lt;UL&gt;
&lt;UL&gt;
&lt;LI&gt;All respiratory diseases are covered 
&lt;LI&gt;Practice tips are included for the out-patient clinic or ward setting 
&lt;LI&gt;Unique sections on practical procedures assist the novice 
&lt;LI&gt;Difficult areas - anatomy, lung function, and blood gases - are made clear 
&lt;LI&gt;The symptoms section helps the reader in differential diagnosis and reflects the clinical situation&lt;/LI&gt;&lt;/UL&gt;&lt;/UL&gt;
&lt;P&gt;This handbook provides a fast, reliable look-up reference on all chest diseases - for junior doctors, trainee specialists in respiratory medicine, and other health workers. &lt;/P&gt;
&lt;P&gt;First there are chapters on all the major respiratory symptoms. Once the differential diagnosis has been made, the reader can turn to the pages on the respiratory diseases, each of which is covered in a consistent format including practical tips for the out-patient clinic or ward setting. There is a unique section on how to do practical procedures, together with essential technical and reference information. Useful pages on lung and bronchial anatomy, CT anatomy, lung function and blood-gas nomograms, and a list of useful web sites are included for easy reference. &lt;/P&gt;
&lt;P&gt;Like all the Oxford Handbooks, this handbook combines authority, relevance and reliability.&lt;/P&gt;
&lt;P&gt;ISBN: 9780198529774&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access: &lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;NHS Staff wishing to access&amp;nbsp;e-books need a (free) Athens username and password which can be arranged at any local NHS Library or online at &lt;A href="https://register.athensams.net/nhs/" target="_blank"&gt;https://register.athensams.net/nhs/&lt;/A&gt;.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6012</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/623066/description]]&gt;</url>
    <title>Paediatric Respiratory Reviews</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ CHILD HEALTH,RESPIRATORY,JOURNALS,RESPIRATORY,SPECIALTIES,PUBLICATIONS,ASTHMA,PUBLICATIONS,JOURNALS,DIAGNOSIS AND MONITORING,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Paediatric Respiratory Reviews is aimed at general paediatricians but is also relevant to specialist paediatric physicians and nurses, respiratory physicians and general practitioners. It publishes commissioned articles relevant to the continuing medical and professional development of paediatricians specialising in the diagnosis, treatment and management of respiratory disease. &lt;BR&gt;The review-based articles cover all aspects of paediatric respiratory disease, function, diagnosis, management and therapy. &lt;/P&gt;
&lt;P&gt;Covering, epidemiology, immunology and cell biology, physiology, occupational disorders and the role of allergens and pollutants. A particular emphasis is given to the recommendation of "best practice" for primary care physicians and paediatricians. &lt;/P&gt;
&lt;P&gt;ISSN: 1526-0542&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Access to full text from the first issue (March 2000) is via subscription, with free access for non subscribers to tables of contents, abstracts and some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312737</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/pallcarecopd_opinion7_final.pdf]]&gt;</url>
    <title>Palliative care for people with COPD</title>
    <publicationDate>2006-09-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It provides information about identifying patients with COPD who would benefit from a palliative care approach and how to go about it.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet No. 7.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>313373</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/disease/swineflu/en/index.html]]&gt;</url>
    <title>Pandemic (H1N1) 2009</title>
    <publicationDate></publicationDate>
    <publisher>World Health Organisation (WHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,INFECTIOUS DISEASES,RESPIRATORY INFECTIONS,INFLUENZA,VIRAL,RESPIRATORY,INFECTIONS,MICROORGANISM,VIRUSES,INFLUENZA VIRUS,APRIL 09,SWINE INFLUENZA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;Information on this page tracks the evolving situation and provides access to both technical guidelines and information useful for the general public. This webpage is published by WHO.&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;WHO is coordinating the global response to human cases of swine influenza A (H1N1) and monitoring the corresponding threat of an influenza pandemic. &lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;A href="http://www.who.int/en/" target="_blank"&gt;World Health Organisation (WHO)&lt;/A&gt; is the directing and coordinating authority for health within the &lt;A href="http://www.un.org/english/" target="_blank"&gt;United Nations system &lt;/A&gt;. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&amp;nbsp;&lt;/P&gt;
&lt;P style="MARGIN: 0cm 0cm 0pt" class=MsoNormal&gt;&lt;o:p&gt;&lt;/o:p&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345264</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.stoptb.org/resource_center/assets/documents/BluePrintTB_annex_web.pdf]]&gt;</url>
    <title>Pathways to better diagnostics for tuberculosis - A blueprint for the development of TB diagnostics</title>
    <publicationDate>2009-11-17T00:00:00</publicationDate>
    <publisher>World Health Organisation (WHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>This publication offers a structure to guide those involved in diagnostic development through the different phases of development – from the discovery of new techniques and tools through to their delivery in previously neglected markets.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This publication is intended to help tuberculosis diagnostics researchers work more effectively with academics, officials and industry professionals. It offers a structure to guide those involved in diagnostic development through the different phases of development – from the discovery of new techniques and tools through to their delivery in previously neglected markets. It is designed to help identify the most promising TB tests, to push them toward alignment with the needs and requirements of the areas where tuberculosis is most prevalent, and to help determine why some are held up in development.&lt;/P&gt;
&lt;P&gt;The blueprint also is intended to help boost coordination and collaboration across the diagnostic research and development landscape, while leading to greater success in advancing new tests by clarifying that landscape and the various development steps&lt;BR&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187248</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187248]]&gt;</url>
    <title>Performing good quality spirometry</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,LUNG FUNCTION TESTING,DIAGNOSIS AND MONITORING,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Performing good quality spirometry&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Dr B G Cooper, &lt;/SPAN&gt;&lt;/B&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Hon Chair ARTP, &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Hon Chair ERS Group 9.1 and &lt;/SPAN&gt;&lt;SPAN style="FONT-FAMILY: Arial"&gt;Clinical Champion in Respiratory Physiology&lt;/SPAN&gt;&lt;/P&gt;&lt;/STRONG&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Spirometry is increasingly being adopted in primary care as a tool for screening for lung disease (principally COPD) and is seen as one of the markers of high quality care.&amp;nbsp;&amp;nbsp; However obtaining high quality, reliable results requires a significant level of competence. No matter how smart the technology becomes, at the end of the day it is the quality and training of the spirometer operator who will determine the effectiveness of the service.&lt;/P&gt;
&lt;P&gt;The current GMS2 contracts, requires a number (FEV1) and a record that a bronchodilator response has been performed so that funding can be obtained for service. A growing body of primary care staff are investing and becoming enthusiastic about quality spirometry for screening their patients but unfortunately the system has no quality aspect built into it so that the quality of spirometry will vary between centres, in part because those who are less enthusiastic may under estimate the expertise required to obtain high quality data.&amp;nbsp; In a recent editorial Mannino states that, “Pulmonary function testing offers an easy, inexpensive and non-invasive means of diagnosis and staging chronic lung disease”.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Let us examine that sentence in more detail.&amp;nbsp; Firstly, obtaining a value that can be recorded is easy but obtaining accurate data is only easy for trained and competent practitioners.&amp;nbsp; While technically non-invasive, asking patients who maybe hyper-inflated, unwell, breathless and uncoordinated to follow a series on manoeuvres that will take them from full inspiration to a forced expiration down to residual volume repeatedly is asking them to perform one of the more uncomfortable, and tiring physiological tests.&amp;nbsp; For a practice to commit to investing in high quality spirometry involves purchasing a quality spirometer [rather than a ‘cheap’ ‘hand held device’], calibration syringe, filters and, most importantly, investing in appropriate training.&amp;nbsp; This package (excluding the time spent out of the practice routine work undergoing training), would probably be in the order of £2,000-£2,500 for the first 12 months of service.&amp;nbsp; Even if they only screen 100 patients, that’s probably twice the price of a quality service provided by out-reach or direct access by trained lung function staff.&amp;nbsp;&amp;nbsp; However, there is no need to see quality spirometry as something provided in secondary care only.&amp;nbsp; The primary/secondary care barrier has to come down, and the quality should pervade all clinical areas where spirometry is requested.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;What is the evidence for lung function training ensuring quality? A recent study has looked at the quality of lung function in a large clinical trial in the US. The report by Enright et al. clearly demonstrates that the performance rate of trained healthcare scientists in a lung function laboratory can be very high.&amp;nbsp; A retrospective chart review of 18,000 consecutive patients, referred to a large outpatient lung function laboratory for testing showed that 90% of the patients were able to reproduce FEV1 within 120 ml (6.1%), FVC within 150 ml (5.3%), and PEF within 0.80 L (12%). They concluded that the ability of patients to meet or exceed spirometry repeatability goals does not depend on patient characteristics when testing is performed by experienced personnel. &lt;/P&gt;
&lt;P&gt;Similar levels of reproducibility can be obtained in primary care with the right investment in equipment and training and competence. Schermer et al. showed a difference between laboratories and primary care as being about 200ml on average for FEV1 and FVC, which is just about the average error between commercial spirometers.&amp;nbsp; In other words suggesting that the differences maybe reflect equipment variation rather than spirometry training/competence.&lt;/P&gt;
&lt;P&gt;These papers re-enforce the point that spirometry is not simple.&amp;nbsp; It requires adequate training to a reasonable level of understanding not only of the physiology, but the pathophysiology for interpretation, and some technical understanding to maintain the equipment and also to ensure the practitioner maintains their competence.&amp;nbsp; A 2 day training programme as recommended by international professional bodies in lung function (ARTP, ANZSRS, AARC) is a good starting point&amp;nbsp; but this needs to be backed up by on going experience, constant honing of skills, and refresher courses. &lt;/P&gt;
&lt;P&gt;One use of spirometry in primary care is to show lung function changes caused by smoking, which is a powerful incentive to smoking cessation (Bednarek et al). This has to be a way forward in stopping the COPD epidemic, by encouraging smokers to give up before serious damage is done.&amp;nbsp; If we add in the concept currently promoted by the UK government that patients need to manage their own care, then this clearly puts the onus on smokers to quit or pay for the consequences with more than their health. &lt;/P&gt;
&lt;P&gt;The guidelines for lung function measurement have changed very little in the last 20 years.&amp;nbsp; The standards and guidance for UK practitioners remains the ARTP/BTS (1994) lung function guidelines.&lt;BR&gt;The take home messages from this article are:&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Spirometry is not cheap and simple.&amp;nbsp; Doing it ‘on the cheap’ undermines quality and is a false economy.&lt;/LI&gt;
&lt;LI&gt;Adequate training of staff and maintaining their critical spirometry skills is essential to providing a quality spirometry service.&lt;/LI&gt;
&lt;LI&gt;Quality spirometry can be used successfully to encourage smokers to give up smoking&lt;/LI&gt;
&lt;LI&gt;In the UK, the standards for spirometry remain the ARTP/BTS guidelines.l&lt;BR&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Bednarek M, Gorecka D, Weilgomas J, et al&amp;nbsp; Smokers with airway obstruction are more likely to quit smoking.&amp;nbsp; Thorax 2006 61:869-873 &lt;A href="http://thorax.bmj.com/cgi/content/full/61/10/869" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Chavannes N, Schermer T, Akkermans R, et al. Impact of spirometry on GPs' diagnostic differentiation and decision-making. Respir Med 2004;98:1124–1130. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15526814&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cooper BG&amp;nbsp;&amp;nbsp; Limitations to spirometry being performed in “the office”. Chron Resp Dis 2005 2(2): 113-115 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16279160&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 2004;169:235–238. &lt;A href="http://ajrccm.atsjournals.org/cgi/reprint/169/2/235" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;
&lt;LI&gt;D Mannino&amp;nbsp; Spirometric screening: does it work? Thorax 2006 61:834-835 &lt;A href="http://thorax.bmj.com/cgi/content/full/61/10/834" target="_blank"&gt;[EXTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Schermer TR, Jacobs JE, Chavannes NH, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003;58:861–866. &lt;A href="http://thorax.bmj.com/cgi/reprint/58/10/866.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt; (PDF)&lt;/LI&gt;
&lt;LI&gt;Recommendations of the BTS &amp;amp; ARTP. Guidelines for the measurement of respiratory function&amp;nbsp;Resp Med&amp;nbsp; 1994;88:165-194.&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Other Resources:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79830&amp;amp;tabID=290" target="_blank"&gt;Chronic obstructive airways disease&lt;/A&gt;&amp;nbsp;BMJ Topic Collection, August 1997 - 28 October 2006.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=155090&amp;amp;tabID=290" target="_blank"&gt;Spirometry in Practice: A Practical Guide to Using Spirometry in Primary Care&lt;/A&gt;&amp;nbsp;British Thoracic Society (BTS) COPD Consortium, 2005.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>312050</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/asthma_action_plans_rev_aug_2008.pdf]]&gt;</url>
    <title>Personal Asthma Action Plans</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It details what personal action plans are and the different types of plans.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet&amp;nbsp;No. 12.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124901</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=124901]]&gt;</url>
    <title>Physiotherapy practice and asthma</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,ASTHMA,NKW ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Physiotherapy practice and asthma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Anne Bruton and Rachel Garrod&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;&lt;BR&gt;[This article was written for the National Knowledge Week for Asthma 22 -&amp;nbsp;26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Asthma is a complex disease characterised by episodes of airway narrowing and inflammation usually in response to triggers. It has a significant impact on individuals in terms of quality of life, reduction in activity levels and increased depression &lt;A href="#refs"&gt;[1]&lt;/A&gt;. Physical inactivity is common, with asthma subjects reported to have significantly lower energy expenditure from leisure time physical activity compared with non asthmatics &lt;A href="#refs"&gt;[2]&lt;/A&gt;. However, in physiological exercise tests, asthmatics demonstrate similar exercise performance to healthy subjects matched for habitual activity.&amp;nbsp; This suggests that reduction in physical ability occurs as a result of physical inactivity rather than pathological processes. &lt;/P&gt;
&lt;P&gt;A recent Cochrane review of 13 trials has shown clear evidence that training programmes are effective in cardio-pulmonary fitness &lt;A href="#refs"&gt;[3]&lt;/A&gt;. Significant differences were found in heart rate, maximal oxygen consumption and ventilation after training versus no training. There was also a non-significant reduction of days with wheeze &lt;A href="#refs"&gt;[7,5]&lt;/A&gt;. There were no changes in lung function, suggesting that mechanisms of benefit arise from factors unrelated to change in lung architecture. Such processes are multi-factorial but may be as a result of improvements in muscle strength, dyspnoea desensitisation, increases in oxidative enzymes, and possible anti-inflammatory pathways &lt;A href="#refs"&gt;[4]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Evidence is weaker concerning the benefits of physical training in asthma on quality of life, however early studies show similar benefits to those experienced by COPD patients after training &lt;A href="#refs"&gt;[5,6]&lt;/A&gt;. One study in which exercise induced bronchospasm (EIB) was associated with limitations to daily life in 30 - 40% subjects &lt;A href="#refs"&gt;[7]&lt;/A&gt; has raised the possibility that exercise training may be deleterious for asthma. A Cochrane review found no evidence to support this and concludes “there is no reason why patients with asthma should not participate in regular physical activity” &lt;A href="#refs"&gt;[3]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;As well as whole body exercise it has been suggested that specific breathing exercises may also have a role in the treatment of asthma &lt;A href="#refs"&gt;[8]&lt;/A&gt;. There are two primary categories of asthma breathing exercises. The first involves manipulating the breathing pattern to become slower and more controlled. The second involves training the respiratory muscles to increase their strength and endurance. &lt;/P&gt;
&lt;P&gt;The aim of breathing pattern retraining is to develop a more efficient pattern of respiration, thereby reducing breathlessness. This is usually accomplished by slowing the breathing rate, and encouraging relaxed, ‘abdominal’ breathing. There have also been suggestions that hypocapnic patients can become acclimatised to carbon dioxide levels higher than their baseline. &lt;/P&gt;
&lt;P&gt;Another potential mechanism for breathing pattern retraining is that by encouraging a longer expiratory time, the effects of any static/ dynamic hyperinflation may be reduced. Respiratory muscle training for asthma is controversial. The principles of overload and specificity can be applied to the respiratory muscles to produce adaptations that will improve strength and endurance, like any other skeletal muscles. The controversy rests on whether this is of any clinical or functional value to patients. Specific training usually involves breathing at increased levels of ventilation or against external mechanical loads. &lt;/P&gt;
&lt;P&gt;Although there is anecdotal evidence for the effectiveness of breathing retraining, and respiratory muscle training; and some encouraging results from recent trials &lt;A href="#refs"&gt;[9-11]&lt;/A&gt;, there is currently insufficient evidence to support their recommendation for all asthmatic patients &lt;A href="#refs"&gt;[12,13]&lt;/A&gt; &lt;STRONG&gt;&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/STRONG&gt;&lt;/P&gt;&lt;A name=refs&gt;&lt;/A&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The references were supplied by the authors. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via PubMed)&amp;nbsp;of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Sandez E, Vázquez MI, Romero-Frais E, Blanco-Aparicio M, Otero I and Verea H. Depression, Panic-Fear, and Quality of Life in Near-Fatal Asthma Patients. Journal of Clinical Psychology in Medical Settings 2005; 12:175 - 184&amp;nbsp; &lt;A href="http://www.springerlink.com/(k3cegtjb5vloqk3ayc42dz55)/app/home/contribution.asp?referrer=parent&amp;amp;backto=searcharticlesresults,1,1;" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ford ES, Heath GW, Mannino DM, Redd SC. Leisure-time physical activity patterns among US adults with asthma. Chest 2003 Aug; 124:432-7&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12907526&amp;amp;query_hl=7&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ram FS, Robinson SM, Black PN, Picot J. Physical training for asthma. Cochrane Database Syst. Rev. 2005 Issue 4.&amp;nbsp;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001116/frame.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J. Appl. Physiol 2005; 98:1154-62&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15772055&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cambach W, Wagenaar RC, Koelman TW, van Keimpema AR, Kemper HC. The long-term effects of pulmonary rehabilitation in patients with asthma and chronic obstructive pulmonary disease: a research synthesis. Arch. Phys. Med. Rehabil. 1999; 80:103-11&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9915381&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cox NJ, Hendricks JC, Binkhorst RA, van Herwaarden CL. A pulmonary rehabilitation program for patients with asthma and mild chronic obstructive pulmonary diseases (COPD). Lung 1993; 171:235-44 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8341090&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Carlsen KH, Carlsen KC. Exercise-induced asthma. Paediatr. Respir Rev. 2002; 3:154-60 &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=pubmed&amp;amp;dopt=Abstract&amp;amp;list_uids=12297065&amp;amp;query_hl=17&amp;amp;itool=pubmed_docsum" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Bruton A, Holgate ST. Hypocapnia and asthma: a mechanism for breathing retraining? Chest 2005; 127:1808-11&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15888863&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Stalmatski A. Freedom From Asthma: Buteyko's revolutionary treatment. London: Kyle Cathie Ltd; 1997.&lt;/LI&gt;
&lt;LI&gt;Thomas M, McKinley RK, Freeman E, Foy C, Prodger P, Price D. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax 2003; 58:110-5&amp;nbsp;&lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;amp;db=pubmed&amp;amp;list_uids=12554890&amp;amp;dopt=abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Cooper S, Oborne J, Newton S, Harrison V, Thompson CJ, Lewis S, Tattersfield A. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. Thorax 2003; 58:674-9&amp;nbsp;&lt;A href="http://thorax.bmjjournals.com/cgi/content/full/58/8/674" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Weiner P, Berar-Yanay N, Davidovich A, Magadle R, Weiner M. Specific inspiratory muscle training in patients with mild asthma with high consumption of inhaled beta(2)-agonists. Chest 2000; 117:722-7&amp;nbsp;&lt;A href="http://intl.chestjournal.org/cgi/content/full/117/3/722" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Holloway E, Ram FS. Breathing exercises for asthma. Cochrane. Database. Syst. Rev. 2004. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001277/frame.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Ram FS, Wellington SR, Barnes NC. Inspiratory muscle training for asthma. Cochrane. Database. Syst. Rev. 2003.&amp;nbsp;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003792/frame.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;
&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Patient Information:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.lunguk.org/you-and-your-lungs/you-and-your-lungs/exerciseandthelungs.htm" target="_blank"&gt;Exercise and the lungs&lt;/A&gt; British Lung Foundation (BLF).&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>263026</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/webfiles/publications/allergdisorder/HSCICallergiesreportfromQRESEARCHJune2007[1].pdf]]&gt;</url>
    <title>Primary care epidemiology of allergic disorders: analysis using QResearch database 2001-2006</title>
    <publicationDate>2007-06-01T00:00:00</publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,ASTHMA,SINUSITIS,IMMUNOLOGICALLY BASED DISORDERS,INFECTIONS,THERAPEUTIC INTERVENTION,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Researchers have been trying to make better use of existing NHS data. In 2006, The Information Centre for health and social care commissioned an assessment of patterns allergic diseases in patients diagnosed in primary care England. This five year report is based on an analysis of a new primary care database called QRESEARCH and it will assist the government in the policy decision process and around the development of standards and services for this area of healthcare. &lt;/P&gt;
&lt;P&gt;Professor Julia Hippisley-Cox, director of QRESEARCH (a joint University of Nottingham and EMIS partnership) said: "This is the largest most detailed evaluation of allergic diseases ever to be conducted in primary care internationally and the analysis was only possible because thousands of family doctors freely contribute data for medical research. The rapidly changing disease patterns described in the report highlight the need for ongoing surveillance in this area, and suggest that services will need to continue to evolve over the next few decades to meet the anticipated growing disease burden posed by allergic problems." &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>5998</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thepcrj.org]]&gt;</url>
    <title>Primary Care Respiratory Journal</title>
    <publicationDate></publicationDate>
    <publisher>GPIAG Publications</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The Primary Care Respiratory Journal (formerly Asthma in General Practice) is the official journal of the General Practice Airways Group (GPIAG, formerly known as the GPs in Asthma Group) and the International Primary Care Respiratory Group (IPCRG). It publishes original research papers, reviews, discussion papers and letters relating to all aspects of repiratory conditions in primary care and also aims to encourage research in primary care by publishing short reports of preliminary work and final reports or observations not requiring a lengthy write-up. 
&lt;P&gt;Published 4 times a year.&lt;BR&gt;ISSN: 1471-4418 
&lt;P&gt;Access to previous and current issues is available through the website. They may be downloaded and printed for individual use, reproduction of copies may be arranged for a fee.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>281438</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/Portals/0/IMPRESS/Principles.pdf]]&gt;</url>
    <title>Principles, definitions and standards for pulmonary rehabilitation</title>
    <publicationDate>2008-02-29T00:00:00</publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,PUBLICATIONS,THERAPEUTIC INTERVENTION,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ The profile of COPD as a debilitating condition is increasing in the light of the publication of the recent NICE guidelines and the forthcoming National Service Framework (NSF). Pulmonary rehabilitation is an important non-pharmacological therapy that, when correctly applied, can improve physical performance, health status and reduce some health care costs. Rehabilitation programmes are effective and popular with patients and it is likely that the demand for them will increase after the NSF is published. The outcomes of a rehabilitation programme are more likely than pharmacological treatments to be subject to the vagaries of form and delivery. Knowledge now exists to guide the construction and delivery of a rehabilitation programme that has the best chance of success for the majority of participants. From a population perspective it is important to ensure in future that organisations that offer pulmonary rehabilitation do so with regard to effective structure and ongoing quality control. The purpose of this paper is to define the minimum standards for an effective pulmonary rehabilitation and provide advice about what form of quality control might be appropriate.]]&gt;</body>
  </document>
  <document>
    <id>275769</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://pats.atsjournals.org/]]&gt;</url>
    <title>Proceedings of the American Thoracic Society</title>
    <publicationDate></publicationDate>
    <publisher>American Thoracic Society (ATS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The American Thoracic Society publishes the &lt;EM&gt;Proceedings of the American Thoracic Society&lt;/EM&gt; in furtherance of its educational and scientific purposes as a nonprofit and tax-exempt organization. All articles published in the Publication are subject to copyrights owned by the American Thoracic Society or other individual(s) or entity(ies). &lt;/P&gt;
&lt;P&gt;Reproduction of any article by any means without the express prior authorisation of the American Thoracic Society is prohibited. The statements and opinions expressed in the Publication only represent those of individual author(s) and do not reflect the policies or opinions of the American Thoracic Society. Statements and claims concerning the effectiveness, quality, or safety of the products or procedures advertised in the Publication are solely those of the advertiser and do not represent any endorsement or approval by the American Thoracic Society. The American Thoracic Society assumes no responsibility for the content of the Publication and expressly disclaims all liability for any damages arising out of use, reference to, or reliance on the contents of the Publication.&lt;/P&gt;
&lt;P&gt;Published 12 times a year.&lt;/P&gt;
&lt;P&gt;ISSN 1546-3222&lt;/P&gt;
&lt;P&gt;Access to full text is via subscription, with free access for non subscribers to abstracts from&amp;nbsp;2004 onwards.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>294567</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.immunisation.nhs.uk/files/protectingcareworkers.pdf]]&gt;</url>
    <title>Protecting health and social care workers from flu</title>
    <publicationDate>2004-08-25T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,VIRAL,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Information on immunising health and social care workers to reduce the spread of influenza in health and social care premises.]]&gt;</body>
  </document>
  <document>
    <id>89271</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/niceMedia/docs/2nd_smoke_summary_EB.pdf]]&gt;</url>
    <title>Public Health interventions for the prevention and reduction of exposure to second-hand smoke: a review of reviews Evidence briefing</title>
    <publicationDate>2005-06-10T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence (NICE)</publisher>
    <publicationType>BRIEFING</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This briefing (a review of reviews) aims to:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Identify all relevant systematic reviews, syntheses, meta-analyses and review-level papers on public health interventions relating to second-hand smoke (SHS) 
&lt;LI&gt;Review these papers and highlight 'what works' to prevent and reduce exposure to second-hand smoke (SHS) for all population groups, but with particular reference to to disadvantaged and vulnerable groups 
&lt;LI&gt;Highlight gaps in the evidence and provide recommendations for future research.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This briefing also draws out any findings that relate to inequalities in health and the cost effectiveness of interventions.&lt;/P&gt;
&lt;P&gt;This briefing is intended to inform policy and decision makers, NHS providers, public health physicians and other public health practitioners in the widest sense.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>37072</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.bhsoc.org/bhf_factfiles/jan_2003_factfile.doc]]&gt;</url>
    <title>Pulmonary Hypertension</title>
    <publicationDate></publicationDate>
    <publisher>British Hypertension Society (BHS)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PULMONARY HYPERTENSION,MISCELLANEOUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This factfile is produced by the British Hypertension Society (BHS). The document is aimed at clinicians and includes the following information: 
&lt;UL&gt;
&lt;LI&gt;introduction 
&lt;LI&gt;causes of pulmonary hypertension 
&lt;LI&gt;when to suspect pulmonary hypertension 
&lt;LI&gt;treatment of pulmonary hypertension 
&lt;LI&gt;national speciliast centres 
&lt;LI&gt;references&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This Pulmonary Hypertension factfile was published in January 2003. 
&lt;P&gt;&lt;A href="http://www.bhsoc.org/publications_leaflets.stm" target="_blank"&gt;Click here to view the full list of BHS factfiles&lt;/A&gt; 
&lt;P&gt;This resource has been included because it satisfies the BIOME evaluation criteria for quality. &lt;A href="http://www.intute.ac.uk/healthandlifesciences/policy.html" target="_blank"&gt;Click here to see the full BIOME guidelines&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6094</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/622936/description]]&gt;</url>
    <title>Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology)</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS),OCCUPATIONAL LUNG DISEASE,PUBLICATIONS,BRONCHITIS - ACUTE,JOURNALS,ICU,INFECTIONS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Concerned with lung pharmacology from molecular to clinical aspects.&lt;BR&gt;Encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphesyma and drug delivery. Publishes original research papers, including studies related to chemotherapy of cancer, tuberculosis and infection, review articles and book reviews. &lt;/P&gt;
&lt;P&gt;ISSN: 1094-5539&lt;/P&gt;
&lt;P&gt;Published 6 times a year. &lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>187251</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187251]]&gt;</url>
    <title>Pulmonary rehabilitation for COPD</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,THERAPEUTIC INTERVENTION,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Pulmonary rehabilitation for COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr Mike Morgan, Consultant Physician in Respiratory Medicine &lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13-17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;In many patients with COPD the progressive decline in lung function will eventually result in significant disability. Once they reach this point, the damage to the lungs may not be easily reversible and the therapeutic options are limited. However, disability in COPD may be accompanied by some wider systemic features and behavioural characteristics that can be improved by a process of rehabilitation. The principles of rehabilitation for lung disease are similar to those for any chronic disabling condition and include the application of physical training, disease education and psychosocial support. These methods have been demonstrated to provide clear improvements in health status, exercise performance and dyspnoea. It is also becoming evident that pulmonary rehabilitation may have a health economic effect by reducing the frequency or duration of hospital admissions and may even improve survival. Unfortunately the lack of provision in the United Kingdom means that rehabilitation is not available for most patients. The recent announcement of a forthcoming National Service Framework for COPD will hopefully correct this anomaly.&lt;/P&gt;
&lt;P&gt;The scientific literature supporting the value of pulmonary rehabilitation is growing rapidly. Early studies were thought to be disappointing because they did not improve lung function. However, there is now widespread realisation that lung function is an inappropriate outcome measure. As a result pulmonary rehabilitation is now seen as an integral part of the management of people with advanced COPD and is reflected in the advice given in all the recent guidelines including NICE and the joint European Respiratory and American Thoracic Society COPD Statements&lt;A href="#refs"&gt;[1,2]&lt;/A&gt;. Aspects of pulmonary rehabilitation have also been the subject of Cochrane and other systematic reviews&lt;A href="#refs"&gt;[3,4]&lt;/A&gt;. More recently there has been the publication of the joint ERS/ATS statement on pulmonary rehabilitation that sets out recommendations for best practice&lt;A href="#refs"&gt;[5]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The current literature supports the practice of effective pulmonary rehabilitation in a number of different settings. Hospital outpatient rehabilitation is the most popular form but inpatient, community or home-based programmes have also been successful. Individually prescribed, supervised, physical exercise training is the cornerstone of therapy and has to be present for success. This usually takes the form of predominant lower limb endurance and strength training in a group environment. The key massages for the delivery and conduct of pulmonary rehabilitation are:-&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Pulmonary rehabilitation forms part of the integrated care of people with chronic lung disease.&lt;/LI&gt;
&lt;LI&gt;Pulmonary rehabilitation programmes have proved successful in several health care settings. &lt;/LI&gt;
&lt;LI&gt;Rehabilitation programmes are delivered by a multi &amp;nbsp;disciplinary team&lt;/LI&gt;
&lt;LI&gt;Individually prescribed physical training is a mandatory component of the programme.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;There have been few direct comparisons of the setting or duration of a rehabilitation programme. &lt;/LI&gt;
&lt;LI&gt;The role of continuous maintenance rehabilitation is unclear but repeated programmes may confer some benefit. &lt;/LI&gt;
&lt;LI&gt;The professional delivery of a rehabilitation programme requires attention to audit, safety and quality control. &lt;/LI&gt;
&lt;LI&gt;Common standards will be needed to ensure uniform quality of provision.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;The recommendation from the NICE guidelines, pressure from patient organisations and the impending national Service framework will mean that capacity for pulmonary rehabilitation will have to improve. It is like that this will occur in community settings in order to meet the demand.&lt;BR&gt;&amp;nbsp;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.] &lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 Suppl 1:1-232. &lt;A href="http://www.nice.org.uk/page.aspx?text-size=8&amp;amp;o=cg012" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946. &lt;A href="http://www.ersnet.org/ers/lr/browse/viewPDF.aspx?id_attach=7553" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;
&lt;LI&gt;Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(3):CD003793. &lt;A href="http://dx.doi.org/10.1002/14651858.CD003793.pub2" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(1):19-38. &lt;A href="http://ajrccm.atsjournals.org/cgi/data/172/1/19/DC1/1" target="_blank"&gt;[FULL TEXT]&lt;/A&gt; (PDF)&lt;/LI&gt;
&lt;LI&gt;Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173(12):1390-1413. &lt;A href="http://www.ersnet.org/ers/lr/browse/viewPDF.aspx?id_attach=14674" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;Other Resources:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=187892&amp;amp;tabID=288" target="_blank"&gt;Commissioning guide : pulmonary rehabilitation service for patients with COPD&lt;/A&gt;&amp;nbsp;NICE, October 2006.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79830&amp;amp;tabID=290" target="_blank"&gt;Chronic obstructive airways disease&lt;/A&gt;&amp;nbsp;BMJ Topic Collection, August 1997 - 28 October 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=113584&amp;amp;tabID=289" target="_blank"&gt;Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190158&amp;amp;tabID=289" target="_blank"&gt;Pulmonary rehabilitation for chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006. Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=143963&amp;amp;tabID=289" target="_blank"&gt;The management of chronic obstructive pulmonary disease (COPD)&lt;/A&gt;&amp;nbsp;MeReC Bulletin 2006, Vol. 16, No. 5.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>126843</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ncchta.org/project/1040.asp]]&gt;</url>
    <title>Quality-of-Life Measures in Chronic Diseases of Childhood</title>
    <publicationDate></publicationDate>
    <publisher>NHS Health Technology Assessment Programme</publisher>
    <publicationType>RESEARCH STUDY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,ASTHMA,HTA,PROGRAMME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The HTA Programme conducts research into the costs, effectiveness and impact of health technologies.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Published in Health Technology Assessment 2001; Vol. 5: No. 4 
&lt;P&gt;&lt;STRONG&gt;Executive summary (abridged): &lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives of the study:&lt;/STRONG&gt; 
&lt;UL&gt;
&lt;LI&gt;to review the state of the art with regard to measurement of QoL for children 
&lt;LI&gt;to make recommendations regarding the value of currently available measures for different purposes 
&lt;LI&gt;to identify further research needs&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; 
&lt;UL&gt;
&lt;LI&gt;three studies were identified where adult measures were used with very few changes made for children. In 11 studies involving nine separate measures of QoL, adult measures were used as a model for work with children 
&lt;LI&gt;adult measures may fail to tap the specific aspects of QoL that are important to the child. More basic research is needed to determine the level of response burden that children of different ages can manage. Assessments of difficulty (e.g. reading age) need to be routinely included with information about new measures 
&lt;LI&gt;there was some evidence for greater concordance between child and parent for physical functioning compared with social and emotional domains, but greater heterogeneity in the latter measures may contribute to inconsistent results&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>187062</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/ClinicalInformation/RareLungDiseasesBOLD/tabid/110/Default.aspx]]&gt;</url>
    <title>Rare Lung Diseases (BOLD)</title>
    <publicationDate></publicationDate>
    <publisher>British Thoracic Society (BTS)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ALVEOLAR PROTEINOSIS,PRIMARY CILIARY DYSKINESIA,PULMONARY HYPERTENSION,CHRONIC SUPPURATIVE DISEASES,IMMUNOLOGICALLY BASED DISORDERS,MISCELLANEOUS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Rare lung diseases are often described as "orphan" diseases because patients are less well treated than those with common conditions. &lt;/P&gt;
&lt;P&gt;The British Orphan Lung Disease (BOLD) Register was set up in January 2000 and is a database of patients suffering with such rare diseases. The project's main aims are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;To facilitate research into rare lung disease 
&lt;LI&gt;To improve clinicians' knowledge of rare lung diseases 
&lt;LI&gt;To help patients establish self help groups&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>6019</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.sciencedirect.com/science/journal/15699048]]&gt;</url>
    <title>Respiration Physiology and Neurobiology</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,RESPIRATORY FAILURE - ACUTE,RESPIRATORY FAILURE - CHRONIC,JOURNALS,ICU]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Formerly known as Respiration Physiology</description>
    <body>&lt;![CDATA[ &lt;P&gt;Respiratory Physiology &amp;amp; Neurobiology publishes original articles and invited reviews concerning the field of respiration in its broadest sense. Although a special focus is on topics in neurobiology, high quality papers in respiratory molecular and cellular biology are also welcome, as are high quality papers in traditional areas, such as mechanics of breathing; gas exchange in lungs, gills, skin, and tissues; acid-base balance; respiration at rest and exercise; respiration in normal and unusual conditions, like high or low pressure or changes of temperature, low ambient oxygen; embryonic and adult respiration; comparative respiratory physiology. Papers on clinical aspects, articles on original methods, as well as theoretical papers are also considered as long as they foster the understanding of respiratory physiology. 
&lt;P&gt;ISSN: 1569-9048&lt;BR&gt;Published 15 times a year. 
&lt;P&gt;Access to full text is via subscription, non-subsribers can access tables of contents plus additional features. 
&lt;P&gt;&lt;BR&gt;&amp;nbsp; 
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6102</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&amp;ProduktNr=224278]]&gt;</url>
    <title>Respiration: International Review of Thoracic Diseases</title>
    <publicationDate></publicationDate>
    <publisher>Karger Publishers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,JOURNALS,DIAGNOSIS AND MONITORING,IMMUNOLOGICALLY BASED DISORDERS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Journal of the European Association for Bronchology and Interventional Pulmonology.&lt;/P&gt;
&lt;P&gt;Peer reviewed journal covering clinical improvements in the diagnosis and treatment of chest and lung diseases, the latest findings in physiology, biochemistry, pathology, immunology and pharmacology.&lt;/P&gt;
&lt;P&gt;Publishing results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease, along with editorials, case reports and letters to the editor. &lt;/P&gt;
&lt;P&gt;ISSN: 1423-0356&lt;BR&gt;Published 6 times a year 
&lt;P&gt;Online access to full text, January 1998 (Volume 65, 1) onwards, is via subscription, with free access for non subscribers to tables of contents and abstracts some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6109</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/623069/description#description]]&gt;</url>
    <title>Respiratory Medicine</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,OCCUPATIONAL LUNG DISEASE,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An international forum for new information of relevance to practitioners in the field of respiratory disease.&lt;/P&gt;
&lt;P&gt;Publishes peer reviewed original papers on the physiology, pathology, immunology, genetics and epidemiology of respiratory disease and therapeutic interventions.&lt;/P&gt;
&lt;P&gt;Includes editorials and topical reviews geared towards both higher training and continuous medical education courses. &lt;/P&gt;
&lt;P&gt;ISSN: 0954-6111&lt;BR&gt;Published 12 times a year. 
&lt;P&gt;Online access to full text is available to subscribers from June 1999 (Volume 93, 6) onwards on ScienceDirect:&lt;BR&gt;&lt;A href="http://www.elsevierhealth.com/product.jsp?isbn=09546111" target="_blank"&gt;http://www.elsevierhealth.com/product.jsp?isbn=09546111&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;Information about the journal can be freely accessed by non-subscribers through the journal homepage.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6010</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://respiratory-research.com/]]&gt;</url>
    <title>Respiratory Research</title>
    <publicationDate></publicationDate>
    <publisher>Biomed Central</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,CYSTIC FIBROSIS,IMMUNODEFICIENCIES AND THE LUNG,LUNG CANCER,MALIGNANT DISEASE,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS,CHRONIC SUPPURATIVE DISEASES,IMMUNOLOGICALLY BASED DISORDERS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>Open Access Journal</description>
    <body>&lt;![CDATA[ &lt;P&gt;Respiratory Research will accept original papers on all aspects of respiratory function and disease. We welcome studies of asthma; chronic obstructive pulmonary disease; cystic fibrosis; genetics; infectious diseases; interstitial lung diseases; lung development; lung tumors; occupational and environmental factors; pulmonary circulation; pulmonary pharmacology and therapeutics; respiratory critical care; respiratory immunology; respiratory physiology; and sleep. The journal also publishes state-of-the-art reviews on topics related to this research. These articles are usually commissioned, but suggestions (in the form of a brief summary and an outline with section headings) are welcome and should be sent to the Editorial Office. 
&lt;P&gt;ISSN: 1465-9921 
&lt;P&gt;Open access to all articles from June 2000 onwards.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>112993</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/AvianInfluenza/Guidelines/influaAvianInfluenzaGuidanceandAlgorithms/]]&gt;</url>
    <title>Revised Avian Influenza Guidance and Algorithms</title>
    <publicationDate></publicationDate>
    <publisher>Health Protection Agency (HPA)</publisher>
    <publicationType>SERVICE GUIDANCE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,VIRAL,GUIDELINES,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The revised&amp;nbsp;algorithms aim to assist in&amp;nbsp;the management of:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;
&lt;DIV&gt;suspected or confirmed human cases of avian influenza&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;contacts of confirmed human cases&lt;/DIV&gt;
&lt;LI&gt;
&lt;DIV&gt;people exposed to birds where avian influenza is suspected or confirmed.&lt;/DIV&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P dir=ltr style="MARGIN-RIGHT: 0px"&gt;Occupational guidance is also provided for those involved in the response to an avian influenza incident.&lt;/P&gt;
&lt;P class=added-updated&gt;Last reviewed: 21 January 2009&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>325784</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/rhinosinusitis_final.pdf]]&gt;</url>
    <title>Rhinosinusitis</title>
    <publicationDate>2008-09-07T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SINUSITIS,IMMUNOLOGICALLY BASED DISORDERS,INFECTIONS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the GPIAG, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;This opinion sheet details the diagnosis, treatment and management of Rhinosinusitis &lt;/P&gt;
&lt;P&gt;Opinion Sheets on other related topics are available from the GPIAG website &lt;BR&gt;&lt;A href="http://www.gpiag.org/pubs/opinionsheets.php" target="_blank"&gt;http://www.gpiag.org/pubs/opinionsheets.php&lt;/A&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187258</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187258]]&gt;</url>
    <title>Role of Pharmacist in patients with Chronic Obstructive Pulmonary Disease (COPD)</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ STAFF USE,RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Role of the pharmacist in management of COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Anna Murphy, Consultant Respiratory Pharmacist&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;&lt;BR&gt;
&lt;P&gt;Pharmacists specialise in the area of drugs and medicine. They work in a variety of settings, usually beginning their career in an NHS hospital or community pharmacy. Increasingly, there is a wealth of pharmacy expertise in PCTs, including PCT medicines management and prescribing teams. The pharmacist already has a fundamental role in the on-going management and support of patients with Chronic Obstructive Pulmonary Disease (COPD). It has been well documented that patients with chronic long standing diseases, or their carers, see their community pharmacist more often than their General Practitioner (GP) whether it be to simply collect a prescription or to seek advice.&lt;A href="#refs"&gt;[1]&lt;/A&gt; Hospital pharmacists have a role in ensuring patients are discharged on appropriate safe medicines and that communication about patients’ medicines across the interface to colleagues in nursing homes or primary care is effective. &lt;/P&gt;
&lt;P&gt;There are a number of key areas where the pharmacist can advance the care of patients with COPD:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;By the time COPD is diagnosed, many patients will already have noticed the effect of the disease on their daily routine.&lt;A href="#refs"&gt;[2]&lt;/A&gt; Community pharmacists can significantly improve the level of COPD diagnosis through positive intervention. They are ideally placed to identify customers with mild to moderate COPD whose breathing is laboured and who constantly purchase over the counter (OTC) cough medicines to treat their “smokers cough” or collect prescriptions for repeated courses of antibiotics. Similarly, the alert pharmacist will recognise the long-term diagnosed asthmatic collecting repeat prescriptions, but constantly complaining that the treatment has little beneficial effect. Early identification of these patients may facilitate appropriate disease management and lifestyle changes, such as smoking cessation and exercise, before the end stage of the illness when disability is substantial.&lt;A href="#refs"&gt;[2,3]&lt;/A&gt; &lt;/LI&gt;
&lt;LI&gt;Health education is stressed in the NICE COPD guidelines&lt;A href="#refs"&gt;[2]&lt;/A&gt; as an&amp;nbsp;important factor in the outcome of COPD in all stages of the disease.&amp;nbsp; A lack of understanding of their condition is likely to adversely affect disease management and this may result in poorer quality of life.&amp;nbsp; Education of patients should be honest and should involve the patient’s carers and family, if he or she concurs.&amp;nbsp; Most community pharmacists are aware of the patient’s family background and social circumstances and can use this knowledge to provide relevant personal care and education. &lt;/LI&gt;
&lt;LI&gt;Pharmacists have another role and that is in helping to prevent this chronic disease from happening in the first place through health promotion. The pharmacist’s role in health promotion is not new; they have been active in this area for many years. Stopping smoking is the most important factor in reducing lung function decline and the single most important way of affecting outcome of all stages of COPD.&lt;A href="#refs"&gt;[4,5,6]&lt;/A&gt;&amp;nbsp; Advice from a healthcare professional has been shown to be a strong motivational factor in helping an individual to stop. It should be offered at every opportunity.&amp;nbsp; The pharmacist is often the first port of call for those wishing to stop smoking and has a key role in providing advice as well as providing replacement therapy.&lt;A href="#refs"&gt;[4,7]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Medication is not curative of COPD.&lt;A href="#refs"&gt;[2]&lt;/A&gt; If a treatment has no impact on the patient’s symptoms or exercise tolerance the patient should be referred back to their GP for assessment.&amp;nbsp; Through clinical medication reviews, pharmacists can identify problems that patients are having in taking their medicines and help resolve them before they become more serious, preventing unnecessary hospital admissions. The pharmacist can ensure that patients are receiving the appropriate level of pharmacological intervention for their disease severity and guarantee the patient’s medication is reviewed frequently.&lt;A href="#refs"&gt;[2,8]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;The choice of inhaler device should be individualised to ensure its acceptability to the patient and its effectiveness in practice. It is important to ensure that the patient is able to manipulate the device. Patients often require reinforcement of technique by repeated advice and encouragement.&lt;A href="#refs"&gt;[9,10]&lt;/A&gt;&amp;nbsp; The community pharmacist can provide this support when the patient collects their inhaler device from the pharmacy.&lt;/LI&gt;
&lt;LI&gt;Over the next few years other new drugs may reach the UK market.&amp;nbsp; It will be necessary for pharmacists to work with their local GP practice / hospital to ensure that appropriate patients are prescribed these new therapies, outcomes are monitored and patients are educated on how and when to use them.&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Identifying patients with early stages of COPD, reducing the risk factors for developing COPD, such as smoking cessation, and managing the disease are key roles for the pharmacist in the pharmaceutical care of the COPD patient. As our understanding of COPD changes, there are opportunities for collaboration between those caring for patients with the disease. It might, for instance, mean that the pharmacist is involved more formally in diagnosis, inhaler device selection and technique teaching and long-term monitoring of lung function.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible&amp;nbsp;links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Department of Health. Chronic Disease Management: A compendium of information. May 2004.&lt;/LI&gt;
&lt;LI&gt;National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease. Clinical Guideline No. 12, 2004. &lt;A href="http://www.nice.org.uk/page.aspx?o=cg012" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;National Collaborating Centre for Chronic Conditions. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1):1–232.&lt;/LI&gt;
&lt;LI&gt;Van der Meer RM, Wagena EJ, Ostelo RWJG, et al. Smoking cessation for chronic obstructive pulmonary disease. In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley &amp;amp; Sons, Ltd. 2002 &lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=189483&amp;amp;tabID=289" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality. A randomized clinical trial. Ann Intern Med 2005;142:233–9&lt;/LI&gt;
&lt;LI&gt;Fletcher C, Peto R. The national history of chronic airflow obstruction. Br Med J (1997); 1:1645-1648.&lt;/LI&gt;
&lt;LI&gt;National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NTR) and bupropion for smoking cessation. Technology Appraisal No 39; March 2002. &lt;A href="http://guidance.nice.org.uk/download.aspx?o=TA039guidance&amp;amp;template=download.aspx" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Kerstjens H, Pstma D, ten Hacken N. Chronic obstructive pulmonary disease. In: Barton S, editor. Clinical Evidence, Issue 14. London. BMJ Publishing Group 2005. &lt;/LI&gt;
&lt;LI&gt;Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technology Assessment 2001;5(26). &lt;A href="http://www.hta.nhsweb.nhs.uk/execsumm/summ526.htm" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Wright J (2001). Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. The Research Findings Register. Summary number 630. &lt;A href="http://www.refer.nhs.uk/ViewRecord.asp?id=630" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;STRONG&gt;Other Resources:&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=29879&amp;amp;tabID=288" target="_blank"&gt;Practice guidance on the care of people with asthma and COPD (Chronic Obstructive Pulmonary Disease)&lt;/A&gt; Royal Pharmaceutical Society, July 2006.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>66448</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4101474]]&gt;</url>
    <title>Secondhand smoke: Review of evidence since 1998</title>
    <publicationDate>2004-11-16T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P align=left&gt;In 1998, the Scientific Committee on Tobacco and Health (SCOTH) issued a report which concluded that exposure to secondhand tobacco smoke causes lung cancer and heart disease in adult non-smokers and a variety of conditions including respiratory disease, cot death and middle ear disease in children. 
&lt;P align=left&gt;This report is an update of evidence on health effects of secondhand smoke since 1998.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6017</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme-connect.com/ejournals/toc/srccm]]&gt;</url>
    <title>Seminars in Respiratory and Critical Care Medicine</title>
    <publicationDate></publicationDate>
    <publisher>Thieme Medical Publishers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,FUNGAL,PUBLICATIONS,JOURNALS,ICU,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ 1&lt;/FIRSTPAGE&gt;&lt;FIRSTPAGEID&gt;1&lt;/FIRSTPAGEID&gt;&lt;PAGE&gt;&lt;PAGEID&gt;1&lt;/PAGEID&gt;&lt;PAGESEQUENCE&gt;-1&lt;/PAGESEQUENCE&gt;&lt;PAGETITLE&gt;&lt;/PAGETITLE&gt;&lt;PAGEBODY&gt;&lt;P&gt;A clinician's resource for developments in pulmonology, immunology, critical care medicine, and related disciplines. Guest edited by leading experts, each issue features a range of carefully selected articles on a single current topic, providing an in-depth seminar in that area. From new diagnostic and therapeutic procedures to laboratory studies, genetic breakthroughs, pathology, clinical features and management techniques, this journal covers the field in the depth clinicians need. 
&lt;P&gt;ISSN: 1069-3424&lt;BR&gt;Published 6 times a year. 
&lt;P&gt;Access to full text from the Journal homepage is via subscription, non-subsribers can access tables of contents plus additional features. 
&lt;P&gt;Selected key articles from Seminars in Respiratory and Critical Care Medicine (one to two per issue) can be freely accessed via Medscape &lt;A href="http://www.medscape.com/viewpublication/144_index" target="_blank"&gt;http://www.medscape.com/viewpublication/144_index&lt;/A&gt;.&lt;/P&gt;&lt;/PAGEBODY&gt;&lt;/PAGE&gt;&lt;/ARTICLE&gt;]]&gt;</body>
  </document>
  <document>
    <id>6111</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme.com/SID2411716234792/journals/pubid1393790216.html]]&gt;</url>
    <title>Seminars in Respiratory Infections</title>
    <publicationDate></publicationDate>
    <publisher>Thieme Medical Publishers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,OCCUPATIONAL LUNG DISEASE,MALIGNANT DISEASE,IMAGING,FUNGAL,LUNG CANCER,PUBLICATIONS,ASTHMA,JOURNALS,BACTERIAL,ALLERGY,THERAPEUTIC INTERVENTION,INFECTIONS,IMMUNOLOGICALLY BASED DISORDERS,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A review journal to provide in-depth coverage of topics related to respiratory infections.&lt;/P&gt;
&lt;P&gt;Each issue deals with one specific type of infection relative to pulmonary or chest disorders. The goal is to provide all necessary information on a given subject that a practitioner might need to care for patients with respiratory-related diseases. &lt;/P&gt;
&lt;P&gt;ISSN: 0882-0546&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text is via subscription, with free access for non subscribers to tables of contents and abstracts some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6117</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/623190/description#description]]&gt;</url>
    <title>Seminars in Thoracic and Cardiovascular Surgery</title>
    <publicationDate></publicationDate>
    <publisher>WB Saunders</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,JOURNALS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Aims to keep the practicing surgeon current.&lt;/P&gt;
&lt;P&gt;Each issue includes two topics, one on cardiac surgery and one on general thoracic surgery. Each topic is explored in approximately five articles that present descriptions and evaluations of developments in diagnosis and treatment, new techniques, and scientific and technologic advances. &lt;/P&gt;
&lt;P&gt;ISSN: 1532-9488&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text starts with 2003 and is complimentary for a limited time, after which access will be via subscription, with free access for non subscribers to tables of contents and abstracts from 1998 onwards.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187255</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187255]]&gt;</url>
    <title>Setting Standards for the Delivery of Integrated Respiratory Care (S-DIRC)</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;Setting Standards for the Delivery of Integrated Respiratory Care (S-DIRC)&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr Tony Davison and Dr Dermot Ryan&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 -&amp;nbsp;17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;BTS GPIAG working party – Setting Standards for the Delivery of Integrated Respiratory Care (S-DIRC)&lt;/P&gt;
&lt;P&gt;Following a series of meetings between the two organisations representing clinicians providing respiratory care in the UK a working party has been set up under the co-chairmanship of Dr Tony Davison, representing the BTS (&lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;www.brit-thoracic.org.uk&lt;/A&gt;) and Dr Dermot Ryan, representing the GPIAG (&lt;A href="http://www.gpiag.org/" target="_blank"&gt;www.gpiag.org&lt;/A&gt;). The initial focus will be on COPD but other areas will also be examined, such as asthma.&lt;/P&gt;
&lt;P&gt;The full terms of reference of the group are currently evolving but the broad principles are to propose how to optimise the provision of clinical services within the NHS commissioning environment, suggesting solutions to the complex problems which are bewildering both clinicians and managers, commissioners and providers.&lt;/P&gt;
&lt;P&gt;It is recognised that there has been much money pumped into the NHS but this has not been used in the most effective manner. It should be possible to identify areas of inefficiency and redesign services in such a manner that the patient receives the right care from the right person at the right time.&lt;/P&gt;
&lt;P&gt;Changes to the NHS bring new opportunities.&amp;nbsp; However they also bring the possibility of a wedge being driven between primary and secondary care. This could dislocate services and make for discontinuity and fragmentation for patients. By forming collaborative local respiratory networks primary and secondary care clinicians should be able to examine pathways for patient flows and work together with commissioners and patients to improve them. This could apply to outpatient visits, specialist diagnostics, inpatient care, home care and palliative care. &lt;/P&gt;
&lt;P&gt;Hospitalisations for COPD are both common and costly: not only financially but in terms of patient suffering. Care pathways which avert unnecessary admissions, focus admissions to specialist units and facilitate early discharge to community teams that are skilled to deal with them are some of the aspects that need to be examined.&lt;/P&gt;
&lt;P&gt;It is also hoped that this group will come up with a tool-kit which will both aid understanding of the commissioning and provider split, using familiar language and suggest solutions which may inform implementation by providing examples of what is already being achieved currently. &lt;/P&gt;
&lt;P&gt;What is known, is that improving one process without looking at its impact on the whole healthcare system may make things worse overall.&amp;nbsp; Thus improvement models need to look at systems, and in particular at the people who work in those systems.&amp;nbsp; Patients with the same disease may have differing needs; by working collaboratively across traditional boundaries, it should be possible to meet these. It should also be possible to seek patients’ views about their needs in terms of helping them to help themselves and on service delivery design. &lt;/P&gt;
&lt;P&gt;The BTS/GPIAG working party believes it is possible to build a robust standard of integrated care for the future that will improve the care of patients with respiratory disease.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;For more information:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="https://rmsadmin.nelh.nhs.uk/admin/wizards/articles/www.brit-thoracic.org.uk" target="_blank"&gt;British Thoracic Society (BTS)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="https://rmsadmin.nelh.nhs.uk/admin/wizards/articles/www.gpiag.org" target="_blank"&gt;General Practice in Airways Group (GPIAG)&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/A&gt;&amp;nbsp;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>282575</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.journalsleep.org/]]&gt;</url>
    <title>SLEEP</title>
    <publicationDate></publicationDate>
    <publisher>Associated Professional Sleep Societies</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The journal &lt;I&gt;SLEEP&lt;/I&gt; is the official publication of the Associated Professional Sleep Societies, LLC (APSS) a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. Primary readers are scientists engaged in the study of sleep and its disorders, and clinicians practicing sleep disorders medicine. &lt;/P&gt;
&lt;P&gt;This journal is published monthly and access is available via subscription. Archives older than 6 months old back to June 2007 are available freely via PubMed Central.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6099</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thieme-connect.com/ejournals/toc/sbr]]&gt;</url>
    <title>Sleep and Breathing</title>
    <publicationDate></publicationDate>
    <publisher>Thieme Medical Publishers</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,OBSTRUCTIVE SLEEP APNOEA,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Concerned with&amp;nbsp;topics related to the diagnosis and treatment of sleep disordered breathing, including upper airway resistance syndrome and sleep apnea.&lt;/P&gt;
&lt;P&gt;Publishes peer reviewed original reports on physiologic or clinical observations, case reports, outcome studies and studies of patient satisfaction.&lt;/P&gt;
&lt;P&gt;Additional features include editorials, summaries of research from other publications in the field, a calendar listing key meetings, as well as news from the societies that sponsor the journal. &lt;/P&gt;
&lt;P&gt;ISSN: 1522-1709&lt;BR&gt;Published 4 times a year. 
&lt;P&gt;Online access to full text, from 1999 (Volume 3, 1) onwards, is via subscription, with free access for non subscribers to tables of contents and abstracts some full text articles plus additional features.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79858</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/collection/sleep_disorders3]]&gt;</url>
    <title>Sleep disorders</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SLEEP DISORDERED BREATHING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since March 1994 relevant to sleep disorders.&lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6118</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/620282/description#description]]&gt;</url>
    <title>Sleep Medicine</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;International and multidisciplinary in scope. The journal aims to bridge the gap between basic sleep research and clinical relevance.&lt;/P&gt;
&lt;P&gt;Publishes original research, reviews, controversies, letters to the editor, case reports, and brief commentaries on recently published sleep articles in different journals. &lt;/P&gt;
&lt;P&gt;ISSN: 1389-9457&lt;BR&gt;Published 6 times a year. 
&lt;P&gt;Online access to full text is available to subscribers from February 2000 (Volume 1, 1) onwards on ScienceDirect:&lt;BR&gt;&lt;A href="http://www.elsevier.com/wps/find/journaldescription.cws_home/620282/description#description" target="_blank"&gt;http://www.elsevier.com/wps/find/journaldescription.cws_home/620282/description#description&lt;/A&gt;&lt;BR&gt;Information about the journal can be freely accessed by non-subscribers through the journal homepage.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6114</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/623074/description#description]]&gt;</url>
    <title>Sleep Medicine Reviews</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,SLEEP DISORDERED BREATHING,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Provides international coverage of sleep disorders, their aetiology, diagnosis, treatment and implications for related conditions at an individual and public health level. &lt;/P&gt;
&lt;P&gt;Reviews clinical information published in multidisciplinary peer-reviewed journals in sleep medicine and publishes narrative reviews, systematic reviews and editorials covering area of controversy and debate, as well as areas of future research. &lt;/P&gt;
&lt;P&gt;ISSN: 1087-0792&lt;BR&gt;Published 6 times a year. 
&lt;P&gt;Online access to full text is available to subscribers from December 1999 (Volume 3, 4) onwards on ScienceDirect:&lt;BR&gt;&lt;A href="http://www.sciencedirect.com/science/journal/10870792" target="_blank"&gt;http://www.sciencedirect.com/science/journal/10870792&lt;/A&gt;&lt;BR&gt;Information about the journal can be freely accessed by non-subscribers through the journal homepage.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>261616</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_074970]]&gt;</url>
    <title>Smokefree and smiling: helping dental patients to quit tobacco</title>
    <publicationDate>2007-05-25T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,PUBLICATIONS,SMOKING,GUIDELINES,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Guidance to general dental practitioners on the contribution that dental teams can make to smoking cessation.]]&gt;</body>
  </document>
  <document>
    <id>289429</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085815]]&gt;</url>
    <title>Smoke-free bars 07</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,OCCUPATIONAL LUNG DISEASE,PUBLICATIONS,SMOKING,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=introText&gt;A report to the Department of Health on preliminary findings relating to air quality in English bars before and after implementation of smokefree legislation. &lt;BR&gt;&lt;BR&gt;This collaborative study by the University of Aberdeen, the Institute of Occupational Medicine, and Liverpool John Moore’s University examines changes in bar workers’ and customers’ exposure to second-hand smoke, health and attitudes.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>289427</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_085811]]&gt;</url>
    <title>Smokefree England - one year on</title>
    <publicationDate>2008-07-01T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ DRUG USE DISORDERS,PUBLICATIONS,OCCUPATIONAL LUNG DISEASE,SMOKING,MENTAL HEALTH,ADULT CONDITIONS,DETERMINANTS,POLICY,RESPIRATORY,PUBLIC HEALTH,REPORTS,MANAGEMENT &amp; INTERVENTIONS,INDIVIDUAL BEHAVIOUR,TOBACCO USE,SMOKING,GOVERNMENT &amp; LAW,LAW,MANAGEMENT &amp; POLICY,MONTHLY ADDITIONS,2008-JULY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ A report examining the impact of the smokefree law, one year on since it was introduced in England on 1 July 2007. &lt;BR&gt;&lt;BR&gt;Research amongst businesses and consumers clearly suggests that the nation has quickly adapted to, is benefiting from, and is showing growing support for the smokefree law in England.]]&gt;</body>
  </document>
  <document>
    <id>79862</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://bmj.bmjjournals.com/cgi/collection/smoking]]&gt;</url>
    <title>Smoking</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ SMOKING,JOURNALS,PUBLICATIONS,OUTCOMES,LUNG CANCER,CANCER,RESPIRATORY DISORDERS,RESPIRATORY,PUBLIC HEALTH,DETERMINANTS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,ANALYSIS &amp; RESEARCH]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since January 1994 relevant to smoking. &lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>236082</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.nice.org.uk/nicemedia/pdf/Smoking_and_public_health_V6.pdf]]&gt;</url>
    <title>Smoking and public health: a compendium of smoking behaviour initiatives that address socially disadvantaged populations</title>
    <publicationDate>2007-01-19T00:00:00</publicationDate>
    <publisher>National Institute for Clinical Excellence (NICE)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ SMOKING,EDUCATION,EDUCATION,SKILLS,EMPLOYMENT,UNEMPLOYMENT,DISADVANTAGED GROUPS,ETHNIC GROUPS,SMOKING CESSATION,POPULATION BASED &amp; PREVENTATIVE SERVICES,POLICY,RESPIRATORY,DETERMINANTS,PUBLIC HEALTH,MANAGEMENT &amp; INTERVENTIONS,LIFESTYLE,SOCIAL DETERMINANTS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,HEALTH SERVICES,SERVICES,PUBLIC SERVICES,MANAGEMENT &amp; POLICY,HEALTHCARE &amp; HEALTH SERVICES,GOVERNMENT &amp; LAW,POPULATIONS,ANALYSIS &amp; RESEARCH,GROUPS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The aim of this compendium is to identify a wide range of material that might contribute to the development, design, implementation and impact of future initiatives on smoking behaviour in a broad range of socially disadvantaged population groups.&lt;/P&gt;
&lt;P&gt;Specifically, this compendium aims to: &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;identify smoking behaviour initiatives that focus on socially disadvantaged populations 
&lt;LI&gt;incorporate evidence from as wide a range of published sources as possible (eg from randomised controlled trials [RCTs] through to qualitative studies and expert opinion pieces) 
&lt;LI&gt;highlight cost-effectiveness data, conflicting findings, gaps in the findings and provide a steer for commissioning further research to address these issues. &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>312755</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/smokingcessation_final.pdf]]&gt;</url>
    <title>Smoking cessation</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SMOKING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It provides infromation about the identification of smokers, the implementation of smoking cessation programmes, motivating change in behaviour and pharmacology.&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet&amp;nbsp;No. 17.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>67041</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsStatistics/PublicationsStatisticsArticle/fs/en?CONTENT_ID=4050240&amp;chk=tAKMRJ]]&gt;</url>
    <title>Smoking-related behaviour and attitudes 2002</title>
    <publicationDate>2003-07-03T00:00:00</publicationDate>
    <publisher>Department of Health</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLICATIONS,SMOKING,RESPIRATORY,DETERMINANTS,REPORTS,PUBLIC HEALTH,PSYCHOLOGICAL DETERMINANTS,TOBACCO USE,SMOKING,INDIVIDUAL BEHAVIOUR,HEALTH BELIEFS,SOCIAL DETERMINANTS,LIFESTYLE,MANAGEMENT &amp; INTERVENTIONS,ANALYSIS,METHODS,NATIONAL,GEOGRAPHY,MANAGEMENT &amp; POLICY,INFORMATION,ANALYSIS &amp; RESEARCH,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report presents the results of a survey on smoking bevaviour and attitudes carried out in 2002. The survey is the latest in a series of surveys carried out as part of the ONS Omnibus Survey for the Department of Health. The surveys are designed to explore views on passive smoking, smoking restrictions and giving up smoking.]]&gt;</body>
  </document>
  <document>
    <id>93699</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/11/47/31/04114731.pdf]]&gt;</url>
    <title>Smoking-related behaviour and attitudes, 2004</title>
    <publicationDate>2005-07-07T00:00:00</publicationDate>
    <publisher>Office for National Statistics (ONS)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ PUBLICATIONS,SMOKING,RESPIRATORY,REPORTS,PUBLIC HEALTH,DETERMINANTS,MANAGEMENT &amp; INTERVENTIONS,SOCIAL DETERMINANTS,HEALTH BELIEFS,LIFESTYLE,INDIVIDUAL BEHAVIOUR,TOBACCO USE,PSYCHOLOGICAL DETERMINANTS,SMOKING,INFORMATION,MANAGEMENT &amp; POLICY,METHODS,ANALYSIS,NATIONAL,GEOGRAPHY,ANALYSIS &amp; RESEARCH,SETTINGS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report presents the results of a survey on smoking behaviour and attitudes.&lt;/P&gt;
&lt;P&gt;The survey was the eighth in a series of studies carried out for the Department of Health and was conducted in October and November 2004 as part of the ONS Omnibus Survey. Earlier surveys were carried out in November and December 1995, 1996 and 1997 and October and November 1999, 2000, 2001, 2002 and 2003.&lt;/P&gt;
&lt;P&gt;In addition to examining trends, the analysis also explores the relationship between various smoking-related attitudes and behaviour. The key topics examined and presented in this report include:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;smoking behaviour and habits 
&lt;LI&gt;views about giving up smoking 
&lt;LI&gt;attempts to stop smoking 
&lt;LI&gt;perceptions and awareness of issues related to smoking 
&lt;LI&gt;attitudes related to smoking 
&lt;LI&gt;smokers' response to their attitudes. &lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>124654</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/spirometry_revised_final_version_03.pdf]]&gt;</url>
    <title>Spirometry</title>
    <publicationDate>2004-09-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,LUNG FUNCTION TESTING,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;It details the different types of spirometry, how it is performed and how to interpret it.&lt;/P&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheet No. 1 (v2).&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>155090</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/COPD/COPD%20Consortium/spirometry_in_practice051.pdf]]&gt;</url>
    <title>Spirometry in Practice: A Practical Guide to Using Spirometry in Primary Care</title>
    <publicationDate>2005-04-01T00:00:00</publicationDate>
    <publisher>British Thoracic Society (BTS) COPD Consortium</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,LUNG FUNCTION TESTING,DIAGNOSIS AND MONITORING]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This booklet&amp;nbsp;has been produced as a working reference tool&amp;nbsp;to encourage the use of spirometry (incorporating recommendations on the use of spirometry in the NICE guideline in COPD). The booklet covers the following topics:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;providing information on how to perform spirometry 
&lt;LI&gt;explaining the interpretation of spirometry results 
&lt;LI&gt;giving practical examples and case studies 
&lt;LI&gt;explaining the importance of spirometry in the management of COPD 
&lt;LI&gt;using quotes from nurses which reveal their personal experiences of spirometry.&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>342400</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles/nhs-stop-smoking-services]]&gt;</url>
    <title>Statistics on NHS stop Smoking Services - Various years</title>
    <publicationDate></publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,SMOKING,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This page provides the statistics for various periods from May-2005 about the NHS stop smoking services.&lt;/P&gt; &lt;P&gt;These reports provide breakdown on the services based on &lt;/P&gt; &lt;UL&gt; &lt;LI&gt;gender&lt;/LI&gt; &lt;LI&gt;age&lt;/LI&gt; &lt;LI&gt;ethnicity&lt;/LI&gt; &lt;LI&gt;pregnancy&lt;/LI&gt; &lt;LI&gt;geographical areas&lt;/LI&gt;&lt;/UL&gt; &lt;P&gt;&lt;A href="http://www.ic.nhs.uk/" target="_blank"&gt;Click here &lt;/A&gt;to access the IC website&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>308751</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ic.nhs.uk/statistics-and-data-collections/health-and-lifestyles/nhs-stop-smoking-services]]&gt;</url>
    <title>Statistics on NHS Stop Smoking Services in England - various periods</title>
    <publicationDate></publicationDate>
    <publisher>The Information Centre for Health and Social Care</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,SMOKING,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Tahoma"&gt;The reports of Statistics on NHS Stop Smoking Services in England for various periods are available from&amp;nbsp;this page&amp;nbsp; in the &lt;A href="http://www.ic.nhs.uk/statistics-and-data-collections" target="_blank"&gt;Statistics &amp;amp; Data Collections &lt;/A&gt;page of The Information Centre for Health &amp;amp; Social Care web site.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Tahoma"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Tahoma"&gt;The Information Centre for Health &amp;amp; Social Care is England's central, authoritative source of health and social care information. They Act as a hub for high quality, national, comparative data for secondary uses and &lt;SPAN style="mso-spacerun: yes"&gt;&amp;nbsp;&lt;/SPAN&gt;deliver information for local decision makers to improve the quality and efficiency of frontline care.&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Tahoma"&gt;&lt;o:p&gt;&amp;nbsp;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P class=MsoNormal style="MARGIN: 0cm 0cm 0pt"&gt;&lt;SPAN style="FONT-SIZE: 9pt; FONT-FAMILY: Verdana; mso-bidi-font-family: Tahoma"&gt;&lt;A href="http://www.ic.nhs.uk/" target="_blank"&gt;The Information Centre for Health &amp;amp; Social Care &lt;/A&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>61357</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.dh.gov.uk/assetRoot/04/09/01/88/04090188.pdf]]&gt;</url>
    <title>Stopping tuberculosis in England: An action plan from the Chief Medical Officer</title>
    <publicationDate>2004-10-07T00:00:00</publicationDate>
    <publisher>Department of Health (DH)</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ PUBLICATIONS,OUTCOMES,TUBERCULOSIS,COMMUNICABLE DISEASES,RESPIRATORY,TUBERCULOSIS,REPORTS,PUBLIC HEALTH,MONTHLY ADDITIONS,2009 FEBRUARY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This action plan sets out steps which the Government, health services and local communities need to take to reverse the rise in Tuberculosis (TB).]]&gt;</body>
  </document>
  <document>
    <id>396901</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.thepcrj.org/journ/view_article.php?article_id=761]]&gt;</url>
    <title>Summary of the Consultation on a Strategy for Services for Chronic Obstructive Pulmonary Disease (COPD) in England</title>
    <publicationDate>2010-12-02T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Journal</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This supplement summarises the English Department of Health (DOH) COPD Strategy consultation document that was published in February 2010. It elucidates the practical implications of the DOH strategy and also summarises relevant information from the 2010 NICE Clinical Guideline on the management of COPD.]]&gt;</body>
  </document>
  <document>
    <id>313389</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.hpa.org.uk/webw/HPAweb&amp;Page&amp;HPAwebAutoListName/Page/1240732817665?p=1240732817665]]&gt;</url>
    <title>Swine Influenza [Pandemic (H1N1) 2009 influenza]</title>
    <publicationDate></publicationDate>
    <publisher>Health Protection Agency</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ INFECTIONS,RESPIRATORY,VIRAL,INFECTIONS,MICROORGANISM,RESPIRATORY INFECTIONS,INFLUENZA,INFLUENZA VIRUS,VIRUSES,INFECTIOUS DISEASES,SWINE INFLUENZA,APRIL 09]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;This webpage is published by the Health Protection Agency (HPA) providing information to general public and health professionals about Swine Influenza [Pandemic (H1N1)]. &lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;The &lt;B style="mso-bidi-font-weight: normal"&gt;&lt;A href="http://www.hpa.org.uk/" target="_blank"&gt;Health Protection Agency (HPA) &lt;/A&gt;&lt;/B&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;an independent &lt;/SPAN&gt;&lt;?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /&gt;&lt;st1:country-region&gt;&lt;st1:place&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt;UK&lt;/SPAN&gt;&lt;/st1:place&gt;&lt;/st1:country-region&gt;&lt;SPAN style="mso-ansi-language: EN" lang=EN&gt; organisation that was set up by the government in 2003 to protect the public from threats to their health from infectious diseases and environmental hazards.&amp;nbsp; It does this by providing advice and information to the general public, to health professionals such as doctors and nurses, and to national and local government.&lt;?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/SPAN&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;SPAN style="FONT-FAMILY: 'Times New Roman'; COLOR: white; FONT-SIZE: 12pt; mso-ansi-language: EN; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-bidi-language: AR-SA" lang=EN&gt;.&lt;/SPAN&gt;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>262333</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.abpi.org.uk/publications/publication_details/targetCOPD/content.asp]]&gt;</url>
    <title>Target COPD</title>
    <publicationDate></publicationDate>
    <publisher>The Association of the British Pharmaceutical Industry (ABPI)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PUBLICATIONS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ Chronic Obstructive Pulmonary Disease has been estimated to cost the NHS more than £800 million a year, resulting in more than 114,000 hospital admissions, most of them emergencies.&amp;nbsp; COPD is caused primarily by smoking, with a smaller number of cases caused by pollutants.&amp;nbsp; A wide range of new treatments is in the development pipeline, with the potential to help the millions of people who suffer from the condition.]]&gt;</body>
  </document>
  <document>
    <id>187247</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187247]]&gt;</url>
    <title>The Burden of COPD in the UK</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The Burden of COPD in the UK&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Peter Burney, Professor of Respiratory Epidemiology and Public Health and Deborah Jarvis, Senior Lecturer in Respiratory Epidemiology and Public Health&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Chronic obstructive pulmonary disease is thought to be the fourth most common cause of death worldwide and the World Health Organisation anticipates that by 2020 it will have become the third – primarily related to changes in smoking behaviour in the developing world and changes in the population age structures&lt;A href="#refs"&gt;[1]&lt;/A&gt;. In 2004, 27,478 men and women living in the UK died of chronic obstructive lung disease, the vast majority (more than 90%) of these deaths occurring in those aged over 65 years&lt;A href="#refs"&gt;[2]&lt;/A&gt;. However as COPD is an important comorbidity in those dying from other causes (ischemic heart disease, lung cancer) it appears in either Part I or Part II of about twice this number of death certificates.&lt;A href="#refs"&gt;[3]&lt;/A&gt;&amp;nbsp; Mortality from COPD in England shows a strong urban rural gradient&lt;A href="#refs"&gt;[4]&lt;/A&gt; with high mortality rates in the large conurbations in the North of England. There are also striking social inequalities with men aged 20-64 employed in unskilled manual occupations being 14 times more likely to die from chronic obstructive pulmonary disease than those in professional occupations&lt;A href="#refs"&gt;[2]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The proportion of the population who suffer from COPD is less easy to quantify largely due to the difficulty of defining the disease by symptoms alone and due to variations in disease definitions used in community based studies. A systematic review of all population based studies of COPD from anywhere in the world and published from 1990-2004 estimated that the prevalence of COPD in adults above the age of 40 years was 9-10%&lt;A href="#refs"&gt;[5]&lt;/A&gt;. This figure fails to capture variation in age-specific rates and variation in prevalence with a history of past and current smoking in these older generations. In adults under the age of 45 years living in Europe the prevalence of COPD as defined by GOLD stage criteria is about 2.5% for Stage 1 and about 1% for stage 2 or 3.&lt;A href="#refs"&gt;[6]&lt;/A&gt; This study suggests that the prevalence of disease in young adults in the UK is about average compared to other European countries.&amp;nbsp; In all countries the prevalence of disease was associated with smoking and exposure to occupational vapours gas, dust and fumes.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;The Health Survey for England periodically measures lung function in representative samples of the English population. Although reversibility testing is not conducted as part of the examination data show airway obstruction increases with age in both men and women irrespective of smoking status (see graphs below).&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage0 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID187247/nelhImp_0000_copdg1.jpg" name=nelh_tempImage0&gt;&lt;/P&gt;
&lt;P&gt;&lt;IMG id=nelh_tempImage1 src="https://rmsadmin.nelh.nhs.uk/libraryImages/Respiratory/contentID187247/nelhImp_0001_copdg2.jpg" name=nelh_tempImage1&gt;&lt;/P&gt;
&lt;P&gt;[ Graphs are drawn using data from: National Centre for Social Research and University College London. Department of Epidemiology and Public Health, Health Survey for England, 2001 [computer file]. 2nd Edition. Colchester, Essex: UK Data Archive [distributor], June 2004. SN: 4628.&amp;nbsp; Data from the Health Survey for England are Crown Copyright and were used by permission of the UK Office for National Statistics (ONS) and the Data Archive, University of Essex, England. Neither the Data Archive nor ONS bear any responsibility for the analysis and interpretation presented here. ]&lt;/P&gt;
&lt;P&gt;Chronic obstructive pulmonary disease places a substantial burden on the health services. It is estimated that there are 1.4 million consultations in primary care for COPD which is four times more than for angina&lt;A href="#refs"&gt;[7]&lt;/A&gt;. Only a small proportion of COPD patients will be admitted for hospital care each year but within respiratory disease it is the most common reason for emergency admission to hospital, accounts for the most finished consultant episodes of care (80% of them in those aged over 60 years of age) and is second only to pneumonia&amp;nbsp; in total bed-days per year&lt;A href="#refs"&gt;[2]&lt;/A&gt;. Emergency hospital admissions show the same geographical variations as observed for mortality and are substantially higher in more deprived communities than affluent communities. About 30% of patients admitted with COPD for the first time will be readmitted within three months and 15% of patients admitted will die within three months of discharge. This latter figure varies between hospitals and is higher in those with fewer respiratory consultants and in those serving more deprived communities&lt;A href="#refs"&gt;[7]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;The Chief Medical Officer has reported COPD accounts for more than £800 million in direct health care costs&lt;A href="#refs"&gt;[8]&lt;/A&gt; although the National Institute for Clinical Excellence estimated slightly lower costs&lt;A href="#refs"&gt;[7]&lt;/A&gt;. More than half the costs are related to hospital care and costs are, as expected, greater for those with more severe disease (£149 for a person with mild COPD, £307 for someone with moderate COPD and £1,307 for someone with severe COPD). The estimated cost of an acute episode ranges from £8 - £15 for someone with mild, £23 - £95 for someone with mild to moderate COPD to £1,400 - £1,600 for someone with severe COPD.&amp;nbsp; However the indirect costs of this chronic condition are substantial impacting on annual productivity with an estimated 24 million lost working days per annum&lt;A href="#refs"&gt;[8]&lt;/A&gt;.&amp;nbsp; There is little UK data available to quantify other indirect costs such as carer time and inability to carry out non-occupationally related activities.&lt;/P&gt;
&lt;P&gt;There is argument over whether the clinical need for medical supervision and treatment of COPD is fully met. There are reports of under recognition of mild disease in the elderly although such patients may not perceive themselves to be unwell and may refuse medical intervention. In one study in a semi-rural practice screening of 353 patients aged 60-75 years identified 22 new cases of COPD&lt;A href="#refs"&gt;[9]&lt;/A&gt;. Of these only one patient had severe disease, none of the current smokers wished to attend smoking cessation clinics and only one of the patients agreed to commence any treatment. &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1 http: www.who.int respiratory copd burden en index.html? target="_blank"&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;World Health Organization (WHO). 2006.&amp;nbsp;COPD: Burden. World Health Organization&amp;nbsp;[Online]. &lt;A href="http://www.who.int/respiratory/copd/burden/en/index.html" target="_blank"&gt;http://www.who.int/respiratory/copd/burden/en/index.html&lt;/A&gt; &lt;/A&gt;&lt;/LI&gt;&lt;/LI&gt;
&lt;LI&gt;British Thoracic Society. 2006. The Burden of Lung Disease. 2nd Edition. British Thoracic Society [Online]. &lt;A href="http://www.brit-thoracic.org.uk/c2/uploads/finalproof.pdf" target="_blank"&gt;http://www.brit-thoracic.org.uk/c2/uploads/finalproof.pdf&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22(5):809-814. &lt;A href="http://erj.ersjournals.com/cgi/reprint/22/5/809" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;
&lt;LI&gt;Hansell A, Hollowell J, McNiece R, Nichols T, Strachan D. Validity and interpretation of mortality, health service and survey data on COPD and asthma in England. Eur Respir J 2003; 21(2):279-286. &lt;A href="http://erj.ersjournals.com/cgi/reprint/21/2/279.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Halbert R, Natoli J, Gano A, Badamgarav E, Buist A, Mannino D. Global burden of COPD:systematic review and meta-analysis. Eur Respir J 2006; 28:523-532. &lt;A href="http://erj.ersjournals.com/cgi/content/abstract/28/3/523" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59:120-125. &lt;A href="http://thorax.bmj.com/cgi/content/full/59/2/120" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Healthcare Commission. 2006. Clearing the air: A national study of chronic obstructive pulmonary disease.&amp;nbsp; Healthcare Commission &lt;A href="http://www.healthcarecommission.org.uk/_db/_documents/COPD_report1.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;
&lt;LI&gt;Department of Health&amp;nbsp;and&amp;nbsp;Chief Medical Officer. 2005.&amp;nbsp;On the State of the Public Health 2004. Department of Health &lt;A href="http://www.dh.gov.uk/PublicationsAndStatistics/Publications/AnnualReports/CMOAnnualReportsArticle/fs/en?CONTENT_ID=4115776&amp;amp;chk=4cbJGT" target="_blank"&gt;[FULL TEXT]&amp;nbsp;&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Dickinson J, Meaker M, Ratcliffe G. Screening older patients for obstructive airways disease in a semi-rural practice. Thorax 1999; 54:501-505. &lt;A href="http://thorax.bmj.com/cgi/content/full/54/6/501" target="_blank"&gt;[FULL TEXT]&lt;/A&gt; 
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1 http: www.who.int respiratory copd burden en index.html? target="_blank"&gt;
&lt;/LI&gt;&lt;/OL&gt;
&lt;P align=center&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?catID=5880&amp;amp;tabID=292" target="_blank"&gt;Click here to view COPD patient information within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>262930</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.ncchta.org/project/1239.asp]]&gt;</url>
    <title>The Clinical Effectiveness and Cost-Effectiveness of Bupropion and Nicotine Replacement Therapy for Smoking Cessation: a Systematic Review and Economic Evaluation</title>
    <publicationDate></publicationDate>
    <publisher>NHS Health Technology Assessment Programme</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,HTA,PROGRAMME]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>The HTA Programme conducts research into the costs, effectiveness and impact of health technologies.</description>
    <body>&lt;![CDATA[ &lt;P&gt;Published in Health Technology Assessment 2002; Vol. 6: No. 16. 
&lt;P&gt;&lt;STRONG&gt;Executive summary (abridged): &lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;Objectives of the study:&lt;/STRONG&gt; 
&lt;UL&gt;
&lt;LI&gt;to assess the clinical effectiveness, cost-effectiveness and adverse effects of bupropion SR (sustained-release) and nicotine replacement therapy (NRT) for smoking cessation 
&lt;LI&gt;to assess the effects of therapy in assisting long-term reduction in the amount smoked by smokers who are unwilling or unable to quit were not assessed&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;Conclusions:&lt;/STRONG&gt; 
&lt;UL&gt;
&lt;LI&gt;both NRT and bupropion SR are effective interventions to assist smoking cessation 
&lt;LI&gt;the relative effectiveness of bupropion SR and NRT still needs further research 
&lt;LI&gt;information on how to maximise effectiveness in practice is still lacking, but motivational support is probably involved 
&lt;LI&gt;the most significant differences between NRT and bupropion SR relate to the adverse events and safety profiles of these interventions 
&lt;LI&gt;overall, the safety profile of NRT is more favourable, particularly given the small but real risk of seizure with bupropion SR&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>286715</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.csp.org.uk/uploads/documents/evidencebrief_pulmonary_EB05.pdf]]&gt;</url>
    <title>The Effectiveness of Pulmonary Rehabilitation: Evidence and Implications for Physiotherapists</title>
    <publicationDate>2003-03-01T00:00:00</publicationDate>
    <publisher>Chartered Society of Physiotherapy (CSP)</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,PUBLICATIONS,THERAPEUTIC INTERVENTION]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This report contains detailed critical analysis of the literature concerning the clinical and cost-effectiveness of pulmonary rehabilitation, with particular emphasis on the implications for physiotherapy. The report was published in March 2003 and considers the following topics: 
&lt;UL&gt;
&lt;LI&gt;benefits of pulmonary rehabilitation 
&lt;LI&gt;selection of patients 
&lt;LI&gt;delivery of pulmonary rehabilitation 
&lt;LI&gt;exercise 
&lt;LI&gt;adjuncts to pulmonary rehabilitation 
&lt;LI&gt;additional components&lt;/LI&gt;&lt;/UL&gt;]]&gt;</body>
  </document>
  <document>
    <id>124598</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://journals.elsevierhealth.com/periodicals/ymai]]&gt;</url>
    <title>The Journal of Allergy and Clinical Immunology</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,JOURNALS,IMMUNOLOGICALLY BASED DISORDERS,ALLERGY]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;This journal is the&amp;nbsp;official publication of the American Academy of Allergy, Asthma, and Immunology. Articles cover topics such&amp;nbsp;as allergic and immunologic diseases, the latest therapies and treatment programs, occupational/industrial allergy, and studies of antigens, allergens, and the environment.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;ISSN: 0091-6749&lt;BR&gt;Published monthly. 
&lt;P&gt;Online access to full-text articles and abstracts&amp;nbsp;from&amp;nbsp;2002 onwards is via subscription.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>187253</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=187253]]&gt;</url>
    <title>The management of acute exacerbation</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The management of acute exacerbation&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Dr Tom Wilkinson&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Chronic obstructive pulmonary disease (COPD) is a progressive, inflammatory disorder which leads to the development of airways obstruction and to worsening respiratory symptoms. The chronic course of COPD is complicated by acute episodes of worsening symptoms and lung function termed exacerbations. These events are increasingly recognised as an important component of the disease; as they are not only a major cause of physician consultation, hospitalisation, and mortality but also contribute directly to the disease progression &lt;A href="#refs"&gt;[1]&lt;/A&gt; and to the poor health status associated with this disease &lt;A href="#refs"&gt;[2]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The cause of exacerbations is the focus of ongoing studies, but there is considerable evidence to suggest that airway infection plays an important role in these events. Common respiratory pathogens such as human rhinovirus; the cause of the common cold; may trigger increases in airway inflammation and indeed interact with airway bacteria to cause more severe events &lt;A href="#refs"&gt;[3]&lt;/A&gt;. &lt;/P&gt;
&lt;P&gt;Appropriate treatment of exacerbations relies on both correct initial diagnosis and assessment of severity. It is important to note that deteriorating symptoms in patients with COPD can be due to respiratory diagnoses other than COPD as well as cardiovascular disease which is common in this patient group.&amp;nbsp; Whilst the majority of COPD exacerbations can be managed safely in the community, a proportion will require more intensive in-patient care and potentially ventilatory support in patients developing respiratory failure. &lt;/P&gt;
&lt;P&gt;Medical therapy for exacerbations of COPD often includes bronchodilators and oral corticosteroids. Bronchodilators such as inhaled or nebulised beta-2 agonists and anti-cholinergics can give rapid symptom relief by bronchodilation and reduction in hyperexpansion due to air trapping &lt;A href="#refs"&gt;[4]&lt;/A&gt;. Although nebulised treatments are often prescribed there is little evidence that they are superior to inhaled therapy if technique is adequate. Oral corticosteroids, particularly prednisolone at a dose of around 30mg per day for 10 days, is a key treatment for acute exacerbations and has been shown to improve rate of lung function recovery &lt;A href="#refs"&gt;[5]&lt;/A&gt; and reduce length of hospital stay &lt;A href="#refs"&gt;[6]&lt;/A&gt;. Side effects of repeated or prolonged courses of oral corticosteroids are potentially serious and care should be taken to minimise these by limiting course duration and the use of prophylaxis for osteoporosis in at risk patients. &lt;/P&gt;
&lt;P&gt;The role of antibiotic therapy in the management of exacerbations is less clear &lt;A href="#refs"&gt;[7]&lt;/A&gt;. Although airway bacteria are commonly identified in sputum samples during these events the evidence from clinical trials does not suggest a role for&amp;nbsp;antibiotics in all events, but those associated with sputum purulence should be targeted with anti-microbial therapy &lt;A href="#refs"&gt;[8]&lt;/A&gt;. The microbial resistance patterns associated with COPD and currently in the UK first line antibiotic therapy remains a penicillin although a role for new generation quinolones and macrolide therapies may be emerging.&lt;/P&gt;
&lt;P&gt;In patients with severe disease and respiratory failure supplementary oxygen therapy is a cornerstone of supportive therapy at exacerbation. Whereas patients with established type two respiratory failure may require ventilatory support. This development of non-invasive ventilation has transformed the management of these patients and is the focus of evidence-based guidelines. &lt;A href="#refs"&gt;[9]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;The management of exacerbations of COPD remains a challenge for health care professionals in both primary and secondary care. Treatment strategies are developing to offer optimal care in the patient’s home environment when possible, and have been shown to be a safe alternative to hospitalisation &lt;A href="#refs"&gt;[10]&lt;/A&gt;. Prompt recognition of exacerbations and early therapy may lead to a faster recovery &lt;A href="#refs"&gt;[11]&lt;/A&gt; and therefore the aim of COPD services should be to offer appropriate care in the timeliest fashion. &lt;/P&gt;
&lt;P&gt;The management of COPD exacerbations is rapidly evolving and the important role that preventative strategies may play is increasingly recognised &lt;A href="#refs"&gt;[12]&lt;/A&gt;. Indeed only by reducing the health impact of the major cause of COPD; tobacco smoking will we eventually conquer this common and disabling disease.&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the author. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847–52. &lt;A href="http://thorax.bmj.com/cgi/content/full/57/10/847?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=donaldson&amp;amp;fulltext=lung&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=57&amp;amp;firstpage=847&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–22. &lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/157/5/1418?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=seemungal&amp;amp;titleabstract=pulmonary&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;volume=157&amp;amp;firstpage=1418&amp;amp;fdate=1/1/1998&amp;amp;tdate=12/31/1998&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Wilkinson TM, Hurst JR, Perera WR et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD.Chest 2006;129(2):317-24. &lt;A href="http://www.chestjournal.org/cgi/content/abstract/129/2/317?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=wilkinson&amp;amp;fulltext=airway&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=129&amp;amp;firstpage=317&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(ABSTRACT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967–75. &lt;A href="http://ajrccm.atsjournals.org/cgi/content/abstract/153/3/967?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=belman&amp;amp;titleabstract=inhaled&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;fdate=1/1/1996&amp;amp;tdate=12/31/1996&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(ABSTRACT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Singh JM, Palda VA, Stanbrook MB, et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease. A systematic review. Arch Intern Med 2002;162:2527–36. &lt;A href="http://archinte.ama-assn.org/cgi/content/abstract/162/22/2527" target="_blank"&gt;(ABSTRACT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Davies L, Angus R, Calverley P. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial The Lancet 1999;354, 9177,456-460. &lt;A href="http://www.thelancet.com/journals/lancet/issue?volume=354&amp;amp;issue=9177" target="_blank"&gt;(ABSTRACT)&lt;/A&gt;&amp;nbsp;(free registration required)&lt;/LI&gt;
&lt;LI&gt;Saint S , Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957–60. &lt;A href="http://jama.ama-assn.org/cgi/content/abstract/273/12/957" target="_blank"&gt;(ABSTRACT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;National Institute for Clinical Excellence. Chronic obstructive pulmonary disease (COPD): management of chronic obstructive pulmonary disease in primary and secondary care. Thorax 2004;59 (suppl) :i1–i232.&lt;/LI&gt;
&lt;LI&gt;British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002;57:192–211. &lt;A href="http://thorax.bmj.com/cgi/content/full/57/3/192?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;fulltext=british+thoracic&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=57&amp;amp;firstpage=192&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Davies L, Wilkinson M, Bonner S, et al.."Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. BMJ. 2000;321(7271):1265-8. &lt;A href="http://www.bmj.com/cgi/content/full/321/7271/1265?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=davies&amp;amp;fulltext=hospital&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=321&amp;amp;firstpage=1265&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Wilkinson TM, Donaldson GC, Hurst JR et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Jun 15;169(12):1298-303. &lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/169/12/1298?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;volume=169&amp;amp;firstpage=1298&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Hurst JR, Wedzicha JA. Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation.&lt;BR&gt;Postgrad Med J. 2004;80(947):497-505.&amp;nbsp;&lt;A href="http://pmj.bmj.com/cgi/content/full/80/947/497?maxtoshow=&amp;amp;HITS=10&amp;amp;hits=10&amp;amp;RESULTFORMAT=&amp;amp;author1=hurst&amp;amp;fulltext=pulmonary&amp;amp;andorexactfulltext=and&amp;amp;searchid=1&amp;amp;FIRSTINDEX=0&amp;amp;sortspec=relevance&amp;amp;volume=80&amp;amp;firstpage=497&amp;amp;resourcetype=HWCIT" target="_blank"&gt;(FULL TEXT)&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&amp;nbsp;&amp;nbsp;Other Resources:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79830&amp;amp;tabID=290" target="_blank"&gt;Chronic obstructive airways disease&lt;/A&gt;&amp;nbsp;BMJ Topic Collection, August 1997 - 28 October 2006.&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Evidence:&lt;BR&gt;&lt;/P&gt;&lt;/STRONG&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190290&amp;amp;tabID=289" target="_blank"&gt;Antibiotics for exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188607&amp;amp;tabID=289" target="_blank"&gt;Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188608&amp;amp;tabID=289" target="_blank"&gt;Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2005, Issue 1.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=122221&amp;amp;tabID=289" target="_blank"&gt;Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2006.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>124949</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=124949]]&gt;</url>
    <title>The management of asthma in primary care</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The management of asthma in primary care&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Dr Hilary Pinnock&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 - 26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Almost all routine asthma management, and about 90% of acute management,&lt;A href="#refs"&gt;[1]&lt;/A&gt; is provided by primary care.&amp;nbsp;In UK general practice, asthma reviews are seen as the remit of trained asthma nurses as a result of an initiative that began in a single practice in Stratford-on-Avon,&lt;A href="#refs"&gt;[2]&lt;/A&gt; which led to the development of the Asthma Training Centre (now the &lt;A href="http://www.educationforhealth.org.uk/" target="_blank"&gt;Education for Health&lt;/A&gt;).&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Routine asthma management&lt;BR&gt;&lt;/STRONG&gt;Structured review of people with asthma improves morbidity,&lt;A href="#refs"&gt;[3]&lt;/A&gt; and is recommended by the British Thoracic Society / Scottish Intercollegiate Guideline Network (BTS/SIGN) Guideline on Asthma Management.&lt;A href="#refs"&gt;[4]&lt;/A&gt;&amp;nbsp;The General Medical Services contract (GMS contract), endorses this recommendation by rewarding practices for providing regular reviews for people with asthma.&lt;A href="#refs"&gt;[5]&lt;/A&gt;&lt;/P&gt;
&lt;P&gt;The content of a review should meet the clinical needs of the patient, but key functions are:&lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Assessment of asthma control. Because asthma is, by definition, a variable condition a ‘one-off’ peak flow in a routine check is of limited value, though it is helpful to record the patient’s best peak flow as a baseline against which to assess the severity of a subsequent deterioration.&amp;nbsp;Use of standard morbidity questions (for example, the Royal College Physicians 3 questions, available from &lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;www.brit-thoracic.org.uk&lt;/A&gt;) allow assessment and monitoring of symptoms. Future refinements to improve sensitivity to change may include replacing the ‘yes/no’ answers with a ‘0 to 7’ score to reflect the number of days affected in the previous week.&lt;/LI&gt;
&lt;LI&gt;Identification of other allergic conditions.&amp;nbsp;A third of people with rhinitis will develop symptoms of asthma and over half of asthma suffers will also have rhinitis.&lt;A href="#refs"&gt;[6]&lt;/A&gt; Assessment and treatment of rhinitis should be part of routine asthma reviews.&lt;/LI&gt;
&lt;LI&gt;Discussion of current treatment and recommendations for change.&amp;nbsp;This could encompass concordance with prescribed medication, concerns about side-effects, perceived efficacy of medication and assessment of inhaler technique.&amp;nbsp;Treatment may be stepped up or down in line with BTS-SIGN step-wise management guidelines.&lt;A href="#refs"&gt;[7]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Self-management education.&amp;nbsp;Issuing a personalised asthma action plan, or reviewing an existing plan is an important component of an asthma review.&amp;nbsp;‘Be in Control’ asthma action plans are available from the &lt;A href="http://www.asthma.org.uk/" target="_blank"&gt;Asthma UK&lt;/A&gt;&lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;Only about a third of patients have a routine asthma review each year,&lt;A href="#refs"&gt;[6]&lt;/A&gt; perhaps because asthma is not perceived as sufficiently serious to warrant the investment of time and effort involved in attending a clinic review. This is recognised in the GMS contract as the target has been set at ‘only’ 70%.&amp;nbsp;Strategies for increasing the proportion of patients reviewed include:&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/P&gt;
&lt;UL&gt;
&lt;LI&gt;Organising an efficient recall procedure (e.g. attaching invitations to repeat prescriptions, invitation letters for non-attenders, personal invitations issued opportunistically) ensure that all patients receive reminders about the need for regular review.&amp;nbsp; &lt;/LI&gt;
&lt;LI&gt;Offering patient-friendly review arrangements. Flexible appointment schedules and provision of opportunistic reviews are important strategies.&amp;nbsp;The 2004 update of the BTS SIGN guideline recognises that telephone asthma reviews are an option.&lt;A href="#refs"&gt;[4]&lt;/A&gt;&amp;nbsp;&amp;nbsp; &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;&lt;STRONG&gt;General Practitioners with a Special Interest&lt;/STRONG&gt;&lt;BR&gt;General Practitioners with a Special Interest (GPwSIs) in respiratory disease may contribute to the provision of primary care services for people with asthma.&lt;A href="#refs"&gt;[8]&lt;/A&gt;&amp;nbsp;Specific roles may include leading the strategic planning for respiratory services,&amp;nbsp; setting quality standards and providing clinical expertise for conditions most common in general practice, including asthma, and allergies.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The references were supplied by the authors. Where possible links have been provided to the full text or abstracts (via PubMed) of these articles. Where there is no link it has not been possible to find the reference online.]&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;Neville RG, Clark RC, Hoskins G, Smith B. National asthma attack audit 1991-2. General Practitioners in Asthma Group. BMJ 1993; 306:559-562. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8461773&amp;amp;dopt=Abstract" target="_blank"&gt;[Abstract]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Barnes G. Nurse-run asthma clinics in general practice.&amp;nbsp;J Coll Gen Pract 1985; 35: 447.&lt;/LI&gt;
&lt;LI&gt;Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma. The Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD001117. DOI: 10.1002/14651858.CD001117. &lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001117/frame.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;The British Thoracic Society / Scottish Intercollegiate Guideline Network.&amp;nbsp;&amp;nbsp; British Guideline on the management of asthma.&amp;nbsp;Thorax 2003; 58 (S1): i1-i94&amp;nbsp; &lt;A href="http://www.sign.ac.uk/guidelines/fulltext/63/index.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;NHS Confederation, British Medical Association.&amp;nbsp;New GMS Contract 2003:&amp;nbsp; investing in general practice. London.&amp;nbsp;March 2003. &lt;A href="http://www.bma.org.uk/ap.nsf/Content/investinggp" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Bousquet J, van Cauwenberge P, Khaltaev N for the ARIA group.&amp;nbsp;&amp;nbsp; Allergic Rhinitis and its Impact on Asthma.&amp;nbsp;J Allergy Clin Immunol 2001; 108s: s147-s333&amp;nbsp;&lt;A href="http://www.whiar.org/docs.html" target="_blank"&gt;[Full Text]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Price D et al.&amp;nbsp;Delivery of asthma care:&amp;nbsp;patient's use of and views on healthcare services, as determined from a nationwide interview survey.&amp;nbsp;Asthma J 2000; 5: 141-144.&lt;/LI&gt;
&lt;LI&gt;Department of Health.&amp;nbsp;Guidelines for the appointment of General Practitioners with a Special Interests in the delivery on clinical services: Respiratory Medicine.&amp;nbsp;April 2003.&amp;nbsp; &lt;A href="http://www.dh.gov.uk/assetRoot/04/06/83/77/04068377.pdf" target="_blank"&gt;[Full Text]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;
&lt;/STRONG&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Guidelines:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://libraries.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D60587" target="_blank"&gt;Guidelines for the prevention, identification and management of occupational asthma: evidence review and recommendations&lt;/A&gt;,&amp;nbsp;British Occupational Health Research Foundation, September 2004.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D30346&amp;amp;categoryID=5872" target="_blank"&gt;British guideline on the management of asthma&lt;/A&gt;. British Thoracic Society/SIGN, November 2005.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=243177&amp;amp;tabID=289" target="_blank"&gt;Continuing medical education for asthma in primary care settings: a review of randomised controlled trials&lt;/A&gt; Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D5966" target="_blank"&gt;General Practice Airways Group (GPIAG)&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>143963</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.npc.co.uk/ebt/merec/resp/copd/resources/merec_bulletin_vol16_no5.pdf]]&gt;</url>
    <title>The management of chronic obstructive pulmonary disease (COPD)</title>
    <publicationDate>2006-08-23T00:00:00</publicationDate>
    <publisher>National Prescribing Centre (NPC)</publisher>
    <publicationType>REVIEW</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,PULMONARY REHABILITATION,SMOKING,THERAPEUTIC INTERVENTION,MEREC]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description>MeReC Bulletin, Vol. 16, No. 5, June 2006.</description>
    <body>&lt;![CDATA[ &lt;P&gt;This is one of a series of bulletins published by the National Prescribing Centre. The bulletin was published in&amp;nbsp; June 2006 and focuses on the management of chronic obstructive pulmonary disease (COPD). The topics covered by the bulletin include: 
&lt;UL&gt;
&lt;LI&gt;Introduction&amp;nbsp; 
&lt;LI&gt;Management of stable COPD&amp;nbsp; 
&lt;LI&gt;What is the role of long-acting bronchodilators? 
&lt;LI&gt;When should an inhaled corticosteroid be added to treatment? &lt;/LI&gt;&lt;/UL&gt;
&lt;P&gt;This resource has been included because it satisfies the INTUTE (formerly BIOME) evaluation criteria for quality. &lt;A href="http://www.intute.ac.uk/healthandlifesciences/policy.html" target="_blank"&gt;Click here&lt;/A&gt; to&amp;nbsp;view the full INTUTE evaluation guidelines.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312015</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/anti_ige_opinion_sheet5_final.pdf]]&gt;</url>
    <title>The role of anti-IgE therapy in the treatment of severe allergic asthma</title>
    <publicationDate>2006-05-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It looks at what anti-IgE is and its use in treating severe allergic asthma.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet&amp;nbsp;No. 5.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>312075</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.gpiag.org/opinions/laba_ics_asthma_final.pdf]]&gt;</url>
    <title>The role of inhaled corticosteroids and long-acting &amp;#946;2-agonists, alone and in combination, in the management of asthma</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;It details the use of inhaled corticosteroids and long acting ß&lt;SUB&gt;2&lt;/SUB&gt;-agonists in the management of asthma. 
&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Primary Care Respiratory Society UK Opinion Sheet No. 19.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>197364</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=197364]]&gt;</url>
    <title>The role of physical therapies in preventing exacerbation in COPD</title>
    <publicationDate>2006-11-13T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,STAFF USE,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NKW COPD]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The role of physical therapies in preventing exacerbation in COPD&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;&lt;STRONG&gt;Written by Rachel Garrod&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for COPD 13 - 17 November 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;Chronic Obstructive Pulmonary Disease (COPD) is characterised by fixed airflow obstruction and systemic inflammatory complications. There are approximately 900,000 people in the UK with Chronic Obstructive Pulmonary Disease (COPD)&lt;A href="#refs"&gt;[1]&lt;/A&gt; with most presenting after 40 years of age, prevalence has been estimated as 5 % of men aged 65-74 and 10 % of men older than 75 years. 27,478 people died as a result of COPD in 2004, respiratory disease is the fifth leading cause of death in the UK. COPD leads to significant morbidity and causes heavy cost burden to the health service, estimated at £486 million between 1995 and 1996 &lt;A href="#refs"&gt;[1]&lt;/A&gt;. Much of the cost associated with COPD comes from exacerbations and in particular, acute hospital admissions &lt;A href="#refs"&gt;[2]&lt;/A&gt;. Admission to hospital accounts for about 35% of annual expenditure and readmission rates are high in COPD. In one study examining factors associated with readmission high levels of physical activity were associated with reduced risk for readmission&lt;A href="#refs"&gt;[3]&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Pulmonary rehabilitation, a package of exercise and education is known to improve breathlessness for patients, increase exercise tolerance and performance of daily activities and improve quality of life&lt;A href="#refs"&gt;[4]&lt;/A&gt;. Recently, Man and colleagues showed that pulmonary rehabilitation provided within 10 days of discharge from hospital resulted in significant improvement in exercise tolerance in COPD patients &lt;A href="#refs"&gt;[5]&lt;/A&gt;. They studied 42 patients who had been admitted to hospital with a primary diagnosis of acute exacerbation of COPD, who were randomised to either an 8-week community pulmonary rehabilitation programme consisting of twice-weekly exercise and education, or a control group that received usual care. The programme was run in the normal fashion for stable COPD patients: exercises comprised walking, cycling, and strength training for upper and lower limbs for one hour, followed by a multidisciplinary education programme with the emphasis on self-management. This community programme provided early post discharge, demonstrated clinically important improvements in exercise capacity and health status at three months. Importantly re-admissions to hospital were also significantly reduced in the active group compared with the controls; encouragingly adverse events were similar between groups, and hence unrelated to early exercise.&amp;nbsp; What was most compelling about this research was what happened to the control group who did not receive early rehabilitation, walking distance in this group deteriorated from 115 to 90 meters at 3 months. After hospital admission patients do not recover previous levels of mobility and are increasingly likely to become housebound &lt;A href="#refs"&gt;[6]&lt;/A&gt;. Exercise tolerance and functional ability is of course further limited contributing to repeat exacerbation and admission.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;Maintenance of physical activity, strength and functional performance are of utmost importance in the long term management of COPD patients and prevention of damaging admissions. Physiotherapists, in the community and acute trust are well placed to identify patients at risk of readmission and frequent exacerbation. Assessment of exercise tolerance and muscle strength early after discharge and&amp;nbsp; the provision of physical training programmes may contribute to slowing the deterioration of disease associated with frequent exacerbation &lt;A href="#refs"&gt;[7,8]&lt;/A&gt;.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A name=refs&gt;&lt;/A&gt;&lt;STRONG&gt;References:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;/P&gt;
&lt;OL&gt;
&lt;LI&gt;British Thoracic Society. The Burden of Lung Disease. London, UK: British Thoracic Society; 2006. Report No.: 2nd. &lt;A href="http://www.brit-thoracic.org.uk/c2/uploads/BurdenofLungDisease.pdf" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&amp;nbsp;(PDF)&lt;/LI&gt;
&lt;LI&gt;Ram FSF, Wedzicha JA, Wright J, Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2004 Aug 7;329(7461):315. &lt;A href="http://www.bmj.com/cgi/content/full/329/7461/315" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006 Sep;61(9):772-8. &lt;A href="http://thorax.bmj.com/cgi/content/full/61/9/772" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Lacasse Y , Goldstein R , Lasserson TJ, Martin S Pulmonary rehabilitation for chronic obstructive pulmonary disease Cochrane Database of Systematic Reviews : Reviews 2006 Issue 4 John Wiley &amp;amp; Sons , Ltd Chichester, UK DOI : 10 1002 /14651858 CD003793 pu 2006. &lt;A href="http://dx.doi.org/10.1002/14651858.CD003793.pub2" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Man WD, Polkey MI, Donaldson N, Gray BJ, Moxham J. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ 2004 Nov 20;329(7476):1209. &lt;A href="http://www.bmj.com/cgi/content/full/329/7476/1209" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 Mar 1;171(5):446-52. &lt;A href="http://ajrccm.atsjournals.org/cgi/content/full/169/12/1298" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Bestall JC, Paul EA, Garrod R, Garnham R, Jones RW, Wedzicha AJ. Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respir Med 2003 Feb;97(2):173-80. &lt;A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=12587969&amp;amp;dopt=Abstract" target="_blank"&gt;[ABSTRACT]&lt;/A&gt;&lt;/LI&gt;
&lt;LI&gt;Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 Dec;22(6):931-6. &lt;A href="http://www.erj.ersjournals.com/cgi/content/full/22/6/931" target="_blank"&gt;[FULL TEXT]&lt;/A&gt;&lt;/LI&gt;&lt;/OL&gt;&lt;STRONG&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;Other Resources:&lt;/STRONG&gt; &lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;&lt;BR&gt;&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=101444&amp;amp;tabID=288" target="_blank"&gt;The treatment and prevention of exacerbations in COPD: the role of primary care&lt;/A&gt;&amp;nbsp;British Lung Foundation (BLF), 2004.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=79830&amp;amp;tabID=290" target="_blank"&gt;Chronic obstructive airways disease&lt;/A&gt;&amp;nbsp;BMJ Topic Collection, August 1997 - 28 October 2006.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Evidence:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188707&amp;amp;tabID=289" target="_blank"&gt;Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=189966&amp;amp;tabID=289" target="_blank"&gt;Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 4.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=190745&amp;amp;tabID=289" target="_blank"&gt;Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2006, Issue 3.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=188608&amp;amp;tabID=289" target="_blank"&gt;Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease&lt;/A&gt;&amp;nbsp;The Cochrane Library 2005, Issue 1.&lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=112321&amp;amp;tabID=289" target="_blank"&gt;The efficacy of corticosteroids in exacerbations of chronic obstructive pulmonary disease: meta-analysis of published studies&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2005.&amp;nbsp; &lt;/P&gt;
&lt;P&gt;&lt;A title="View a detailed summary" href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=122221&amp;amp;tabID=289" target="_blank"&gt;Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation: a systematic review of the literature&lt;/A&gt;&amp;nbsp;Database of Abstracts of Reviews of Effects (DARE), 2006.&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;A href="http://www.library.nhs.uk/respiratory/SearchResults.aspx?tabID=292&amp;amp;catID=5880&amp;amp;" target="_blank"&gt;Click here to view COPD patient information&amp;nbsp;within the Respiratory Specialist Library&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>125067</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=125067]]&gt;</url>
    <title>The role of respiratory function laboratories in asthma</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;The role of respiratory function laboratories in asthma&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Dr Andy Robson&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 -&amp;nbsp;26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;Respiratory function laboratories play an important part in the detection and monitoring of patients with asthma. Clinical Physiologists carry out a number of different tests, which are intended to assist in the diagnosis and monitoring of patients with asthma.&lt;/P&gt;
&lt;P&gt;Daily monitoring of peak expiratory flow (PEF) in patients with suspected asthma should reveal any diurnal variability in peak flow, which is a common hallmark of asthma. Respiratory function laboratory staff can teach a patient how to use a peak flow meter correctly and then instruct them how to record their peak flow readings. In addition to measurements of peak flow, measurements of spirometry (FEV1 and FVC) can be used to determine the degree of airflow obstruction present. &lt;/P&gt;
&lt;P&gt;Patients with asthma often show a very good response to bronchodilators and so assessment of response to bronchodilators is regularly carried out in respiratory function labs. Well-controlled asthmatics may show very little response to bronchodilators as their values may well be entirely normal to start with. Conversely, patients in the middle of an acute exacerbation of asthma may show little response to bronchodilators due to the excessive inflammatory changes that take place during an acute attack.&lt;/P&gt;
&lt;P&gt;If a patient does show a response to bronchodilators Clinical Physiologists can then assess which inhaler device a patient can use well, so that patients can be prescribed the most appropriate inhaler devices. If patients are prescribed inhaler devices that they feel comfortable using (and can use well) then their compliance with treatment will be increased and this should help to reduce the frequency of asthma exacerbations. Patients with more severe asthma may be issued with a nebuliser, which can be used to deliver higher doses of medication to the lungs. Many respiratory function laboratories have a nebuliser issue service where patients are instructed in the correct use of a nebuliser which they then take home with them. The loan nebuliser with then be maintained by the laboratory on a regular basis.&lt;/P&gt;
&lt;P&gt;Measurements of carbon monoxide transfer factor (Tco or TLco) can often be used to determine between patients with asthma and those with emphysema. Transfer factor is usually well preserved in asthma but is significantly reduced in patients with emphysema.&lt;/P&gt;
&lt;P&gt;One of the characteristics of asthma is bronchial hyperreactivity, where patients can have an adverse reaction to a number of different non-specific insults, such as cold air, smoke or industrial pollutants. The level of bronchial hyperreactivity can be determined in a respiratory function laboratory by carrying out either a histamine or methacholine challenge or by isocapnic hyperventilation (cold air challenge). Isocapnic hyperventilation is a complex test for both the patient and the Clinical Physiologist but can provide information which is not available from other tests. Although a positive challenge tests is not entirely diagnostic of asthma it certainly help to narrow down the cause of a patient’s symptoms.&lt;/P&gt;
&lt;P&gt;Sometimes asthma can be brought on by exercise, probably due to cooling and drying of the airways and often does not occur during exercise but after exercise has ended. Specific tests can be carried out to identify patients with exercise-induced asthma either by exercising them within the laboratory and then measuring FEV1 and FVC after exercise at fixed intervals for up to 30 minutes after exercise has been completed or by performing a cold air challenge (isocapnic hyperventilation). Once identified, patients with exercise-induced asthma will be able to use their medication to prevent this from occurring.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Other Resources:&lt;/STRONG&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The other resources identified below are evidence-based publications and&amp;nbsp;information relevant to this subject.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Reference:&lt;/STRONG&gt;&lt;BR&gt;&lt;A href="http://bmj.bmjjournals.com/cgi/collection/lung_function" target="_blank"&gt;Lung Function&lt;/A&gt; BMJ Topic collection.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://libraries.nelh.nhs.uk/respiratory/viewResource.asp?uri=http%3A//libraries.nelh.nhs.uk/common/resources/%3Fid%3D124654" target="_blank"&gt;Spirometry&lt;/A&gt; General Practice Airways Group (GPAIG) Opinion, September 2004.&amp;nbsp;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.artp.org.uk/" target="_blank"&gt;The Association for Technology and Physiology (ARTP)&lt;/A&gt;&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>311612</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.pcrs-uk.org/opinions/laba_copd_final.pdf]]&gt;</url>
    <title>The use of long-acting bronchodilators and inhaled corticosteroids in the management of COPD</title>
    <publicationDate>2008-08-01T00:00:00</publicationDate>
    <publisher>Primary Care Respiratory Society UK</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;One of&amp;nbsp;a range of concise, easy-to-follow summary publications, called opinion sheets produced by the Primary Care Respiratory Society UK, aimed at providing practical guidance on respiratory medicine to those working in primary care.&lt;/P&gt;
&lt;P&gt;This includes:&lt;/P&gt;
&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P&gt;The role of ICS and long-acting bronchodilators&lt;/P&gt;
&lt;P&gt;Practical implications&lt;/P&gt;
&lt;P&gt;Short and long term benefits&lt;/P&gt;
&lt;P&gt;Exacerbations&lt;/P&gt;
&lt;P&gt;Side Effects&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P&gt;Primary Care Respiratory Society UK Opinion Sheer No. 18.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>82779</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://thorax.bmj.com/]]&gt;</url>
    <title>Thorax</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,LUNG CANCER,MALIGNANT DISEASE,PUBLICATIONS,SMOKING,JOURNALS,INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Thorax publishes clinical and experimental research articles on respiratory medicine, paediatrics, immunology, pharmacology, pathology, and surgery. Thorax is one of the highest ISI ranked journals covering all aspects of pulmonary medicine. Each issue covers topics such as COPD, asthma, smoking, respiratory infection and lung cancer; and includes editorials, short papers, review series, case reports, images in thorax, and letters.&lt;/P&gt;
&lt;P&gt;Thorax is the official journal of the &lt;A href="http://www.brit-thoracic.org.uk/" target="_blank"&gt;British Thoracic Society&lt;/A&gt;.&lt;/P&gt;
&lt;P&gt;Published 12 times a year &lt;BR&gt;ISSN: 0040-6376&lt;/P&gt;
&lt;P&gt;&lt;STRONG&gt;Access through the publisher's website:&lt;/STRONG&gt;&lt;BR&gt;Access to full text is also available via Athens or subscription. Non subscribers can access some full text articles, abstracts and tables of contents from 1966 plus additional features: &lt;A href="http://thorax.bmjjournals.com/" target="_blank"&gt;http://thorax.bmjjournals.com/&lt;/A&gt;.&lt;BR&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P&gt;&amp;nbsp;&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>282429</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://tobaccocontrol.bmj.com/content/current]]&gt;</url>
    <title>Tobacco Control</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,PUBLICATIONS,SMOKING,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;An international peer review journal for health professionals and others in tobacco control. Access via subscription with some articles freely available.&lt;/P&gt;
&lt;P&gt;&lt;B&gt;ISSN:&lt;/B&gt; 0964-4563&lt;BR&gt;&lt;B&gt;Online ISSN:&lt;/B&gt; 1468-3318&lt;/P&gt;
&lt;P&gt;Published&amp;nbsp;bimonthly.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>345447</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf]]&gt;</url>
    <title>Treatment of Tuberculosis: guidelines for national programmes - 4th edition</title>
    <publicationDate>2010-01-26T00:00:00</publicationDate>
    <publisher>World Health Organisation (WHO)</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;The World Health Organization’s Stop TB Department has prepared this fourth edition of Treatment of tuberculosis: guidelines, adhering&amp;nbsp;to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html" target="_blank"&gt;Click here &lt;/A&gt;to accesses the report on the WHO website&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>6089</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.elsevier.com/wps/find/journaldescription.cws_home/638428/description#description]]&gt;</url>
    <title>Tuberculosis</title>
    <publicationDate></publicationDate>
    <publisher>Elsevier Science Inc</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A speciality journal focusing on the research advances relevant to tuberculosis control and elimination.&lt;/P&gt;
&lt;P&gt;Publishes original research and reviews on the host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism. &lt;/P&gt;
&lt;P&gt;ISSN: 1472-9792&lt;BR&gt;Published 6 times a year 
&lt;P&gt;Online access to full text is available to subscribers from February 2001 (Volume 81, 1) onwards on ScienceDirect:&lt;BR&gt;&lt;A href="http://www.sciencedirect.com/science/journal/14729792" target="_blank"&gt;http://www.sciencedirect.com/science/journal/14729792&lt;/A&gt;&lt;BR&gt;Information about the journal can be freely accessed by non-subscribers through the journal homepage.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>79856</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.bmj.com/cgi/collection/tuberculosis]]&gt;</url>
    <title>Tuberculosis - BMJ collections</title>
    <publicationDate></publicationDate>
    <publisher>BMJ Publishing Group Ltd</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,TUBERCULOSIS,PUBLICATIONS,JOURNALS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;A collection of articles and news items published in the British Medical Journal (BMJ) since April 1999 relevant to tuberculosis.&lt;/P&gt;
&lt;P&gt;Full text is available and in some cases the articles can be downloaded in Portable Document Format (PDF). &lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>284185</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.airquality.co.uk/]]&gt;</url>
    <title>UK Air Quality Archive</title>
    <publicationDate></publicationDate>
    <publisher>AEA Energy &amp; Environment</publisher>
    <publicationType>REFERENCE MATERIAL</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,CHRONIC OBSTRUCTIVE PULMONARY DISEASE]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;P&gt;Details of air quality in Scotland, England, Wales and Northern Ireland. &lt;/P&gt; &lt;P&gt;&lt;BR&gt;Includes interactive map of UK regions, updated hourly bulletins and forecast for the next 24 hours.&lt;/P&gt;]]&gt;</body>
  </document>
  <document>
    <id>124996</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.library.nhs.uk//respiratory/ViewResource.aspx?resID=124996]]&gt;</url>
    <title>What’s new in asthma?</title>
    <publicationDate>2006-05-22T00:00:00</publicationDate>
    <publisher>Respiratory Specialist Library</publisher>
    <publicationType>EDITORIAL OR OPINION PIECE</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA]]&gt;</topics>
    <resourceType>Article</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &lt;article&gt;&lt;firstPage&gt;1&lt;/firstPage&gt;&lt;firstPageID&gt;1&lt;/firstPageID&gt;&lt;page&gt;&lt;pageID&gt;1&lt;/pageID&gt;&lt;pageSequence&gt;-1&lt;/pageSequence&gt;&lt;pageTitle&gt;What’s new in asthma?&lt;/pageTitle&gt;&lt;pageBody&gt;&lt;BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px"&gt;
&lt;P align=left&gt;&lt;STRONG&gt;Written by Prof Peter Barnes&lt;/STRONG&gt;&lt;/P&gt;&lt;/BLOCKQUOTE&gt;
&lt;P align=center&gt;[This article was written for the National Knowledge Week for Asthma 22 - 26 May 2006]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;There have been important advances in understanding the underlying mechanisms of asthma and how different treatment strategies work.&lt;/P&gt;
&lt;P&gt;There has been particular interest in severe asthma, which does not respond well to conventional inhaler therapy. Although only a minority of patients are affected in this way, they account for a large proportion of health care spending in asthma. We need to understand why patients with severe asthma do not respond to conventional therapy as this may lead to new treatments. A large proportion of the patients who fail to respond show a reduced response to steroids and there a various molecular mechanisms that appear to account for this steroid resistance. The type of inflammation may also change in more severe asthma, with different inflammatory cells and mediators. One mediator that appears to be important in severe asthma is tumour necrosis factor-a (TNF-a), a mediator that is known to amplify inflammation and to block the response to steroids. Blocking TNF-a, which has been successful in severe rheumatoid arthritis, appears to be a useful treatment in some patients with severe asthma.&lt;/P&gt;
&lt;P&gt;Many studies have now shown how effective combination inhalers that contain a steroid and long-acting beta-agonists are, with improved control of asthma achieved at lower doses of inhaled steroids and better compliance with long-term therapy. Several recent studies have shown the surprising finding that rescue treatment with the combination therapy is much more effective than using a conventional short-acting beta agonist (like Ventolin). This appears to be because the steroid component prevents the escalation of inflammation to nip exacerbations in the bud. This makes it feasible to control asthma with a single inhaler and this strategy also works well in children.&lt;/P&gt;
&lt;P&gt;There has been a lot of interest in the genetic causes of asthma, but this is a difficult field as it turns out that many genes are involved and each one has a very small effect. This has made it difficult to reproduce findings of association between specific gene variants and asthma in different populations. Research now suggests that a combination of multiple single nucleotide genetic polymorphisms (SNPs) may determine whether atopy and airway hyperresponsiveness are inherited, but may also determine how severe the asthma is. Identification of several new genes is providing new insights into the underlying mechanisms of asthma, and might even lead to new approaches to therapy.&lt;/P&gt;
&lt;P&gt;An area of very active research, which as now advancing almost to the point of introduction into clinical practice, is non-invasive monitoring of airway inflammation in asthma. Several years ago it was shown that the gas nitric oxide (NO) is increased in the breath of patients with asthma and is reduced by treating airway inflammation with inhaled steroids. Measurement of NO in the breath is a simple non-invasive test that can be used to measure inflammation in the airways of asthmatic patients. Although the original NO analysers were very expensive, new smaller and cheaper analysers are now in development. Measuring exhaled NO may indicate if asthma is adequately controlled and may predict exacerbations, so that patients can step-up therapy to prevent an exacerbation. It is likely to become a routine clinical measurement in a few years.&lt;/P&gt;&lt;BR&gt;
&lt;HR width="75%" SIZE=1&gt;

&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Further information:&lt;/STRONG&gt;&lt;BR&gt;&lt;/P&gt;
&lt;P align=center&gt;&lt;BR&gt;[The resources identified below are evidence-based publications and&amp;nbsp;information published this year.]&lt;/P&gt;
&lt;P&gt;&lt;BR&gt;&lt;STRONG&gt;Please note the Cochrane reviews are not yet available via the Respiratory Specialist Library, so links are provided directly to the publisher web site.&lt;/STRONG&gt;&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=238078&amp;amp;tabID=289" target="_blank"&gt;Anti-IgE for chronic asthma in adults and children&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004460/frame.html" target="_blank"&gt;Capsaicin for allergic rhinitis in adults&lt;/A&gt; The Cochrane Library 2006, Issue 2. &lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.library.nhs.uk/respiratory/ViewResource.aspx?resID=257188&amp;amp;tabID=289" target="_blank"&gt;Exhaled nitric oxide monitoring as a guide to treatment decisions in chronic asthma&lt;/A&gt; Health Technology Assessment (HTA) Database,&amp;nbsp; March 2006.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD005309/frame.html" target="_blank"&gt;Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000052/frame.html" target="_blank"&gt;Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;
&lt;P&gt;&lt;A href="http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003558/frame.html" target="_blank"&gt;Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma&lt;/A&gt; The Cochrane Library 2006, Issue 2.&lt;/P&gt;&lt;/pageBody&gt;&lt;/page&gt;&lt;/article&gt;]]&gt;</body>
  </document>
  <document>
    <id>70226</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.asthma.org.uk/document.rm?id=18]]&gt;</url>
    <title>Where Do We Stand? - Asthma in the UK today</title>
    <publicationDate>2004-12-01T00:00:00</publicationDate>
    <publisher>Asthma UK</publisher>
    <publicationType>REPORT</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,ASTHMA,PUBLICATIONS,REPORTS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ This report was produced by the charity&amp;nbsp;Asthma UK in 2004 . The report contains key statistics documenting the extent of asthma in the UK. The report further reveals the effect of asthma on people living with the condition, how many people die from asthma, and the impact on the NHS.]]&gt;</body>
  </document>
  <document>
    <id>51265</id>
    <name>&lt;![CDATA[ Respiratory]]&gt;</name>
    <rootDirectory>/respiratory</rootDirectory>
    <url>&lt;![CDATA[http://www.who.int/csr/sars/en/index.html]]&gt;</url>
    <title>WHO Guidance on SARS</title>
    <publicationDate></publicationDate>
    <publisher>World Health Organisation (WHO)</publisher>
    <publicationType>POLICY</publicationType>
    <topics>&lt;![CDATA[ RESPIRATORY,SEVERE ACUTE RESPIRATORY SYNDROME (SARS),INFECTIONS]]&gt;</topics>
    <resourceType>CARDEX</resourceType>
    <description></description>
    <body>&lt;![CDATA[ &amp;nbsp;]]&gt;</body>
  </document>
</documents>